<SEC-DOCUMENT>0001213900-21-034372.txt : 20210628
<SEC-HEADER>0001213900-21-034372.hdr.sgml : 20210628
<ACCEPTANCE-DATETIME>20210628114131
ACCESSION NUMBER:		0001213900-21-034372
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		19
FILED AS OF DATE:		20210628
DATE AS OF CHANGE:		20210628

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inspira Technologies OXY B.H.N. Ltd
		CENTRAL INDEX KEY:			0001837493
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-253920
		FILM NUMBER:		211051187

	BUSINESS ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
		BUSINESS PHONE:		972-9-9664488

	MAIL ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>ea143325-f1a6_inspiratech.htm
<DESCRIPTION>AMENDMENT NO. 6 TO FORM F-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>As filed with the Securities and Exchange
Commission on June 28, 2021</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> <B>Registration No. 333-253920</B> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND
EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, DC
20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>AMENDMENT NO. 6</B> </P>

<P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"> <B>TO</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;F-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INSPIRA TECHNOLOGIES
OXY B.H.N. LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Exact name of
registrant as specified in its charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>State&nbsp;of&nbsp;Israel</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3841</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not&nbsp;Applicable</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of</I><BR>
    <I>incorporation&nbsp;or&nbsp;organization)</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Primary&nbsp;Standard&nbsp;Industrial</I><BR>
    <I>Classification&nbsp;Code&nbsp;Number)</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(I.R.S.&nbsp;Employer</I><BR>
    <I>Identification&nbsp;Number)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2 Ha-Tidhar St.,</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Ra&rsquo;anana, 4366504 Israel</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tel: +972.4.6230333</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Puglisi &amp; Associates</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>850 Library Ave., Suite 204</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Newark, DE 19711</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: (302) 738-6680</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Address,
    including zip code, and telephone number,</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Name,
    address, including zip code, and telephone</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>including
    area code, of registrant&rsquo;s principal executive offices)</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>number,
    including area code, of agent for service)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>Copies to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; text-align: center; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Oded
    Har-Even, Esq. </B></FONT> </TD>
    <TD STYLE="width: 2%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 32%; text-align: center; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reut
    Alfiah, Adv.</B></FONT> </TD>
    <TD STYLE="width: 2%; text-align: center; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 32%; text-align: center; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gregory
    Sichenzia, Esq.</B></FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>David Huberman, Esq.</B> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Sullivan &amp; Worcester LLP</B> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>1633 Broadway </B> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>New York, NY 10019</B> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Tel: 212.660.3000</B> </P></TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Sullivan &amp; Worcester Tel-Aviv<BR>
    (Har-Even &amp; Co.)</B> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>28 HaArba&rsquo;a St. HaArba&rsquo;a<BR>
    Towers,<BR>
    North Tower, 35th Floor</B> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Tel-Aviv, Israel 6473925<BR>
    T&nbsp;+972.74.758.0480</B> </P></TD>
    <TD STYLE="text-align: center; font-size: 10pt"> &nbsp; </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Darrin M. Ocasio, Esq.</B> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Sichenzia Ross Ference LLP</B> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>1185 Avenue of the Americas,<BR>
    31<SUP>st </SUP>Floor</B> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>New York, NY 10036</B> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Tel: 212.930.9700</B> </P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Approximate date of commencement of proposed sale to the
public:</B> As soon as practicable after the effective date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> If any of the securities being registered on this form are to be
offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act, check the following box.&nbsp;&#9746; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this form is filed to register additional securities for
an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this form is a post-effective amendment filed pursuant to
Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering.&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this form is a post-effective amendment filed pursuant to
Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering.&nbsp; &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&nbsp;&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company that prepares its financial statements
in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards &dagger; provided pursuant to Section 7(a)(2)(B) of the Securities
Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&dagger;The term &ldquo;new or revised financial accounting
standard&rdquo; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification
after April 5, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>CALCULATION
OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of each class of securities to be registered</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed
    <BR>
    maximum<BR>
    aggregate <BR>
    offering<BR>
    price <SUP>(1)(2)</SUP></B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
    of<BR>
    registration <BR>
    fee <SUP>(3)</SUP></B></FONT> </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Units
    consisting of:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> 17,250,000 </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> 1,881.96 </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) Ordinary shares no
    par value <SUP>(4)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) Warrants to purchase
    Ordinary shares <SUP>(4)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-funded Units consisting
    of:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) Pre-funded warrants
    to purchase Ordinary shares <SUP>(4)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) Warrants to purchase
    Ordinary shares <SUP>(4)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representative&rsquo;s
    warrants to purchase ordinary shares&nbsp;<SUP>(5)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary shares issuable
    upon exercise of warrants</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> 17,250,000 </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="text-align: right"> 1,881.96 </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary shares issuable
    upon exercise of pre-funded warrants</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    shares issuable upon exercise of representative&rsquo;s warrants&nbsp;<SUP>(6)</SUP></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 991,875 </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;$</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 108.22 </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 4pt; width: 76%; padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Registration Fee</FONT> </TD>
    <TD STYLE="padding-bottom: 4pt; width: 1%"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right"> 35,491,875 </TD>
    <TD STYLE="padding-bottom: 4pt; width: 1%"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt; width: 1%"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right; width: 9%"> 3,872.17 </TD>
    <TD STYLE="white-space: nowrap; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(6)(7)</SUP></FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, the ordinary shares, or Ordinary Shares, registered hereby also include an indeterminate number of additional Ordinary Shares as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations or other similar transactions.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Estimated solely for purposes of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act.&nbsp;Includes the offering price of Ordinary Shares that the Underwriters have the option to purchase to cover over-allotments, if any.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT></TD>
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4)</FONT> </TD>
<TD> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">No separate fee is required pursuant to Rule 457(i) of the Securities Act.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(5)</FONT> </TD>
<TD> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">In accordance with Rule 457(g) under the Securities Act, because the Ordinary Shares of the Registrant underlying the warrants are registered hereby, no separate registration fee is required with respect to the warrants registered hereby.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(6)</FONT> </TD>
<TD> Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed
maximum aggregate offering price of the representative&rsquo;s warrants is equal to 125% of $862,500&nbsp;(which is 5% of $17,250,000.) </TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7) </FONT> </TD>
<TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously paid. </FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The registrant hereby amends this registration statement
on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of
the Securities Act or until the registration statement shall become effective on such date as the Commission, acting pursuant
to said Section&nbsp;8(a), may determine.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Red"><B>The information in this prospectus
is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities
and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer
to buy these securities in any state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 30%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>PRELIMINARY
    PROSPECTUS</B></FONT> </TD>
    <TD STYLE="padding: 2pt; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 40%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>SUBJECT
    TO COMPLETION</B></FONT> </TD>
    <TD STYLE="padding: 2pt; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 30%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>DATED
    JUNE 28, 2021</B></FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="color: Red"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Up to 2,307,692 Units Each Consisting
of</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>One Ordinary Share and One Warrant to Purchase
One Ordinary Share</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Up to 2,307,692 Pre-Funded Units Each
Consisting of</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>One Pre-Funded Warrant to Purchase One Ordinary
Share and One Warrant to Purchase One Ordinary Share</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <IMG SRC="image_001.jpg" ALT=""><B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Inspira Technologies Oxy B.H.N. Ltd. </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> This is the initial public offering in the United States of Inspira
Technologies Oxy B.H.N. Ltd., an Israeli company. We are offering 2,307,692 units, or Units, each consisting of one of our ordinary shares,
no par value, or Ordinary Shares and one warrant to purchase one of our Ordinary Shares, or each, a Warrant. We anticipate that the initial
public offering price per Unit will be between $5.50&nbsp;and $7.50, and the assumed exercise price of each Warrant included in the Unit
will be $6.50 (based on an assumed public offering price of $6.50 per Unit, the midpoint of the price range of the Units) per Ordinary
Share (100% of the public offering price per Unit). The Units have no stand-alone rights and will not be certificated or issued as stand-alone
securities. The Ordinary Shares and Warrants are immediately separable and will be issued separately in this offering. The Warrant offered
hereby will be immediately exercisable on the date of issuance and will expire five years from the date of issuance. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We are also offering to those purchasers, if any, whose
purchase of Units in this offering would otherwise result in the purchaser, together with its affiliates and certain related
parties, beneficially owning more than 4.99% of our outstanding Ordinary Shares immediately following the consummation of this
offering, the opportunity to purchase, if they so choose, up to 2,307,692 pre-funded units, or, each, a Pre-funded Unit, in lieu of
the Units that would otherwise result in ownership in excess of 4.99% (or at the election of the purchaser, 9.99%) of our
outstanding Ordinary Shares, with each Pre-funded Unit consisting of a pre-funded warrant to purchase one Ordinary Share, or a
Pre-funded Warrant, and one Warrant. The purchase price of each Pre-funded Unit will equal the price per Unit, minus $0.01, and the
exercise price of each Pre-funded Warrant included in the Pre-funded Unit will be $0.01 per Ordinary Share. The Pre-funded Units
have no stand-alone rights and will not be certificated or issued as stand-alone securities. The Pre-funded Warrants and Warrants
are immediately separable and will be issued separately in this offering. There can be no assurance that we will sell any of the
Pre-funded Units being offered. The Pre-funded Warrants offered hereby will be immediately exercisable and may be exercised on the
date of issuance at any time until exercised in full. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> For each Pre-funded Unit we sell, the number of Units we are offering
will be decreased on a one-for-one basis. Because we will issue a Warrant as part of each Unit or Pre-funded Unit, the number of Warrants
sold in this offering will not change as a result of a change in the mix of the Units and Pre-funded Units sold. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We refer to the Ordinary Shares, the Warrants, the Pre-funded Warrants
and the Ordinary Shares issued or issuable upon exercise of the Warrants and Pre-funded Warrants, collectively, as the securities. See
&ldquo;Description of Securities we are Offering&rdquo; for more information. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We have applied to list our Ordinary Shares and Warrants on the
Nasdaq Capital Market, or Nasdaq, under the symbols &ldquo;IINN&rdquo; and &ldquo;IINNW,&rdquo; respectively. No assurance can be given
that our application will be approved or that a trading market will develop. We do not intend to apply for listing of the Pre-funded
Warrants on any securities exchange or other nationally recognized trading system. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We are an emerging growth company, as defined in the Jumpstart
Our Business Startups Act of 2012, or the JOBS Act, and are subject to reduced public company reporting requirements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Investing in our securities involves a high degree of risk.&nbsp;See
&ldquo;Risk Factors&rdquo; beginning on page 8.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Neither the Securities and Exchange Commission, or the SEC,
nor any state or other foreign securities commission has approved nor disapproved these securities or determined if this prospectus is
truthful or complete.&nbsp;Any representation to the contrary is a criminal offense.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
                                            Unit</B></FONT> </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center"> &nbsp; </TD><TD STYLE="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
                                            Pre-Funded Unit&nbsp;</B></FONT> </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center"> &nbsp; </TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
                                            </B>&nbsp;</FONT> </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%"> Public offering price </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="width: 9%; text-align: right"> &nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="width: 9%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="width: 9%; text-align: right"> &nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discounts
    and commissions <SUP>(1)</SUP></FONT> </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to us (before
    expenses) <SUP>(2)</SUP></FONT> </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
<TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
<TD> Does not include a non-accountable expense allowance equal to 1.0% of the initial public offering price payable to the underwriters.
In addition, we have agreed to issue warrants to the representative of the underwriters in an amount equal to 5% of the aggregate number
of ordinary shares sold in this offering (including any ordinary shares underlying the Pre-Funded Warrants, but excluding the shares
sold through the exercise of the over-allotment option). See the section titled &ldquo;Underwriting&rdquo; beginning on page 118 of this
prospectus for additional disclosure regarding underwriter compensation and offering expenses. </TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT> </TD>
<TD> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Does not include proceeds from the exercise of the warrants in cash, if any.</FONT> </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We have granted the representative of the underwriters an option to purchase
from us, up to 346,153&nbsp;additional Ordinary Shares and/or Pre-Funded Warrants, and/or up to an additional 346,153&nbsp;Warrants, within&nbsp;45
days from the date of this prospectus to cover over-allotments, if any. The purchase price to be paid per additional Ordinary Share or
Pre-Funded Warrant will be equal to the public offering price of one Unit or Pre-Funded Unit (less $0.001 allocated to the Warrants),
as applicable, less the underwriting discount, and the purchase price to be paid per additional Warrant will be $0.001. If the representative
exercises the option in full, the total underwriting discounts and commissions and management fees payable will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the total proceeds
to us, before expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The underwriters expect to deliver the Units on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021.<I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Aegis Capital Corp.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021 </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 7pt; color: Red">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 92%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Prospectus Summary</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk Factors</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">8</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cautionary Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">45</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Listing Details</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">47</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Use of Proceeds</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">48</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_006"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dividend Policy</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">49</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_007"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Capitalization</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">50</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_008"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Selected Financial Data </FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">51</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_009"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dilution</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">52</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_010"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">54</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_011"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Business</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">64</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_012"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Management</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">83</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_013"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Beneficial Ownership of Principal Shareholders and Management </FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">100</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_014"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Related Party Transactions</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">101</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_015"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Description of Share Capital</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">103</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_015a">Description of Securities we are Offering</A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">107</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_016"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Shares Eligible for Future Sale</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">109</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_017"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Taxation</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">110</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_018"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Underwriting</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">118</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_019"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Expenses</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">120</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_020"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal Matters</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">120</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_021"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Experts</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">120</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_022"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Enforceability of Civil Liabilities</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">121</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#i_023"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Where You Can Find Additional Information</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">122</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#toc_01"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Index of Financial Statements</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">F-1</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white"><B>You
should rely only on the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to
which we have referred you. We have not authorized anyone to provide you with information that is different. We are offering to sell
our securities, and seeking offers to buy our securities, only in jurisdictions where offers and sales are permitted. The information
in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale
of our securities.</B></FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">For investors
outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession
or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States.
You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">In this prospectus,
&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company&rdquo; and &ldquo;Inspira&rdquo; refer to Inspira Technologies
Oxy B.H.N. Ltd. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">All trademarks
or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks
and trade names in this prospectus are referred to without the &reg; and &trade; symbols, but such references should not be construed
as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.
We do not intend the use or display of other companies&rsquo; trademarks and trade names to imply a relationship with, or endorsement
or sponsorship of us by, any other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Our reporting
currency is the U.S. dollar and our functional currency is New Israeli Shekels.&nbsp;Unless otherwise expressly stated or the
context otherwise requires, references in this prospectus to &ldquo;NIS&rdquo; are to New Israeli Shekels, references to A$ are
to Australian dollars, and references to &ldquo;dollars&rdquo; or &ldquo;$&rdquo; are to U.S. dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">This prospectus
includes statistical, market and industry data and forecasts which we obtained from publicly available information and independent
industry publications and reports that we believe to be reliable sources. These publicly available industry publications and reports
generally state that they obtain their information from sources that they believe to be reliable, but they do not guarantee the
accuracy or completeness of the information. Although we believe that these sources are reliable, we have not independently verified
the information contained in such publications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
report under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board,
or the IASB.&nbsp;None of the financial statements were prepared in accordance with generally accepted accounting principles in
the United States.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In November 2020, we issued bonus shares
under Israeli law to all of our shareholders on a basis of 68.097927 bonus shares for each ordinary share outstanding (equivalent
to a 69.097927-for-1 stock split) and made the customary adjustments to our outstanding options. Unless the context expressly
dictates otherwise, all references to share and per share amounts referred to herein reflect the bonus shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On March 18, 2021, our shareholders approved
a one-for-12.5&nbsp;consolidation (hereinafter referred to as a reverse stock split) of our Ordinary Shares pursuant to which holders
of our Ordinary Shares received one Ordinary Share for every 12.5&nbsp;Ordinary Shares held. On June 1, 2021, our shareholders approved
an additional reverse split at a ratio of one-for-2.94, pursuant to which holders of our Ordinary Shares received one Ordinary Share
for every 2.94&nbsp;Ordinary Shares held. Unless the context expressly dictates otherwise, all references to share and per share amounts
referred to herein reflect the foregoing reverse stock splits. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp;&nbsp; </P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4pt; padding-left: 4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="i_001"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><I>This summary
highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our securities. Before you decide to invest in our securities, you should read the entire prospectus
carefully, including the &ldquo;Risk Factors&rdquo; section and the financial statements and related notes appearing at the end
of this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are a specialty medical device company engaged
in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide deteriorating
patients with respiratory failure early saturation elevation and stabilization, which is key in preventing mechanical ventilation, or
MV, which is the standard of care today for the treatment of respiratory failure. Although it may be considered lifesaving, MV is associated
with increased costs of care, extended lengths of stay in the hospital, frequent incidence of infections, ventilator dependence and mortality.
Using our state-of-the-art respiratory support technology, our goal is to set a new standard of care and to provide patients with respiratory
insufficiency/failure an opportunity to remain awake, maintain spontaneous breathing and avoid the various risks associated with the
use of MV. As part of our strategy to reach this goal, and in parallel to pursuing regulatory approvals, we are actively working to establish
collaborations with strategic partners and globally ranked health centers, to provide endorsement and clinical adoption for regional
deployments of our respiratory support technology. We plan to target intensive care units, or ICUs, general medical units, emergency
medical services and small urban and rural hospitals. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Conditions
leading to respiratory insufficiency (a condition in which the lungs cannot perform sufficient gas exchange to support the body&rsquo;s
metabolism) and respiratory failure happen quickly and are initially hard to observe. These conditions are often caused by a disease
or injury that affects breathing, such as pneumonia. Acute respiratory failure requires emergency treatment) and is among the leading
causes of death globally.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a report published in 2017, the World Health Organization, or WHO, estimates that over 400 million people globally are affected
by respiratory insufficiency. Each year, an estimated 20 million people worldwide receive invasive MV, requiring induced coma
and intubation, which is primarily attributed to acute respiratory failure (69%) and chronic lung disease (10%). According to
July 2020 report &ldquo;Global Respiratory Care Devices Market (2019 to 2025) &ndash; Growing Demand for Home Care Therapeutic
Devices Presents Opportunities&rdquo;&nbsp;by Research and Markets, the global respiratory care devices market size was estimated
to reach approximately $29.86 billion by 2025. The major factors influencing this growth include the high prevalence of respiratory
diseases, the rapid growth of the aging population, the high prevalence of smoking, rising urbanization and pollution levels and
western lifestyle changes.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The COVID-19 pandemic has further exposed the
weaknesses and disadvantages of invasive MV that has both high association with considerable medical risks and iatrogenic complications,
which further burdens the healthcare system with long hospital stays and high costs of treatment. COVID-19 has seen the failure of some
of the most advanced healthcare systems worldwide in their ability to respond flexibly, quickly and at scale to rapid growth in demand
for respiratory support. According to the WHO, as of July 2020, the exponential increase in COVID-19 cases across the world requires
long-term and short-term respiratory support and increased demand for new solutions. Even prior to COVID-19, approximately 20 million
patients were treated annually with MV in ICUs.&nbsp; </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> COVID-19 led to a rise in the number
of ICU admissions worldwide of patients suffering from respiratory failure and require respiratory support solutions, such as
MV. According to an article in the <I>Clinical Infectious Diseases</I> medical journal published in August 2020 by Oxford University
Press, titled &ldquo;Patient Characteristics and Outcomes of 11 721 Patients with Coronavirus Disease 2019 (COVID-19) Hospitalized
Across the Unites States&rdquo;, during 2020, as a result of the COVID-19 pandemic, the mortality rate for patients on MV in the
United States is estimated to have increased to 70%. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, MV
treatment may result in ventilator-associated complications, such as ventilator-associated pneumonia and ventilator-induced lung
injury, which, in turn, increase morbidity and mortality. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Early saturation elevation and stabilization
are key in preventing MV. Our vision is to become the new standard of care for deteriorating patients with respiratory failure. Therefore,
we have developed a direct blood oxygenation technology called Augmented Respiration Technology, or ART. Our device, the ART500, is comprised
of a minimally invasive, portable dual lumen cannula which is inserted into the jugular vein and utilizes our extra-corporeal direct
blood oxygenation unit to elevate and stabilize declining oxygen saturation levels. The ART500&rsquo;s structure provides the potential
to extend respiratory treatment beyond ICU environments making acute respiratory treatment available in regions and medical facilities
without the need for ICUs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="background-color: white">Our </FONT>ART500
is designed to treat patients while awake, mobile and breathing spontaneously. Although our ART500 has not been tested in humans, and
is not cleared or approved by the U.S. Food and Drug Administration, or FDA, or similar foreign regulatory bodies, we believe that our
ART500 has the potential to reduce the patients&rsquo; length of stay in ICU, rehabilitation period in the hospital due to the absence
of the need to wean the patients after intubation and/or coma, and re-admissions compared to MV. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We completed and tested the first prototype
of our ART500 in March 2020. Throughout 2020, over 40 pre-clinical studies were performed in conjunction with our team and headed by
the veterinary team at LAHAV CRO in Israel to examine the feasibility of direct blood oxygenation to preempt the need for MV. The main
goal of these studies was to use our ART500 and show temporary increase of oxygen gas exchange during respiratory failure by transferring
clinically significant amounts of oxygen to the venous blood, while simultaneously extracting quantities of carbon dioxide. To date,
the ART500 has not been tested on humans and any future testing on humans will be subject to the request of the appropriate regulators,
including the FDA. Based on our regulatory strategy, for the key component sources we intend to pursue as a Class II the 510(k) pathway
based on predicates, which are not currently expected to require human trials for FDA clearance. We are taking a multi-step approach
to the regulatory clearance process. We are currently working on submitting our first Class I 510(k) filing planned for fourth quarter
of 2021 relating to key component sources of the ART500, to be followed by Class II 510(k) filing in 2022, including the submission of
the ART500 in the fourth quarter of 2022, to support extracorporeal life support, or ECLS, treatment and sales. An additional regulatory
filing is planned in 2023 for the multi-function sources of ART500, with modifications to support early direct blood oxygenation under
a new intent of use to elevate and stabilize oxygen saturation levels in awake patients. Any modification that could significantly affect
its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) marketing
clearance or, depending on the modification, a de novo or other type of approval. We are planning to apply for the break-through device
designation with the FDA for the ART500. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

</DIV>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4pt; padding-left: 4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The ART500, subject to regulatory approvals,
is intended to be our commercial respiratory support system. When and if we receive the necessary regulatory approvals, we plan to deploy
the first ART500 in ICUs. We expect to commercially launch our ART500 in the United States, subject to the receipt of the FDA clearance,
and in Europe following the receipt of the CE Mark, and we plan to submit an application for the CE Mark in the first half of 2023. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">In
parallel to pursuing regulatory approval for our ART500, we are implementing a go-to-market strategy, establishing and growing multiple
recurring revenue streams across medical sectors and markets in a variety of geographical territories.&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Our
go-to-market strategy includes, but is not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"> &nbsp; </TD>
<TD STYLE="width: 24px"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT> </TD>
<TD> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Pursuing world-wide regulatory approvals</I></B><I>: </I>we plan to pursue regulatory approvals in the United States, Europe, Asia, South America, Africa and the Middle East. </FONT> </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> &nbsp; </TD>
<TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT> </TD>
<TD> <B><I>Collaborating with leading medical centers</I> <I>and health organizations</I></B>: we are working with leading medical
centers and health organizations to reach regional deployment of the ART500. This also includes collaborations with top ranked hospitals
and to expose our ART500 and attain both clinical endorsement and adoption of use in acute respiratory care. </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> &nbsp; </TD>
<TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT> </TD>
<TD> <B><I>Identifying potential customer profiles</I></B>: we will be targeting leading medical centers that are interested in acquiring
the key components of our ART500 for blood enrichment applications. We will be also targeting emergency medical services to offer our
ART for early saturation elevation and stabilization in awake patients. Potentially, our ART500 can be used to treat patients with respiratory
failure to prevent MV. Moreover, our ART500 can potentially be used together with MV to reduce the risk of ventilator induced lung injury
by reducing MV pressure level in&nbsp;lungs and shortening the weaning period. </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> &nbsp; </TD>
<TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;&nbsp;</FONT> </TD>
<TD> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Strategic partners</I></B>: we have entered into discussions to establish collaborations with leading medical device companies, manufactures and distributors. This will include efforts that may generate a strategic investment by the strategic partners. The development of a strategic team is key in order to enable our company to rapidly deploy the ART500 to meet potentially growing demand as well as reach and service clientele internationally, subject to regulatory approval. </FONT> </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> &nbsp; </TD>
<TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT> </TD>
<TD> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Investing in marketing and public relations to increase awareness of our solution</I></B>: in order to drive market demand for the ART500, we are building our pre-commercialization infrastructure to support sales following regulatory approvals. We are focusing our efforts within the medical community to introduce our product and technology to leading hospitals, military branches and government bodies. We also believe that our ART500 has potential for use outside of the ICU, so we also intend to focus on conventional hospital wards as well as ambulatory settings. Although our ART500 remains in development, has not yet been used in humans, and is not cleared or approved by the FDA or similar foreign regulatory bodies, we believe that due to the potential ease of use and affordability of the ART500, we will also be able to target smaller urban and rural hospitals that do not have ICUs, in order to make acute respiratory care accessible to patients living outside of major city centers.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> &nbsp; </TD>
<TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
<TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Garnering appropriate reimbursement and insurance
coverage</I></B>: it is paramount for us to receive reimbursement and insurance coverage to enable hospitals and medical centers to provide
treatment utilizing the ART500. With intensive care becoming increasingly expensive, the ART500 may provide treatment at significantly
reduced cost and without compromising quality of care to patients. We are working on a health economics model as part of the reimbursement
strategy. Our goal is to publish medical literature to provide the Centers for Medicare &amp; Medicaid Services, or CMS, actual data,
presented by us together with top-ranking hospitals. The data collected will be used to demonstrate our ART500&rsquo;s efficiency and
reduced cost of treatment. We intend to pursue reimbursement under specified Medicare Severity-Diagnosis Related Group, or MS-DRG, and
have already begun discussions with some of the required parties. We plan to explore using existing Current Procedural Terminology (CPT)
Codes using a &ldquo;New Approach&rdquo; to an existing procedure, because potentially certain codes selected for COVID-19 may be relevant
for the ART500.</FONT> </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business is subject to numerous risks,
as more fully described in the section entitled &ldquo;Risk Factors&rdquo; immediately following this prospectus summary. You
should read these risks before you invest in the Ordinary Shares. In particular, our risks include, but are not limited to, the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we have a limited operating history on which to
    assess the prospects for our business, have incurred losses since inception and anticipate that we will continue to incur significant
    losses until we are able to successfully commercialize our ART500. In addition, we have not generated revenue from the sale of our
    products and may never be profitable;&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">given our lack of positive cash flow, we will
    likely need to raise additional capital after this offering, which may be unavailable to us and which, if obtained, will cause
    dilution to our shareholders;&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4pt; padding-left: 4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not succeed in completing the development
    and commercialization of our products and generating significant revenues;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our business and operations have been and are
    likely to continue to be adversely affected by the evolving and ongoing COVID-19 global pandemic;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our success depends on a broad degree of market
    acceptance of our product ART500 and any future product candidates, physician adoption and use, which are necessary for commercial
    success;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">medical device development is costly and involves
    continual technological change which may render our current or future products obsolete. In addition, if our competitors are
    able to develop and market products that are more effective, safer or more affordable than ours, or obtain marketing approval
    before we do, our commercial opportunities may be limited;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we will be dependent upon success in our customer
    acquisition strategy and successfully integrating acquired companies and technology;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are dependent upon third-party manufacturers
    and service suppliers making us vulnerable to supply shortages and problems, increased costs and quality or compliance issues,
    which could harm our business. We may not be able to replace our current manufacturing capabilities in a timely manner and
    we anticipate that we will incur significant losses once we initiate our in-house manufacturing until we are able to successfully
    commercialize our products globally;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exchange rate fluctuations between the U.S.
    dollar, the New Israeli Shekel, the Euro and other foreign currencies, may negatively affect our future revenues and expenses;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we manage our business through a small number
    of employees and key consultants. The loss of the services of any of our executive officers or any key employees or consultants
    would adversely affect our ability to execute our business plan and harm our operating results;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may need to expand our organization and may
    not be able to attract and retain highly skilled managerial, scientific and technical personnel, which will adversely affect
    our ability to implement our business model successfully;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">international expansion of our business exposes us to business, regulatory, political, operational,
    financial and economic risks associated with doing business outside of the United States or Israel; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">if third-party payors do not provide adequate coverage and reimbursement for the use of our
    ART500 or any future product candidates, our revenue will be negatively impacted;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our products and operations are subject to extensive
    government regulation and oversight both in the United States and abroad. Regulatory requirements for development of our product
    candidates are uncertain and evolving. Our failure to comply with applicable requirements or to obtain FDA or other regulatory
    clearances or approvals to market and sell future products could harm our business;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our products may cause or contribute to adverse
    medical events or be subject to failures or malfunctions that we are required to report to the FDA, and if we fail to do so,
    we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations.
    The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction
    of the FDA or another governmental authority, could have a negative impact on us;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be party to or target of lawsuits, investigations
    and proceedings arising out of claims alleging product liability, breach of warranty or similar claims that may involve large
    claims and significant defense costs whether or not such liability is imposed. Such potential claims may be costly to defend,
    could consume management resources and could adversely affect our reputation and business;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are subject to uncertainty relating to healthcare
    reform measures and reimbursement policies that, if not favorable to our products, could hinder or prevent our products&rsquo;
    commercial success and adversely affect our financial condition;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4pt; padding-left: 4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are dependent on patents and other forms
    of non-patent intellectual property protection. If we fail to adequately protect this intellectual property our ability to
    commercialize products could suffer. If we infringe the rights of third parties, we could be prevented from selling products,
    forced to pay damages and/or royalties, and forced to defend against litigation which might be very expensive to us;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the market price of our securities may be highly
    volatile, and you may not be able to resell your Ordinary Shares or Warrants at or above the initial public offering price;</FONT> </TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="text-align: left; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> our principal shareholders, officers and directors currently
        beneficially own approximately 70% of our Ordinary Shares and will therefore be able to exert significant control over matters
        submitted to our shareholders for approval; </P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our relationships with healthcare professionals,
    institutional providers, consultants, third-party payors and customers are subject to applicable anti-kickback, fraud and
    abuse and other healthcare laws and regulations in the United States and similar laws in other countries, which could expose
    us to penalties, including without limitation, civil, criminal and administrative penalties, damages, monetary fines, disgorgement,
    possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational
    harm, diminished profits and future earnings and the curtailment or restructuring of our operations;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject to security breaches and other
    disruptions could compromise our information, expose us to liability under privacy laws, and harm our reputation and business;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a public company following the conclusion
    of this offering, we will need to comply with extensive additional U.S. governmental and Nasdaq regulations, which will be
    expensive, and which will require significant management attention;</FONT> <FONT STYLE="font-size: 10pt">and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">political, military and economic conditions
    in Israel could materially and adversely affect our business. In addition, as an Israeli company, we are subject to provisions
    of Israeli law which govern the rights and responsibilities of our shareholders, may prevent us from enforcing covenants not-to-compete
    and delay, prevent or otherwise impede an acquisition of us or our merger with another company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We are an Israeli
corporation based in Ra&rsquo;anana, Israel and were incorporated in Israel in 2018 under the name Clearx Medical Ltd. On April
10, 2018, our name was changed to Insense Medical Ltd. and on July 30, 2020, our name was changed to our current name, Inspira
Technologies Oxy B.H.N. Ltd. Our principal executive offices are located at 2 Ha-Tidhar St., Ra&rsquo;anana, 4366504 Israel. Our
telephone number in Israel is 972 996 644 88. Our website address is <I>www.inspira-technologies.com</I>. The information contained
on, or that can be accessed through, our website is not part of this prospectus. We have included our website address in this
prospectus solely as an inactive textual reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Implications of Being an Emerging
Growth Company </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> We are an &ldquo;emerging
growth company,&rdquo; as defined in Section&nbsp;2(a) of the <FONT STYLE="background-color: white">Securities Act,</FONT> as
modified by the JOBS Act. As such, we are eligible to, and intend to, take advantage of certain exemptions from various reporting
requirements applicable to other public companies that are not &ldquo;emerging growth companies&rdquo; such as not being required
to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley
Act. We could remain an &ldquo;emerging growth company&rdquo; for up to five years, or until the earliest of (a)&nbsp;the last
day of the first fiscal year in which our annual gross revenue exceeds $1.07&nbsp;billion, (b)&nbsp;the date that we become a
&ldquo;large accelerated filer&rdquo; as defined in Rule&nbsp;12b-2 under the U.S. Securities Exchange Act of 1934, as amended,
or the Exchange Act, which would occur if the market value of our Ordinary Shares that is held by non-affiliates exceeds $700&nbsp;million
as of the last business day of our most recently completed second fiscal quarter, or (c)&nbsp;the date on which we have issued
more than $1&nbsp;billion in nonconvertible debt during the preceding three-year period. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Implications of being a Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are subject to the information reporting
requirements of the Exchange Act that are applicable to &ldquo;foreign private issuers,&rdquo; and under those requirements we
file reports with the SEC. As a foreign private issuer, we are not subject to the same requirements that are imposed upon U.S.
domestic issuers by the SEC. Under the Exchange Act, we are subject to reporting obligations that, in certain respects, are less
detailed and less frequent than those of U.S. domestic reporting companies. For example, we are not required to issue quarterly
reports, proxy statements that comply with the requirements applicable to U.S. domestic reporting companies, or individual executive
compensation information that is as detailed as that required of U.S. domestic reporting companies. We also have four months after
the end of each fiscal year to file our annual report with the SEC and are not required to file current reports as frequently
or promptly as U.S. domestic reporting companies. Our officers, directors and principal shareholders are exempt from the requirements
to report transactions in our equity securities and from the short-swing profit liability provisions contained in Section 16 of
the Exchange Act. As a foreign private issuer, we are not subject to the requirements of Regulation FD (Fair Disclosure) promulgated
under the Exchange Act. In addition, as a foreign private issuer, we are permitted to follow certain home country corporate governance
practices instead of those otherwise required under the Nasdaq Stock Market, or Nasdaq, rules for domestic U.S. issuers. See &ldquo;Risk
Factors&mdash;Risks Related to this Offering and the Ownership of Our Ordinary Shares.&rdquo; These exemptions and leniencies
will reduce the frequency and scope of information and protections available to you in comparison to those applicable to a U.S.
domestic reporting company. We intend to take advantage of the exemptions available to us as a foreign private issuer during and
after the period we qualify as an &ldquo;emerging growth company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 6pt"></FONT></P>
<DIV STYLE="padding-right: 4pt; padding-left: 4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary Shares currently
    issued and outstanding</B></FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 64%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,542,317 Ordinary Shares</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Units offered by us</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 2,307,692 Units (based on an assumed public
    offering price of $6.50 per Unit, the midpoint of the range set forth on the cover page of this prospectus), each consisting of
    one Ordinary Share and one Warrant to purchase one Ordinary Share. The Units have no stand-alone rights and will not be certificated
    or issued as stand-alone securities. The Ordinary Shares and Warrants are immediately separable and will be issued separately in
    this offering.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-funded Units offered by us</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are also offering to those purchasers, if any,
    whose purchase of Units in this offering would otherwise result in the purchaser, together with its affiliates and certain related
    parties, beneficially owning more than 4.99% of our outstanding Ordinary Shares immediately following the consummation of this offering,
    Pre-funded Units, each consisting of one Pre-funded Warrant to purchase one Ordinary Share and one Warrant to purchase one Ordinary
    Share. The Pre-funded Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The Pre-funded
    Warrants and Warrants are immediately separable and will be issued separately in this offering. For each Pre-funded Unit we sell,
    the number of Units we are offering will be decreased on a one-for-one basis. Because we will issue a Warrant as part of each Unit
    or Pre-funded Unit, the number of Warrants sold in this offering will not change as a result of a change in the mix of the Units
    and Pre-funded Units sold.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Warrant will have an exercise price of $6.50
    (based on an assumed public offering price of $6.50 per Unit, the midpoint of the range set forth on the cover page of this prospectus),
    per Ordinary Share (100% of the public offering price per Unit), will be immediately exercisable and will expire five years from
    the date of issuance. To better understand the terms of the Warrants, you should carefully read the &ldquo;Description of Securities
    we are Offering&rdquo; section of this prospectus. You should also read the form of Warrant, which is filed as an exhibit to the
    registration statement that includes this prospectus.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-funded Warrants</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Pre-funded Warrant will be immediately exercisable
    at an exercise price of $0.01 per Ordinary Share and may be exercised at any time until exercised in full. To better understand the
    terms of the Pre-funded Warrants, you should carefully read the &ldquo;Description of Securities we are Offering&rdquo; section of
    this prospectus. You should also read the form of Pre-funded Warrant, which is filed as an exhibit to the registration statement
    that includes this prospectus.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary Shares to be outstanding after this
    offering</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> 6,850,014 Ordinary Shares (assuming no exercise of the representative&rsquo;s warrants and assuming the exercise of any Pre-Funded
    Warrants and excluding 2,307,692 Ordinary Shares issuable upon exercise of the Warrants sold in this offering), or 7,196,167 Ordinary
    Shares if the underwriters exercise in full the over-allotment option to purchase additional Ordinary Shares. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-allotment option</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD><P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have
        granted the representative of the underwriters an option to purchase from us, up to 346,153&nbsp;additional Ordinary Shares and/or
        Pre-Funded Warrants, and/or up to an additional 346,153 Warrants, within 45 days from the date of this prospectus to cover
        over-allotments, if any. The purchase price to be paid per additional Ordinary Share or Pre-Funded Warrant will be equal to the
        public offering price of one Unit or Pre-Funded Unit (less $0.001 allocated to the Warrants), as applicable, less the underwriting
        discount, and the purchase price to be paid per additional Warrant will be $0.001.</FONT> </P>
        <P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> The
                                            underwriters may exercise this option with respect to Ordinary Shares only, Pre-Funded Warrants
                                            only, Warrants only, or a combination thereof. </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative&rsquo;s Warrants</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will issue to&nbsp;Aegis Capital Corp., the representative
    of the underwriters, or its permitted designees warrants to purchase up to&nbsp;115,385 Ordinary Shares (or&nbsp;132,692 Ordinary
    Shares if the underwriters exercise their over-allotment option in full). The representative&rsquo;s warrants will have an exercise
    price of&nbsp;100% of the per Ordinary Share public offering price, will be exercisable on the date of issuance and will expire five
    years from the effective date of the registration statement of which this prospectus forms a part. </FONT> </TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds</B></FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 64%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We expect to receive approximately $13.6 million in net proceeds
    from the sale of&nbsp;securities offered by us in this offering (approximately $15.7 million if the&nbsp;underwriters exercise their
    over-allotment option in full), based upon an assumed public offering price of $6.50&nbsp;per Unit, which is the midpoint of the
    price range set forth on the cover page of this prospectus, and after deducting the underwriting discounts and commissions and estimated
    offering expenses payable by us. </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  </TABLE>
<P STYLE="margin: 0"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4pt; padding-left: 4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"></TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 64%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We currently expect to use the net proceeds from this offering
    for the following purposes: </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.4pt; text-indent: -0.15in"> &#9679; &nbsp;approximately
    $1&nbsp;million for product integration; </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.4pt; text-indent: -0.15in"> &#9679; &nbsp;approximately
    $7 million for research and development, including human observational studies, system engineering and other regulatory approval
    process; </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.4pt; text-indent: -0.15in"> &#9679; &nbsp;approximately
    $2 million for million for business development and marketing activities and implementation of our go-to-market strategy; and </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.4pt; text-indent: -0.15in"> &#9679; &nbsp;the remainder
    for working capital and general corporate purposes and possible future acquisitions. </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The amounts and schedule of our actual expenditures will depend
    on multiple factors. As a result, our management will have broad discretion in the application of the net proceeds of this offering. </P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing in our securities
    involves a high degree of risk. You should read the &ldquo;Risk Factors&rdquo; section starting on page 8 of
    this prospectus for a discussion of factors to consider carefully before deciding to invest in our Ordinary Shares.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed Nasdaq Capital Market symbol:&nbsp;</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> We have applied to list our Ordinary Shares and Warrants
        to be issued in this offering on the Nasdaq under the symbol &ldquo;IINN&rdquo; and &ldquo;IINNW,&rdquo; respectively. </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The number of Ordinary Shares to be outstanding
immediately after this offering as shown above assumes that all of the Ordinary Shares offered hereby are sold, and is based on 4,542,317
Ordinary Shares outstanding as of June 25, 2021. This number excludes: </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">559,912 Ordinary Shares issuable upon the exercise
    of options to directors, employees and consultants under our equity incentive plan, outstanding as of such date, with exercise prices
    ranging between NIS 0.37 (approximately $0.12) to NIS 0.97 (approximately $0.29) per share, of which 378,419 were vested as of such
    date; </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,038 Ordinary Shares reserved for future issuance
    under our equity incentive plan; </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">169,016 Ordinary Shares issuable upon the exercise
    of warrants issued to InSense Medical Pty Ltd. in connection with a certain termination agreement, with an exercise price equal to
    the price per Ordinary Share in this offering;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">673,402 Ordinary Shares issuable upon the exercise
    of warrants to be issued in connection with certain equity investment agreements, which we refer to as Simple Agreements for Future
    Equity, or SAFEs&nbsp;and an additional 2,747 Ordinary Shares issuable upon the exercise of warrants to be issued to promoters in
    connection with such SAFEs; and </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">293,650 Ordinary Shares issuable upon the exercise
    of warrants issued in connection with a certain convertible loan, and an additional 11,288 Ordinary Shares issuable upon the exercise
    of warrants to be issued to promoters in connection with such convertible loan agreements. </FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Unless otherwise
indicated, all information in this prospectus assumes or gives effect to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise of the underwriters&rsquo; over-allotment
    option; </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise of the representative&rsquo;s warrants;
    </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the issuance in November 2020 of bonus shares under
    Israeli law to all of our shareholders on a basis of 68.097927 bonus shares for each ordinary share outstanding (equivalent to a
    69.097927-for-1 stock split) and the customary adjustments to our outstanding options; </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,190,050 Ordinary Shares to be issued upon the
    conversion of SAFEs, for aggregate proceeds of $5,414,593, which will automatically convert upon the consummation of this offering,
    based on an assumed public offering price of $6.50 per Unit, which is the midpoint of the price range set forth on the cover page
    of this prospectus;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">587,297 Ordinary Shares to be issued upon the conversion
    of convertible loan agreements for aggregate proceeds of $3,053,920, which will automatically convert upon the consummation of this
    offering, based on an assumed public offering price of $6.50 per Unit, which is the midpoint of the price range set forth on the
    cover page of this prospectus;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97,762 Ordinary Shares to be issued to financial
    advisors, upon completion of this offering; and</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a 1-for-12.5&nbsp;reverse stock split effected on
    March 18, 2021, and an additional 1-for-2.94 reverse stock split effected on June 1, 2021. </FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">See
&ldquo;Description of Share Capital&rdquo; for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4pt; padding-left: 4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SUMMARY FINANCIAL
DATA </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following table summarizes our financial
data. We have derived the following statements of operations data for the years ended December 31, 2020 and 2019, from our audited financial
statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected
in the future. The following summary financial data should be read in conjunction with &ldquo;Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations&rdquo; and with the selected financial data and our financial statements and related
notes included elsewhere in this prospectus.&nbsp;Our financial statements included in this prospectus were prepared in accordance with
IFRS, as issued by the IASB. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center; font-weight: bold"> Year Ended<BR> December 31, </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid"> U.S. dollars in thousands, except per share
    data </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> 2020 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> 2019 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"> Research and development expenses </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 3,873 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 887 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> general and administrative expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,447 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 384 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Other income </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 51 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Total operating expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,269 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,271 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Operating loss </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,269 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,271 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Finance expenses, net </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 959 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,304 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Loss before taxes on income </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,228 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,575 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Income tax expense (benefit) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Loss for the year </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,228 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,575 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Other comprehensive income (loss) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (599 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (37 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Net comprehensive loss </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,827 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,612 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Net comprehensive loss for the period attributable to: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Inspira technologies Oxy B.H.N. Ltd. Shareholders </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,827 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,612 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Basic and diluted loss per share </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3.6
                                            7)</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (2.401 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> As of December 31, 2020 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid"> U.S. dollars in thousands </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Actual * </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro<BR>
    Forma <SUP>(1)</SUP></B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro
    Forma <BR> As Adjusted <SUP>(2)</SUP></B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center"> (Unaudited) </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold"> Balance Sheet Data: </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left"> Cash and cash equivalents </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 496 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 7,309 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 20,283 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Total assets </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 987 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,800 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 20,774 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Total current liabilities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 951 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 951 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 951 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Accumulated deficit </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (11,836 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (12,465 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (12,687 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Total shareholders&rsquo; equity (deficit) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (1,704 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,382 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 19,356 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT> </TD><TD STYLE="text-align: left"> The pro forma data gives effect to the issuance of (i) 1,190,050&nbsp;Ordinary
Shares to be issued upon the conversion of the SAFEs; (ii) 587,297 Ordinary Shares to be issued upon the conversion of &nbsp;certain
convertible loan agreements; and (iii) 97,762 Ordinary Shares to be issued to financial advisors upon the consummation of this offering<FONT STYLE="background-color: white">.</FONT> </TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT></TD><TD STYLE="text-align: left">The pro forma as adjusted data give effect to the additional issuance
of securities in this offering, at an assumed public offering price of $6.50 per Unit, which is the midpoint of the price range set forth
on the cover page of this prospectus, and after deducting underwriting discounts and commissions and estimated offering expenses, as
if the sale of the Ordinary Share had occurred on December 31, 2020.</TD>
</TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="i_002"></A>RISK FACTORS</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Investing in our securities involves a high
degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information
in this prospectus, including the financial statements and related notes, before deciding whether to purchase our securities. Our business,
operating results, financial condition and prospects could be materially and adversely affected by these risks. In that event, the price
of our Ordinary Shares could decline, and you could lose part or all of your investment.</I> <I> </I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Our Financial Condition
and Capital Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have a limited operating history and we have incurred
significant operating losses since our inception, and anticipate that we will incur continued losses for the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are a development-stage medical device company
with a limited operating history. To date, we have focused almost exclusively on developing our ART500. We have funded our operations
to date primarily through convertible loans and royalty-bearing and non-royalty bearing grants that we received from the Israeli Innovation
Authority, or the IIA, formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have only a limited operating history upon
which you can evaluate our business and prospects. In addition, we have limited experience and have not yet demonstrated an ability to
successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly
in the medical device industry. To date, we have not generated revenue from the sale of our product candidate (see &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; for additional information). We have incurred losses
in each year since our inception, including net losses of approximately $7.2&nbsp;million and $4.6 million for the years ended December&nbsp;31,
2020 and 2019, respectively. As of December&nbsp;31, 2020, we had an accumulated deficit of approximately $11.8&nbsp;million. Substantially
all of our operating losses resulted from costs incurred in connection with our development of our ART500 and from general and administrative
costs associated with our operations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We expect our research and development expenses
to increase in connection with our planned expanded studies. In addition, if we obtain marketing approval for our ART500 we will likely
incur significant sales, marketing and outsourced manufacturing expenses, as well as continued research and development expenses. Furthermore,
in the period following this offering, we expect to incur additional costs associated with operating as a public company, which we estimate
will be at least several hundred thousand dollars annually. As a result, we expect to continue to incur significant and increasing operating
losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing a medical device, we are
unable to predict the extent of any future losses or when we will become profitable, if at all. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We expect to continue to incur significant
losses until we are able to commercialize our ART500, which we may not be successful in achieving. We anticipate that our expenses will
increase substantially if and as we: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> continue the research and development of our ART500; </P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> seek regulatory and marketing approvals for our ART500; </P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> establish a sales, marketing, and distribution infrastructure
        to commercialize our ART500; </P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to identify, assess, acquire, license,
    and/or develop other product candidates and subsequent generations of our current product candidate;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to maintain, protect, and expand our intellectual
    property portfolio;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to attract and retain skilled personnel;
    </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">create additional infrastructure to support
    our operations as a public company and our product candidate development and planned future commercialization efforts; and
    </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience any delays or encounter issues with
    respect to any of the above, including, but not limited to, failed studies, complex results, safety issues or other regulatory
    challenges that require longer follow-up of existing studies or additional supportive studies in order to pursue marketing
    approval.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">The
amount of any future operating losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding
through equity or debt financings, strategic collaborations or grants. Even if we obtain regulatory approval to market our ART500 or
any future product candidates<SUB>,</SUB> our future revenue will depend upon the size of any markets in which our ART500 or any future
product candidates receive approval and our ability to achieve sufficient market acceptance, pricing, reimbursement from third-party
payors for our ART500 or any future product candidates. Further, the operating losses that we incur may fluctuate significantly from
quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication
of our future performance. Other unanticipated costs may also arise.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have not generated any revenue from product sales
and may never be profitable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">We
have no products approved for marketing in any jurisdiction and we have never generated any revenue from product sales. Our ability to
generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration partners, to successfully complete
the development of, and obtain the regulatory and marketing approvals necessary to commercialize our ART500 or any future product candidates.
We do not know when, or if, we will generate any such revenue. Our ability to generate future revenue from product sales will depend
heavily on our success in many areas, including but not limited to:</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete research and development of our ART500
    and any future product candidates in a timely and successful manner;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain regulatory and marketing approval for any
    product candidates;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain and enhance a commercially viable, sustainable,
    scalable, reproducible and transferable manufacturing process for our ART500 and any future product candidates that is compliant
    with current good manufacturing practices, or cGMPs;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish and maintain supply and, if applicable,
    manufacturing relationships with third parties that can provide, in both amount and quality, adequate products to support development
    and the market demand for our ART500 and any future product candidates, if and when approved;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying, assessing, acquiring and/or developing
    new product candidates;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launch and commercialize any product candidates
    for which we obtain regulatory and marketing approval, either directly by establishing a sales force, marketing and distribution
    infrastructure, and/or with collaborators or distributors;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accurately identifying demand for our ART500 or
    any future product candidates;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expose and educate physicians and other medical
    professionals to use our products;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain market acceptance, if and when approved,
    of our ART500 and any future product candidates from the medical community and third-party payors;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensure our product candidates are approved for reimbursement
    from governmental agencies, health care providers and insurers in jurisdictions where they have been approved for marketing;</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> address any competing technological and market developments
        that impact our ART500 and any future product candidates or their prospective usage by medical professionals; </P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiate favorable terms in any collaboration,
    licensing or other arrangements into which we may enter and perform our obligations under such collaborations;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain, protect and expand our portfolio of intellectual
    property rights, including patents, patent applications, trade secrets and know-how;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">avoid and defend against third-party interference
    or infringement claims;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract, hire and retain qualified personnel; and</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">locate and lease or acquire suitable facilities
    to support our clinical development, manufacturing facilities and commercial expansion.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Even
if our ART500 or any future product candidates are approved for marketing and sale, we anticipate incurring significant incremental costs
associated with commercializing such product candidates. Our expenses could increase beyond expectations if we are required by the FDA,
or other regulatory agencies, domestic or foreign, to change our manufacturing processes or assays or to perform studies in addition
to those that we currently anticipate. Even if we are successful in obtaining regulatory approvals to market our ART500 or any future
product candidates, our revenue earned from such product candidates will be dependent in part upon the size of the markets in the territories
for which we gain regulatory approval for such products, the accepted price for such products, our ability to obtain reimbursement for
such products at any price, whether we own the commercial rights for that territory in which such products have been approved and the
expenses associated with manufacturing and marketing such products for such markets. Therefore, we may not generate significant revenue
from the sale of such products, even if approved. Further, if we are not able to generate significant revenue from the sale of our approved
products, we may be forced to curtail or cease our operations. Due to the numerous risks and uncertainties involved in product development,
it is difficult to predict the timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Even if this offering is successful,
we will need to raise substantial additional funding, which may not be available on acceptable terms, or at all. Failure to obtain
funding on acceptable terms and on a timely basis may require us to curtail, delay or discontinue our product development efforts
or other operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of December 31, 2020, our cash and cash
equivalents were approximately $496,000, and we had a working capital deficit of approximately $267,000 and an accumulated deficit of
approximately $11.8 million. Based upon our currently expected level of operating expenditures, we expect that our existing cash and
cash equivalents, will only be sufficient to fund operations through December 2021. Even if this offering is completed, we expect that
we will require substantial additional capital to commercialize our ART. In addition, our operating plans may change as a result of many
factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future funding requirements
will depend on many factors, including but not limited to: </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress, results and costs of our ongoing and
    planned studies and, if applicable, clinical trials of ART500 and any future product candidates;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost, timing and outcomes of regulatory review
    of ART500 and any future product candidates;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of maintaining our own commercial-scale
    cGMP manufacturing facility, including costs related to obtaining and maintaining regulatory compliance, and/or engaging third-party
    manufacturers therefor;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, progress, results and costs of product
    development, testing, manufacturing, preclinical development and, if applicable, clinical trials for any other product candidates
    that we may develop or otherwise obtain in the future;</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of our future activities, including
    establishing sales, marketing and distribution capabilities for any product candidates in any particular geography where we
    receive marketing approval for such product candidates</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms and timing of any collaborative, licensing
    and other arrangements that we may establish;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of preparing, filing and prosecuting
    patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related
    claims; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the level of revenue, if any, received from
    commercial sales of any product candidates for which we receive marketing approval.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Any additional fundraising efforts may divert
our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our ART500 and any
future product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms
acceptable to us, if at all, during or after the COVID-19 pandemic. Moreover, the terms of any financing may adversely affect the holdings
or the rights of holders of our securities and the issuance of additional securities, whether equity or debt, by us, or the possibility
of such issuance, may cause the market price of our Ordinary Shares to decline. The incurrence of indebtedness could result in increased
fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur
additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions
that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative
partners or otherwise at an earlier stage than otherwise would be desirable, and we may be required to relinquish rights to some of our
technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on
our business, operating results and prospects. Even if we believe that we have sufficient funds for our current or future operating plans,
we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> If we are unable to obtain funding on a timely
basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the development
or commercialization, if any, of our ART500 or any other product candidates or be unable to expand our operations or otherwise capitalize
on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.&nbsp; </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Raising additional capital would cause dilution to our
existing shareholders, and may adversely affect the rights of existing shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may seek additional capital through
a combination of private and public equity offerings, debt financings and collaborations and strategic and licensing arrangements.
To the extent that we raise additional capital through the issuance of equity (such as this offering) or otherwise including through
convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences
that adversely affect your rights as a shareholder. Future sales of our Ordinary Shares or of securities convertible into our
Ordinary Shares, or the perception that such sales may occur, could cause immediate dilution and adversely affect the market price
of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our financial statements contain an explanatory paragraph
regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing
on reasonable terms or at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our audited financial statements for the period
ended December 31, 2020, contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.
We have incurred losses in each year since our inception, including net losses of approximately $7.2&nbsp;million and $4.6 million for
the years ended December&nbsp;31, 2020 and 2019, respectively. As of December&nbsp;31, 2020, we had an accumulated deficit of approximately
$11.8&nbsp;million. These events and conditions, along with other matters, indicate that a material uncertainty exists that may cast
significant doubt on our ability to continue as a going concern. The financial statements for 2020 do not include any adjustments that
might result from the outcome of this uncertainty. This going concern opinion could materially limit our ability to raise additional
funds through the issuance of equity or debt securities or otherwise. Further financial statements may include an explanatory paragraph
with respect to our ability to continue as a going concern. Until we can generate significant recurring revenues, we expect to satisfy
our future cash needs through debt or equity financing. We cannot be certain that additional funding will be available to us on acceptable
terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development
plans for, or commercialization efforts with respect to our products. This may raise substantial doubts about our ability to continue
as a going concern. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Risks Related
to Our Business and Industry</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>We are highly dependent on the successful development, marketing
and sale of our ART500.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our ART500 for the treatment of respiratory
failure is the basis of our business. As a result, the success of our business plan is highly dependent on our ability to develop, manufacture
and commercialize our ART500, and our failure to do so could cause our business to fail. Successful commercialization of medical devices
is a complex and uncertain process, dependent on the efforts of management, manufacturers, local operators, integrators, medical professionals,
third-party payors, as well as general economic conditions, among other factors. Any factor that adversely impacts the development and
commercialization of our ART500, will have a negative impact on our business, financial condition, results of operations and prospects.
We have limited experience in commercializing our ART500 and we may face several challenges with respect to our commercialization efforts,
including, among others, that: </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not have adequate financial or other resources
    to complete the development of our ART500;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to manufacture our ART500 in
    commercial quantities, at an adequate quality or at an acceptable cost;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to establish adequate sales,
    marketing and distribution channels;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">healthcare professionals and patients may not accept
    our products;&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be aware of possible complications from
    the continued use of our ART500 since we have limited clinical experience with respect to the actual use of our ART500;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to compete with existing solutions
    for respiratory failure;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">technological breakthroughs in the respiratory support
    solutions may reduce the demand for our ART500;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party payors may not agree to reimburse patients
    for any or all of the purchase price of our ART500, which may adversely affect patients&rsquo; willingness to use our ART500;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may face third-party claims of intellectual property
    infringement; and</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may fail to obtain or maintain regulatory clearance
    or approvals in our target markets or may face adverse regulatory or legal actions even if regulatory approval is obtained.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we are unable to meet any one or more
of these challenges successfully, our ability to effectively commercialize our products and services could be limited, which in
turn could have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We face business disruption and related risks resulting
from the recent outbreak of the COVID-19 pandemic, which could have a material adverse effect on our business and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The outbreak of COVID-19, which originated
in Wuhan, China in 2019, has since spread across the globe, including the United States, Israel, many European and other countries
in which we operate. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. While COVID-19 is still
spreading and the final implications of the pandemic are difficult to estimate at this stage, it is clear that it has affected
the lives of a large portion of the global population. At this time, the pandemic has caused states of emergency to be declared
in various countries, travel restrictions imposed globally, quarantines established in certain jurisdictions and various institutions
and companies being closed. We are actively monitoring the pandemic and we are taking any necessary measures to respond to the
situation in cooperation with the various stakeholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> COVID-19 infection of our workforce resulted
in minimal disruption to our business activities, including manufacturing, and other functions. Based on the guidelines provided by the
Israeli government, employers (including us) are also required to prepare and increase as much as possible the capacity and arrangement
for employees to work remotely. Currently, our employees are vaccinated, which allows us to operate under normal working conditions with
all employees working daily out of the company facility. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The spread of an infectious disease, including
COVID-19, may also result in the inability of our manufacturers to deliver components or finished products on a timely basis and
may also result in the inability of our suppliers to deliver the parts required by our manufacturers to complete manufacturing
of components or finished products. Since March 2020 we have experienced delays in supply of some components of our products from
abroad. In addition, governments may divert spending from other budgeted resources as they seek to reduce and/or stop the spread
of an infectious disease, such as COVID-19. Such events may result in a period of business and manufacturing disruption, and in
reduced operations, any of which could materially affect our business, financial condition and results of operations. The extent
to which COVID-19 impacts our business will depend on future developments, which are highly uncertain and cannot be predicted,
including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its
impact, among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Our success depends upon market acceptance of our ART500,
our ability to develop and commercialize new products and generate revenues and our ability to identify new markets for our technology.
</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have developed, and are engaged in the development
of, respiratory support technology. Our success will depend on the approval and acceptance of our ART500 and any future products in the
healthcare market. We are faced with the risk that the marketplace will not be receptive to our ART500 or any future products over competing
products and that we will be unable to compete effectively. Factors that could affect our ability to successfully commercialize our current
and any potential future products: </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the challenges of developing (or acquiring externally-developed)
    technology solutions that are adequate and competitive in meeting the requirements of next-generation design challenges; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dependence upon referrals from physicians
    for the sale of our products and provision of our service.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">We
cannot assure that our ART500 or any future products will gain broad market acceptance. If the market for our products fails to develop
or develops more slowly than expected, our business and operating results would be materially and adversely affected.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I></I></B></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Medical device development is costly and involves continual
technological change which may render our current or future products obsolete.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The market for medical device technologies
and products is characterized by factors such as rapid technological change, medical advances, changing consumer requirements,
short device lifecycles, changing regulatory requirements and evolving industry standards. Any one of these factors could reduce
the demand for our devices or require substantial resources and expenditures for, among other things, research, design and development,
to avoid technological or market obsolescence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our success will depend on our ability
to enhance our current technology and develop or acquire new technologies to keep pace with technological developments and evolving
industry standards, while responding to changes in customer needs. A failure to adequately develop or acquire device enhancements
or new devices that will address changing technologies and customer requirements adequately, or to introduce such devices on a
timely basis, may have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We might have insufficient financial resources
to improve our ART500, advance technologies and develop new devices at competitive prices. Technological advances by one or more competitors
or future entrants into the field may result in our present services or devices becoming non-competitive or obsolete, which may decrease
revenues and profits and adversely affect our business and results of operations. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may encounter significant competition
across our product lines and in each market in which we will sell our products and services from various companies, some of which
may have greater financial and marketing resources than we do. Our competitors may include any companies engaged in the research,
development, manufacture, and marketing of respiratory support solutions and technologies, as well as a wide range of medical
device companies that sell a single or limited number of competitive products and services or participate in only a specific market
segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will be dependent upon success in our customer acquisition
strategy</I>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our business will be dependent upon success
in our customer acquisition strategy. If we fail to maintain a high quality of device technology, we may fail to retain or add new customers.
If we fail, our revenue, financial results and business may be significantly harmed. Our future success depends upon expanding our commercial
operations in the United States, Israel and Europe, as well as entering additional markets to commercialize our ART500 and any future
products. We believe that our expanded growth will depend on the further development, regulatory approval and commercialization of our
ART500, which we anticipate can be used by nearly all targeted individuals. If we fail to expand the use of our products in a timely
manner, we may not be able to expand our markets or to grow our revenue, and our business may be adversely impacted. If people do not
perceive our products to be useful and reliable, we may not be able to attract or retain new customers. A decrease in costumer growth
could render less attractive to developers, which may have a material and adverse impact on our revenue, business, financial condition
and results of operations. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Our business and operations
would suffer in the event of computer system failures, cyber attacks or a deficiency in our cybersecurity.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">Despite the
implementation of security measures intended to secure our data against impermissible access and to preserve the integrity
and confidentiality of our data, our internal computer systems, and those of third parties on which we rely, are vulnerable
to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures,
cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with
access to systems inside our organization. The risk of a security breach or disruption, particularly through cyber attacks or
cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the
number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an
event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug
development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could
result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To
the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or
inappropriate disclosure of confidential or proprietary information, we could incur material legal claims and liability,
including under data privacy laws such as the General Data Protection Regulation, or the GDPR, damage to our reputation, and
the further development of our drug candidates could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are dependent upon third-party manufacturers and suppliers
making us vulnerable to supply shortages and problems, increased costs and quality or compliance issues, any of which could harm
our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our ART500 is comprised of a number of components.
We are planning to sell an assembled product as well as its disposable respiratory support unit. The components of the assembled product
and the disposable unit consist of both proprietary and off the shelf components. Proprietary components will be manufactured on our
behalf at good manufacturing practices, or GMP, approved production plant to adhere to regulatory requirements, whereas off the shelf
components will be sourced and manufactured by GMP suppliers. GMP sub-contractors will assemble proprietary and off the shelf components
together to create our ART500. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therefore,
we rely on third parties to manufacture and supply us with proprietary custom components. Although we rely on a number of suppliers
who provide us materials and components as well as manufacture and assemble certain components of our products, we do not rely
on single-source suppliers. Our suppliers may encounter problems during manufacturing for a variety of reasons, including, for
example, failure to follow specific protocols and procedures, failure to comply with applicable legal and regulatory requirements,
equipment malfunction and environmental factors, failure to properly conduct their own business affairs, and infringement of third-party
intellectual property rights, any of which could delay or impede their ability to meet our requirements. Our reliance on these
third-party suppliers also subjects us to other risks that could harm our business, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are not currently a major customer of many
    of our suppliers, and these suppliers may therefore give other customers&rsquo; needs higher priority than ours;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to obtain an adequate supply
    in a timely manner or on commercially reasonable terms;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our suppliers, especially new suppliers, may
    make errors in manufacturing that could negatively affect the efficacy or safety of our products or cause delays in shipment;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may have difficulty locating and qualifying
    alternative suppliers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">switching components or suppliers may require
    product redesign and possibly submission to the FDA or other similar foreign regulatory agencies, which could impede or delay
    our commercial activities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one or more of our suppliers may be unwilling
    or unable to supply components of our products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the occurrence of a fire, natural disaster or
    other catastrophe impacting one or more of our suppliers may affect their ability to deliver products to us in a timely manner;
    and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our suppliers may encounter financial or other
    business hardships unrelated to our demand, which could inhibit their ability to fulfill our orders and meet our requirements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to quickly establish additional or alternative suppliers if necessary, in part because we may need to undertake
additional activities to establish such suppliers as required by the regulatory approval process. Any interruption or delay in
obtaining products from our third-party suppliers, or our inability to obtain products from qualified alternate sources at acceptable
prices in a timely manner, could impair our ability to meet the demand of our customers and cause them to switch to competing
products. Given our reliance on certain suppliers, we may be susceptible to supply shortages whilst looking for alternate suppliers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have limited manufacturing history on which to assess
the prospects for our business, and we anticipate that we will incur significant losses once we initiate our in-house manufacturing
until we are able to successfully commercialize our products globally.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If our manufacturing operation or any contracted
manufacturing operation is unreliable or unavailable, we may not be able to move forward with our intended business operations
and our entire business plan could fail. There is no assurance that our manufacturing operation or any third-party manufacturers
will be able to meet commercialized scale production requirements in a timely manner or in accordance with applicable standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may not be able to replace our current manufacturing
capabilities in a timely manner.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If our manufacturing facility suffers any
type of prolonged interruption, whether caused by regulator action, equipment failure, critical facility services (such as water
purification, clean steam generation or building management and monitoring system), fire, natural disaster or any other event
that causes the cessation of manufacturing activities, we may be exposed to long-term loss of sales and profits. There are limited
facilities which are capable of contract manufacturing some of our products and product candidates. Replacement of our current
manufacturing capabilities may have a material adverse effect on our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are dependent upon third-party service providers.
If such third-party service providers fail to maintain a high quality of service, the utility of our products could be impaired,
which could adversely affect the penetration of our products, our business, operating results and reputation. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The success of certain services and products
that we provide are dependent upon third-party service providers. Such service providers include manufacturers of proprietary custom
components for our ART500. As we expand our commercial activities, an increased burden will be placed upon the quality of such third-party
providers. If third-party providers fail to maintain a high quality of service, our products, business, reputation and operating results
could be adversely affected. In addition, poor quality of service by third-party service providers could result in liability claims and
litigation against us for damages or injuries. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We expect to be exposed to fluctuations in currency exchange
rates, which could adversely affect our results of operations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We incur expenses
mainly in NIS and U.S. dollars, but our financial statements are denominated in U.S. dollars. Accordingly, we face exposure to
adverse movements in currency exchange rates. Our foreign operations will be exposed to foreign exchange rate fluctuations as
the financial results are translated from the functional currency into U.S. dollars. Specifically, the U.S. dollar cost of our
operations in Israel is influenced by any movements in the currency exchange rate of the NIS. Such movements in the currency exchange
rate may have a negative effect on our financial results. If the U.S. dollar weakens against foreign currencies, the translation
of these foreign currency denominated transactions will result in increased operating expenses and net losses. Similarly, if the
U.S. dollar strengthens against foreign currencies, the translation of these foreign currency denominated transactions will result
in decreased operating expenses and net losses. As exchange rates vary, sales and other operating results, when translated, may
differ materially from our or the capital market&rsquo;s expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Non-U.S. governments often impose strict price controls,
which may adversely affect our future profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">We
may be subject to rules and regulations in the United States and non-U.S. jurisdictions relating to our ART500 or any future products.
In some countries, including countries of the European Union, or the EU, each of which has developed its own rules and regulations, pricing
may be subject to governmental control under certain circumstances. In these countries, pricing negotiations with governmental agencies
can take considerable time after the receipt of marketing approval for a medical device candidate. To obtain reimbursement or pricing
approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other
available products.<B>&nbsp;</B>If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, we may be unable to achieve or sustain profitability.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>We manage our business through
a small number of employees and key consultants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of June 25, 2021, we had twelve full-time
employees, three part-time employees, three independent contractors and four consultants. Our future growth and success depend to a large
extent on the continued services of members of our current management including, in particular, Dagi Ben-Noon, our Chief Executive Officer,
Joe Hayon, our President and Chief Financial Officer and Dr. Udi Nussinovitch, our Chief Scientific Officer. Any of our employees and
consultants may leave our company at any time, subject to certain notice periods. The loss of the services of any of our executive officers
or any key employees or consultants would adversely affect our ability to execute our business plan and harm our operating results. Our
operational success will substantially depend on the continued employment of senior executives, technical staff and other key personnel.
The loss of key personnel may have an adverse effect on our operations and financial performance. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I></I></B></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>We may need to expand our organization
and we may experience difficulties in recruiting needed additional employees and consultants, which could disrupt our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As our development and commercialization
plans and strategies develop and because we are leanly staffed, we may need additional managerial, operational, sales, marketing,
financial, legal and other resources. The competition for qualified personnel in the medical device industry is intense. Due to
this intense competition, we may be unable to attract and retain qualified personnel necessary for the development of our business
or to recruit suitable replacement personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our management may need to divert its attention
away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be
able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational
mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth
could require significant capital expenditures and may divert financial resources from other projects, such as the development
of additional medical device products. If our management is unable to effectively manage our growth, our expenses may increase
more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business
strategy. Our future financial performance and our ability to commercialize medical device products and services and compete effectively
will depend, in part, on our ability to effectively manage any future growth.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>International expansion of our business exposes us to
business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United
States or Israel.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other than our headquarters and other operations
which are located in Israel (as further described below), our business strategy incorporates significant international expansion,
particularly in anticipated expansion of regulatory approvals of our products. Doing business internationally involves a number
of risks, including but not limited to:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple, conflicting and changing laws and
    regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements
    and other governmental approvals, permits and licenses;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us to obtain regulatory approvals
    for the use of our products and services in various countries;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional potentially relevant third-party
    patent rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities and difficulties in obtaining protection
    and enforcing our intellectual property;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in staffing and managing foreign
    operations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities associated with managing multiple
    regulatory, governmental and reimbursement regimes;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits in our ability to penetrate international
    markets;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial risks, such as longer payment cycles,
    difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our
    products and exposure to foreign currency exchange rate fluctuations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural disasters, political and economic instability,
    including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain expenses including, among others, expenses
    for travel, translation and insurance; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory and compliance risks that relate
    to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign
    Corrupt Practices Act, or the FCPA, its books and records provisions or its anti-bribery provisions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Any of these factors
could significantly harm our future international expansion and operations and, consequently, our results of operations.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We face intense competition in the market, and as a result
we may be unable to effectively compete in our industry.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The major market players within the respiratory
care market and our primary competitors in the United States include Boston Scientific Corporation (NYSE: BSX), ResMed Inc., (NYSE: RMD),
Masimo Corporation (Nasdaq: MASI), Becton, Dickinson and Company (NYSE: BDX), Chart Industries, Inc. (Nasdaq: GTLS). Other competitors
outside the United states include Philips Healthcare, headquartered in the Netherlands, Medtronic plc, headquartered in Ireland (NYSE:
MDT), Fisher &amp; Paykel Healthcare Corporation Limited, headquartered in New Zealand, Dr&auml;gerwerk AG &amp; Co. KGaA, Dr&auml;gerwerk
AG, headquartered in Germany, Hamilton Medical AG, headquartered in Switzerland, Smiths Medical Inc., headquartered in Minnesota, the
United States, Siemens Healthineers AG ADR (Nasdaq: SMMNY), headquartered in Germany, Baxter International (NYSE: BAX), headquartered
in Illinois, the United States, Getinge, headquartered in Sweden, GE Healthcare, headquartered in Illinois, the United States and Terumo
Corporation (TYO: 4543, Nikkei 225 Component), headquartered in Shibuya City, Tokyo, Japan. Some of these companies hold significant
market share. Their dominant market position and significant control over the market could significantly limit our ability to introduce
or effectively market and generate sales of our ART500. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many of our competitors have long histories
and strong reputations within the industry. They have significantly greater brand recognition, financial and human resources than
we do. They also have more experience and capabilities in researching and developing testing devices, obtaining and maintaining
regulatory clearances and other requirements, manufacturing and marketing those products than we do. There is a significant risk
that we may be unable to overcome the advantages held by our competition, and our inability to do so could lead to the failure
of our business and the loss of your investment. In addition, we may be unable to develop additional products in the future or
to keep pace with developments and innovations in the market and lose market share to our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Competition in the medical devices and more
specifically respiratory support technologies and solutions markets is intense, which can lead to, among other things, price reductions,
longer selling cycles, lower product margins, loss of market share and additional working capital requirements. To succeed, we must,
among other critical matters, gain consumer acceptance for our ART500, as compared to other solutions currently available in the market
for the treatment of respiratory failure and potential future medical devices incorporating our principal technology or offering other
advanced respiratory support solutions. If our competitors offer significant discounts on certain products and solutions, we may need
to lower our prices or offer other favorable terms in order to compete successfully. Moreover, any broad-based changes to our prices
and pricing policies could make it difficult to generate revenues or cause our revenues to decline. Moreover, if our competitors develop
and commercialize products and solutions that are more effective or desirable than products and solutions that we may develop, we may
not convince our customers to use our products and solutions. Any such changes would likely reduce our commercial opportunity and revenue
potential and could materially adversely impact our operating results. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>If third-party payors do not provide adequate coverage and
reimbursement for the use of our ART500 or any future products, our revenue will be negatively impacted.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our ART500 is not yet approved for third-party
payor coverage or reimbursement. Such reimbursement may vary based on the particular device used in providing services and is based on
the identity of the third-party. Our ability to maintain a leading position in the medical device market, and specifically in the respiratory
care market, depends on our relationships with private third parties. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> We expect to engage
with private third parties to allow our customers to receive reimbursement from insurance companies for our ART500. The loss of a significant
number of private third-party contracts may have an adverse effect on our revenues, which could have an adverse effect on our business,
financial condition and results of operations. Over the past few years, reimbursement rates from certain third parties have declined,
in some cases significantly. There can be no assurance that this trend will not continue or apply on more third parties. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, private
third parties may not reimburse any new products offered by us or reimburse those new products at commercially viable rates. The
failure to receive reimbursement at adequate levels for our existing or future products may adversely affect demand for those
products, our revenues and expected growth. This could have an adverse effect on our business, financial condition and results
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be subject to litigation for a variety of claims,
which could adversely affect our results of operations, harm our reputation or otherwise negatively impact our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may be subject to litigation for a variety
of claims arising from our normal business activities. These may include claims, suits, and proceedings involving labor and employment,
wage and hour, commercial and other matters. The outcome of any litigation, regardless of its merits, is inherently uncertain.
Any claims and lawsuits, and the disposition of such claims and lawsuits, could be time-consuming and expensive to resolve, divert
management attention and resources, and lead to attempts on the part of other parties to pursue similar claims. Any adverse determination
related to litigation could adversely affect our results of operations, harm our reputation or otherwise negatively impact our
business. In addition, depending on the nature and timing of any such dispute, a resolution of a legal matter could materially
affect our future operating results, our cash flows or both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Changes in financial accounting standards may cause adverse
and unexpected revenue fluctuations and impact our results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A change in accounting standards or practices
could harm our operating results. New accounting pronouncements and varying interpretations of accounting pronouncements have
occurred and may occur in the future. Changes to existing rules or the questioning of current practices may harm our operating
results or the way we conduct our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>We could become subject to product
liability, warranty or similar claims and product recalls that could be expensive, divert management&rsquo;s attention and harm
our business reputation and financial results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business exposes us to an inherent
risk of potential product liability, warranty or similar claims and product recalls. The medical device industry has historically
been litigious, and we face financial exposure to product liability, warranty or similar claims if the use of any of our products
were to cause or contribute to injury or death. There is also the possibility that defects in the design or manufacture of any
of our products might necessitate a product recall. Although we plan to maintain product liability insurance, the coverage limits
of these policies may not be adequate to cover future claims. In the future, we may be unable to maintain product liability insurance
on acceptable terms or at reasonable costs and such insurance may not provide us with adequate coverage against potential liabilities.
A product liability claim, regardless of merit or ultimate outcome, or any product recall could result in substantial costs to
us, damage to our reputation, customer dissatisfaction and frustration and a substantial diversion of management attention. A
successful claim brought against us in excess of, or outside of, our insurance coverage could have a material adverse effect on
our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our business may be impacted by changes in general economic
conditions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business is subject to risks arising
from changes in domestic and global economic conditions, including adverse economic conditions in markets in which we operate,
which may harm our business. For example, the current COVID-19 pandemic has caused significant volatility and uncertainty in U.S.
and international markets. If our future customers significantly reduce spending in areas in which our technology and products
are utilized, or prioritize other expenditures over our technology and products, our business, financial condition, results of
operations and prospects would be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Disruption to the global economy could
also result in a number of follow-on effects on our business, including a possible slow-down resulting from lower customer expenditures;
inability of customers to pay for products, solutions or services on time, if at all; more restrictive export regulations which
could limit our potential customer base; negative impact on our liquidity, financial condition and share price, which may impact
our ability to raise capital in the market, obtain financing and secure other sources of funding in the future on terms favorable
to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the occurrence of catastrophic
events, such as hurricanes, storms, earthquakes, tsunamis, floods, medical epidemics and other catastrophes that adversely affect
the business climate in any of our markets could have a material adverse effect on our business, financial condition and results
of operations. Some of our operations are located in areas that have been in the past, and may be in the future, susceptible to
such occurrences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our management team has limited experience managing a
public company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Most members of our management team have
limited experience managing a publicly traded company, interacting with public company investors and complying with the increasingly
complex laws pertaining to public companies in the United States. Our management team may not successfully or efficiently manage
our transition to being a public company subject to significant regulatory oversight and reporting obligations under the U.S.
federal securities laws and the continuous scrutiny of securities analysts and investors. These new obligations and constituents
will require significant attention from our senior management and could divert their attention away from the day-to-day management
of our business, which could adversely affect our business, financial condition, results of operations and prospects.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>Risks Related
to Product Development and Regulatory Approval</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Our product candidate and operations are subject to extensive
government regulation and oversight both in the United States and abroad, and our failure to comply with applicable requirements could
harm our business.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We expect our ART500 and any future products
we develop to be regulated by the FDA as medical devices. Our product candidate is subject to extensive regulation in the United States
and elsewhere, including by the FDA and its foreign counterparts, the U.S. Department of Justice, or the DOJ, and the U.S. Health and
Human Services-Office of the Inspector General, or the HHS. The FDA and foreign regulatory agencies regulate, among other things, with
respect to medical devices: design, development and manufacturing; testing, labeling, content and language of instructions for use and
storage; clinical trials; product safety; establishment registration and device listing; marketing, sales and distribution; pre-market
clearance and approval; conformity assessment procedures; record keeping procedures; advertising and promotion; recalls and field safety
corrective actions; post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to
occur, could lead to death or serious injury; post-market approval studies; and product import and export. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The regulations our product candidate is subject
to are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability to
carry on or expand our operations, higher than anticipated costs or lower than anticipated sales for any approved product. Failure to
comply with applicable regulations could jeopardize our ability to sell our future products, if cleared or approved, and result in enforcement
actions such as: warning or untitled letters; fines; injunctions; consent decrees; civil penalties; customer notifications; termination
of distribution; recalls or seizures of products; administrative detention of medical devices believed to be adulterated or misbranded;
delays in the introduction of products into the market; operating restrictions; total or partial suspension of production; refusal to
grant future clearances or approvals for new products, new intended uses or modifications to our products; withdrawals or suspensions
of current approvals, resulting in prohibitions on sales of our products; and in the most serious cases, criminal prosecution or penalties.
The occurrence of any of these events would have a material adverse effect on our business, financial condition and results of operations
and could result in shareholders losing their entire investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>We may not receive, or may be delayed in receiving, the necessary
clearances or approvals for our ART500 or future products, and failure to timely obtain necessary clearances or approvals for our ART500
or future products would adversely affect our ability to grow our business.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the United States, before we can market
a new medical device, or a new use of, new claim for or significant modification to an existing product, we must first receive
either clearance under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, or the FDCA, or approval of a pre-market approval
application, or a PMA, from the FDA, unless an exemption applies. In the 510(k) clearance process, before a device may be marketed,
the FDA must determine that a proposed device is &ldquo;substantially equivalent&rdquo; to a legally-marketed &ldquo;predicate&rdquo;
device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed
prior to May&nbsp;28, 1976 (pre-amendments device), a device that was originally on the U.S. market pursuant to an approved PMA
and later down-classified, or a 510(k)-exempt device. To be &ldquo;substantially equivalent,&rdquo; the proposed device must have
the same intended use as the predicate device, and either have the same technological characteristics as the predicate device
or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate
device. Clinical data are sometimes required to support substantial equivalence. In the process of obtaining PMA approval, the
FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including,
but not limited to, technical, pre-clinical, clinical trial, manufacturing and labeling data. The PMA process is typically required
for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Modifications to products that are approved
through a PMA application generally require FDA approval. Similarly, certain modifications made to products cleared through a
510(k) may require a new 510(k) clearance. Both the PMA approval and the 510(k) clearance process can be expensive, lengthy and
uncertain. The FDA&rsquo;s 510(k) clearance process usually takes from three to 12 months, but can last longer. The process of
obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years,
or even longer, from the time the application is submitted to the FDA. In addition, a PMA generally requires the performance of
one or more clinical trials. Despite the time, effort and cost, a device may not be approved or cleared by the FDA. Any delay
or failure to obtain necessary regulatory clearances or approvals could harm our business. Furthermore, even if we are granted
regulatory clearances or approvals, they may include significant limitations on the indicated uses for the device or other restrictions
or requirements, which may limit the market for the device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In the United States, we expect to take a multi-step
approach to the regulatory clearance process. As a first step, we intend to submit a 510(k) application for our ART500 to an accredited
Review Organization under the Third Party Review Program. The review process is an iterative process and may be more costly and time
consuming than we expect and we may not ultimately be successful in completing the review process and our 510(k) application may not
be cleared by the FDA in a timely manner or at all. If cleared, any modification to our ART500 that has not been previously cleared may
require us to submit a new 510(k) premarket notification and obtain clearance, or submit a PMA and obtain FDA approval prior to implementing
the change. Specifically, any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or
that would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval
of a PMA. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer&rsquo;s
decision. The FDA may not agree with our decisions regarding whether new clearances or approvals are necessary. We may make modifications
or add additional features in the future that we believe do not require a new 510(k) clearance or approval of a PMA. If the FDA disagrees
with our determination and requires us to submit new 510(k) notifications or PMA applications for modifications to our previously cleared
products for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall
the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties. If the
FDA requires us to go through a lengthier, more rigorous examination for future products or modifications to existing products than we
had expected, product introductions or modifications could be delayed or canceled, which could adversely affect our ability to grow our
business. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA can delay, limit or deny clearance or approval of a
medical device for many reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to demonstrate to the satisfaction
    of the FDA or the applicable regulatory entity or notified body that our product candidates are safe or effective for their
    intended uses;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the disagreement of the FDA or the applicable
    foreign regulatory body with the design or the interpretation of data from pre-clinical studies or clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious and unexpected adverse effects experienced
    by participants in our clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the data from our pre-clinical studies and clinical
    trials may be insufficient to support clearance or approval, where required;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to demonstrate that the clinical
    and other benefits of the device outweigh the risks;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the manufacturing process or facilities we use
    may not meet applicable requirements; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential for approval policies or regulations
    of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory
    filings insufficient for clearance or approval.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to sell our products in member
countries of the European Economic Area, or EEA, our products must comply with the essential requirements of the EU Medical Devices
Directive (Council Directive 93/42/EEC). Compliance with these requirements is a prerequisite to be able to affix the Conformit&eacute;
Europ&eacute;ene, or CE, mark to our products, without which they cannot be sold or marketed in the EEA. To demonstrate compliance
with the essential requirements we must undergo a conformity assessment procedure, which varies according to the type of medical
device and its classification. Except for low-risk medical devices (Class&nbsp;I non-sterile, non-measuring devices), where the
manufacturer can issue a European Community, or EC, Declaration of Conformity based on a self-assessment of the conformity of its
products with the essential requirements of the EU Medical Devices Directive, a conformity assessment procedure requires the intervention
of an organization accredited by a member state of the EEA to conduct conformity assessments, or a Notified Body. Depending on
the relevant conformity assessment procedure, the Notified Body would typically audit and examine the technical file and the quality
system for the manufacture, design and final inspection of our devices. The Notified Body issues a certificate of conformity following
successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer and
their conformity with the essential requirements. This certificate entitles the manufacturer to affix the CE mark to its medical
devices after having prepared and signed a related EC Declaration of Conformity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a general rule, demonstration of conformity
of medical devices and their manufacturers with the essential requirements must be based, among other things, on the evaluation
of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer
must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable
risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and
that any claims made about the performance and safety of the device are supported by suitable evidence. If we fail to remain in
compliance with applicable European laws and directives, we would be unable to continue to affix the CE mark to our products, which
would prevent us from selling them within the EEA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Failure to comply with post-marketing regulatory requirements
could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product
from the market.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> If we receive regulatory clearance or approval
of the ART500 or other future products, we will remain subject to ongoing and pervasive regulatory requirements governing, among other
things, the manufacture, marketing, advertising, medical device reporting, sale, promotion, import, export, registration, and listing
of devices. For example, we will be required to submit periodic reports to the FDA as a condition of 510(k)&nbsp;clearance. These reports
include information about failures and certain adverse events associated with the device after its clearance. Failure to submit such
reports, or failure to submit the reports in a timely manner, could result in enforcement action by the FDA. Following its review of
the periodic reports, the FDA might ask for additional information or initiate further investigation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The regulations to which we are subject
are complex and have become more stringent over time. Regulatory changes could result in restrictions on our ability to continue
or expand our operations, higher than anticipated costs, or lower than anticipated sales. Even after we have obtained the proper
regulatory clearance to market a device, we have ongoing responsibilities under FDA regulations and applicable foreign laws and
regulations. The FDA, state and foreign regulatory authorities have broad enforcement powers. Our failure to comply with applicable
regulatory requirements could result in enforcement action by the FDA, state or foreign regulatory authorities, which may include
any of the following sanctions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled letters or warning letters;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, injunctions, consent decrees and civil penalties;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls, termination of distribution, administrative detention, or seizure of our products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer notifications or repair, replacement or refunds;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating restrictions or partial suspension or total shutdown of production;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in or refusal to grant our requests for future clearances or approvals or foreign marketing authorizations of new products, new intended uses, or modifications to existing products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawals or suspensions of product clearances or approvals, resulting in prohibitions on sales of our products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal prosecution.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of these sanctions could result in higher
than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business, financial
condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the FDA or state or foreign
authorities may change their clearance and approval policies, adopt additional regulations or revise existing regulations, or take
other actions, which may prevent or delay clearance or approval of our future products under development on a timely basis. Such
policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain new clearances
or approvals, increase the costs of compliance or restrict our ability to maintain any approvals we are able to obtain. For example,
the FDA recently announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under
Section 510(k) of the FDCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our products must be manufactured in accordance with federal,
state and foreign regulations, and we could be forced to recall our devices or terminate production if we fail to comply with these
regulations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The methods used in, and the facilities
used for, the manufacture of our products must comply with the Quality System Regulation, or QSR, which is a complex regulatory
scheme that covers the procedures and documentation of the design, testing, production, process controls, quality assurance, labeling,
packaging, handling, storage, distribution, installation, servicing and shipping of medical devices. As manufacturers of electron
radiation-emitting products, we are also responsible for compliance with the radiological health regulations and certain radiation
safety performance standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, we are required to verify that
our suppliers maintain facilities, procedures and operations that comply with our quality standards and applicable regulatory requirements.
The FDA enforces the QSR through periodic announced or unannounced inspections of medical device manufacturing facilities, which
may include the facilities of subcontractors. Our products are also subject to similar state regulations and various laws and regulations
of foreign countries governing manufacturing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our third-party manufacturers may not take
the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our products. In addition,
failure to comply with applicable FDA or state or foreign requirements or later discovery of previously unknown problems with our
products or manufacturing processes could result in, among other things: warning letters or untitled letters; fines, injunctions
or civil penalties; suspension or withdrawal of approvals; seizures or recalls of our products; total or partial suspension of
production or distribution; administrative or judicially imposed sanctions; the FDA&rsquo;s refusal to grant pending or future
clearances or approvals for our products; clinical holds; refusal to permit the import or export of our products; and criminal
prosecution of us, our suppliers or our employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of these actions could significantly
and negatively affect supply of our products. If any of these events occurs, our reputation could be harmed, we could be exposed
to product liability claims and we could lose customers and experience reduced sales and increased costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The misuse or off-label use of our products may harm our
reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines
or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly
to our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Advertising and promotion of our future
products that obtains approval in the United States may be heavily scrutinized by the FDA, the DOJ, HHS, state attorneys general,
members of Congress, and the public. In addition, advertising and promotion of any future product that obtains approval outside
of the United States will be heavily scrutinized by comparable foreign regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We expect that, if cleared or approved, our
products, including the ART500, will be cleared by the requisite regulatory authorities for specific indications. We expect to train
our marketing personnel and direct sales force to not promote our devices for uses outside of the FDA-approved indications for use, known
as &ldquo;off-label uses.&rdquo; We cannot, however, prevent a physician from using our devices off-label, when in the physician&rsquo;s
independent professional medical judgment he or she deems it appropriate. There may be increased risk of injury to patients if physicians
attempt to use our devices off-label. Furthermore, the use of our devices for indications other than those approved by the FDA or approved
by any foreign regulatory body may not effectively treat such conditions, which could harm our reputation in the marketplace among healthcare
providers and patients. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the FDA or any state or foreign regulatory
body determines that our promotional materials or training constitute promotion of an off-label use, it could request that we modify
our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance or imposition
of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine or
criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action under other
regulatory authority, such as false claims laws, if they consider our business activities to constitute promotion of an off-label
use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties,
damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations.
We may become subject to such actions and, if we are not successful in defending against such actions, those actions may have a
material adverse effect on our business, financial condition and results of operations. Equivalent laws and potential consequences
exist in foreign jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, if our products are cleared
or approved, healthcare providers may misuse our products or use improper techniques if they are not adequately trained, potentially
leading to injury and an increased risk of product liability. If our devices are misused or used with improper technique, we may
become subject to costly litigation by our customers or their patients. As described above, product liability claims could divert
management&rsquo;s attention from our core business, be expensive to defend and result in sizeable damage awards against us that
may not be covered by insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our products may cause or contribute to adverse medical
events or be subject to failures or malfunctions that we are required to report to the FDA, and if we fail to do so, we would be
subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of
serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another
governmental authority, could have a negative impact on us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> If our ART500 or our other future products
receive clearance or approval, we will be subject to the FDA&rsquo;s medical device reporting regulations and similar foreign regulations,
which require us to report to the FDA when we receive or become aware of information that reasonably suggests that one or more of our
products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur,
could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date we become aware
of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed
timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to
us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to
comply with our reporting obligations, the FDA or other regulatory bodies could take action, including warning letters, untitled letters,
administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance or approval,
seizure of our products or delay in clearance or approval of future products. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA and foreign regulatory bodies have
the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture
of a product or in the event that a product poses an unacceptable risk to health. The FDA&rsquo;s authority to require a recall
must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also
choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us could
occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design
deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other
errors may occur in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Depending on the corrective action we take
to redress a product&rsquo;s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new clearances
or approvals for the device before we may market or distribute the corrected device. Seeking such clearances or approvals may delay
our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with
our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions,
administrative penalties or civil or criminal fines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Companies are required to maintain certain
records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections
for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations,
it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement
could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales.
Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication
of our time and capital, distract management from operating our business and may harm our reputation and financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>We may be subject, directly or
indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security
laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many federal, state
and foreign healthcare laws and regulations apply to medical devices. We may be subject to certain federal and state regulations,
including the federal healthcare programs&rsquo; Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully
soliciting, offering, receiving, or paying any remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing,
ordering or arranging for or recommending the purchase or order of any item or service for which payment may be made, in whole
or in part, under a federal healthcare program such as Medicare and Medicaid; the federal Health Insurance Portability and Accountability
Act of 1996, or HIPAA, which imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute,
a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material
fact or making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or
services; the federal Civil Monetary Penalties Law, which authorizes the imposition of substantial civil monetary penalties against
an entity that engages in activities including, among others (1) knowingly presenting, or causing to be presented, a claim for
services not provided as claimed or that is otherwise false or fraudulent in any way; (2) arranging for or contracting with an
individual or entity that is excluded from participation in federal healthcare programs to provide items or services reimbursable
by a federal healthcare program; (3) violations of the federal Anti-Kickback Statute; or (4) failing to report and return a known
overpayment; the federal False Statements Statute, which prohibits knowingly and willfully falsifying, concealing, or covering
up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any
false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry, in connection
with the delivery of or payment for healthcare benefits, items, or services; the federal civil False Claims Act, or the FCA, which
prohibits, among other things, knowingly presenting, or causing to be presented claims for payment of government funds that are
false or fraudulent, or knowingly making, using or causing to be made or used a false record or statement material to such a false
or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay
money to the federal government; and other federal and state false claims laws. The FCA prohibits anyone from knowingly presenting,
conspiring to present, making a false statement in order to present, or causing to be presented, for payment to federal programs
(including Medicare and Medicaid) claims for items or services that are false or fraudulent, claims for items or services not provided
as claimed, or claims for medically unnecessary items or services. This law also prohibits anyone from knowingly underpaying an
obligation owed to a federal program. Increasingly, U.S. federal agencies are requiring nonmonetary remedial measures, such as
corporate integrity agreements in FCA settlements. The DOJ announced in 2016 its intent to follow the &ldquo;Yates
Memo,&rdquo; taking a far more aggressive approach in pursuing individuals as FCA defendants in addition to corporations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The majority of
states also have statutes similar to the federal Anti-Kickback Statute and false claims laws that apply to items and services reimbursed
under Medicaid and other state programs, or, in several states, that apply regardless of whether the payer is a government entity
or a private commercial entity. The Federal Open Payments, or Physician Payments Sunshine Act, program requires manufacturers of
products for which payment is available under Medicare, Medicaid or the State Children&rsquo;s Health Insurance Program, to track
and report annually to the federal government (for disclosure to the public) certain payments and other transfers of value made
to physicians and teaching hospitals as well as disclosure of payments and other transfers of value provided to physicians and
teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate
family members and applicable group purchasing organizations. Our failure to appropriately track and report payments to the government
could result in civil fines and penalties, which could adversely affect the results of our operations. In addition, several U.S.
states and localities have enacted legislation requiring medical device companies to establish marketing compliance programs, file
periodic reports with the state, and/or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other
activities. Other state laws prohibit certain marketing-related activities including the provision of gifts, meals or other items
to certain healthcare providers. Many of these laws and regulations contain ambiguous requirements that government officials have
not yet clarified. Given the lack of clarity in the laws and their implementation, our reporting actions could be subject to the
penalty provisions of the pertinent federal and state laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The medical device industry has been under
heightened scrutiny as the subject of government investigations and enforcement actions involving manufacturers who allegedly offered
unlawful inducements to potential or existing customers in an attempt to procure their business, including arrangements with physician
consultants. If our operations or arrangements are found to be in violation of such governmental regulations, we may be subject
to civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs and the curtailment of our operations.
All of these penalties could adversely affect our ability to operate our business and our financial results.<B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we do not obtain and maintain international regulatory
registrations, clearances or approvals for our products, we will be unable to market and sell our products outside of the United
States.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sales of our products outside of the United
States are subject to foreign regulatory requirements that vary widely from country to country. Approval procedures vary among
countries and can involve additional testing. The time required to obtain approval outside of the United States may differ substantially
from that required to obtain FDA approval. In addition, the FDA regulates exports of medical devices from the United States. While
the regulations of some countries may not impose barriers to marketing and selling our products or only require notification, others
require that we obtain the clearance or approval of a specified regulatory body. Complying with foreign regulatory requirements,
including obtaining registrations, clearances or approvals, can be expensive and time-consuming, and we may not receive regulatory
clearances or approvals in each country in which we plan to market our products or we may be unable to do so on a timely basis.
The time required to obtain registrations, clearances or approvals, if required by other countries, may be longer than that required
for FDA clearance or approval, and requirements for such registrations, clearances or approvals may significantly differ from FDA
requirements. If we modify our products, we may need to apply for additional regulatory clearances or approvals before we are permitted
to sell the modified product. In addition, we may not continue to meet the quality and safety standards required to maintain the
authorizations that we have received. If we are unable to maintain our authorizations in a particular country, we will no longer
be able to sell the applicable product in that country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regulatory clearance or approval by the
FDA does not ensure registration, clearance or approval by regulatory authorities in other countries, and registration, clearance
or approval by one or more foreign regulatory authorities does not ensure registration, clearance or approval by regulatory authorities
in other foreign countries or by the FDA. However, a failure or delay in obtaining registration or regulatory clearance or approval
in one country may have a negative effect on the regulatory process in others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Legislative or regulatory reforms in the United States
or the European Union may make it more difficult and costly for us to obtain regulatory clearances or approvals for our products
or to manufacture, market or distribute our products after clearance or approval is obtained.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From time to time, legislation is drafted
and introduced in Congress that could significantly change the statutory provisions governing the regulation of medical devices.
In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations,
or take other actions, which may prevent or delay approval or clearance of our future products under development or impact our
ability to modify our currently cleared products on a timely basis. Over the last several years, the FDA has proposed reforms to
its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period,
or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in November
2018, FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under
Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing
the 510(k)&nbsp;pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older
devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have
been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10&nbsp;years old. In
May 2019, the FDA solicited public feedback on these proposals. The FDA requested public feedback on whether it should consider
certain actions that might require new authority, such as whether to sunset certain older devices that were used as predicates
under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may work with Congress
to implement such proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted, could
impose additional regulatory requirements on us that could delay our ability to obtain new 510(k) clearances, increase the costs
of compliance, or restrict our ability to maintain our current clearances, or otherwise create competition that may negatively
affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">More recently, in September 2019, the FDA
finalized guidance describing an optional &ldquo;safety and performance based&rdquo; premarket review pathway for manufacturers
of &ldquo;certain, well-understood device types&rdquo; to demonstrate substantial equivalence under the 510(k) clearance pathway
by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need
for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance
process. The FDA intends to develop and maintain a list device types appropriate for the &ldquo;safety and performance based&rdquo;
pathway and will continue to develop product-specific guidance documents that identify the performance criteria for each such device
type, as well as the testing methods recommended in the guidance documents, where feasible. The FDA may establish performance criteria
for classes of devices for which we or our competitors seek or currently have received clearance, and it is unclear the extent
to which such performance standards, if established, could impact our ability to obtain new 510(k) clearances or otherwise create
competition that may negatively affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, FDA regulations and guidance
are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new statutes,
regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any
future products or make it more difficult to obtain clearance or approval for, manufacture, market or distribute our products.
We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted
or adopted may have on our business in the future. Such changes could, among other things, require: additional testing prior to
obtaining clearance or approval; changes to manufacturing methods; recall, replacement or discontinuance of our products; or additional
record keeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA&rsquo;s and other regulatory authorities&rsquo;
policies may change and additional government regulations may be promulgated that could prevent, limit or delay regulatory clearance
or approval of our future products. We cannot predict the likelihood, nature or extent of government regulation that may arise
from future legislation or administrative action, either in the United States or abroad. For example, certain policies of the Trump
administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including
the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA&rsquo;s
ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review
and approval of marketing applications. It is difficult to predict how these executive actions will be implemented, and the extent
to which they will impact the FDA&rsquo;s ability to exercise its regulatory authority. If these executive actions impose restrictions
on the FDA&rsquo;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively
impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies,
or if we are not able to maintain regulatory compliance, we may lose any marketing approval or clearance that we may have obtained
and we may not achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April&nbsp;5, 2017, the European Parliament
passed the Medical Devices Regulation (Regulation 2017/745), which repeals and replaces the EU Medical Devices Directive. Unlike
directives, which must be implemented into the national laws of the EEA member states, the regulations would be directly applicable,
i.e., without the need for adoption of EEA member state laws implementing them, in all EEA member states and are intended to eliminate
current differences in the regulation of medical devices among EEA member States. The Medical Devices Regulation, among other things,
is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices
and ensure a high level of safety and health while supporting innovation. Among other things, the Medical Devices Regulation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthen the rules on placing devices on the market and reinforce surveillance once they are available;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish explicit provisions on manufacturers&rsquo; responsibilities for follow-up regarding the quality, performance and safety of devices placed on the market;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthened rules for the assessment of certain high-risk devices, which may have to undergo an additional check by experts before they are placed on the market.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These modifications may have an effect on
the way we conduct our business in the EEA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Healthcare legislative and regulatory reform measures
may have a material adverse effect on our business and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
industry is highly regulated and changes in law may adversely impact our business, operations or financial results. The Patient
Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the PPACA, is a sweeping
measure intended to, among other things, expand healthcare coverage within the United States, primarily through the imposition
of health insurance mandates on employers and individuals and expansion of the Medicaid program. Several provisions of the law
may affect us and increase certain of our costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, other legislative changes have
been adopted since the PPACA was enacted. These changes include aggregate reductions in Medicare payments to providers of 2% per
fiscal year, which went into effect on April 1, 2013 and, following passage of the Bipartisan Budget Act of 2018, will remain in
effect through 2027 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American
Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several types of providers and increased
the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws
may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our
customers and, accordingly, our financial operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We anticipate that the PPACA, as well as other
healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and an additional downward
pressure on the reimbursement our customers may receive for our products. Further, there have been, and there may continue to be, judicial
and Congressional challenges to certain aspects of the PPACA. For example, the U.S. Tax Cuts and Jobs Act of 2017, or TCJA, includes
a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals
who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &ldquo;individual mandate.&rdquo;
Additional legislative and regulatory changes to the PPACA, its implementing regulations and guidance and its policies, remain possible
in Congress and under the Biden administration. However, it remains unclear how any new legislation or regulation might affect the prices
we may obtain for any of our product candidates for which regulatory approval is obtained. Any reduction in reimbursement from Medicare
and other government programs may result in a similar reduction in payments from private payers. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In addition, the delivery of healthcare in
the European Union, including the establishment and operation of health services, is almost exclusively a matter for national, rather
than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of
health care and the pricing and reimbursement of products in that context. Coupled with ever-increasing EU and national regulatory burdens
on those wishing to develop and market products, this could prevent or delay marketing approval of our ART500 or any future product candidates,
restrict or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are currently unable to predict what
additional legislation or regulation, if any, relating to the health care industry may be enacted in the future or what effect
recently enacted federal legislation or any such additional legislation or regulation would have on our business. The pendency
or approval of such proposals or reforms could result in a decrease in the price of our Ordinary Shares or limit our ability to
raise capital or to enter into collaboration agreements for the further development and potential commercialization of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Disruptions at the FDA and other government agencies caused
by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel,
or otherwise prevent new or modified products from being developed, cleared or approved or commercialized in a timely manner or
at all, which could negatively impact our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ability of the FDA to review and clear
or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory,
and policy changes, the FDA&rsquo;s ability to hire and retain key personnel and accept the payment of user fees, and other events
that may otherwise affect the FDA&rsquo;s ability to perform routine functions. Average review times at the FDA have fluctuated
in recent years as a result. In addition, government funding of other government agencies that fund research and development activities
is subject to the political process, which is inherently fluid and unpredictable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Disruptions at the FDA and other agencies
may also slow the time necessary for new medical devices or modifications to cleared or approved medical devices to be reviewed
and/or approved by necessary government agencies, which would adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Separately, in response to the COVID-19
pandemic, on March&nbsp;10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities,
and on March&nbsp;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities.
Subsequently, on July&nbsp;10, 2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing
facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify
the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections
to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or
other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns
continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory
activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our
regulatory submissions, which could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>Risks Related
to Our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are unable to obtain and maintain effective patent
rights for our products and services, we may not be able to compete effectively in our markets. If we are unable to protect the
confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our success and future revenue growth will
depend, in part, on our ability to protect our patent rights. In addition to the protection afforded by any patents that may be
granted, historically, we have relied on trade secret protection and confidentiality agreements with our employees, consultants,
and contractors to protect proprietary know-how that is not patentable or that we elect not to patent, processes that are not easily
known, knowable or easily ascertainable, and for which patent infringement is difficult to monitor and enforce and any other elements
of our product candidate discovery and development processes that involve proprietary know-how, information or technology that
is not covered by patents. However, agreements may be breached, trade secrets may be difficult to protect, and we may not receive
adequate remedies for any breach. In addition, our trade secrets and intellectual property may otherwise become known or be independently
discovered by competitors or other unauthorized third parties.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There is no guarantee that the patent registration
applications that we submitted with regards to our technologies will result in patent registration. In the event of failure to
complete patent registration, our developments will not be proprietary, which might allow other entities to manufacture our products
or design our services and compete with them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT>Further,
there is no assurance that all potentially relevant prior art relating to our patent applications has been found, which can invalidate
a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if
such patents cover our products or services, third parties may challenge their validity, enforceability, or scope, which may result
in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patent applications
and any future patents may not adequately protect our intellectual property, products or services and provide exclusivity for our
new products or services or prevent others from designing around our claims. </FONT>Furthermore, there is no guarantee that third
parties will not infringe or misappropriate our patents or similar proprietary rights. In addition, there can be no assurance that
we will not have to pursue litigation against other parties to assert its rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT>Any
of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we cannot obtain and maintain effective
patent rights for our products and services, we may not be able to compete effectively, and our business and results of operations
would be harmed.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We cannot provide
any assurances that our trade secrets and other confidential proprietary information will not be disclosed in violation of our
confidentiality agreements or that competitors will not otherwise gain access to our trade secrets or independently develop substantially
equivalent information and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of our trade secrets and
intellectual property could impair our competitive position and may have a material adverse effect on our business. Additionally,
if the steps taken to maintain our trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse
against third parties for misappropriating any trade secret.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Intellectual property rights of third parties could adversely
affect our ability to commercialize our products and services, and we might be required to litigate or obtain licenses from third
parties in order to develop or market our product candidates. Such litigation or licenses could be costly or not available on commercially
reasonable terms.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">It is inherently
difficult to conclusively assess our freedom to operate without infringing on third-party rights. Our competitive position may
be adversely affected if existing patents or patents resulting from patent applications issued to third parties or other third-party
intellectual property rights are held to cover our products or services or elements thereof, or our manufacturing or uses relevant
to our development plans. In such cases, we may not be in a position to develop or commercialize products or services or our product
candidates (and any relevant services) unless we successfully pursue litigation to nullify or invalidate the third-party intellectual
property right concerned or enter into a license agreement with the intellectual property right holder, if available on commercially
reasonable terms. There may also be pending patent applications that if they result in issued patents, could be alleged to be infringed
by our new products or services. If such an infringement claim should be brought and be successful, we may be required to pay substantial
damages, be forced to abandon our new products or services or seek a license from any patent holders. No assurances can be given
that a license will be available on commercially reasonable terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">It is also possible
that we have failed to identify relevant third-party patents or applications. For example, U.S. patent applications filed before
November 29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the United States remain
confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months
after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority
date. Therefore, patent applications covering our new products or services could have been filed by others without our knowledge.
Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a
manner that could cover our services, our new products or the use of our new products. Third-party intellectual property right
holders may also actively bring infringement claims against us. We cannot guarantee that we will be able to successfully settle
or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us,
we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience
substantial delays in pursuing the development of and/or marketing our new products or services. If we fail in any such dispute,
in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing our new products
or services that are held to be infringing. We might, if possible, also be forced to redesign our new products so that we no longer
infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require
us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Third-party claims of intellectual property infringement
may prevent or delay our development and commercialization efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our commercial success depends in part on
our avoiding infringement of the patents and proprietary rights of third parties. Numerous U.S. and foreign issued patents and
pending patent applications, which are owned by third parties, exist in the fields in which we are developing new products and
services. As our industries expand and more patents are issued, the risk increases that our products and services may be subject
to claims of infringement of the patent rights of third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Third parties may
assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications
with claims to materials, designs or methods of manufacture related to the use or manufacture of our products or services. There
may be currently pending patent applications or continued patent applications that may later result in issued patents that our
products or services may infringe. In addition, third parties may obtain patents or services in the future and claim that use of
our technologies infringes upon these patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any third-party
patents were held by a court of competent jurisdiction to cover aspects of our processes for designs, or methods of use, the holders
of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain
a license or until such patent expires or is finally determined to be invalid or unenforceable. In either case, such a license
may not be available on commercially reasonable terms or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Parties making
claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop
and commercialize one or more of our products or services. Defense of these claims, regardless of their merit, would involve substantial
litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim
of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&rsquo; fees for willful
infringement, pay royalties, redesign our infringing products or services, or obtain one or more licenses from third parties, which
may be impossible or require substantial time and monetary expenditure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Patent policy and rule changes could increase the uncertainties
and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT>Changes
in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value
of any patents that may issue from our patent applications or narrow the scope of our patent protection. The laws of foreign countries
may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature
often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not
published until 18 months after filing, or in some cases not at all. We therefore cannot be certain that we were the first to file
the invention claimed in our owned and licensed patent or pending applications, or that we or our licensor were the first to file
for patent protection of such inventions. Assuming all other requirements for patentability are met, in the United States prior
to March 15, 2013, the first to make the claimed invention without undue delay in filing, is entitled to the patent, while generally
outside the United States, the first to file a patent application is entitled to the patent. After March 15, 2013, under the Leahy-Smith
America Invents Act (the &ldquo;Leahy-Smith Act&rdquo;), enacted on September 16, 2011, the United States has moved to a first
to file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will
be prosecuted and may also affect patent litigation. In general, the Leahy-Smith Act and its implementation could increase the
uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents,
all of which could have a material adverse effect on our business and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be involved in lawsuits to protect or enforce our
intellectual property, which could be expensive, time consuming, and unsuccessful. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Competitors may infringe
our intellectual property. If we were to initiate legal proceedings against a third-party to enforce a patent covering one of our new
products or services, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable.
In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds
for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness,
or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent
withheld relevant information from the United States Patent and Trademark Office, or USPTO, or made a misleading statement, during prosecution.
Under the Leahy-Smith Act, the validity of U.S. patents may also be challenged in post-grant proceedings before the USPTO. The outcome
following legal assertions of invalidity and unenforceability is unpredictable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Derivation proceedings
initiated by third parties or brought by us may be necessary to determine the priority of inventions and/or their scope with respect
to our patent or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology
or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer
us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful,
may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation
could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research
programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our new products
or services to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, because
of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements
of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, it could have a material adverse effect on the price of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be subject to claims challenging the inventorship
of our intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may be subject
to claims that former employees, collaborators or other third parties have an interest in, or right to compensation, with respect
to our current patent and patent applications, future patents or other intellectual property as an inventor or co-inventor. For
example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing
our products or services. Litigation may be necessary to defend against these and other claims challenging inventorship or claiming
the right to compensation. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome
could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could
result in substantial costs and be a distraction to management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may not be able to protect our intellectual property
rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Filing, prosecuting,
and defending patents on products and services, as well as monitoring their infringement in all countries throughout the world
would be prohibitively expensive, and our intellectual property rights in some countries can be less extensive than those in the
United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as
federal and state laws in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Competitors may
use our technologies develop their own products or services in jurisdictions where we have not obtained patent protection to and
may export infringing products or services to territories where we have patent protection, but where patents are not enforced as
strictly as they are in the United States. These products or services may compete with our products or services. Future patents
or other intellectual property rights may not be effective or sufficient to prevent them from competing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many companies have encountered significant
problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property
protection, which could make it difficult for us to stop the marketing of competing products or services in violation of our proprietary
rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in
substantial costs and divert our efforts and attention from other aspects of our business, could put our future patents at risk
of being invalidated or interpreted narrowly, put the issuance of our patent applications at risk, and could provoke third parties
to assert claims against us. We may not prevail in any lawsuits that we initiate, and any damages or other remedies that we may
be awarded, may not be commercially meaningful. Accordingly, our efforts to monitor and enforce our intellectual property rights
around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop
or license.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Risks Related
to this Offering and the Ownership of the Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>The market price of our securities may be highly volatile,
and you may not be able to resell your Ordinary Shares or Warrants at or above the initial public offering price.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Prior to this offering, there has not been
a public market for our securities. Although we have applied to list our Ordinary Shares and Warrants on Nasdaq, an active trading market
for the Ordinary Shares or Warrants may not develop or be sustained. If an active trading market for our Ordinary Shares or Warrants
does not develop following this offering, you may not be able to sell your Ordinary Shares or Warrants quickly or at the market price.
The initial public offering price for the Units will be determined by negotiations between us and representative of the underwriters
and may not be indicative of prices that will prevail in the trading market. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The trading price of each of our Ordinary Shares
and Warrants is likely to be volatile. The following factors, in addition to other risk factors described in this section, may have a
significant impact on the market price of such securities: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">inability to obtain the
    approvals necessary to commence further clinical trials;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unsatisfactory results of clinical trials;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of regulatory approval or the failure
    to obtain it, or specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of innovations or new products by
    us or our competitors;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse actions taken by regulatory authorities
    with respect to our clinical trials, manufacturing supply chain or sales and marketing activities;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any adverse changes to our relationship with manufacturers
    or suppliers;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any intellectual property infringement actions in
    which we may become involved;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achievement of expected product sales and profitability
    or our failure to meet expectations;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our commencement of, or involvement in, litigation;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any major changes in our board of directors or management;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit and retain qualified regulatory,
    research and development personnel;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legislation in the United States relating to the
    sale or pricing of medical devices;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the depth of the trading market in our Ordinary
    Shares and Warrants;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> termination of the lock-up agreements or other restrictions
    limiting our ability or that of any of our existing shareholders to sell our Ordinary Shares (or any other securities that we may
    issue, if any) after this offering; </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic weakness, including inflation, or political
    instability in particular foreign economies and markets;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">business interruptions resulting from a local or
    worldwide pandemic, such as COVID-19, geopolitical actions, including war and terrorism, or natural disasters;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the granting or exercise of employee stock options
    or other equity awards; and</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in investors&rsquo; and securities analysts&rsquo;
    perception of the business risks and conditions of our business.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In addition, the stock market in general, and
the Nasdaq in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to
the operating performance of small companies. Broad market and industry factors may negatively affect the market price of our Ordinary
Shares and Warrants, regardless of our actual operating performance. Further, a systemic decline in the financial markets and related
factors beyond our control may cause our share price to decline rapidly and unexpectedly. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>The Warrants included in the Units and Pre-funded Units are
expected to be listed on Nasdaq separately upon the pricing of this offering, and may provide investors with an arbitrage opportunity
that could adversely affect the trading price of our Ordinary Shares.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Because the Units and Pre-funded Units will
never trade as a unit, and the Warrants are expected to be traded on Nasdaq, investors may be provided with an arbitrage opportunity
that could depress the price of our Ordinary Shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>The Warrants and Pre-funded Warrants are speculative in nature.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Except as otherwise set forth therein, the
Warrants and Pre-funded Warrants offered in this offering do not confer any rights of Ordinary Share ownership on their holders, such
as voting rights, but rather merely represent the right to acquire Ordinary Shares at a fixed price for a limited period of time. Specifically,
commencing on the date of issuance, holders of the Warrants may exercise their right to acquire Ordinary Shares and pay an exercise price
of $6.50 (based on an assumed public offering price of $6.50 per Unit, the midpoint of the range set forth on the cover page of this
prospectus) per Ordinary Share, 100% of the public offering price per Unit, prior to five years from the date of issuance, after which
date any unexercised Warrants will expire and have no further value. In addition, commencing on the date of issuance, holders of the
Pre-funded&nbsp;Warrants may exercise their right to acquire Ordinary Shares and pay an exercise price of $ per Ordinary Share, subject
to adjustment upon certain events. There can be no assurance that the market price of our Ordinary Shares will ever equal or exceed the
exercise price of the Warrants offered by this prospectus. In the event that our Ordinary Shares price does not exceed the exercise price
of such Warrants during the period when such Warrants are exercisable, the Warrants may not have any value. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>There is no established market for the Warrants and Pre-funded
Warrants being offered in this offering.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> There is no established trading market for
the Warrants and Pre-funded Warrants offered in this offering. We do not intend to apply for listing of the Pre-funded Warrants on any
securities exchange or other nationally recognized trading system. Although we have applied to list the Warrants on Nasdaq there can
be no assurance that there will be an active trading market for the Warrants. Without an active trading market, the liquidity of the
Warrants will be limited. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Future sales of our Ordinary Shares could reduce the market
price of our Ordinary Shares.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Substantial sales of our Ordinary Shares on Nasdaq, including
following this offering, may cause the market price of our Ordinary Shares to decline. Sales by us or our security holders of substantial
amounts of our Ordinary Shares, or the perception that these sales may occur in the future, could cause a reduction in the market
price of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The issuance of any additional Ordinary
Shares or any securities that are exercisable for or convertible into Ordinary Shares, may have an adverse effect on the market
price of our Ordinary Shares and will have a dilutive effect on our existing shareholders and holders of Ordinary Shares.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our principal shareholders, officers and directors currently
beneficially own approximately 70% of our Ordinary Shares. They will therefore be able to exert significant control over matters
submitted to our shareholders for approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of the date of this prospectus, our principal
shareholders, officers and directors beneficially own approximately 70% of our Ordinary Shares. This significant concentration
of share ownership may adversely affect the trading price for our Ordinary Shares because investors often perceive disadvantages
in owning shares in companies with controlling shareholders. As a result, these shareholders, if they acted together, could significantly
influence or even unilaterally approve matters requiring approval by our shareholders, including the election of directors and
the approval of mergers or other business combination transactions. The interests of these shareholders may not always coincide
with our interests or the interests of other shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>If you purchase securities in this offering, you will incur
immediate and substantial dilution in the book value of your shares.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The offering price of the Ordinary Shares
is substantially higher than the net tangible book value per share of our Ordinary Shares. Therefore, if you purchase securities in
this offering, you will pay a price per Ordinary Share that substantially exceeds our net tangible book value per Ordinary Share
after this offering. To the extent outstanding options or warrants are exercised, you will incur further dilution. Based on an
assumed public offering price of $6.50&nbsp;per Unit, which is the midpoint of the price range set forth on the cover page of this
prospectus, you will experience immediate dilution of $3.67 per Ordinary Share, representing the difference between our pro forma
net tangible book value per Ordinary Share after giving effect to this offering and the offering price. See &ldquo;Dilution&rdquo;
for further information. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We do not know whether a market for the Ordinary Shares
will be sustained or what the trading price of the Ordinary Shares will be and as a result it may be difficult for you to sell
your Ordinary Shares</I></B>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Although we have applied to list the Ordinary
Shares on Nasdaq, an active trading market for the Ordinary Shares may not develop or be sustained. It may be difficult for you to sell
your Ordinary Shares without depressing the market price for the Ordinary Shares or at all. As a result of these and other factors, you
may not be able to sell your Ordinary Shares at or above the offering price or at all. Further, an inactive market may also impair our
ability to raise capital by selling Ordinary Shares and may impair our ability to enter into strategic partnerships or acquire companies,&nbsp;products,
or services by using our equity securities as consideration. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have never paid cash dividends on our share capital,
and we do not anticipate paying any cash dividends in the foreseeable future.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have never declared or paid cash dividends,
and we do not anticipate paying cash dividends in the foreseeable future. Therefore, you should not rely on an investment in Ordinary
Shares as a source for any future dividend income.&nbsp;Our board of directors has complete discretion as to whether to distribute
dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends,
if any, will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions,
if any, received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant
by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Management will have broad discretion as to the use of
the proceeds from this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our management will have broad discretion
in the allocation of the net proceeds and could use them for purposes other than those contemplated at the time of this offering
and as described in the section titled &ldquo;Use of Proceeds.&rdquo;&nbsp;Our shareholders may not agree with the manner in which
our management chooses to allocate and spend the net proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may need additional capital, and the sale of additional
shares or equity or debt securities could result in additional dilution to our stockholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may need to raise additional capital
through a combination of private and public equity offerings, debt financings and collaborations, and strategic and licensing arrangements.
To the extent that we raise additional capital through the issuance of equity (such as this offering) or convertible debt securities,
your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your
rights as a holder of our Ordinary Shares. Debt financing, if available, may involve agreements that include covenants limiting
or restricting our ability to take certain actions, such as incurring debt, making capital expenditures or declaring dividends.
If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may
have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that are not favorable
to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be required to delay, limit,
reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates
that we would otherwise prefer to develop and market ourselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The JOBS Act will allow us to postpone the date by which
we must comply with some of the laws and regulations intended to protect investors and to reduce the amount of information we provide
in our reports filed with the SEC, which could undermine investor confidence in our company and adversely affect the market price
of the Ordinary Shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For so long as we remain an &ldquo;emerging
growth company&rdquo; as defined in the JOBS Act, we intend to take advantage of certain exemptions from various requirements that
are applicable to public companies that are not &ldquo;emerging growth companies&rdquo; including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the provisions of the Sarbanes-Oxley Act requiring that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 107 of the JOBS Act, which provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This means that an &ldquo;emerging growth company&rdquo; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are electing to delay such adoption of new or revised accounting standards. As a result of this adoption, our financial statements may not be comparable to companies that comply with the public company effective date;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor&rsquo;s report on the financial statements; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to furnish two rather than three years of income statements and statements of cash flows in various required filings.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to take advantage of these exemptions
until we are no longer an &ldquo;emerging growth company.&rdquo; We will remain an emerging growth company until the earlier of
(1) the last day of the fiscal year (a) following the fifth anniversary of the date of our first sale of ordinary equity securities
pursuant to an effective registration statement under the Securities Act, (b) in which we have total annual gross revenue of at
least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our Ordinary
Shares that is held by non-affiliates exceeds $700 million as of the prior June 30, and (2) the date on which we have issued more
than $1.0 billion in non-convertible debt during the prior three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We cannot predict if investors will find
the Ordinary Shares less attractive because we may rely on these exemptions. If some investors find the Ordinary Shares less attractive
as a result, there may be a less active trading market for the Ordinary Shares, and our market prices may be more volatile and
may decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>As a &ldquo;foreign private issuer&rdquo;
we are permitted, and intend, to follow certain home country corporate governance practices instead of otherwise applicable SEC
and Nasdaq requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S.
issuers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
status as a foreign private issuer also exempts us from compliance with certain SEC laws and regulations and certain regulations
of Nasdaq, including the proxy rules, the short-swing profits recapture rules, and certain governance requirements such as independent
director oversight of the nomination of directors and executive compensation. In addition, we will not be required under the Exchange
Act to file current reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose
securities are registered under the Exchange Act and we will generally be exempt from filing quarterly reports with the SEC. Also,
although the Israeli Companies Law, 5759-1999, or the Companies Law, requires us to disclose the annual compensation of our five
most highly compensated senior officers on an individual basis (rather than on an aggregate basis), this disclosure will not be
as extensive as that required of a U.S. domestic issuer. We intend to commence providing such disclosure, at the latest, in the
annual proxy statement for our first annual meeting of shareholders following the closing of this offering, which will be filed
under cover of a report on Form 6-K. Furthermore, as a foreign private issuer, we are also not subject to the requirements of
Regulation FD (Fair Disclosure) promulgated under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">These exemptions and
leniencies will reduce the frequency and scope of information and protections to which you are entitled as an investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The determination of foreign private issuer
status is made annually on the last business day of an issuer&rsquo;s most recently completed second fiscal quarter and, accordingly,
the next determination will be made with respect to us on June 30, 2021. In the future, we would lose our foreign private issuer
status if a majority of our shareholders, directors or management are U.S. citizens or residents and we fail to meet additional
requirements necessary to avoid loss of foreign private issuer status. The regulatory and compliance costs to us under U.S. securities
laws as a U.S. domestic registrant may be significantly higher.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be a &ldquo;passive foreign investment company,&rdquo;
or PFIC, for U.S. federal income tax purposes in the current taxable year or may become one in any subsequent taxable year. There
generally would be negative tax consequences for U.S. taxpayers that are holders of the Ordinary Shares if we are or were to become
a PFIC.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Based on the projected composition of our income and valuation of our
assets, we do not expect to be a PFIC for 2021, and we do not expect to become a PFIC in the future, although there can be no assurance
in this regard. The determination of whether we are a PFIC is made on an annual basis and will depend on the composition of our income
and assets from time to time. We will be treated as a PFIC for U.S. federal income tax purposes in any taxable year in which either (1)
at least 75% of our gross income is &ldquo;passive income&rdquo; or (2) on average at least 50% of our assets by value produce passive
income or are held for the production of passive income. Passive income for this purpose generally includes, among other things, certain
dividends, interest, royalties, rents and gains from commodities and securities transactions and from the sale or exchange of property
that gives rise to passive income. Passive income also includes amounts derived by reason of the temporary investment of funds, including
those raised in a public offering. In determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets
of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account. The tests for
determining PFIC status are applied annually, and it is difficult to make accurate projections of future income and assets which are relevant
to this determination. In addition, our PFIC status may depend in part on the market value of the Ordinary Shares. Accordingly, there
can be no assurance that we currently are not or will not become a PFIC in the future. If we are a PFIC in any taxable year during which
a U.S. taxpayer holds the Ordinary Shares, such U.S. taxpayer would be subject to certain adverse U.S. federal income tax rules. In particular,
if the U.S. taxpayer did not make an election to treat us as a &ldquo;qualified electing fund&rdquo;, or QEF, or make a &ldquo;mark-to-market&rdquo;
election, then &ldquo;excess distributions&rdquo; to the U.S. taxpayer, and any gain realized on the sale or other disposition of the
Ordinary Shares by the U.S. taxpayer: (1) would be allocated ratably over the U.S. taxpayer&rsquo;s holding period for the Ordinary Shares;
(2) the amount allocated to the current taxable year and any period prior to the first day of the first taxable year in which we were
a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of the other taxable years would be subject to tax at the
highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest charge for the deemed deferral benefit
would be imposed with respect to the resulting tax attributable to each such other taxable year. In addition, if the U.S. Internal Revenue
Service, or the IRS, determines that we are a PFIC for a year with respect to which we have determined that we were not a PFIC, it may
be too late for a U.S. taxpayer to make a timely QEF or mark-to-market election. U.S. taxpayers that have held the Ordinary Shares during
a period when we were a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC in subsequent years, subject to exceptions
for U.S. taxpayer who made a timely QEF or mark-to-market election. A U.S. taxpayer can make a QEF election by completing the relevant
portions of and filing IRS Form 8621 in accordance with the instructions thereto. We do not intend to notify U.S. taxpayers that hold
the Ordinary Shares if we believe we will be treated as a PFIC for any taxable year in order to enable U.S. taxpayers to consider whether
to make a QEF election. In addition, we do not intend to furnish such U.S. taxpayers annually with information needed in order to complete
IRS Form 8621 and to make and maintain a valid QEF election for any year in which we or any of our subsidiaries are a PFIC. U.S. taxpayers
that hold the Ordinary Shares are strongly urged to consult their tax advisors about the PFIC rules, including tax return filing requirements
and the eligibility, manner, and consequences to them of making a QEF or mark-to-market election with respect to the Ordinary Shares in
the event that we are a PFIC. See &ldquo;Taxation&mdash;U.S. Federal Income Tax Considerations&mdash;Passive Foreign Investment Companies&rdquo;
for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be subject to securities litigation, which is expensive
and could divert management attention.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the past, companies that have experienced
volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of
this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management&rsquo;s
attention and resources, which could seriously hurt our business. Any adverse determination in litigation could also subject us
to significant liabilities.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="background-color: white"><B>Risks
Related to Israeli Law and Our Operations in Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Potential political, economic and military instability
in the State of Israel, where our headquarters, members of our management team and our research and development facilities are
located, may adversely affect our results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Our executive offices,
research and development laboratories and manufacturing facility are located in Ra&rsquo;anana, Israel. In addition, the majority
of our key employees, officers and directors are residents of Israel. Accordingly, political, economic and military conditions
in Israel may directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed conflicts
have taken place between Israel and groups in its neighboring countries, Hamas (an Islamist militia and political group that has
historically controlled the Gaza Strip) and Hezbollah (an Islamist militia and political group based in Lebanon). In addition,
several countries, principally in the Middle East, restrict doing business with Israel, and additional countries may impose restrictions
on doing business with Israel and Israeli companies whether as a result of hostilities in the region or otherwise. Any hostilities
involving Israel, terrorist activities, political instability or violence in the region or the interruption or curtailment of trade
or transport between Israel and its trading partners could adversely affect our operations and results of operations and the market
price of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Our commercial
insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle East.
Although the Israeli government is currently committed to covering the reinstatement value of direct damages that are caused by
terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or, if maintained, will
be sufficient to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect
on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Further, many Israeli
citizens are obligated to perform several days, and in some cases more, of annual military reserve duty each year until they reach
the age of 40 (or older for certain reservists) and, in the event of a military conflict, may be called to active duty. In response
to increases in terrorist activity, there have been periods of significant call-ups of military reservists. It is possible that
there will be military reserve duty call-ups in the future. Our operations could be disrupted by such call-ups, which may include
the call-up of members of our management. Such disruption could materially adversely affect our business, prospects, financial
condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The termination or reduction of tax and other incentives
that the Israeli government provides to Israeli companies may increase our costs and taxes.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Israeli government currently provides
tax and capital investment incentives to Israeli companies, as well as grant and loan programs relating to research and development
and marketing and export activities. In recent years, the Israeli government has reduced the benefits available under these programs
and the Israeli governmental authorities may in the future further reduce or eliminate the benefits of these programs. We may take
advantage of these benefits and programs in the future; however, there can be no assurance that such benefits and programs will
be available to us. If we qualify for such benefits and programs and fail to meet the conditions thereof, the benefits could be
canceled and we could be required to refund any benefits we might already have enjoyed and become subject to penalties. Additionally,
if we qualify for such benefits and programs and they are subsequently terminated or reduced, it could have an adverse effect on
our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be required to pay monetary remuneration to our
Israeli employees for their inventions, even if the rights to such inventions have been duly assigned to us. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We enter into agreements with our Israeli
employees pursuant to which such individuals agree that any inventions created in the scope of their employment are either owned
exclusively by us or are assigned to us, depending on the jurisdiction, without the employee retaining any rights. A portion of
our intellectual property has been developed by our Israeli employees during their employment for us. Under the Israeli Patent
Law, 5727-1967, or the Patent Law, inventions conceived by an employee during the course of his or her employment and within the
scope of said employment are considered &ldquo;service inventions. Service inventions belong to the employer by default, absent
a specific agreement between the employee and employer otherwise. The Patent Law also provides that if there is no agreement regarding
the remuneration for the service inventions, even if the ownership rights were assigned to the employer, the Israeli Compensation
and Royalties Committee, or the Committee, a body constituted under the Patent Law, shall determine whether the employee is entitled
to remuneration for these inventions. The Committee has not yet determined the method for calculating this Committee-enforced remuneration.
While it has previously been held that an employee may waive his or her rights to remuneration in writing, orally or by conduct,
litigation is pending in the Israeli labor court is questioning whether such waiver under an employment agreement is enforceable.
Although our Israeli employees have agreed that we exclusively own any rights related to their inventions, we may face claims demanding
remuneration in consideration for employees&rsquo; service inventions. As a result, we could be required to pay additional remuneration
or royalties to our current and/or former employees, or be forced to litigate such claims, which could negatively affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>We received Israeli government
grants for certain of our research and development activities, the terms of which may require us to pay royalties and to satisfy
specified conditions in order to manufacture products and transfer technologies outside of Israel. If we fail to satisfy these
conditions, we may be required to pay penalties and refund grants previously received.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Our
research and development efforts have been financed in part through royalty-bearing and non-royalty-bearing grants in an aggregate amount
of $0.785&nbsp;million that we received from the IIA as of June 25, 2021. With respect to the royalty-bearing grants we are committed
to pay royalties at a rate of 3% on sales proceeds from our products that were developed under IIA programs up to the total amount of
grants received, linked to the U.S. dollar and bearing interest at an annual rate of LIBOR applicable to U.S. dollar deposits. Due to
the accrual of interest, the total amount of the grants that will be repaid through royalties will increase until repayments begin. We
are further required to comply with the requirements of the Israeli Encouragement of Industrial Research, Development and Technological
Innovation Law, 5744-1984, as amended, and related regulations, or the Research Law, with respect to those past grants. When a company
develops know-how, technology or products using IIA grants, the terms of these grants and the Research Law restrict the transfer or license
of such know-how, and the transfer of manufacturing or manufacturing rights of such products, technologies or know-how outside of Israel,
without the prior approval of the IIA. Therefore, the discretionary approval of an IIA committee would be required for any transfer or
license to third parties inside or outside of Israel of know how or for the transfer outside of Israel of manufacturing or manufacturing
rights related to those aspects of such technologies. We may not receive those approvals. Furthermore, the IIA may impose certain conditions
on any arrangement under which it permits us to transfer technology or development.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The transfer or
license of IIA-supported technology or know-how outside of Israel and the transfer of manufacturing of IIA-supported products,
technology or know-how outside of Israel may involve the payment of significant amounts, depending upon the value of the transferred
or licensed technology or know-how, our research and development expenses, the amount of IIA support, the time of completion of
the IIA-supported research project and other factors. These restrictions and requirements for payment may impair our ability to
sell, license or otherwise transfer our technology assets outside of Israel or to outsource or transfer development or manufacturing
activities with respect to any product or technology outside of Israel. Furthermore, the consideration available to our shareholders
in a transaction involving the transfer outside of Israel of technology or know-how developed with IIA funding (such as a merger
or similar transaction) may be reduced by any amounts that we are required to pay to the IIA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may not be able to enforce covenants not-to-compete
under current Israeli law that might result in added competition for our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have non-competition agreements with
all of our employees, all of which are governed by Israeli law. These agreements prohibit our employees from competing with or
working for our competitors, generally during their employment and for up to 12 months after termination of their employment. However,
Israeli courts are reluctant to enforce non-compete undertakings of former employees and tend, if at all, to enforce those provisions
for relatively brief periods of time in restricted geographical areas, and only when the employee has obtained unique value to
the employer specific to that employer&rsquo;s business and not just regarding the professional development of the employee. If
we are not able to enforce non-compete covenants, we may be faced with added competition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Provisions of Israeli law and
our amended and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us,
which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Israeli corporate
law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions
involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions.
For example, a merger may not be consummated unless at least 50&nbsp;days have passed from the date on which a merger proposal is filed
by each merging company with the Israel Registrar of Companies and at least 30&nbsp;days have passed from the date on which the shareholders
of both merging companies have approved the merger. In addition, a majority of each class of securities of the target company must approve
a merger. Moreover, a tender offer for all of a company&rsquo;s issued and outstanding shares can only be completed if the acquirer receives
positive responses from the holders of at least 95% of the issued share capital. Completion of the tender offer also requires approval
of a majority of the offerees that do not have a personal interest in the tender offer, unless, following consummation of the tender
offer, the acquirer would hold at least 98% of our outstanding shares. Furthermore, the shareholders, including those who indicated their
acceptance of the tender offer, may, at any time within six months following the completion of the tender offer, claim that the consideration
for the acquisition of the shares does not reflect their fair market value, and petition an Israeli court to alter the consideration
for the acquisition accordingly, unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not
seek such appraisal rights, and the acquirer or the company published all required information with respect to the tender offer prior
to the tender offer&rsquo;s response date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Furthermore, Israeli
tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not
have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free
share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain
circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding
period of two years from the date of the transaction during which sales and dispositions of shares of the participating companies
are subject to certain restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in
time, and when such time expires, the tax becomes payable even if no disposition of the shares has occurred. These provisions could
delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be
beneficial to us or to our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>It may be difficult to enforce
a judgment of a U.S. court against us and our executive officers and directors and the Israeli experts named in this prospectus
in Israel or the United States, to assert U.S. securities laws claims in Israel or to serve process on our executive officers and
directors and these experts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We were incorporated
in Israel. Substantially all of our executive officers and directors reside outside of the United States, and all of our assets
and most of the assets of these persons are located outside of the United States. Therefore, a judgment obtained against us, or
any of these persons, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not
be collectible in the United States and may not be enforced by an Israeli court. It also may be difficult for you to effect service
of process on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel.
Additionally, it may be difficult for an investor, or any other person or entity, to initiate an action with respect to U.S. securities
laws in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that
Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a
claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the
content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming and costly process.
Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that addresses the
matters described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, you may not be
able to collect any damages awarded by either a U.S. or foreign court. See &ldquo;Enforceability of Civil Liabilities&rdquo; for
additional information on your ability to enforce a civil claim against us and our executive officers or directors named in this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Your rights and responsibilities
as a shareholder will be governed in key respects by Israeli laws, which differs in some material respects from the rights and
responsibilities of shareholders of U.S. companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The rights and
responsibilities of the holders of our Ordinary Shares are governed by our amended and restated articles of association and by
Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders
in U.S. companies. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner
in exercising its rights and performing its obligations towards the company and other shareholders, and to refrain from abusing
its power in such company, including, among other things, in voting at a general meeting of shareholders on matters such as amendments
to a company&rsquo;s amended and restated articles of association, increases in a company&rsquo;s authorized share capital, mergers and acquisitions
and related party transactions requiring shareholder approval, as well as a general duty to refrain from discriminating against
other shareholders. In addition, a shareholder who is aware that it possesses the power to determine the outcome of a vote at a
meeting of the shareholders or to appoint or prevent the appointment of a director or executive officer in the company has a duty
of fairness toward the company. There is limited case law available to assist us in understanding the nature of these duties or
the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on holders
of our ordinary shares that are not typically imposed on shareholders of U.S. companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>General Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will incur significant increased costs as a result
of the listing of our securities for trading on Nasdaq. By becoming a public company in the United States, our management will
be required to devote substantial time to new compliance initiatives as well as compliance with ongoing U.S. requirements.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon the listing of securities on&nbsp;Nasdaq,
we will become a publicly traded company in the United States. As a public company in the United States, we will incur additional
significant accounting, legal and other expenses that we did not incur before the offering. We also anticipate that we will incur
costs associated with corporate governance requirements of the SEC, as well as requirements under Section 404 and other provisions
of the Sarbanes-Oxley Act. We expect these rules and regulations to increase our legal and financial compliance costs, introduce
new costs such as investor relations, stock exchange listing fees and shareholder reporting, and to make some activities more time
consuming and costly. The implementation and testing of such processes and systems may require us to hire outside consultants and
incur other significant costs. Any future changes in the laws and regulations affecting public companies in the United States,
including Section 404 and other provisions of the Sarbanes-Oxley Act, and the rules and regulations adopted by the SEC, for so
long as they apply to us, will result in increased costs to us as we respond to such changes. These laws, rules and regulations
could make it more difficult or more costly for us to obtain certain types of insurance, including director and officer liability
insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the
same or similar coverage. The impact of these requirements could also make it more difficult for us to attract and retain qualified
persons to serve on our board of directors, our board committees, or as executive officers.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are not able to attract and retain highly skilled
managerial, scientific, technical and marketing personnel, we may not be able to implement our business model successfully.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Our
success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific
personnel. We are highly dependent upon our senior management as well as other employees, consultants and scientific and medical
collaborators. Our management team must be able to act decisively to apply and adapt our business model in the rapidly changing
markets in which we will compete. In addition, we will rely upon technical and scientific employees or third-party contractors
to effectively establish, manage and grow our business. Consequently, we believe that our future viability will depend largely
on our ability to attract and retain highly skilled managerial, sales, scientific and technical personnel. In order to do so, we
may need to pay higher compensation or fees to our employees or consultants than currently expected and such higher compensation
payments may have a negative effect on our operating results. Competition for experienced, high-quality personnel in the medical
device field is intense. We may not be able to hire or retain the necessary personnel to implement our business strategy. Our failure
to hire and retain quality personnel on acceptable terms could impair our ability to develop new products and services and manage
our business effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we engage in future acquisitions or strategic partnerships,
this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and
subject us to other risks.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may evaluate various acquisition opportunities
and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies
or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased operating expenses and cash requirements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the assumption of additional indebtedness or contingent liabilities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the issuance of our equity securities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the diversion of our management&rsquo;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are subject to certain U.S. and foreign anticorruption,
anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Among other matters, U.S. and foreign anticorruption,
anti-money laundering, export control, sanctions and other trade laws and regulations, which are collectively referred to as Trade
Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants,
contractors and other partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly,
corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade
Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments,
breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with
officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also
expect our non-U.S. activities to increase over time. We plan to engage third parties for clinical trials and/or to obtain necessary
permits, licenses, patent registrations and other regulatory approvals, and we can be held liable for the corrupt or other illegal
activities of our personnel, agents or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our business and operations might be adversely affected
by security breaches, including any cybersecurity incidents.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We depend on the efficient and uninterrupted
operation of our computer and communications systems, and those of our consultants, contractors and vendors, which we use for,
among other things, sensitive company data, including our intellectual property, financial data and other proprietary business
information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While certain of our operations have business
continuity and disaster recovery plans and other security measures intended to prevent and minimize the impact of IT-related interruptions,
our IT infrastructure and the IT infrastructure of our consultants, contractors and vendors are vulnerable to damage from cyberattacks,
computer viruses, unauthorized access, electrical failures and natural disasters or other catastrophic events. We could experience
failures in our information systems and computer servers, which could result in an interruption of our normal business operations
and require substantial expenditure of financial and administrative resources to remedy. System failures, accidents or security
breaches can cause interruptions in our operations and can result in a material disruption of our targeted phage therapies, product
candidates and other business operations. The loss of data from completed or future studies or clinical trials could result in
delays in our research, development or regulatory approval efforts and significantly increase our costs to recover or reproduce
the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications,
or inappropriate disclosure of confidential or proprietary information, we could incur regulatory investigations and redresses,
penalties and liabilities and the development of our product candidates could be delayed or otherwise adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Even though we believe we carry commercially
reasonable business interruption and liability insurance, we might suffer losses as a result of business interruptions that exceed
the coverage available under our insurance policies or for which we do not have coverage. For example, we are not insured against
terrorist attacks or cyberattacks. Any natural disaster or catastrophic event could have a significant negative impact on our operations
and financial results. Moreover, any such event could delay the development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Sales of a significant number of our Ordinary Shares in the
public markets or significant short sales of our Ordinary Shares, or the perception that such sales could occur, could depress the market
price of our Ordinary Shares and impair our ability to raise capital.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Sales of a substantial number of our Ordinary
Shares or other equity-related securities in the public markets, could depress the market price of our Ordinary Shares. If there are
significant short sales of our Ordinary Shares, the price decline that could result from this activity may cause the share price to decline
more so, which, in turn, may cause long holders of the Ordinary Shares to sell their shares, thereby contributing to sales of Ordinary
Shares in the market. Such sales also may impair our ability to raise capital through the sale of additional equity securities in the
future at a time and price that our management deems acceptable, if at all. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If securities or industry analysts do not publish or cease
publishing research or reports about us, our business or our market, or if they adversely change their recommendations or publish
negative reports regarding our business or the Ordinary Shares, our share price and trading volume could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The trading market for the Ordinary Shares
will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our market
or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover
us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation regarding the Ordinary
Shares, or provide more favorable relative recommendations about our competitors, the price of our Ordinary Shares would likely
decline. If any analyst who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could
lose visibility in the financial markets, which in turn could cause the price of our Ordinary Shares or trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Changes in laws or regulations relating to data protection,
or any actual or perceived failure by us to comply with such laws and regulations or our privacy policies, could materially and
adversely affect our business or could lead to government enforcement actions and significant penalties against us, and adversely
impact our operating results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect to receive health information
and other highly sensitive or confidential information and data of patients and other third parties (e.g., healthcare providers
who refer patients for scans), which we expect to compile and analyze. Collection and use of this data might raise privacy and
data protection concerns, which could negatively impact our business. There are numerous federal, state and international laws
and regulations regarding privacy, data protection, information security, and the collection, storing, sharing, use, processing,
transfer, disclosure, and protection of personal information and other data, and the scope of such laws and regulations may change,
be subject to differing interpretations, and may be inconsistent among countries and regions we intend to operate in (e.g., the
United States, the European Union and Israel), or conflict with other laws and regulations. The regulatory framework for privacy
and data protection worldwide is, and is likely to remain for the foreseeable future, uncertain and complex, and this or other
actual or alleged obligations may be interpreted and applied in a manner that we may not anticipate or that is inconsistent from
one jurisdiction to another and may conflict with other rules or practices including ours. Further, any significant change to applicable
laws, regulations, or industry practices regarding the collection, use, retention, security, or disclosure of data, or their interpretation,
or any changes regarding the manner in which the consent of relevant users for the collection, use, retention, or disclosure of
such data must be obtained, could increase our costs and require us to modify our services and candidate products, possibly in
a material manner, which we may be unable to complete, and may limit our ability to store and process patients&rsquo; data or develop
new services and features.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In particular, we will be subject to U.S.
data protection laws and regulations (i.e., laws and regulations that address privacy and data security) at both the federal and
state levels. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been
an increasing focus on privacy and data security issues. Numerous federal and state laws, including state data breach notification
laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, and disclosure
of health-related and other personal information. Failure to comply with such laws and regulations could result in government enforcement
actions and create liability for us (including the imposition of significant civil or criminal penalties), private litigation and/or
adverse publicity that could negatively affect our business. For instance, California enacted the California Consumer Privacy Act
(CCPA) on June 28, 2018, which took effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers
and increases the privacy and security obligations of entities handling certain personal data. The CCPA provides for civil penalties
for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The
CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and
in other states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we expect to obtain health
information that is subject to privacy and security requirements under the Health Information Technology for Economic and Clinical
Health Care Act, or HITECH, and its implementing regulations. The Privacy Standards
and Security Standards under HIPAA establish a set of standards for the protection of individually identifiable health information
by health plans, health care clearinghouses and certain health care providers, referred to as Covered Entities, and the business
associates with whom Covered Entities enter into service relationships pursuant to which individually identifiable health information
may be exchanged. Notably, whereas HIPAA previously directly regulated only Covered Entities, HITECH makes certain of HIPAA&rsquo;s
privacy and security standards also directly applicable to Covered Entities&rsquo; business associates. As a result, both Covered
Entities and business associates are now subject to significant civil and criminal penalties for failure to comply with Privacy
Standards and Security Standards. As part of our normal operations, we expect to collect, process and retain personal identifying
information regarding patients, including as a business associate of Covered Entities, so we expect to be subject to HIPAA, including
changes implemented through HITECH, and we could be subject to criminal penalties if we knowingly obtain or disclose individually
identifiable health information in a manner that is not authorized or permitted by HIPAA. A data breach affecting sensitive personal
information, including health information, also could result in significant legal and financial exposure and reputational damages
that could potentially have an adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">HIPAA requires Covered Entities (like many
of our potential customers) and business associates, like us, to develop and maintain policies and procedures with respect to protected
health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect
such information. HITECH expands the notification requirement for breaches of patient-identifiable health information, restricts
certain disclosures and sales of patient-identifiable health information and provides for civil monetary penalties for HIPAA violations.
HITECH also increased the civil and criminal penalties that may be imposed against Covered Entities and business associates and
gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA
and its implementing regulations and seek attorney&rsquo;s fees and costs associated with pursuing federal civil actions. Additionally,
certain states have adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Internationally, many jurisdictions have
or are considering enacting privacy or data protection laws or regulations relating to the collection, use, storage, transfer,
disclosure and/or other processing of personal data, as well as certification requirements for the hosting of health data specifically.
Such laws and regulations may include data hosting, data residency or data localization requirements (which generally require that
certain types of data collected within a certain country be stored and processed within that country), data export restrictions,
international transfer laws (which prohibit or impose conditions upon the transfer of such data from one country to another), or
may require companies to implement privacy or data protection and security policies, enable users to access, correct and delete
personal data stored or maintained by such companies, inform individuals of security breaches that affect their personal data or
obtain individuals&rsquo; consent to use their personal data. For example, European legislators adopted the European Union&rsquo;s
GDPR, which became effective on May 25, 2018, and are now in the process of finalizing
the ePrivacy Regulation to replace the European ePrivacy Directive (Directive 2002/58/EC as amended by Directive&nbsp;2009/136/EC).
The GDPR, supplemented by national laws and further implemented through binding guidance from the European Data Protection Board,
imposes more stringent European Union data protection requirements and provides for significant penalties for noncompliance. Further,
the United Kingdom&rsquo;s initiating a process to leave the European Union has created uncertainty with regard to the regulation
of data protection in the United Kingdom. In particular, the United Kingdom has brought the GDPR into domestic law with the Data
Protection Act 2018 which will remain in force, even if and when the United Kingdom leaves the European Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Virtually every jurisdiction in which we
expect to operate has established its own data security and privacy legal framework with which we must, and our target customers
will need to, comply, including the rules and regulation mentioned above. We may also need to comply with varying and possibly
conflicting privacy laws and regulations in other jurisdictions. As a result, we could face regulatory actions, including significant
fines or penalties, adverse publicity and possible loss of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While we are preparing to implement various
measures intended to enable us to comply with applicable privacy or data protection laws, regulations and contractual obligations,
these measures may not always be effective and do not guarantee compliance. Any failure or perceived failure by us to comply with
our contractual or legal obligations or regulatory requirements relating to privacy, data protection, or information security may
result in governmental investigations or enforcement actions, litigation, claims, or public statements against us by consumer advocacy
groups or others and could result in significant liability, cause our customers, partners or patients to lose trust in us, and
otherwise materially and adversely affect our reputation and business. Furthermore, the costs of compliance with, and other burdens
imposed by, the laws, regulations, and policies that are applicable to the businesses of our customers or partners may limit the
adoption and use of, and reduce the overall demand for, our products and services. Additionally, if third parties we work with
violate applicable laws, regulations, or agreements, such violations may put the data we have received at risk, could result in
governmental investigations or enforcement actions, fines, litigation, claims, or public statements against us by consumer advocacy
groups or others and could result in significant liability, cause our customers, partners or patients to lose trust in us, and
otherwise materially and adversely affect our reputation and business. Further, public scrutiny of, or complaints about, technology
companies or their data handling or data protection practices, even if unrelated to our business, industry or operations, may lead
to increased scrutiny of technology companies, including us, and may cause government agencies to enact additional regulatory requirements,
or to modify their enforcement or investigation activities, which may increase our costs and risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="background-color: white"><B><A NAME="i_003"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Some
of the statements made under &ldquo;Prospectus Summary,&rdquo; &ldquo;Risk Factors,&rdquo; &ldquo;Use of Proceeds,&rdquo; &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; &ldquo;Business&rdquo; and elsewhere in this prospectus
constitute forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential&rdquo; &ldquo;intends&rdquo; or &ldquo;continue,&rdquo; or the
negative of these terms or other comparable terminology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">These
forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements
that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements relating
to the research, development, completion and use of our products, and all statements (other than statements of historical facts)
that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the
future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Forward-looking
statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking
statements on assumptions and assessments made by our management in light of their experience and their perception of historical
trends, current conditions, expected future developments and other factors they believe to be appropriate</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Important
factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these
forward-looking statements include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectation regarding the sufficiency of our
    existing cash and cash equivalents to fund our current operations;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to advance the development of our ART500
    and future potential product candidates;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to commercialize our ART500 and future
    potential product candidates and future sales of our ART500 or any other future potential product candidates;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our assessment of the potential of our ART500 and
    future potential product candidates to treat certain indications;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our planned level of capital expenditures and liquidity;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our plans to continue to invest in research and
    development to develop technology for new products;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">anticipated actions of the FDA, state regulators,
    if any, or other similar foreign regulatory agencies, including approval to conduct clinical trials, the timing and scope of those
    trials and the prospects for regulatory approval or clearance of, or other regulatory action with respect to our products or services;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the regulatory environment and changes in the health
    policies and regimes in the countries in which we intend to operate, including the impact of any changes in regulation and legislation
    that could affect the medical device industry;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to meet our expectations regarding the
    commercial supply of our ART and future product candidates;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to retain key executive members;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to internally develop new inventions
    and intellectual property;</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the overall global economic environment;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of COVID-19 and resulting government actions on us;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of competition and new technologies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general market, political and economic conditions in the countries in which we operate;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of competition and new technologies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to internally develop new inventions and intellectual property;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding the use of proceeds from this offering</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in our strategy; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">These
statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause
our or our industry&rsquo;s actual results, levels of activity, performance or achievements to be materially different from those
anticipated by the forward-looking statements. We discuss many of these risks in this prospectus in greater detail under the heading
&ldquo;Risk Factors&rdquo; and elsewhere in this prospectus. You should not rely upon forward-looking statements as predictions
of future events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the
forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="i_004"></A>LISTING DETAILS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have applied to list our Ordinary Shares
and Warrants on Nasdaq under the symbols &ldquo;IINN&rdquo; and &ldquo;IINNW,&rdquo; respectively. This offering is contingent upon our
Ordinary Shares being listed; however, no assurance can be given that our application will be approved. All of the Ordinary Shares including
those to be offered pursuant to this prospectus, have the same rights and privileges. See &ldquo;Description of Share Capital.&rdquo; </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="i_005"></A>USE OF PROCEEDS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We expect to receive approximately $13.6 million
in net proceeds from the sale of the securities offered by us in this offering (approximately $15.7 million if the underwriters exercise
their over-allotment option in full), based upon an assumed public offering price of $6.50 per Unit, which is the midpoint of the price
range set forth on the cover page of this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> A $1.00 increase or decrease in the assumed
public offering price of $6.50 per Unit would increase or decrease the proceeds from this offering by approximately $2.1 million, assuming
that the number of Units offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated
underwriting discounts and commissions. Similarly, each increase or decrease of 1,000,000 in the number of Units offered would increase
or decrease our proceeds by approximately $5.9 million, assuming the assumed public offering price remains the same, and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="background-color: white">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">We
currently expect to use the net proceeds from this offering for the following purposes: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately $1&nbsp;million for product integration;
    </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately $7 million for research and development,
    including human observational studies, system engineering and other regulatory approval process; </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately $2 million for business development
    and marketing activities and implementation of our go-to-market strateg<FONT STYLE="background-color: white">y; and</FONT></FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the remainder for working capital and general corporate
    purposes and next generation product development.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
integration is the process, in which our engineering department configures the components into the final product in a manner that
allows for maximum flexibility in relation to reliance on individual sources for procurement and assembly. Changing circumstances
may cause us to consume capital significantly faster than we currently anticipate. The amounts and timing of our actual expenditures
will depend upon numerous factors, including&nbsp;the progress of our global marketing and sales efforts, the development efforts
and the overall economic environment. Therefore, our management will retain broad discretion over the use of the proceeds from
this offering. We may ultimately use the proceeds for different purposes than what we currently intend. Pending any ultimate use
of any portion of the proceeds from this offering, if the anticipated proceeds will not be sufficient to fund all the proposed
purposes, our management will determine the order of priority for using the proceeds, as well as the amount and sources of other
funds needed. We believe that the funds raised in this offering will be sufficient to finance the purposes described above, and
we do not think that material amounts of other funds will be necessary.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">Pending
our use of the net proceeds from this offering, we may invest the net proceeds in a variety of capital preservation investments,
including short-term, investment grade, interest bearing instruments and U.S. government securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="i_006"></A>DIVIDEND POLICY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">We
have never declared or paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable
future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on
then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements,
business prospects and other factors our board of directors may deem relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Under
the Companies Law, we may declare and pay dividends only if, upon the determination of our board of directors, there is no reasonable
concern that the distribution will prevent us from being able to meet the terms of our existing and foreseeable obligations as
they become due. Under the Companies Law, the distribution amount is further limited to the greater of retained earnings or earnings
generated over the two most recent years legally available for distribution according to our then last reviewed or audited financial
statements, provided that the end of the period to which the financial statements relate is not more than six months prior to the
date of distribution. In the event that we do not meet such earnings criteria, we may seek the approval of the court in order to
distribute a dividend. The court may approve our request if it is convinced that there is no reasonable concern that the payment
of a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Payment
of dividends may be subject to Israeli withholding taxes. See &ldquo;Taxation&mdash;Israeli Tax Considerations and Government Programs&rdquo;
for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="i_007"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following table sets forth our cash and
cash equivalents and our capitalization as of December 31, 2020: &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
an actual basis.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on a pro forma basis to
    give effect the issuance of: (i) 1,190,050 Ordinary Shares to be issued upon the conversion of the SAFEs; (ii) 587,297 Ordinary Shares
    to be issued upon the conversion of&nbsp;certain convertible loan agreements; and (iii) 97,762 Ordinary Shares to be issued to financial
    advisors upon the consummation of this offering<FONT STYLE="background-color: white">.</FONT></FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on a pro forma as adjusted basis to give effect to the additional issuance
of&nbsp;securities in this offering (assuming the exercise of any Pre-Funded Warrants that are sold in the offering and assuming no exercise
of the Warrants to be issued to investors), at an assumed public offering price of $6.50 per Unit, which is the midpoint of the price
range set forth on the cover page of this prospectus, and after deducting underwriting discounts and commissions and estimated offering
expenses, as if the sale of the securities had occurred on December 31, 2020. </FONT> </TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The pro forma as adjusted information set
forth in the table below is illustrative only and will be adjusted based on the actual public offering price and other terms of
this offering determined at pricing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should read this table in conjunction
with the sections titled &ldquo;Selected Financial Data&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations&rdquo; and our financial statements and related notes included elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> As of December 31, 2020 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid"> U.S. dollars in thousands </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Actual </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Pro Forma </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro
    Forma<BR> As&nbsp;Adjusted&nbsp;<SUP>(1)</SUP></B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center"> (Unaudited) </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left"> Cash and cash equivalents </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 496 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 7,309 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 20,283 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Convertible note </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,273-
                                            </FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Shareholders&rsquo; equity (deficit): </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Share capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 304 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 514 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 771 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Share premium </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,749 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 16,255 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 29,193 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Foreign exchange reserve </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (635 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (635 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (635 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Share base compensation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,714 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,714 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,714 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Accumulated deficit </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (11,836 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (12,465 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (12,687 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Total shareholders&rsquo; equity (deficit) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (1,704 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,382 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 19,356 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Total capitalization </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (1,704 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,382 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 19,356 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The number of Ordinary Shares purchased from
us by existing shareholders is based on 4,542,317 Ordinary Shares issued and outstanding as of June 25, 2021, and excludes the following
as of such date:&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">559,912 Ordinary Shares
    issuable upon the exercise of options to directors, employees and consultants under our equity incentive plan, outstanding as of
    such date, with exercise prices ranging between NIS 0.37 (approximately $0.12) to NIS 0.97 (approximately $0.29) per share, of which
    378,419 were vested as of such date; </FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,038 Ordinary Shares reserved for future issuance
    under our equity incentive plan; </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">169,016 Ordinary Shares issuable upon the exercise
    of warrants issued to InSense Medical Pty Ltd. in connection with a certain termination agreement, with an exercise price equal to
    the price per Ordinary Share in this offering;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">673,402 Ordinary Shares issuable upon the exercise
    of warrants issued in connection with the SAFEs and an additional 2,747 Ordinary Shares issuable upon the exercise of warrants to
    be issued to promoters in connection with such safe agreements; and</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">293,650 Ordinary Shares issuable upon the exercise
    of warrants issued in connection with a certain convertible loan, and an additional 11,288 Ordinary Shares issuable upon the exercise
    of warrants to be issued to promoters in connection with such convertible loan agreements. </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A $1.00 increase or decrease in the assumed public
    offering price of $6.50 per Unit would increase or decrease the amount of each of cash and cash equivalents and total stockholders&rsquo;
    equity by approximately $2.10 million, assuming that the number of Unit offered by us, as set forth on the cover page of this prospectus,
    remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by
    us. An increase of decrease of&nbsp;1,000,000&nbsp;in the number of Units offered by us would increase or decrease each of cash and
    cash equivalents and total shareholders&rsquo; equity by approximately $5.90 million after deducting estimated underwriting discounts
    and commissions and any estimated offering expenses payable by us.</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">
    </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><A NAME="i_008"></A>SELECTED FINANCIAL DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following table summarizes our financial
data. We have derived the following statements of operations data for the years ended December 31, 2020 and 2019, and the balance sheet
data as of December 31, 2020 and 2019, from our audited financial included elsewhere in this prospectus. We have derived the following
statements of operations data for the year ended December 31, 2020 and 2019, from our unaudited interim condensed financial statements
included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in the
future. The following selected financial data should be read in conjunction with &ldquo;Management&rsquo;s Discussion and Analysis of
Financial Condition and Results of Operations&rdquo; and our financial statements and related notes included elsewhere in this prospectus.
Our financial statements included in this prospectus were prepared in accordance with IFRS, as issued by the IASB. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Year Ended<BR> December 31, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid"> U.S. dollars in thousands, except per share
    data </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2020 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2019 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"> Research and development expenses </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 3,873 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 887 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> general and administrative expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,447 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 384 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> Other income </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 51 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> Total operating expenses </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 6,269 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,271 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> Operating loss </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 6,269 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,271 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> Finance expenses, net </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 959 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 3,304 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Loss before taxes on income </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,228 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,575 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> Income tax expense (benefit) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> Loss for the year </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 7,228 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 4,575 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Other comprehensive income (loss) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (599 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (37 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-align: left"> Net comprehensive loss </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 7,827 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 4,612 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Net comprehensive loss for the period attributable to: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Inspira technologies Oxy B.H.N. Ltd. Shareholders </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,827 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,612 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-align: left"> Basic and diluted loss per share </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (3.67 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (2.401 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> As of December 31, 2020 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid"> U.S. dollars in thousands </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Actual * </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro<BR>
    Forma <SUP>(1) </SUP></B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro
    Forma <BR> As Adjusted <SUP>(2) </SUP></B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center"> (Unaudited) </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold"> Balance Sheet Data: </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left"> Cash and cash equivalents </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 496 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 7,309 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 20,283 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Total assets </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 987 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,800 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 20,774 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Total Current liabilities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 951 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 951 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 951 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Accumulated deficit </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (11,836 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (12,465 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (12,687 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Total shareholders&rsquo; equity (deficit) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (1,704 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,382 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 19,356 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            pro forma data gives effect to the issuance of the issuance of (i) 1,190,050 Ordinary Shares
                                            to be issued upon the conversion of the SAFEs; (ii) 587,297 Ordinary Shares to be issued
                                            upon the conversion of certain convertible loan agreements; and (iii) 97,762 Ordinary Shares
                                            to be issued to financial advisors upon the consummation of this offering<FONT STYLE="background-color: white">.</FONT></FONT> </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pro forma as adjusted data give effect to the additional issuance of securities in this offering (assuming the exercise of any Pre-Funded
Warrants that are sold in the offering and assuming no exercise of the Warrants to be issued to investors), at an assumed public offering
price of $6.50&nbsp;per Unit, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting
underwriting discounts and commissions and estimated offering expenses, as if the sale of the securities had occurred on December 31,
2020.</FONT> </TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><A NAME="i_009"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> If you invest in our securities, your interest
will be diluted immediately to the extent of the difference between the public offering price per Ordinary Share you will pay in this
offering and the pro forma net tangible book value per Ordinary Share after this offering. On December 31, 2020, we had a negative net
tangible book value of $1,704,000, corresponding to a negative net tangible book value of $(0.64) per Ordinary Share. Net tangible book
value per share or per Ordinary Share represents the amount of our total tangible assets less our total liabilities, divided by 2,661,095
the total number of Ordinary Shares issued and outstanding on December 31, 2020. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our pro forma net tangible book value as of
December 31, 2020 was $6,382,000, representing approximately $1.40 per Ordinary Share. Pro forma net tangible book value per Ordinary
Share represents the amount of our total tangible assets less our total liabilities, divided by 4,542,317 shares, the total number of
Ordinary Shares outstanding at December 31, 2020, after giving effect to the issuance of: (i) 1,190,050 Ordinary Shares to be issued
upon the conversion of the SAFEs; (ii) 587,297 Ordinary Shares to be issued upon the conversion of certain convertible loan agreements;
and (iii) 97,762 Ordinary Shares to be issued to financial advisors upon the consummation of this offering<FONT STYLE="background-color: white">.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> After giving effect to the sale of the securities offered by us in this
offering (assuming the exercise of any Pre-Funded Warrants that are sold in the offering and assuming no exercise of the Warrants to be
issued to investors, and assuming no exercise of the underwriter&rsquo;s option to purchase additional Ordinary Shares) and after deducting
the estimated underwriting discounts and commissions and management fees and estimated offering expenses payable by us, our pro forma
net tangible book value estimated at December 31, 2020 would have been approximately $19.3 million, representing $2.83 per Ordinary Share.
At the assumed public offering price for this offering of $6.50 per Unit, which is the midpoint of the price range set forth on the cover
page of this prospectus, this represents an immediate increase in historical net tangible book value of $1.90 per Ordinary Share to existing
shareholders and an immediate dilution in net tangible book value of $3.67 per Ordinary Share to new investors.&nbsp;Dilution for this
purpose represents the difference between the price per Ordinary Share paid by these purchasers and pro forma net tangible book value
per Ordinary Share immediately after the completion of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following table illustrates this dilution
on a per Ordinary Share basis to new investors: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left"> Assumed public offering price per Unit </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 6.50 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Pro Forma net tangible book value per Ordinary Share as of December 31, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.93 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Increase in pro forma net tangible book value per Ordinary Share attributable to new investors </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.90 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Pro forma as adjusted net tangible book value per Ordinary Share after this offering </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.83 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dilution per Ordinary Share to new investors </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 3.67 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Percentage of dilution in net tangible book value per Ordinary Share for new investors </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 56 </TD><TD STYLE="text-align: left"> % </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The dilution information set forth in the table
above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined
at pricing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"> A $1.00 increase or decrease in the assumed
initial public offering price of $6.50 per Ordinary Share would increase or decrease our pro forma net tangible book value per Ordinary
Share after this offering &nbsp;by $0.30 and the dilution per Ordinary Share to new investors by $0.69, assuming the number of Units offered
by us, as set forth on the cover page of this prospectus, remains the same, after deducting the estimated underwriting discounts and
commissions and estimated offering expenses payable by us.&nbsp;We may also increase or decrease the number of Ordinary Shares we are
offering.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"> An increase of&nbsp;1,000,000 in the number
of Units offered by us would increase our pro forma net tangible book value after this offering by approximately $5.90&nbsp;million and
the increase pro forma net tangible book value per Ordinary Share after this offering to $3.22 per Ordinary Share and would increase
the dilution per Ordinary Share to new investors by $0.39, after deducting estimated underwriting discounts and estimated offering expenses
payable by us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-indent: 35.45pt"> A decrease of&nbsp;1,000,000 in the number of Units offered by us would
decrease our pro forma net tangible book value after this offering by approximately $5.90&nbsp;million and decrease pro forma net tangible
book value per Ordinary Share after this offering to $2.30 per Ordinary Share and would increase the dilution per Ordinary Share to new
investors by $0.53, after deducting estimated underwriting discounts and estimated offering expenses payable by us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following table summarizes, on a pro forma
basis as of December 31, 2020, the differences between the number of Ordinary Shares acquired from us as part of the Units and Pre-funded
Units, the total amount paid and the average price per Ordinary Share paid by the existing holders of our Ordinary Shares and by investors
in this offering and based upon an assumed public offering price of $6.50 per Unit, which is the midpoint of the price range set forth
on the cover page of this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares
    </B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Consideration </B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average<BR>
    Price Per<BR>
    Ordinary</B> &nbsp; </FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    </B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent
    </B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
    </B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent
    </B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
    </B>&nbsp; </FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing shareholders </FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,542,317 </FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66.3 </FONT> </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </FONT> </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,943,537
    </FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42 </FONT> </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </FONT> </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.41 </FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    investors </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,307,692
    </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33.7
    </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,000,000
    </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58
    </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.50
    </FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total </FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,850,009
    </FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.0
    </FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </FONT> </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,943,537
    </FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100
    </FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </FONT> </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </FONT> </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">The
number of Ordinary Shares purchased from us by existing shareholders is based on 4,542,317 Ordinary Shares issued and outstanding, and
excludes:&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">559,912 Ordinary Shares issuable upon the exercise
    of options to directors, employees and consultants under our equity incentive plan, outstanding as of such date, with exercise prices
    ranging between NIS 0.37 (approximately $0.12) to NIS 0.97 (approximately $0.29) per share, of which 378,419 were vested as of such
    date; </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,038 Ordinary Shares reserved for future issuance
    under our equity incentive plan;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">169,019 Ordinary Shares issuable upon the exercise
    of warrants issued to InSense Medical Pty Ltd. in connection with a certain termination agreement, with an exercise price equal to
    the price per Ordinary Share in this offering;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">673,402 Ordinary Shares issuable upon the exercise
    of warrants issued in connection with the SAFEs&nbsp;and an additional 2,747 Ordinary Shares issuable upon the exercise of warrants
    to be issued to promoters in connection with such safe agreements; and</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">293,650 Ordinary Shares issuable upon the exercise
    of warrants issued in connection with a certain convertible loan, and an additional 11,288 Ordinary Shares issuable upon the exercise
    of warrants to be issued to promoters in connection with such convertible loan agreements </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> If all of such issued and outstanding options
and warrants had been exercised as of December 31, 2020, the number of Ordinary Shares held by existing shareholders would increase to
6,252,335, or&nbsp;91% of the total number of Ordinary Shares outstanding after this offering, and the average price per Ordinary Share
paid by the existing shareholders would be $2.95.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> If the underwriters exercise their option to
purchase additional Ordinary Shares in full in this offering, the number of Ordinary Shares held by new investors will increase to&nbsp;2,653,846,
or&nbsp;37% of the total number of Ordinary Shares issued and outstanding after this offering and the percentage of Ordinary Shares held
by existing shareholders will decrease to&nbsp;63% of the total Ordinary Shares issued and outstanding. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="background-color: white"><B><A NAME="i_010"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="background-color: white"><B>AND
RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white"><I>The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated
financial statements </I>and <I>the related notes included elsewhere in this prospectus.&nbsp;The discussion below contains forward-looking
statements that are based upon our current expectations and are subject to uncertainty and changes in circumstances. Actual results
may differ materially from these expectations due to inaccurate assumptions and known or unknown risks and uncertainties, including
those identified in &ldquo;Cautionary Note Regarding Forward-Looking Statements&rdquo; and under &ldquo;Risk Factors&rdquo; elsewhere
in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a specialty medical device
company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that
is intended to provide an alternative to invasive MV, which is the standard of care today for the treatment of respiratory
failure. Although it may be lifesaving, MV is associated with increased costs of care, extended lengths of stay, frequent
incidence of infections, ventilator dependence and mortality. Using our state-of-the-art respiratory support technology, our
goal is to set a new standard of care and to provide patients with acute respiratory distress syndrome an opportunity to
maintain spontaneous breathing and avoid the various risks associated with the use of MV. As part of our strategy to reach
this goal, and in parallel to pursuing regulatory approvals, we are actively working to establish collaborations with key
opinion leaders and globally ranked hospitals, to provide endorsement and early clinical adoption of our respiratory support
technology in order for us to achieve strong market penetration at market launch.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Operating Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To date, we have not generated revenue from
the sale of any product, and we do not expect to generate significant revenue within the next year at least.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Operating Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Our
current operating expenses consist of two components&nbsp;&mdash;&nbsp;research and development expenses, general and administrative
expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Expenses, net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Our
research and development expenses consist primarily of salaries and related personnel expenses, share-based compensation expenses,
materials expenses consulting and subcontractor expenses and other related research and development expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In October 2019, we received the approval of
the IIA for its participation in certain development expenses carried out by us, within the framework of determined budgets and time
periods. We received first funds from the IIA in February 2020. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
following table discloses the breakdown of research and development expenses:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Year Ended<BR> December&nbsp;31, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid"> U.S. dollars in thousands </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2020 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> 2019 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"> Salary and related expenses </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 1,237 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 493 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Share based expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,230 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Materials and related expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 440 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 132 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Subcontractors </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 125 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 105 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> IIA participation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> share-based compensation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Depreciation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 196 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 74 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Office maintenance </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 28 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 47 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Travel abroad </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 36 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> IIA participation </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (383 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt"> Total </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 3,873 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 887 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">We
expect that our research and development expenses will materially increase as we continue to develop our products and recruit additional
research and development employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">General
and administrative expenses consist primarily of salaries and related expenses, share based compensation, professional service
fees for accounting and booking, legal fees, facilities, travel expenses and other general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
following table discloses the breakdown of general and administrative expenses:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-style: italic"> Unaudited </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Year Ended<BR> December 31, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid"> U.S. dollars in thousands </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2020 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> 2019 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"> Professional fees </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 154 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 90 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Salary and related expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 140 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Rent and office maintenance </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 77 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 23 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> share-based compensation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 818 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Related IPO expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,235 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 185 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Travel abroad </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 12 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 15 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Depreciation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"> Others </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 4 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt"> Total </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 2,447 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 384 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <FONT STYLE="background-color: white"><B>Comparison
of the Years Ended December 31, 2020 and 2019</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Results of Operations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following table summarizes our results
of operations for the years ended December&nbsp;31, 2020 and 2019: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Year
                                            Ended </B> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>December
                                            31,</B> </P></TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> U.S. dollars in thousands </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2020 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2019 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"> Research and development expenses </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 3,873 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 887 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> General and administrative expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,447 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 384 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Other income </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 51 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Operating loss </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,269 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,271 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Financial expenses </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 959 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 3,304 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Net loss </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,228 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,575 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt"> Loss attributable to holders of Ordinary Shares </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 7,228 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 4,575 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Our
research and development expenses for the year ended December 31, 2020, amounted to $3,873,000 representing an increase of $2,986,000,
or 336 %, compared to $887,000 for the year ended December 31, 2019. The increase was primarily attributable to an increase of $2,230,000
in share-based compensation expenses, since share-based compensation was first granted in April 2020, an increase of $744,000 in salaries
and related personnel expenses reflecting an increase in the number of research and development employees with the efforts to support
the research and trials, and due to the fact that from our inception in February 2018 until May 2019, our founders worked without any
compensation, and to an increase of $308,000 in materials and related expenses.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Our
research and development expenses for the year ended December 31, 2020 includes IIA grants in the amount of $383,000. According to International
Accounting Standard 20 &ldquo;government grants&rdquo;, or IAS, 20, a liability is recognized at its fair value in accordance with the
market interest rate prevailing at the time of receiving the grant. The difference between the consideration received and the liability
recognized at inception was treated as a government grant and recognized as a reimbursement of research expenses or a reduction in capitalized
development costs.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>General and administrative expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Our
general and administrative expenses totaled $2,447,000 for year ended December 31, 2020, an increase of $2,063,000 or 537%, compared
to $384,000 for the year ended December 31, 2019. The increase was primarily attributable to an increase of $818,000 in share-based compensation
expenses, an increase of $73,000 in salaries expenses, reflecting an increase in the number of employees to support business and fundraising
processes and an increase of $1,050,000 in fundraising expenses.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Operating loss</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">As
a result of the foregoing, our operating loss for year ended December 31, 2020 was $6,269,000 compared to an operating loss of $1,271,000
for year ended June 31, 2019, an increase of $4,998,000, or 393%.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Financial expenses </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Financial expenses consist of revaluation
of debt instruments presented at fair value and bank fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We recognized financial expenses for the year
ended December 31, 2020 of $959,000 representing a decrease of $2,345,000 compared to financial expenses of $3,304,000 for year ended
December 31, 2019. The decrease was primarily due to a change in the fair value of debt instruments. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Total comprehensive loss</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="background-color: white">As a
result of the foregoing, our total comprehensive loss for the year ended December 31, 2020 was $</FONT>7,827,000<FONT STYLE="background-color: white">,
compared to $4,612,000 for the year ended December 31, 2019, an increase of $</FONT>3,215,000<FONT STYLE="background-color: white">,
or 70%.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Impact of COVID-19</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The global spread of COVID-19 led many countries,
including Israel, to impose stringent limitations on movement, gatherings, transit of passengers and goods and to close the borders
between countries. The responses of governments have notably impacted many economies as well as capital markets worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our company was able to maintain almost ordinary
levels of operations during the period including the performance of its planned studies. We were affected by service providers lack of
availability and extended times of delivery from suppliers abroad. &nbsp;We also experienced several weeks of delay in receiving components
of the ART500 during the first half of 2020. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Future possible impact of COVID-19 will depend
on future developments with the pandemic which are highly uncertain and cannot be predicted, including new information which may emerge
concerning the severity of COVID-19 and the actions by governments around the world to contain COVID-19 or treat its impact, among others. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We describe our significant accounting policies
more fully in Note 2 to our financial statements for the year ended December 31, 2020. We believe that the accounting policy below is
critical in order to fully understand and evaluate our financial condition and results of operations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We prepare our financial statements in accordance
with IFRS, as issued by the IASB. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The financial statements have been prepared
under the historical cost convention except for the convertible loan, convertible note and warrants that were measured at fair value
through profit or loss, share based compensation that was measured at fair value according to IFRS2 and governments grants that were
measured at amortized cost. We have elected to present the statement of comprehensive loss using the function of expense method. In addition,
these financial statements are presented in the U.S. dollars. All currency amounts have been recorded to the nearest thousand, unless
otherwise indicated. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Use of estimates in the preparation of financial statements:</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The preparation of financial statements requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets
and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Actual results
could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Financial statements in U.S. dollars </I></B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our functional currency is NIS. However, the
presentation currency is US dollars. Transactions and balances in foreign currencies are converted into US dollars in accordance with
the principles set forth by IAS 21 &ldquo;The Effects of Changes in Foreign Exchange Rates.&rdquo; Accordingly, transactions and balances
have been converted as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Assets and liabilities items reported at closing rate of exchange
at the statements of financial position date. </FONT></TD></TR>                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Other comprehensive income items reported at annual average rate of
exchange at the statements of financial position date. </FONT></TD></TR>                                                                        <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Share capital, capital reserve and other capital movement items at
rate of exchange as of the date of recognition of those items. </FONT></TD></TR>                                                                                <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated deficit based on the opening balance for the beginning
of the reporting period in addition to the movements mentioned above. </FONT></TD></TR>                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Rate of exchange rate differentials created were recognized in other
comprehensive income and accumulated in equity. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We incur expenses mainly in NIS and U.S.
dollars, but our financial statements are denominated in U.S. dollars. Accordingly, we face exposure to adverse movements in currency
exchange rates. Our foreign operations will be exposed to foreign exchange rate fluctuations as the financial results are translated
from the functional currency into U.S. dollars. Specifically, the U.S. dollar cost of our operations in Israel is influenced by
any movements in the currency exchange rate of the NIS. Such movements in the currency exchange rate may have a negative effect
on our financial results. If the U.S. dollar weakens against foreign currencies, the translation of these foreign currency denominated
transactions will result in increased operating expenses and net losses. Similarly, if the U.S. dollar strengthens against foreign
currencies, the translation of these foreign currency denominated transactions will result in decreased operating expenses and
net losses. As exchange rates vary, sales and other operating results, when translated, may differ materially from our or the capital
market&rsquo;s expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Fair value of financial instruments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Fair value is the price that would be received
to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place
either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A. In the principal market for the asset or liability, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">B. In the absence of a principal market, in the most advantageous
market for the asset or liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The principal or the most advantageous market
must be accessible by us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">The fair value of an asset or a liability is measured using
the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in
their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant&rsquo;s ability
to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that
would use the asset in its highest and best use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When there are no quoted prices in active
markets for identical assets or liabilities, we use valuation techniques that are appropriate in the circumstances and for which
sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of
unobservable input</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Classification by fair value hierarchy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assets and liabilities measured in the statement
of financial position at fair value are grouped into classes with similar characteristics using the following fair value hierarchy
which is determined based on the source of input used in measuring fair value:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 1</P></TD>
    <TD STYLE="text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- </FONT></TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices (unadjusted) in active markets for identical assets or liabilities. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted prices included within Level 1 that are observable either directly or indirectly. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs that are not based on observable market data (valuation techniques that use inputs that are not based on observable market data). </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Share-based
compensation </I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We measure the share-based expense and the
cost of equity-settled transactions with employees and service providers by reference to the fair value of the equity instruments at
the date at which they are granted. The fair value is determined using an accepted options pricing model. The model is based on share
price, grant date and on assumptions regarding expected volatility, expected life of the options, expected dividend, and a no risk interest
rate. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
selected the Black-Scholes model as our option pricing model to estimate the fair value of the company&rsquo;s options awards. The option-pricing
model requires a number of assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expected
dividend yield</I> &mdash; The expected dividend yield assumption is based on our historical experience and expectation of no future
dividend payouts. We have not historically paid cash dividends and have no foreseeable plans to pay cash dividends in the future.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Volatility</I>&nbsp;&mdash;
The expected volatility is based on similar companies&rsquo; stock volatility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Risk
free interest rate</I>&nbsp;&mdash; The risk-free interest rate is based on the yield of governmental bonds with equivalent terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Contractual
term</I>&nbsp;&mdash; An option&rsquo;s contractual term is the amount of time the holder has to exercise the option, per the
contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
granted options are settled in equity instruments method and not in cash, the fair value of the options at the date of grant is
charged to the statement of comprehensive loss over the vesting period. Non-market vesting conditions are taken into account by
adjusting the number of equity instruments expected to vest at each reporting date so that, ultimately, the cumulative amount
recognized over the vesting period is based on the number of options that eventually vest. Non-vesting conditions and market vesting
conditions are factored into the fair value of the options granted. As long as all other vesting conditions are satisfied, a charge
is made irrespective of whether the market vesting conditions are satisfied. The cumulative expense is not adjusted for failure
to achieve a market vesting condition or where a non-vesting condition is not satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately
before and after the modification, is also charged to the statement of comprehensive income over the remaining vesting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Our
2019 Equity Plan, or 2019 Plan, was adopted by our board of directors on December 2019 (although no options were granted until April
20, 2020). The 2019 Plan provides for the grant of options to our directors, employees, officers, consultants and service providers who
are our employees, officers, directors or consultants, as well as those of our affiliated companies. Under the 2019 Plan, a total of
478,746 options to subscribe for Ordinary Shares have been granted to employees and consultants. The exercise price per share of such
options range between NIS 0.37 (approximately $0.12) and NIS 0.97 (approximately $0.29). The estimated price per share used in the Black
Scholes model to determine the grant-date fair value of these options was $5.88, which was based on our valuation at the grant date.
The vesting period of such options is up to 3 years from the grant date, according to the various vesting periods, between one to three
years. The contractual life of the options issued under the 2019 Plan is ten years. The options were granted under Section 102 of the
Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On December 20, 2020, our board of directors
granted a total of 37,604 options to subscribe for Ordinary Shares to employees and consultants. The vesting period of such options is
up to three years from the grant date. The exercise price per share was NIS 0.37 (approximately $0.12). The estimated price per share
used in the Black Scholes model to determine the grant-date fair value of the options was $10.29, which was based on our valuation at
the grant date. The contractual life of the options issued under the 2019 Plan is ten years. The options were granted under Section 102
of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In order to measure our expense with
regards to equity-based compensation, a valuation was performed by our board of directors, with the assistance of a third-party
expert, and our board of directors considered additional objective and subjective factors that it believed were relevant in determining
such valuation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> During the year ended December 31, 2020,
we recorded a share-based payment expenses in the amount of $3 million. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On February 21, 2021, our board of directors
granted a total of 35,375 options to subscribe for Ordinary Shares to employees and consultants. The vesting period is up to three years
from the grant date. The exercise price per share was NIS 0.37 (approximately $0.12). We estimated the fair value of our ordinary shares
at the grant date using a range of between $11.17 to $13.52. We not yet finalized our valuation of these options, and, therefore, the
estimated value may change. The contractual life of the options under the 2019 Plan is ten years. The options were granted under Section
102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On March 16, 2021, our board of directors granted
a total of 81,633 options to subscribe for Ordinary Shares to a director. The vesting period is up to three years from the grant date.
The exercise price per share was NIS 0.37 (approximately $0.12). We estimated the fair value of the options at the grant date using a
range of between $16.17 to $19.11. We not yet finalized our valuation of these options, and, therefore, the estimated value may change.
The contractual life of the options under the 2019 Plan is ten years. The options were granted under Section 102 of the Israeli Tax Ordinance,
which enables the employee to pay a 25% capital gain tax upon exercise. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In May 2019, we entered into an agreement,
or the May 2019 Agreement, to issue 108,844 shares to certain advisors that assisted with closing a convertible loan agreement. In July
2020, we revised the May 2019 Agreement to decrease the number of shares to 80,273 shares. The shares grant was conditioned upon completion
of a funding in the amount of at least A$3,500,000 at various agreed upon dates. In August 2020, this condition was met, resulting in
the issuance of 80,273 shares. We recorded $848,000 in advisory expenses related to this issuance. The May 2019 Agreement also includes
the grant of an additional 108,844 shares issuable upon an initial public offering event in Australia, according to the agreed timetable
in which the advisors should assist with raising proceeds. In November 2020, we signed an agreement that cancelled the May 2019 Agreement
because we decided to pursue an initial public offering on Nasdaq rather than the Australian Stock Exchange. Therefore, additional 108,844
Ordinary Shares were never issued to such advisors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We agreed to issue to Exchange Listing, LLC,
in consideration for their advisory and consulting services, 73,321 Ordinary Shares upon our initial public offering on the Nasdaq Capital
Market. In addition, we agreed to issue to Peregrine Corporate Limited, in consideration for their advisory and consulting services,
24,440 Ordinary Shares upon our initial public offering on the Nasdaq Capital Market. These issuances resulted in advisory expenses in
the amount of $246,556 recorded in profit and loss. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Research and development costs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Expenditure on research activities is recognized
in profit or loss as incurred. Development expenditure is recognized as an intangible asset when we can demonstrate that: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The product is technically and commercially feasible; </FONT></TD></TR>                                                                                                                                                                                                        <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> We intend to complete the product so that it will
                                            be available for use or sale; </TD></TR>                                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> We have the ability to use or sell the product; </TD></TR>                                                                                                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> We have the technical, financial and other resources to
                                            complete the development and to use or sell the product; </TD></TR>                                                                <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> We can demonstrate that the product will generate future economic
                                            benefits; and </TD></TR>                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> We are able to reliably measure the expenditure attributable
                                            to the product during the development. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the reported years the expenses were
not capitalized, as they do not meet the criteria set forth in IAS 38.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employee benefits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have two types of employee benefit plans
for Israeli employees: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Short-term
                                            employee benefits: Short-term employee benefits include salaries, paid annual leave, paid
                                            sick leave, recreational and social security contributions and are recognized as expenses
                                            as the services are rendered. A liability in respect of a cash bonus or a profit-sharing
                                            plan is recognized when we have a legal or constructive obligation to make such payment
                                            as a result of past service rendered by an employee and a reliable estimate of the amount
                                            can be made. </FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Post-employment
                                            benefits: The plans are normally financed by contributions to insurance companies and are
                                            classified as defined contribution plans. We have contributed to all of its employees
                                            contribution plans pursuant to Section 14 of the Severance Pay Law since 2018, whereby we
                                            pay fixed contributions and will have no legal or constructive obligation to pay further
                                            contributions if the fund does not hold sufficient amounts to pay all employee benefits relating
                                            to employee service in the current and prior periods.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Government grants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Government grants received for the use of research
and development activities, for which we undertook to pay royalties to the state, contingent on future sales arising from this financing,
were treated as forgivable loans. The grant was recognized as a liability in the financial statements, except when there is reasonable
assurance that the company will comply with the conditions for the forgiveness of the loan, then it would be recognized as a government
grant. When the loan bears a below-market rate of interest, the liability is recognized at its fair value in accordance with the market
interest rate prevailing at the time of receiving the grant. The difference between the consideration received and the liability recognized
at inception was treated as a government grant and recognized as a reimbursement of research expenses or a reduction in capitalized development
costs. The repayment of the liability to the state is reviewed every reporting period, with changes in the liability resulting from a
change in the expected royalties recognized in profit or loss. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Use of estimates and judgements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The convertible loan, convertible note and
warrants were designated to be measured at fair value through profit or loss. The fair value of convertible loan, convertible note and
warrants was estimated by using a Monte-Carlo simulation approach, which was aimed to model the value of our assets over time. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Overview </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Since
our inception through December 31, 2020, we have funded our operations principally from the convertible securities and loans&nbsp;and
from government grants. </FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">As
of December 31, 2020, we had $496,000 in cash and cash equivalents.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">The
table below presents our cash flows for the year ended December&nbsp;31, 2019 and 2020:</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Year Ended<BR> December&nbsp;31, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"> U.S. dollars in thousands </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019</B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"> Net cash provided (used in) operating activities </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> (1,876 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> (1,111 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Net cash used in investing activities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (26 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (71 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Net cash provided by financing activities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,289 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,267 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Net increase in cash and cash equivalents </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 387 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 85 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Operating Activities</I></B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Net
cash used in operating activities of $1,876,000 during the year ended December 31, 2020 and net cash used in operating activities of
$1,111,000 during the year ended December 31, 2020 was primarily used for payment of salaries and related personnel expenses, materials
expenses, subcontractors, travel and office maintenance.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="font-size: 6pt">&nbsp;&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Investing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Net
cash used in investing activities of $26,000 during 2020, and net cash used in investing activities of $71,000 during the year ended
December 31, 2019, primarily reflected property purchases and deposit.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Financing Activities </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Net cash provided by financing activities of
$2,289,000 during the year ended December 31, 2020, consisted mainly of $2,157,000 of net proceeds from the convertible note, convertible
loan and from IAA&rsquo;s grant of $308,000. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="font-size: 6pt">&nbsp;&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Net
cash provided by financing activities of $1,267,000 during the year ended December 31, 2019, consisted mainly of $1,355,000 of
net proceeds from the convertible note.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2020 through March 2021, we
entered into certain equity investment agreements, which we refer to as Simple Agreements for Future Equity, or SAFEs, for aggregate
proceeds of $5,414,593. Out of the amounts we received under the SAFEs, $2,803,844 will be converted into our Ordinary Shares,
at a conversion rate equal to the lower of (i) our company valuation cap of $35,000,000, or (ii) a discount of 30% from the per
share price of our Ordinary Share in the event of an initial public offering, merger, acquisition or other liquidity event. However,
if an initial public offering, merger, acquisition, other liquidity event or dissolution event does not take place within 24 months
from December 2020, then the subscription amount under such SAFEs will convert into our Ordinary Shares as follows: (i) investors
representing an aggregate of $1,426,155 of the SAFEs will convert at a conversion price reflecting a company valuation of $17,500,000,
and (ii) investors representing an aggregate of $1,377,689 of the SAFEs will convert at a conversion price reflecting a company
valuation of $35,000,000. In addition, if the subscription amounts under the SAFEs is converted to Ordinary Shares in connection
with an initial public offering, then we will issue the SAFE investors warrants to purchase our Ordinary Shares with an exercise
price equal to the public offering price in such offering, as follows: (i) investors representing an aggregate of $1,426,155 of
the SAFEs shall receive 75% warrant coverage with a four year warrant, and (ii) investors representing an aggregate of $1,377,689
of the SAFEs shall receive 50% warrant coverage with a three year warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The remaining $2,610,749 we received under
the SAFEs will be converted into our Ordinary Shares, at a conversion rate equal to the lower of (i) our company valuation cap
of $70,000,000, or (ii) a discount of 30% from the per share price of our Ordinary Share in the event of an initial public offering,
merger, acquisition or other liquidity event. However, if an initial public offering, merger, acquisition, other liquidity event
or dissolution event does not take place within 24 months from December 2020, then the subscription amount under such SAFEs will
convert into our Ordinary Shares at a conversion price reflecting a company valuation of $70,000,000. In addition, if the subscription
amounts under the SAFEs is converted to Ordinary Shares in connection with an initial public offering, then we will issue the SAFE
investors warrants to purchase our Ordinary Shares with an exercise price equal to the public offering price in such offering with
50% warrant coverage with a three year warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In January through March 2021, we entered into convertible loan agreements
for the aggregate amount of $3,484,113. These convertible loan agreements had a maturity date of May 31, 2021 and bear interest at 5.0%
per year accrued quarterly. Upon completion of this offering, the loan amount under the convertible loan agreements will convert to Ordinary
Shares at a conversion rate equal to a discount of 20% from the per share price of our Ordinary Shares in this offering.
Additionally, the investors will receive warrants to purchase our Ordinary Shares with an exercise price equal to the public offering
price in such offering with 50% warrant coverage with a three year warrant. The conversion of the investment amounts to Ordinary Shares
under the convertible loan agreements results in an additional expense of $200,000 related to a promoters&rsquo; fees in cash. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In May 2021, we offered an extension with a
maturity date of July 15, 2021 for the convertible loan agreements. The convertible loan agreements in the aggregate amount of $3,053,920
were extended. We repaid $430,193 plus interest of 5% per year (approximately $7,000) to the investors who did not agree to the extension. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Current Outlook</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">We
have financed our operations to date primarily through convertible loans and from grants from the IIA. We have incurred losses
and generated negative cash flows from operations since inception in 2018. Since inception, we have not generated any revenue
from the sale of products and we do not expect to generate significant revenues from the sale of our products in the near future.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">As
of December 31, 2020, our cash and cash equivalents were $496,000. We expect that our existing cash and cash equivalents as of the date
of this prospectus will be sufficient to fund our current operations until December 2021, without using the net proceeds from this offering
and/or the net proceeds from exercise of existing warrants. In addition, our operating plans may change as a result of many factors that
may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future capital requirements will depend
on many factors, including:</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress and costs of our research and development activities;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of manufacturing our products;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the magnitude of our general and administrative expenses.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Until
we can generate significant recurring revenues and profit, we expect to satisfy our future cash needs through equity financings. We cannot
be certain that additional funding will be available to us when needed, on acceptable terms, if at all. If funds are not available, we
may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect
to our products. This may raise substantial doubts about our ability to continue as a going concern. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="background-color: white">In addition,
we entered into the SAFEs in December 2020 through March 2021. Pursuant to the SAFEs, we received an aggregate of approximately $</FONT>5,414,593<FONT STYLE="background-color: white">.
</FONT>In January through March 2021, we entered into convertible loan agreements, pursuant to which we received an aggregate of approximately
$3,484,113. In May 2021, we offered an extension with a maturity date of July 15, 2021 for the convertible loan agreements. The convertible
loan agreements in the aggregate amount of $3,053,920 were extended. We repaid $430,193 plus interest of 5% per year (approximately
$7,000) to the investors who did not agree to the extension. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Except for standard
operating leases, we have not engaged in any off-balance sheet arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contractual Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
following table summarizes our contractual obligations at December 31, 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Total </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Less than<BR> 1 year </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 1-3 years </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 3-5 years </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> More than<BR> 5 years </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%"> Cars </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 91 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 51 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 40 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Rent </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 228 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 144 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 84 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Quantitative and Qualitative Disclosures about Market Risk
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are exposed to market risks in the ordinary
course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in
financial market prices and rates. Our current investment policy is to invest available cash in bank deposits with banks that have
a credit rating of at least A-minus. Accordingly, some of our cash and cash equivalents is held in deposits that bear interest.
Given the current low rates of interest we receive, we will not be adversely affected if such rates are reduced. Our market risk
exposure is primarily a result of U.S. dollar/NIS exchange rates, which is discussed in detail in the following paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Impact of Inflation and Currency Fluctuations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our functional is NIS and our reporting
currency is the U.S. dollar. We incur some of our expenses in other currencies. As a result, we are exposed to the risk that the
rate of inflation in countries in which we are active other than the United States will exceed the rate of devaluation of such
countries&rsquo; currencies in relation to the dollar or that the timing of any such devaluation will lag behind inflation in such
countries. To date, we have been affected by changes in the rate of inflation or the exchange rates of other countries&rsquo; currencies
compared to the dollar, and we cannot assure you that we will not be adversely affected in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The annual rate of inflation in Israel was
(0.7)% in 2020 and 0.6% in 2019. The NIS revaluated against the U.S. dollar by approximately (6.97)% in 2020 and (7.8)% in 2019.&nbsp; </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B>&nbsp;</B> </P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="i_011"></A>BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are a specialty medical device company engaged
in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide deteriorating
patients with respiratory failure early saturation elevation and stabilization which is key in preventing mechanical ventilation, or
MV, which is the standard of care today for the treatment of respiratory failure. Although it may be considered lifesaving, <FONT STYLE="background-color: white">MV
is associated with increased costs of care, extended lengths of stay in the hospital, frequent incidence of infections, ventilator dependence
and mortality.</FONT> Using our state-of-the-art respiratory support technology, our goal is to set a new standard of care and to provide
patients with acute respiratory distress insufficiency/failure an opportunity to remain awake maintain spontaneous breathing and avoid
the various risks associated with the use of MV. As part of our strategy to reach this goal, and in parallel to pursuing regulatory approvals,
we are actively working to establish collaborations with strategic partners and globally ranked healthcare centers, to provide endorsement
and clinical adoption for regional deployments of our respiratory support technology. We plan to target intensive care units, or ICUs,
general medical units, emergency medical services and small urban and rural hospitals. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Conditions
leading to respiratory insufficiency (a condition in which the lungs cannot perform sufficient gas exchange to support the body&rsquo;s
metabolism) and respiratory failure happen quickly and are initially hard to observe. These conditions are often caused by a disease
or injury that affects breathing, such as pneumonia. Acute respiratory failure requires emergency treatment and is among the leading
causes of death globally.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In a report published in 2017, the World
Health Organization, or WHO, estimates that over 400 million people globally affected by respiratory insufficiency. Each year,
an estimated 20 million people worldwide receive invasive MV, which is primarily attributed to acute respiratory failure (69%)
and chronic lung disease (10%). In a 2017 report in the Forum of International Respiratory Societies, the global respiratory care
devices market size was estimated to reach approximately $29.86 billion by 2025. The major factors influencing this growth include
the high prevalence of respiratory diseases, the rapid growth of the aging population, the high prevalence of smoking, rising urbanization
and pollution levels and western lifestyle changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic has further exposed the weaknesses and disadvantages of invasive MV that has both high association with considerable
medical risks and iatrogenic complications which further burdens the healthcare system with long hospital stays and high costs
of treatment. COVID-19, has seen the failure of some of the most advanced healthcare systems worldwide in their ability to respond
flexibly, quickly and at scale to rapid growth in demand for respiratory support. COVID-19 led to a rise in the number of intensive
care unit, or ICU, admissions worldwide of patients suffering from respiratory failure and requiring respiratory support solutions,
such as MV. According to an article in the <I>Clinical Infectious Diseases</I> medical journal published in August 2020 by Oxford
University Press, titled &ldquo;Patient Characteristics and Outcomes of 11 721 Patients with Coronavirus Disease 2019 (COVID-19)
Hospitalized Across the Unites States&rdquo;, during 2020, as a result of the COVID-19 pandemic, the mortality rate for patients on MV
in the United States is estimated to have increased to 70%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Redefining Artificial Respiration</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Early saturation elevation and stabilization
are key in preventing MV. Our vision is to become the new standard of care for deteriorating patients with respiratory failure. Therefore,
we have developed a direct blood oxygenation technology called Augmented Respiration Technology, or ART. Our device, the ART500, is comprised
of a minimally invasive, portable dual lumen cannula which is inserted into the jugular vein and utilizes our extra-corporeal direct
blood oxygenation unit to elevate and stabilize declining oxygen saturation levels. The ART500&rsquo;s structure provides the potential
to extend respiratory treatment beyond ICU environments making acute respiratory treatment available in regions and medical facilities
without the need for ICUs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our lead product, the ART500, is a novel respiratory
support system, comprised of a minimally invasive, portable dual lumen cannula which is inserted into the jugular vein and utilizes extra-corporeal
direct blood oxygenation to elevate and stabilize declining oxygen unit saturation levels. In 1 minute, patients can experience immediate
relief. The ART500 will enable patients to be treated while awake, mobile and breathing spontaneously. Accordingly, our ART500 has the
potential to reduce patients&rsquo; length of stay in ICU, rehabilitation period in the hospital, and re-admissions as compared to MV.
The ART500 has yet to be tested in humans and, as such, these claims of a potential advantage in humans are unproven and speculative. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> We completed and tested
the first prototype of our ART500 in March 2020. Throughout 2020, over 40 pre-clinical studies were performed in conjunction with our
team and headed by the veterinary team at LAHAV CRO in Israel to examine the feasibility of direct blood oxygenation to preempt the need
for MV. The main goal of these studies was to use our ART500 and show temporary increase of oxygen gas exchange during respiratory failure
by transferring clinically significant amounts of oxygen to the venous blood, while simultaneously extracting quantities of carbon dioxide.
To date, the ART500 has not been tested on humans and any future testing on humans will be subject to the request of the appropriate
regulators, including the FDA. Based on our regulatory strategy, for the key component sources we intend to pursue a Class II the 510(k)
pathway based on predicates, which are not currently expected to require human trials for FDA clearance. We are taking a multi-step approach
to the regulatory clearance process. We are currently working on submitting our first Class I 510(k) filing planned for Q4-2021 relating
to key component sources of the ART500, to be followed by Class II 510(k) filing in 2022, including the submission of the ART500 in the
fourth quarter of 2022, to support ECLS treatment and sales. An additional regulatory filing is planned in 2023 for the multi-function
sources of ART500, with modifications to support early direct blood oxygenation under a new intent of use to elevate and stabilize oxygen
saturation levels in awake patients. Any modification that could significantly affect its safety or effectiveness, or that would constitute
a major change or modification in its intended use, will require a new 510(k) marketing clearance or, depending on the modification,
a de novo or other. We are planning to apply for the break-through device designation with the FDA for the ART500. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> The ART 500,
subject to regulatory approvals, is intended to be our commercial respiratory support system. When and if we receive the necessary
regulatory approvals, we plan to deploy the first ART500 in ICUs. We expect to commercially launch our ART500 in the United States,
subject to the receipt of the FDA clearance, and in Europe following the receipt of the CE Mark, and we plan to submit an
application for the CE Mark in the first half of 2023. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 249px; width: 616px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"> <FONT STYLE="background-color: white"><I>Figure
1: Description of How ART500 Works</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Figure
1 above depicts how we expect our ART500 to work. Our ART500 is based on our proprietary sub-dynamic technology, which allows for direct
blood oxygenation. We expect that approximately 200 cubic centimeters of blood can be enriched at any given moment, providing a patient
with saturation boost within a minute. Enriched blood will be able to effectively remove carbon dioxide and bond high concentrations
of oxygen.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_003.jpg" ALT="" STYLE="height: 273px; width: 567px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">  <FONT STYLE="font: 10pt Times New Roman, Times, Serif">*When</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">integrated with initiation system</FONT> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"> <FONT STYLE="background-color: white"><I>Figure
2: ART500 Key Sources</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Our
strategic objective is to lead the early oxygenation market with multiple growth drivers, such as potential for ART500 to be used in
small urban and rural hospitals, general medical units, emergency rooms and emergency medical units by offering a new approach to treating
millions of patients, who are currently with MV in ICUs. Approximately 20 million patients are placed on MV annually, and, therefore,
we believe that the ART500 has a total addressable market of $25 billion, based on the targeted patient treatment cost of $1,250 for
each disposable respiratory support unit, multiplied by the number of patients on MV annually. We estimate direct costs for a disposable
unit to be $250 (which includes a cartridge containing oxygenator, pump head, sensors and tubing) and $100 for a cannula, provided that
there will be a mass production of the disposable units. <FONT STYLE="background-color: white">We estimate that the </FONT> direct costs for the disposable unit will form between 25% to 30% of the
sales price to hospitals. Therefore, we estimate the patient treatment cost to be $1,250 for each disposable respiratory support unit.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="background-color: white"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 230px; width: 620px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"> <FONT STYLE="background-color: white"><I>Figure
3: Our Business Model</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">We
believe that we may potentially provide the ART500 and disposable respiratory support units together and separately. Therefore, we are
planning to work with the hospitals based on an operation expense (OPEX) model, as opposed to a capital expense (CAPEX) model. This strategy
will allow us to reduce the need for CAPEX hospital budgets to deploy the entire systems.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">In
parallel to pursuing regulatory approval for our ART500, we are implementing a go-to-market strategy establishing and growing multiple
recurring revenue streams across medical sectors and markets, and in a variety of geographical territories.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Our
go-to-market strategy includes, but is not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"> &nbsp; </TD>
<TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
<TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pursuing world-wide regulatory approvals</I></B><I>:
</I>we plan to pursue regulatory approvals in the United States, Europe, Asia, South America, Africa and the Middle East. </FONT> </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> &nbsp; </TD>
<TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
<TD> <B><I>Collaborating with leading medical centers and health organizations</I></B>: we are working with leading medical centers
and health organizations to reach regional deployment of the ART500. This also includes collaborations with top ranked hospitals to expose
our ART500 and attain both clinical endorsement and adoption of use in acute respiratory care. </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> &nbsp; </TD>
<TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
<TD> <B><I>Identifying potential customer profiles</I></B>: we will be targeting leading medical centers that are interested in acquiring
the key components of our ART500 for blood enrichment applications. We will be also targeting emergency medical services to offer our
ART for early saturation elevation and stabilization in awake patients. Potentially, our ART500 can be used to treat patients with respiratory
failure to prevent MV. Moreover, potentially, our ART500 can be used together with MV to reduce the risk of ventilator induced lung injury
by reducing MV pressure level in lungs and shorten weaning period. </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> &nbsp; </TD>
<TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;</FONT> </TD>
<TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Strategic partners</I></B>: we have entered into
discussions to establish collaborations with leading medical device companies, manufactures and distributors. This will include efforts
that may generate a strategic investment by the strategic partners. The development of a strategic team is key in order to enable our
company to rapidly deploy the ART500 to meet potentially growing demand as well as reach and service clientele internationally, subject
to regulatory approval. </FONT> </TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
<TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Investing in marketing and public relations to
increase awareness of our solution</I></B>: in order to drive market demand for the ART500, we are building our pre-commercialization
infrastructure to support sales following regulatory approvals. We are focusing our efforts within the medical community to introduce
our product and technology to leading hospitals, military branches and government bodies. We also believe that our ART500 has potential
for use outside of the ICU, so we also intend to focus on conventional hospital wards as well as ambulatory settings. Although our ART500
remains in development, has not yet been used in humans, and is not cleared or approved by the FDA or similar foreign regulatory bodies,
we believe that due to the potential ease of use and affordability of the ART500, we will also be able to target smaller urban and rural
hospitals that do not have ICUs, in order to make acute respiratory care accessible to patients living outside of major city centers.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> &nbsp; </TD>
<TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
<TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Garnering appropriate reimbursement and insurance
coverage</I></B>: it is paramount for us to receive reimbursement and insurance coverage to enable hospitals and medical centers to provide
treatment utilizing the ART500. With intensive care becoming increasingly expensive, the ART500 may provide treatment at significantly
reduced cost and without compromising quality of care to patients. We are working on a health economics model as part of the reimbursement
strategy. Our goal is to publish medical literature to provide the Centers for Medicare &amp; Medicaid Services, or CMS, actual data,
presented by us together with top-ranking hospitals. The data collected will be used to demonstrate our ART500&rsquo;s efficiency and
reduced cost of treatment. We intend to pursue reimbursement under specified Medicare Severity-Diagnosis Related Group, or MS-DRG, and
have already begun discussions with some of the required parties. We plan to explore using existing Current Procedural Terminology (CPT)
Codes using a &ldquo;New Approach&rdquo; to an existing procedure, because potentially certain codes selected for COVID-19 may be relevant
for the ART500.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> &nbsp; </TD>
<TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD>
<TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
<TD> Pursuing potential target milestones: In 2021 and 2022, we are planning to pursue a number of potential target milestones, which
include: </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="padding-left: 0.125in"> &#9679;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration
    with Chaim Sheba Medical Center at Tel HaShomer;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 0.125in"> &#9679;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration
    with a pulmonary association;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 0.125in"> &#9679;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration
    with a medical device company;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 0.125in"> &#9679;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic
    manufacturing agreement; </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 0.125in"> &#9679;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    ART500 primary source orders, subject to regulatory clearance; and </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-left: 0.125in"> &#9679;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic
    distribution agreement.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Industry Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Overview of Respiratory Failure </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Respiratory failure is a condition in
which the blood either does not have enough oxygen, has too much carbon dioxide, or both. During inhalation, the lungs take in
oxygen. The oxygen passes into blood, which carries it to the body&rsquo;s organs that need oxygen to function. Carbon dioxide
is removed from the blood during exhaling. An excess of carbon dioxide in blood can harm the body&rsquo;s organs. Inadequate gas
exchange during breathing can lead to respiratory insufficiency, which may lead to hypoxemia and hypercarbia, which are potentially
life-threatening conditions. Diseases that affect breathing, such as chronic obstructive pulmonary disease, or COPD, and various
conditions that affect nerves and muscles controlling breathing, can cause respiratory failure. Respiratory failure is the acute
condition of respiratory insufficiency and is classified as either Type I (involves low oxygen blood levels, and normal or low
carbon dioxide levels) or Type II (involves low oxygen blood levels, with high carbon dioxide levels). According to an article
from 2020 by the Office of Disease Prevention and Health Promotion, titled &ldquo;Respiratory Diseases,&rdquo; currently approximately
15 million American adults have been diagnosed with COPD and it is believed that millions more suffer from COPD but have not been
diagnosed and are not being treated. COPD is the fourth leading cause of death in the United States. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Currently Available Respiratory Support Solutions and
Their Limitations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Key Problem the ART solves</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Dangers and Limited Benefits of Mechanical Ventilation
(MV)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 46%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mechanical
    Ventilation&nbsp; </FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 42%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ART
    </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Procedure </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A high risk and invasive procedure on very sick
    lungs that involves intubating patients whilst in an induced coma </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient can remain awake and breathe spontaneously
    while a minimally invasive cannula is inserted&nbsp;into the patient&rsquo;s jugular vein</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Induced Coma </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Involves intubating patients whilst in an induced
    coma </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients are treated whilst awake &amp; mobile.
    No induced coma </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mortality Rate </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associated with a high rate of mortality&nbsp;(50%
    pre-COVID-19, rising to 80% in COVID-19 patients) </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bypassing lungs will improve patient outcomes &amp;
    is expected to reduce iatrogenic complications </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital Days </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requires long hospital stays 40% have iatrogenic
    complications that extend treatment period </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital days are expected to be reduced by 50%
    with no MV associated complications or weaning required </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weaning </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients have to be weaned off MV, taking up 50%
    of treatment time. It is a traumatic experience, often unsuccessful, extending ICU stay </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No need for weaning, this reduces ICU days by 50%
    on its own </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-admissions </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A 40% re-admission rate with patients eventually
    dying due to the consequences of prolonged MV </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shorter treatment times will reduce complications
    and improve patient outcomes, reducing re-admissions </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Location </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Can only be administered in an ICU setting </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable in ICU &amp; Non-ICU settings (Including
    Ambulatory) </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staff </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requires highly specialized medical staff only available
    in ICU </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No requirement for highly specialized medical staff
    </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Procedure </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A high risk and invasive procedure on very sick
    lungs that involves intubating patients whilst in an induced coma </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A low-risk minimally invasive procedure that bypasses
    the sick lungs &amp; directly oxygenates blood&nbsp;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <I>Table 1: Comparison of MV to our ART500.</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="image_005.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <I>Table 2: Competitive
advantages of our ART500.</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Table 2 above demonstrates competitive advantages
of our ART500 in comparison to MV. Although our ART500 remains in development, has not been tested in humans, and is not cleared or approved
by the FDA or similar foreign regulatory bodies, we believe that our ART500 has competitive advantages over FDA-approved treatments because
our ART500 presents a change to existing solutions, which have significant health risks, which are discussed in detail below. While we
acknowledge that any potential benefits of our ART500 as compared to MV have yet to be observed in human trials, our ART500 is designed
to provide a less invasive and traumatic alternative to MV, which requires patients to undergo intrusive intubation and medically induced
coma, and often adds complications to already diseased lungs. Unlike MV, our ART500 does not require intrusive intubation and inducing
a patient into a medical coma, which means that the patient can be treated while staying awake, mobile and breathing spontaneously. Moreover,
we believe our ART500 is a device with multiple potential modalities because it can potentially be used independently in ICUs and general
medical units and in combination with MV in ICUs. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently
available solutions used to provide respiratory support include oxygen masks and bilevel positive airway pressure (BiPap) masks
for mild to moderate cases of respiratory insufficiency, and MV in more severe cases of respiratory failure, when other, less
invasive methods cannot provide a satisfactory solution. MV performs the work of breathing by providing air to the patient based
on controlled pressure, flow and volume. According to an article from 2016 by RT Magazine, titled &ldquo;Managing the Patient
on Mechanical Ventilation,&rdquo; MV is one of the most common interventions used in the ICUs, with more than half of the patients
being placed on invasive mechanical ventilators within the first 24 hours of their admission to the ICU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Decisions about the
initiation and timing of invasive ventilation can be difficult and early discussion with critical care doctors is essential. Appropriateness
of ventilatory support may also be an issue requiring advanced discussion with patients and families. Once a decision to intubate
has been made, the transition from an awake and self-ventilating patient to controlled invasive ventilation can be very difficult
in the critically ill. Most patients will have evidence of developing or established organ dysfunction, particularly cardiovascular
dysfunction (ischaemic heart disease, sepsis), and commonly such patients are hypovolaemic. Both anesthetic induction agents and
positive pressure ventilation, which decreases venous return, produce cardiovascular depression and peri-intubation hypotension
is common. In addition, cessation of spontaneous ventilation can lead to very rapid desaturation in such patients, due to their
marginal respiratory reserve and circulatory problems.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are several
types of approaches for invasive MV: laryngeal mask airway, or LMA, standard endotracheal tube, or ET, tracheostomy and extracorporeal
membrane oxygenation, or ECMO. During the process for ECMO, large cannulas are used that require fluoroscopy, an imaging technique,
for initial positioning of the cannula, as this is a dangerous process that needs to be done very accurately. Also, MV may lead
to life threatening complications, including ventilator-induced lung injury, or VILI, ventilator associated pneumonia, or VAP,
pneumothorax and tracheomalacia. Patients are also predisposed to develop extrapulmonary complications, such as pressure sores
and muscular atrophy. When a patient is put on MV, the patient is given tranquilizers and sedatives to lower the discomfort associated
with non-physiological positive-pressure ventilation. Tranquilizers and sedatives prevent the patient from coughing, eliminating
secretion or the ability to communicate with his family. Once the individual no longer requires MV support, they are gradually
weaned from the ventilator. They must have adequate oxygenation, carbon dioxide elimination, respiratory muscle strength and reserve
the ability to protect their airway. Unfortunately, since respiratory muscles atrophy during the ventilation process, returning
to normal is quite difficult.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">VILI can result in
pulmonary edema, barotrauma and worsening hypoxemia that itself can prolong MV and lead to multi-system organ dysfunction, thus,
increasing chances of mortality. Alveolar overdistension, atelectrauma and biotrauma are the principal mechanisms of VILI. Alveolar
injury results in high alveolar permeability, interstitial and alveolar edema, alveolar hemorrhage, hyaline membranes, loss of
functional surfactant and alveolar collapse. Thus, adopting a ventilator strategy that reduces VILI is an important goal in ventilatory
management. VAP, a type of hospital acquired pneumonia which is also a common and serious problem in the ICUs, develops more than
48 hours after endotracheal intubation. VAP is associated with an increased risk of death. All-cause mortality associated with
VAP has ranged from 20 to 50% in different studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> An enhanced awareness of the complex and heterogeneous
pulmonary pathophysiology of the various lung syndromes has illuminated the shortcomings of conventional MV. In the United States alone,
approximately 40% of the 5.7 million patients admitted annually to ICUs are placed on MV; up to 70% of these patients end up dying either
from the underlying disorder or from complications stemming from MV.<SUP>27</SUP> With a growing elderly population and more people being
exposed to smoking and pollution, the population requiring MV support is growing rapidly. Given this situation, attention has been focused
on novel supportive measures for managing acute pulmonary failure, which would not have the shortcomings of already available techniques
described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> ECMO is a technique used for gas exchange in
patients who are refractory to ventilator support, when lung function can be only maintained at the expense of further structural lung
damage or severe hemodynamic compromise. The guidelines for considering ECMO include hypoxic respiratory failure due to any cause (primary
or secondary), when the mortality risk is above 50%. The utilization of ECMO is limited by technical complexity, as demonstrated below
in Figure 4, resource implications and associated complications which include hemolysis, blood-borne infections, air-embolism, blood
loss, and others. Moreover, an ongoing effort is aimed towards determining which patients will obtain the largest outcome benefit from
ECMO, as some studies demonstrated MV-equivocal results. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Respiratory
failure and the use of currently available solutions to provide patients with respiratory support are also associated with increased
costs of care and extended lengths of stay. In the United States, COPD alone results in 1.5 million emergency department visits,
and 726,000 hospitalizations each year.<SUP>29</SUP> The Centers for Disease Control and Prevention reports annual financial cost
of COPD to be $29.5 billion direct healthcare medical expenditures and roughly $20 billion in indirect morbidity/mortality costs
in the United States. <SUP>30</SUP></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_006.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <I>Figure 4: a patient connected to an ECMO
device. Source: clevelandclinic.org.</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to an article published in June, 2020 by MarketWatch, total
hospital stay costs for a patient admitted to ICU may reach hundreds of thousands U.S. dollars, especially if infection is suspected.
The daily direct cost of treatment for MV is $1,500 in ICU. For each mechanically ventilated patient, an additional time is required
for weaning off the device, thus, incurring even more hospital resources and costs. Additionally, mechanically ventilated patients
are commonly subject to complications due to exposure to infections, such as VAP, with 8% to 28% of ICU patients requiring an additional
several days of treatment until healed by antibiotics, and mortality rates may reach 33% to 50%. Current MV treatments require
medical specialists and a team of nurses. The longer a person remains in the ICU, the higher the probability that person will require
prolonged ventilation, which in turn exposes the patients to further ventilation-associated complications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Our ART500 Respiratory Support Solution</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our lead product, the ART500, is a form of
respiratory support that utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels
while the patient remains awake, mobile, and breathing spontaneously with their compromised lungs. Unlike other MV alternatives, our
ART500 is a minimally invasive solution which utilizes a single dual lumen cannula inserted into the jugular vein to withdraw blood that
is passed through an external unit designed to filter deoxygenated blood and return it highly oxygenated to the patient&rsquo;s circulatory
system. The ART500 is designed to assure the patient&rsquo;s body and vital organs receive the necessary amount of oxygen. We designed
our ART500 as a low cost, high volume solution for critical care patients requiring advanced respiratory support. It is intended to provide
an alternative to MV, so that patients with respiratory failure will be able to recover from their lung condition without being subjected
to the risk of developing the various common complications brought on by intubation and MV. Our goal is to support healthcare systems
by providing a practical and portable solution facilitating the treatment of respiratory failure, without the need for MV, and with the
ability to deploy ART500 in and outside of ICUs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The ART500 is designed to oxygenate blood directly,
and works in tandem with the underperforming lung, supporting the patients while they are being treated for their underlying medical
condition. We believe this unique approach minimizes or prevents mechanical ventilator associated complications and allows the lungs
to rehabilitate as the patient is kept awake and free of sedatives. Further, the technology is highly applicable in a variety of settings,
which makes it highly accessible, extending acute respiratory care that is currently limited to the ICU, to an ambulatory treatment that
can be administered in all hospital wards as well as in ambulances. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_007.jpg" ALT="" STYLE="height: 231px; width: 411px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <I>Figure 5: our ART500.</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Figure 5 above is a depiction of how we expect
our ART500 to look like once we construct it. Our ART500 is a unit package that will contain all the inner systems. The ART500 includes
a dual lumen cannula inserted into the patient&rsquo;s right jugular vein. The system&rsquo;s centrifugal pump is activated to pump blood
through the dual lumen cannula&rsquo;s outlet drainage tube. The blood is circulated through the system&rsquo;s oxygenator, providing
the blood with an enriched oxygen content and decreased carbon dioxide levels. In a closed system, the oxygenated blood is circulated
back through the cannula&rsquo;s inlet reinfusion tube. The system&rsquo;s dual lumen cannula has numerous proprietary characteristics
that makes it superior in comparison to existing commercial cannulas, including (i) a smaller diameter (the part that enters the jugular
vein), up to 18Fr (approximately 6 millimeters), (ii) safer structure, reducing risk of air embolism, (iii) short length eliminating
the need for positioning through radiography, (iv) low cost of manufacturing, and (v) simplicity of cannulation and application. The
cannula consists of one lumen that drains blood (outer lumen) and one that reinfuses the blood into the cardiovascular system (inner
lumen). The cannula is inserted in the inner jugular vein and positioned in the junction between the subclavian and the superior vena
cava. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> While our ART500 has unique advantages in comparison
to currently available solutions used to provide respiratory support, there is a potential for a number of risks that might be associated
with the use of our ART500. Such risks may include low blood flow that could be associated with generation of thrombi, mechanical damage
to the superior vena cava, generation of a systemic inflammatory response due to bio-compatibility issues, allergic reactions to catheter
or its components, decreased venous returns, local venous bleeding following the extraction of our ART500 or erroneous puncture of an
artery during the insertion of our product. Additionally, any foreign material in a body increases the risk of infections and the patient&rsquo;s
membrane might be clogged for a short period of time. Finally, an individual patient&rsquo;s requirements for gas exchange might significantly
differ from the average, which means that the use of our ART500 might not meet minimum requirements for blood saturation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> &nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_008.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <I>Figure 6: our proprietary ART dual lumen
cannula.</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As a respiratory support
technology, our lead product has the following unique advantages:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Simplicity of administration and minimal invasiveness</I></B>:
    one of the main advantages of our ART500 is that there is no need for an induced coma because there is no intubation involved, and
    the treated patient stays awake. Subject to regulatory clearances, our product will enable small medical teams to perform a simple
    bedside procedure, inserting our dual lumen cannula into the jugular vein. Simplicity of administration and minimal invasiveness
    allow for treatment to be applied at an early stage, thus preventing the need for invasive MV and reducing the need for medically
    induced coma and blood thinners, which, in turn, reduces medical complications and side effects from MV, such as blood clotting,
    hospital days and costs.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dual lumen cannula</I>:</B> our ART cannula <SUB>&nbsp;</SUB>has
    numerous proprietary characteristics that makes it superior in comparison to existing commercial cannulas, such as small diameter
    (up to 18FR) that allows the lumen to be injected directly into a patient&rsquo;s jugular vein while the patient is awake and breathing
    spontaneously, safer structure that reduces risk of air embolism, short length that eliminates the need for positioning that requires
    fluoroscopy or other imaging and simplicity of cannulation and application.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compact and portable allowing for deployment
    in various settings</I></B>: our ART500 is relatively small in size, which allows it to be used both in ICU and non-ICU settings,
    including hospital wards and ambulatory settings, without significant financial burden.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have finalized the preclinical phase for
our ART500, and our development team is now completing work towards product freeze (a stage where development is formally completed,
including design, specifications, operational parameters and components). This will allow the first production of the final product so
that it can undergo safety tests prior to regulatory submissions to the FDA and foreign regulatory agencies, including CE. We are planning
our initial product launch, subject to the receipt of regulatory clearances and reimbursement coding, by the end of 2022. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The WHO estimates that in 2017, over 400
million people globally were affected by respiratory insufficiency. Approximately 20 million patients annually are admitted to
ICUs, requiring acute respiratory care. The respiratory care devices market size is expected to reach $29.86 billion by 2025,
from$16.09 billion in 2019. The major factors influencing this growth include the high prevalence of respiratory diseases, the
rapid growth of the aging population, the high prevalence of smoking, rising urbanization and pollution levels, the increasing
incidence of pre-term births and lifestyle changes. This estimate does not include the expected spike due to the COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Growth
of the global respiratory care device market, which consists of therapeutic devices such as MV and ECMO, monitoring devices, diagnostic
devices, and consumables and accessories, is driven by the (i) rise in the geriatric population, which is prone to respiratory disorders;
(ii) high prevalence of chronic respiratory diseases; and (iii) increase in government expenditures on the healthcare industry due to
an improving of standard of care and extending the availability of treatment to more regions and areas. The aforementioned factors magnify
the need for available and accessible respiratory treatment to support a growing medical need with more people being diagnosed annually
with respiratory disorders as well as suffering from respiratory insufficiencies. However, a number of limitations are associated with
the use of MV, including its high cost of mechanical ventilators and risks associated with the use of MV such as the rise in prevalence
of ventilator-associated pneumonia, or VAP, which hinder the market growth. The urgency to provide medical treatment and save lives are
driving factors that increase the need for respiratory treatment for respiratory failure and insufficiency. The limitations, risks and
costs associated with current solutions are at multiple levels adding excessive strain and burden on the healthcare system, having both
a direct and indirect impact on patient outcomes. This surging need is expected to provide new opportunities for existing market participants
and the entry of new companies with new technological solutions which are high in demand.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The respiratory care devices market is
segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In
2019, North America accounted for the largest share of the respiratory care devices market. In the United States alone, more
than 5.7 million people annually require ICU admission, up to 40% of which require invasive MV, which is the current standard
of care in use since the 1950s, pursuant to an article in the <I>Clinical Infectious Diseases</I> medical journal published
in August 2020 by Oxford University Press, titled &ldquo;Patient Characteristics and Outcomes of 11 721 Patients with
Coronavirus Disease 2019 (COVID-19) Hospitalized Across the Unites States.&rdquo; With a growing elderly population and more
people being exposed to smoking and pollution, the population requiring treatment is growing overwhelmingly. According to
recent estimates in an article &ldquo;Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment&rdquo;
published in February 2018 by JAMA, ARDS accounts for 10% of intensive care unit admissions, representing more than 3 million
patients with ARDS annually. Pursuant to an article &ldquo;The High Cost of Surviving Respiratory Distress Syndrome&rdquo;
published in April 2017 by John Hopkins Medicine, ARDS affects approximately 200,000 Americans every year, and ARDS survivors
often have long-lasting impairments such as cognitive dysfunction, mental health issues and physical impairments, all of
which may affect employment. According to an article &ldquo;Diagnosis and Management of Acute Respiratory Distress Syndrome
in a Time of COVID-19&rdquo;, published in 2020 by the <I>Diagnostics (Basel)</I>, ARDS is a serious clinical illness,
defined by severe hypoxemic respiratory failure, which continues to be associated with significant morbidity, mortality, and
healthcare resource utilization. According to the same source, ARDS comprises 7&ndash;10% of admissions and 15&ndash;25% of
mechanically ventilated patients in the intensive care unit (ICU), is fatal in 30&ndash;50% of patients, and costs on average
over USD 90,000 per patient&rsquo;s ICU stay. According to an article &ldquo;How COVID-19 Will Impact Employer-Sponsored
Health Plans&rdquo; by BKS Partners, the median total cost of an admission for a respiratory condition requiring 96 hours or
more of ventilation is $88,114. Due to its growing geriatric population and environmental conditions that have favored the
spread of respiratory disease, COVID-19 severely affected the region and induced enormous growth in the demand for
respiratory care devices. As a result, participants in this and adjacent markets have focused on or collaborated to expand
the manufacturing of critical care instruments and respiratory care devices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Worldwide demand for
mechanical ventilators has increased substantially, due to the COVID-19 outbreak, resulting in a surge in ICU admissions worldwide. This
exponential increase in COVID-19 cases across the world requires long-term and short-term respiratory support and increased demand for
new solutions. Even prior to COVID-19, approximately 20 million patients were treated annually with MV in ICUs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Study Results</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have completed feasibility studies. In addition,
we intend to continue to perform studies for testing and control purposes, including new purchased and manufactured components, process
integration and automation. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Throughout 2020, over 40 pre-clinical studies
were performed in conjunction with our team and headed by the veterinary team at LAHAV CRO in Israel to examine the feasibility of direct
blood oxygenation to preempt the need for MV. The main goal of these studies was to use our ART500 and show temporary increase of oxygen
gas exchange during respiratory failure by transferring clinically significant amounts of oxygen to the venous blood, while simultaneously
extracting quantities of carbon dioxide. Our scientific advisory board members, who are experts in their fields, were integrally involved
in or viewed the studies at real-time. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
researchers placed seven large-white X landrace pigs (chosen due to resemblance of the anatomy, size scale and other characteristics
to humans), each weighing from 90 to130 kilograms, into an artificial state of hypoxemia (a state when an individual has abnormally
low levels of oxygen in blood) with oxygen saturation levels dropping between 80% to 89%. The oxygen gas concentration was lowered
by mixing pure oxygen with medical air and N2O to reduce the oxygen concentration levels to approximately 15%. The aim of oxygen
decrease was to mimic a state of respiratory failure of compromised sick lungs. When oxygen saturation level drops below 90%,
many doctors will consider using MV to increase the oxygen level.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The researchers used our ART500, which was
primed and then connected to pigs with our proprietary dual lumen cannula, through the right jugular veins of the pigs. Our proprietary
dual lumen cannula allowed simultaneous venous drainage and reinfusion of blood via the jugular vein. Our ART500 includes a centrifugal
pump activated to pump blood from the pig&rsquo;s right jugular vein through the dual lumen cannula&rsquo;s outlet drainage tube. The
blood was circulated through the system&rsquo;s oxygenator, providing the blood with an enriched oxygen content and decreased carbon
dioxide levels. In a closed system, the oxygenated blood was circulated back through the cannula&rsquo;s inlet reinfusion tube. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The pig&rsquo;s oxygen saturation was monitored
at several intervals with blood sampling taken from the testing points. Our ART500 immediately elevated and stabilized the pigs&rsquo;
oxygen saturation level within approximately 60 seconds. The procedure was repeated multiple times on multiple subjects and at different
periods to measure and prove consistency and repeatability of elevated and stabilized blood oxygenation levels following the activation
of our ART500. This effect was achieved in all of our pre-clinical studies. Moreover, our proprietary dual lumen cannula was inserted
and removed without complications. Inspection of the cannulas used in studies demonstrated intact structures without any sign of damage
to the structure or unique characteristics. After the removal of the cannula from the swine&rsquo;s jugular vein, there were no signs
of blood clots or fatigue. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The researchers repeated the procedure described
above to test the efficiency of our ART500 in elevating and stabilizing the oxygen saturation levels on average at 95% to 96%. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> &nbsp; </P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_009.jpg" ALT="" STYLE="height: 238px; width: 624px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"> <I>Table 3: Results of
pre-clinical studies at LAHAV CRO which tested our ART500.</I> </P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>SpO2</B> - oxygen saturation is a measure of the
amount of oxygen-carrying hemoglobin in the blood relative to the amount of hemoglobin not carrying oxygen.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>PaO2</B> - partial arterial oxygen pressure in
arterial blood reflects how well oxygen is able to move from the lungs to the blood.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>PaCO2</B> - partial arterial carbon dioxide pressure,
evaluates the carbon dioxide levels in the blood.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
row in Table 3 above refers to an individual study performed on an individual pig. Occasionally, several tests were performed
on the same pig.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>Third-Party
Reimbursement</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of the date of this prospectus, we do not
have any third-party reimbursement agreements. However, we have plans in place for receiving such reimbursements in the future. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">ICUs represent one of the largest clinical
cost centers in hospitals. MV accounts for a significant share of this cost. There is a relative dearth of information quantifying
the impact of ventilation on daily ICU cost. Therefore, we determine daily costs of ICU care and identify incremental cost of MV
per ICU day and further differentiate cost by underlying diseases. We expect that the reimbursement will be based on a diagnosis-related
groups, or DRG, system. A DRG system classifies hospital cases into groups that are clinically similar and are expected to use
similar amounts of hospital resources. The amount per episode of care is fixed for patients within a single DRG category (based
on an average cost), regardless of the actual cost of care for that individual episode, but the amount may vary across the DRGs.
We intend to pursue a strategy that is based on the CMS guidelines and MS-DRG system as of April 1, 2021.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"> <I>Table 4: MS-DRG
Payments for Selected COVID-19 Treatments.</I> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_010.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>Research and Development and Governmental Grants</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We maintain an active internal research and
development process, which also includes clinical activities and regulatory affairs. Our research and development team consists of 15
persons as of December 2020. We spent $3,873,000 and $887,000 for research and development and related expenses during the year ended
December 31, 2020 and the year ended December&nbsp;31, 2019, respectively. The increase in research and development expenses is primarily
attributable to <FONT STYLE="background-color: white">an increase of $</FONT>2,230,000 <FONT STYLE="background-color: white">in share-based
compensation expenses, since share-based compensation was first granted in April 2020, an increase of $744,000 in salaries and related
personnel expenses reflecting an increase in the number of research and development employees, and due to the fact that from our inception
in February 2018 until May 2019, our founders worked without any compensation, and to an increase of $308</FONT>,000 <FONT STYLE="background-color: white">in
materials and related expenses.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our research and development efforts have been
financed in part through grants in an aggregate amount of approximately $785,126 that we received from the IIA as of June 25, 2021, which
is one of the largest grants provided for a medical device as of the date of this prospectus. We received this grant for the development
of a blood oxygenation system with the goal of providing respiratory support through direct blood oxygenation and elevation of the oxygen
saturation level while removing carbon dioxide. Approximately $677,550 of these are royalty-bearing grants. There is no repayment mechanism,
however, once we reach commercialization stage, we will be obliged to pay royalties for the grant at a rate of 3% from our revenues to
an accumulated royalty earnings of $677,550. Following the full payment of such royalties, there is generally no further liability for
royalty payment. Nonetheless, the restrictions under the Innovation Law will continue to apply even after our company has repaid the
full amount of royalty payable pursuant to the grants.&nbsp;Due to the accrual of interest, the total amount of the grants that will
be repaid through royalties will increase until repayments begin. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white">We
continue to pursue non-dilutive grants from the IIA as well as other organizations in the United States and in Europe. We are specifically
targeting entities in both the medical and military communities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>Production and Manufacturing</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our ART500 is comprised of a number of components.
We are planning to sell an assembled product as well as a disposable respiratory support unit. The components of the assembled product
and the disposable unit consist of both proprietary and off the shelf components. Proprietary components will be manufactured on our
behalf at good manufacturing practices, or GMP, approved production plant to adhere to regulatory requirements, whereas off the shelf
components will be sourced and manufactured by GMP suppliers. GMP sub-contractors will assemble proprietary and off the shelf components
together to create our ART500. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">We have begun the
discussions relating to contracted manufacturing and distribution agreements with leading turnkey OEM vendors that provide end-to-end
solutions. The outsourcing of the supply chain management (such as manufacturing, logistics, shipping and after-market support)
reduces capital expenditure, lead times and costs, while providing us with flexibility and agility.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>Competition</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white">The
medical device industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary
products. There are many medical device companies, biotechnology companies, public and private universities and research organizations
actively engaged in the research and development of products that may be similar to our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> The major market participants
within the respiratory care market and our primary competitors in the United States include Boston Scientific Corporation (NYSE: BSX),
ResMed Inc., (NYSE: RMD), Masimo Corporation (Nasdaq: MASI), Becton, Dickinson and Company (NYSE: BDX), Chart Industries, Inc. (Nasdaq:
GTLS). Other market participants outside the United States include Philips Healthcare, headquartered in the Netherlands, Medtronic plc,
headquartered in Ireland (NYSE: MDT), Fisher &amp; Paykel Healthcare Corporation Limited, headquartered in New Zealand, Dr&auml;gerwerk
AG &amp; Co. KGaA, Dr&auml;gerwerk AG, headquartered in Germany, Hamilton Medical AG, headquartered in Switzerland, Smiths Medical Inc.,
headquartered in Minnesota, the <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">UnitedStates,
Siemens Healthineers AG ADR (Nasdaq: SMMNY), headquartered in Germany, Baxter International (NYSE: BAX), headquartered in Illinois, the
United States, Getinge, headquartered in Sweden, GE Healthcare, headquartered in Illinois, the United States and Terumo Corporation (TYO:
4543, Nikkei 225 Component), headquartered in Shibuya City, Tokyo, Japan. These companies have either developed or acquired respiratory
care devices and solutions, such as mechanical ventilators and ECMO devices.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Our competitors, either alone or
through their strategic partners, have substantially greater name recognition and financial, technical, manufacturing,
marketing and human resources than we do and significantly greater experience and infrastructure in the research and
development of medical devices, obtaining the FDA and other regulatory clearances of those devices and commercializing those
devices around the world.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>Intellectual Property </B></P>




<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">We seek patent protection
as well as other effective intellectual property rights for our products and technologies in the United States and internationally.
Our policy is to pursue, maintain and defend intellectual property rights developed internally and to protect the technology, inventions
and improvements that are commercially important to the development of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">Our intellectual property
portfolio consists of four patent provisional submissions and one PCT application, for which we have either pending status or have
entered national stage and are under examination by national authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 10%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filing
    Date</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%"> <B>&nbsp;</B> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 15%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application
    No.</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%"> <B>&nbsp;</B> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 15%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%"> <B>&nbsp;</B> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%"> <B>&nbsp;</B> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 24%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Type</B></FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/23/2020</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/IB19/51928</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuous Equilibrium-Based Diagnostic &amp; therapeutic
    System</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WIPO, PCT</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/6/2020</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/062282</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submitted</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustable Dual Lumen</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States, Provisional</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/20/2020</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63111803</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submitted</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual Lumen Cannula</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States, Provisional</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/01/2020</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63119997</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submitted </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal Oxygenation Method</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0; margin-top: 0pt; margin-bottom: 0pt"> United
        States, Provisional </P></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/10/2020</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63123809</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submitted </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> A Disposable Set of Consumable Components </P></TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States, Provisional</FONT> </TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">We also rely on trade
secrets, know-how, and continuing innovation to develop and maintain our competitive position. We cannot be certain that patents
will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in
the future, nor can we be sure that any of our existing patents or any patents granted to us in the future will be commercially
useful in protecting our technology.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">Our success depends,
in part, on an intellectual property portfolio that supports future revenue streams and erects barriers to our competitors. We
are maintaining and building our patent portfolio through filing new patent applications, prosecuting existing applications, and
licensing and acquiring new patents and patent applications.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">Despite these measures,
any of our intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or misappropriated.
Intellectual property and proprietary rights may not be sufficient to permit us to take advantage of current market trends or otherwise
to provide competitive one. For more information, see &ldquo;Risk Factors&mdash;Risks Related to our Intellectual Property.&rdquo;&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>Other Products </B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Additional products under development include
our X2 system. The X2 system is an intravenous direct blood oxygenation system designed to provide targeted non-invasive therapeutic
oxygenation therapy for infections and pressure wounds. In June 2020, we entered into a collaboration and license agreement with
B.G. Negev Technologies and Applications Ltd., a wholly-owned subsidiary of Ben-Gurion University of the Negev in Beer Sheva.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>Government Regulation and Product Approval </B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Our products and our operations are subject
to regulation by numerous worldwide regulatory bodies including the FDA and comparable international regulatory agencies.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Our products are subject to regulation as
medical devices under the Federal Food, Drug, and Cosmetic Act, or FDCA, as implemented and enforced by the FDA. The FDA regulates
the development, design, non-clinical and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage, installation,
servicing, recordkeeping, premarket clearance or approval, import, export, adverse event reporting, advertising, promotion, marketing
and distribution, and import and export of medical devices to ensure that medical devices distributed domestically are safe and
effective for their intended uses and otherwise meet the requirements of the FDCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">In addition to U.S. regulations, we are
subject to a variety of regulations in the European Economic Area, or the EEA, governing clinical trials and the commercial sales
and distribution of our products. Whether or not we have or are required to obtain FDA clearance or approval for a product, we
will be required to obtain authorization before commencing clinical trials and to obtain marketing authorization or approval of
our products under the comparable regulatory authorities of countries outside of the United States before we can commence clinical
trials or commercialize our products in those countries. The approval process varies from country to country and the time may be
longer or shorter than that required for FDA clearance or approval. Medical devices are generally subject to varying levels of
regulatory control based on risk level of the device.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>FDA Premarket Clearance and Approval Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Unless an exemption applies, each medical
device commercially distributed in the United States requires FDA clearance of a 510(k) premarket notification, granting of a de
novo request, or approval of an application for premarket approval, or PMA. Under the FDCA, medical devices are classified into
one of three classes&mdash;Class&nbsp;I, Class&nbsp;II or Class&nbsp;III&mdash;depending on the degree of risk associated with
each medical device and the extent of regulatory controls needed to ensure its safety and effectiveness. Class&nbsp;I includes
devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the
FDA&rsquo;s General Controls for medical devices, which include compliance with the applicable portions of the Quality System Regulation,
or QSR, facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling.
Class&nbsp;II devices are subject to the FDA&rsquo;s General Controls, and special controls as deemed necessary by the FDA to ensure
the safety and effectiveness of the device. These special controls can include performance standards, post-market surveillance,
patient registries and FDA guidance documents. While most Class&nbsp;I devices are exempt from the 510(k) premarket notification
requirement, manufacturers of most Class&nbsp;II devices are required to submit to the FDA a premarket notification under Section&nbsp;510(k)
of the FDCA requesting permission to commercially distribute the device. The FDA&rsquo;s permission to commercially distribute
a device subject to a 510(k) premarket notification is generally known as 510(k) clearance.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>The 510(k) Process</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Under the 510(k) process, the manufacturer must submit to the
FDA a premarket notification demonstrating that the device is &ldquo;substantially equivalent&rdquo; to either a device that was
legally marketed prior to May&nbsp;28, 1976, the date upon which the Medical Device Amendments of 1976 were enacted, and for which
a pre-market approval, or PMA, is not required, a device that has been reclassified from Class&nbsp;III to Class&nbsp;II or Class&nbsp;I,
or another commercially available device that was cleared through the 510(k) process. To be &ldquo;substantially equivalent,&rdquo;
the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics
as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness
than the predicate device. Clinical data is sometimes required to support substantial equivalence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">After a 510(k) premarket notification is
submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review,
the FDA will refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. By statute,
the FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical
matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared
without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial
equivalence, which may significantly prolong the review process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">If the FDA agrees that the device is substantially
equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. If
the FDA determines that the device is &ldquo;not substantially equivalent&rdquo; to a previously cleared device, the device is
automatically designated under the FDCA as a Class&nbsp;III device. The device sponsor must then fulfill more rigorous PMA requirements,
or can request a risk-based classification determination for the device in accordance with the de novo process, which is a route
to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">After a device receives 510(k) marketing
clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change
or modification in its intended use, will require a new 510(k) marketing clearance or, depending on the modification, a de novo
grant or PMA approval. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k)
(or a PMA) in the first instance, but the FDA can review any such decision and disagree with a manufacturer&rsquo;s determination.
Many minor modifications today are accomplished by a manufacturer documenting the change in an internal letter-to-file. The FDA
can review these letters to file during an inspection. If the FDA disagrees with a manufacturer&rsquo;s determination, the FDA
can require the manufacturer to cease marketing and/or request the recall of the modified device until 510(k) clearance, de novo
grant or PMA approval is obtained. In these circumstances, we may be subject to significant regulatory fines or penalties.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>De Novo Classification</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Medical device types that the FDA has not
previously classified as Class&nbsp;I, II or III are automatically classified under the FDCA into Class&nbsp;III regardless of
the level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a route to market for low
to moderate risk medical devices that are automatically placed into Class&nbsp;III due to the absence of a predicate device, called
the &ldquo;Request for Evaluation of Automatic Class&nbsp;III Designation,&rdquo; or the de novo classification procedure. This
procedure allows a manufacturer whose novel device is automatically classified into Class&nbsp;III to request down-classification
of its medical device into Class&nbsp;I or Class&nbsp;II on the basis that the device presents low or moderate risk, rather than
requiring the submission and approval of a PMA application. Prior to the enactment of the Food and Drug Administration Safety
and Innovation Act of 2012, or FDASIA, a medical device could be eligible for de novo classification only if the manufacturer
first submitted a 510(k) premarket notification and received a determination from the FDA that the device was not substantially
equivalent to a legally marketed predicate device. FDASIA streamlined the de novo classification pathway by permitting manufacturers
to request de novo classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a
not substantially equivalent determination. Under FDASIA, the FDA is required to classify the device within 120 days following
receipt of the de novo application. If the manufacturer seeks reclassification into Class&nbsp;II, the manufacturer must include
a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of
the medical device. In addition, the FDA may reject the request if it identifies a legally marketed predicate device that would
be appropriate for a 510(k) notification, determines that the device is not low to moderate risk, or that general controls would
be inadequate to control the risks and special controls cannot be developed. After a device receives de novo classification, any
modification that could significantly affect its safety or efficacy, or that would constitute a major change or modification in
its intended use, will require a new 510(k) clearance or, depending on the modification, another de novo petition or even PMA
approval.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>Clinical Trials</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Clinical trials are almost always required
to support a PMA and are sometimes required to support a 510(k) submission. All clinical investigations of investigational devices
to determine safety and effectiveness must be conducted in accordance with the FDA&rsquo;s Investigational Device Exemption, or
IDE, regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an
array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents
a &ldquo;significant risk&rdquo; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE
application to the FDA, which must become effective prior to commencing human clinical trials. A significant risk device is one
that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, used in supporting
or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing
impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported
by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans and that
the testing protocol is scientifically sound. The IDE will automatically become effective 30&nbsp;days after receipt by the FDA
unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or
other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional
approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">In addition, the study must be approved
by, and conducted under the oversight of, an Institutional Review Board, or IRB. The IRB is responsible for the initial and continuing
review of the study and may pose additional requirements for the conduct of the study. If an IDE application is allowed to go
into effect by the FDA and the study approved by the reviewing IRB(s), human clinical trials may begin at a specific number of
investigational sites with a specific number of subjects as set forth in the study protocol. If the device presents a non-significant
risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without
separate review from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring
that the investigators obtain informed consent, and labeling and record-keeping requirements. Acceptance of an IDE application
for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective, the FDA may
or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation
of clinical trials. An IDE supplement must be submitted to, and allowed to go into effect by, the FDA before a sponsor or investigator
may make a change to the investigational plan that may affect its scientific soundness, study plan or the rights, safety or welfare
of human subjects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">During a study, the sponsor is required
to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and
providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on
the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the
clinical study are also subject to FDA regulations and must obtain patient informed consent, follow the investigational plan and
study protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements.
Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various
reasons, including a belief that the risks to study subjects outweigh the anticipated benefits.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>Post-market Regulation</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">After a device is cleared or approved for
marketing, numerous and extensive regulatory requirements may continue to apply. These include but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">annual and updated establishment
    registration and device listing with the FDA;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QSR requirements, which require manufacturers
    to follow stringent design, testing, control, documentation, complaint handling and other quality assurance procedures during
    all aspects of the design and manufacturing process;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">advertising and promotion requirements;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on sale, distribution or use of
    a device;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">labeling and marketing regulations, which require
    that promotion is truthful, not misleading, and provides adequate directions for use and that all claims are substantiated,
    and also prohibit the promotion of products for unapproved or &ldquo;off-label&rdquo; uses and impose other restrictions on
    labeling;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Physician Sunshine Act and various
    state and foreign laws on reporting remunerative relationships with health care customers;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback Statute (and similar
    state laws) prohibiting, among other things, soliciting, receiving, offering or providing remuneration intended to induce
    the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as Medicare or
    Medicaid. A person or entity does not have to have actual knowledge of this statute or specific intent to violate it to have
    committed a violation;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal False Claims Act (and similar state
    laws) prohibiting, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to
    the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or
    transmit money or property to the federal government or knowingly concealing, or knowingly and improperly avoiding or decreasing,
    an obligation to pay or transmit money to the federal government. The government may assert that a claim that includes items
    or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes
    of the false claims statute;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clearance or approval of product modifications
    to legally marketed devices that could significantly affect safety or effectiveness or that would constitute a major change
    in intended use;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">medical device reporting regulations, which
    require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious
    injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to
    a death or serious injury, if the malfunction were to recur;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">correction, removal and recall reporting regulations,
    which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce
    a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complying with the federal law and regulations
    requiring Unique Device Identifiers on devices and also requiring the submission of certain information about each device
    to the FDA&rsquo;s Global Unique Device Identification Database;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&rsquo;s recall authority, whereby the
    agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations
    if there is a reasonable probability that the use of the device would cause a serious, adverse health consequence or death;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-market surveillance activities and regulations,
    which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness
    data for the device.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The FDA has broad regulatory compliance
and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take a
variety of compliance or enforcement actions, which may result in any of the following sanctions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning letters, untitled letters, fines, injunctions,
    consent decrees and civil penalties;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls, withdrawals, or administrative detention
    or seizure of our products;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating restrictions or partial suspension
    or total shutdown of production;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing or delaying requests for 510(k) marketing
    clearance or PMA approvals of new products or modified products;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawing 510(k) clearances or PMA approvals
    that have already been granted;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to grant export or import approvals
    for our products; or</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal prosecution.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">In the European Union, or the EU, we will be required to comply
with the new Medical Device Regulation, or the MDR, effective May 2020 which will supersede the current Medical Device Directives.
The MDR was published in May 2017 with a 3-year transition period. The CE Mark required to sell medical devices in the European
Union is affixed following conformity assessment and either approval from the appointed independent Notified Body or through self-certification
by the manufacturer. The selected pathway to CE marking is based on product risk classification. CE Marking indicates conformity
to the applicable Essential Requirements of the relevant Medical Devices Directive and in the future to the General Safety and
Performance Requirements for the new MDR. The MDR will change multiple aspects of the existing regulatory framework for CE marking,
such as increased clinical evidence requirements and other new requirements, including Unique Device Identification as well as
many other post-market obligations. MDR also significantly modifies and increases the compliance requirements for the industry
and will require significant investment over the next few years to implement.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">We are also required to comply with the
regulations of every other country where we commercialize products before we can launch or maintain new products on the market.
Many countries that previously did not have medical device regulations, or had minimal regulations, are now introducing them.
For example, India is in the process of expanding its current regulations to include all medical device categories while many
countries in the Middle East and Southeast Asia are introducing new regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">The FDA and other worldwide regulatory agencies and competent
authorities actively monitor compliance to local laws and regulations through review and inspection of design and manufacturing
practices, record-keeping, reporting of adverse events, labeling and promotional practices. The FDA can ban certain medical devices,
detain or seize adulterated or misbranded medical devices, order repair, replacement or refund of these devices and require notification
of health professionals and others with regard to medical devices that present unreasonable risks of substantial harm to the public
health. The FDA may also enjoin and restrain a company for certain violations of the FDCA and the Safe Medical Devices Act pertaining
to medical devices or initiate action for criminal prosecution of such violations. Regulatory agencies and authorities in the countries
where we do business can halt production in or distribution within their respective country or otherwise take action in accordance
with local laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">International sales of medical devices
manufactured in the U.S. that are not approved by the FDA for use in the U.S., or that are banned or deviate from lawful performance
standards, are subject to FDA export requirements. Additionally, exported devices are subject to the regulatory requirements of
each country to which the device is exported. Some countries do not have medical device regulations, but in most foreign countries,
medical devices are regulated. Frequently, regulatory approval may first be obtained in a foreign country prior to application
in the U.S. due to differing regulatory requirements; however, other countries, such as China, for example, require approval in
the country of origin first.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Most countries outside of the United States
require that product approvals be recertified on a regular basis, generally every five years. The recertification process requires
that we evaluate any device changes and any new regulations or standards relevant to the device and, where needed, conduct appropriate
testing to document continued compliance. Where recertification applications are required, they must be approved in order to continue
selling our products in those countries.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Planned Regulatory Filings</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are taking a multi-step approach to the
regulatory clearance process. Our ART500 is made up of several key sources that together can provide a new intent of use, allowing use
for direct blood oxygenation to provide saturation elevation in awake patients. We are planning to submit the first 510(k) application
for the key component sources of our ART500 in the fourth quarter of 2021 to support extracorporeal life support treatment and sales.
We are also planning additional applications in relation to multi-function sources of ART500, which will be our commercial respiratory
support system. When and if we receive clearance, we plan to deploy the first ART500 in ICUs at the end of 2022. We are planning to submit
application for CE in 2022. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Based on our regulatory strategy, for the key
component sources we intend to pursue as a Class II the 510(k) pathway based on predicates, which are not currently expected to require
human trials for FDA clearance. For the multi-function sources of ART500, modification that could significantly affect its safety or
effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) marketing clearance
or, depending on the modification, a de novo or other. We are planning to apply for the break-through device designation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="margin: 0pt 0"> Additionally, as a part of our strategy to bring our device to market and streamline reimbursement coding
and clinical adoption of the ART500 that offers a new intent of use, we will collaborate with top ranking hospitals to perform a human
observational study focused on: (i) proving that the ART500 can prevent patient deterioration resulting in the need for invasive MV,
and (i) assisting in weaning patients off MV. </P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>Organizational Structure</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">Currently, we do not
have any subsidiaries.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>Property and Facilities </B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our main business activities are conducted
in Israel. Our offices, research and development and manufacturing facilities are located at Melisron (Millennium Building), 2 Ha-Tidhar
St., Ra&rsquo;anana 4366504, Israel, where we occupy approximately 400 square meters. Our lease ends in July 2022, and we have an option
to extend the lease for an additional year thereafter on the same terms. Our monthly rent payment as of December 2020, was approximately
NIS 25,600 (approximately $7,718). </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">We consider that our
current office space is sufficient to meet our anticipated needs for the foreseeable future and is suitable for the conduct of
our business.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>Employees </B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: left; margin-top: 0pt; text-indent: 0.5in; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> As
of&nbsp;June 25, 2021, we had four members of senior management (including our Chief Executive Officer), of which three are full-time
employees and one is a part-time employee. In addition, we have twelve full-time employees, three part-time and three independent contractors
and three consultants located in Israel&nbsp;and one consultant located in Australia. None of our employees located in Israel are represented
by labor unions or covered by collective bargaining agreements. However, in Israel, we are subject to certain Israeli labor laws, regulations
and national labor court precedent rulings, as well as certain provisions of collective bargaining agreements applicable to us by virtue
of extension orders issued in accordance with relevant labor laws by the Israeli and Industry of Economy and which apply such agreement
provisions to our employees even though they are not part of a union that has signed a collective bargaining agreement. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">All of our employment and consulting agreements
include employees&rsquo; and consultants&rsquo; undertakings with respect to non-competition and assignment to us of intellectual
property rights developed in the course of employment and confidentiality. The enforceability of such provisions is limited by
Israeli law.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>Legal Proceedings</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> From time to time, we may be involved in various
claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any material legal proceedings.
Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources
and other factors. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in"> &nbsp; </P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="i_012"></A>MANAGEMENT</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>Directors
and Senior Management </B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following table sets forth information
regarding our executive officers, key employees and directors as of June 25, 2021: </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> &nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 174px; border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT> </TD>
    <TD STYLE="width: 6px"> &nbsp; </TD>
    <TD STYLE="width: 50px; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT> </TD>
    <TD STYLE="width: 6px"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Director</FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joe Hayon</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer, President, Director</FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Udi Nussinovitch</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Scientific Officer</FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avi Shabtai</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operations Officer</FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prof. Benad Goldwasser <SUP>(1) (2) (3)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tal Parnes <SUP>(1) (2) (3)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Nominee</FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limor Rozen <SUP>(1) (2) (3)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Nominee</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 31px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Compensation Committee</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Audit Committee and Financial
    Statement Examination Committee</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director (as defined under Nasdaq
    Stock Market rules)</FONT> </TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>Dagi Ben-Noon, Chief Executive Officer, Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>Mr. Dagi Ben-Noon</I> has served as
our Chief Executive Officer since July 2020 and as our director since March 2020. Prior to that, Mr. Ben-Noon served as our Chief
Operations Officer from March 2018 to June 2020. Mr. Ben-Noon founded our company together with Dr. Udi Nussinovitch and Mr. Joe
Hayon in July 2017. Mr. Ben-Noon has over 15 years of experience in product development from idea inception to illustration, design,
manufacturing and product launch. Mr. Ben-Noon co-founded Nano Dimension Ltd. (Nasdaq: NNDN) and served as the company&rsquo;s
chief operating officer and director from July 2012 to October 2017. As Nano Dimension Ltd.&rsquo;s chief operating officer, Mr.
Ben-Noon was in charge of the company&rsquo;s research and development, operations, production, quality and information technology.
Mr. Ben-Noon has a BSc in Mechanical Engineering from the Ben-Gurion University of the Negev in Beer Sheva, Israel. We selected
Mr. Ben-Noon to serve on our board of directors because of his strong business background.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>Joe Hayon, Chief Financial Officer, President, Director</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>Mr. Joe Hayon</I> has served as our
President and Chief Financial officer since July 2020 and as our director since November 2020. Prior to that, Mr. Hayon served
as our Chief Executive Officer from March 2018 to June 2020. Mr. Hayon founded our company together with Dr. Udi Nussinovitch
and Mr. Dagi Ben-Noon in July 2017. Mr. Hayon has over 20 years of experience in managerial roles. From 2001 to 2005, Mr. Hayon
worked as a treasurer and cost accountant at Sanmina Ltd. (formerly known as Elscint). From 2006 to 2007, Mr. Hayon worked as
chief financial officer for Arazim Group. He worked for Plasan Sasa Ltd. from 2007 to 2018 as the company&rsquo;s chief information
officer and group controller. Mr. Hayon has a B.A. in Business and Economics and an MBA with a major in Marketing and Finance,
both from the University of Manchester, as well as a Business Management Diploma from Damelin College. We selected Mr. Hayon to
serve on our board of directors because he brings to our board of directors an extensive experience in finance.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"> <B>Dr.
Udi Nussinovitch</B>, <B>MD PhD</B>, <B>Chief Scientific Officer</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <I>Dr. Udi Nussinovitch</I> has served as our
Chief Scientific Officer since March 2018. Dr. Nussinovitch served as our director from March 2018 to June 2021. He started working on
our core technology when he served in the Israeli Navy as a senior diving and hyperbaric physician from 2011 to 2015. Dr. Nussinovitch
founded our company together with Messrs. Dagi Ben-Noon and Joe Hayon in July 2017. Dr. Nussinovitch has over 14 years of clinical experience.
Dr. Nussinovich has been working as a practicing cardiologist and is currently a director at the Applicative Cardiovascular Research
Centre (ACRC) at Meir Medical Centre since 2018. Dr. Nussinovitch worked as a practicing physician at Sheba Medical Centre from 2007
to 2008, Rambam Hospital from 2015 to 2017 and at Meir Medical Centre from September 2017 to 2018. Dr. Udi Nussinovitch qualified as
an MD at the Sackler Faculty of Medicine at Tel Aviv University and has a PhD from the Technion Institute of Technology. Dr. Nussinovitch
is also an educator &ndash; he teaches internal medicine and cardiology to medical students. Dr. Nussinovitch has 69 publications in
peer-reviewed journals and serves as a sole editor for three scientific books, published by Elsevier AP. We selected Dr. Nussinovitch
to serve on our board of directors due to his extensive scientific experience and background in the medical field. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>Avi Shabtai, Vice President of Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>Mr. Avi Shabtai</I> has served as our
Chief Operations Officer from July 2020 and as our Vice President of Research and Development since June 2019. Mr. Mr. Shabtai&rsquo;s
expertise lies in engineering, testing, quality management, regulation, risk management and production across a product&rsquo;s
life cycle from concept to production. He has over 25 years of experience in management of high-tech companies, particularly in
their research and development and operations departments, including roles of vice president of research and development and vice
president of quality and engineering. From July 2015 to March 2018, Mr. Shabtai worked as vice president of research and development
at Nano Dimension Ltd. (Nasdaq: NNDN). Prior to that, Mr. Shabtai worked as vice president of research and development at ZutaCore
from April 2018 to May 2019. Mr. Shabtai is qualified as software quality engineer by the ALD College and the Israeli Standard
Institute.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Prof. Benad Goldwasser, MD MBA,
Chairman of the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Prof. Benad Goldwasser </I>has served
as chairman of our board of directors since February 2021. <FONT STYLE="background-color: white">Prof. Goldwasser is a urologic
surgeon, inventor, entrepreneur and venture capital investor with vast experience in leading high growth, publicly traded medical
companies. In 1993, Prof. Goldwasser co-founded Vidamed Inc., which was acquired by Medtronic Inc. (NYSE: MDT). In 1994, Prof.
Goldwasser co-founded Medinol Ltd., in partnership with Boston Scientific (NYSE: BSX). Prof. Goldwasser has served as chairman
of the board of directors of Save Foods, Inc. (OTC: SAFO) since May 2018 and as chairman of the board of directors of ScoutCam
Inc. (OTC: SCTC) since March 2019, and as a member of the board of directors of Innoventric Ltd. since September 2017. Prior to
that, Prof. Goldwasser has served as chairman of the board of directors of Medigus Ltd. (Nasdaq and TASE: MDGS) from September
2018 to December 2019, and as a consultant to Shanghai-Israel Investment Fund from May 2016 to May 2019. In 2016, Prof. Goldwasser
launched a venture capital fund partnered with Shanghai Alliance Investment Ltd (SAIL), a Shanghai Government investment company.
Prof. Goldwasser has also served on the board of directors of BioCanCell Ltd. (TASE: BICL) from 2013 to 2016. Prof. Goldwasser
holds an MD and MBA from Tel-Aviv University. </FONT>We selected Prof. Goldwasser to serve as chairman of our board of directors
due to his extensive medical and corporate experience. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>Limor Rozen, Director Nominee</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="background-color: white">Mrs.
Limor Rozen has been appointed to serve on our board of directors upon completion of this offering. Mrs. Rozen has been working a senior
consultant at Vecon Ltd. from 2019. Prior to that, Mrs. Rozen was co-founded and served as a chief executive officer and &nbsp;general
manager of zzoo Protocol from 2017 to 2020. From 2012 to 2017, Mrs. Rozen served as a chief operating officer of 365 Technologies Ltd.
Mrs. Rozen also served as VP of product and customer project of Collarity in Palo Alto, California, the United States from 2006 to 2011,
served as senior team leader in Right Order, San Jose, California, the United States from 2000 to 2006 and as a team leader in Converse
between 1999 to 2004. Mrs. Rozen holds an MBA with specialization in Technology Management from University of Phoenix, Phoenix, Arizona,
the United States and a B.A. in Computer Science from Bar-Ilan university. We selected Mrs. Rozen to serve as a director due to her rich
experience as a consultant to technology companies.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Tal Parnes, Director Nominee</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white"><I>Mr. Tal
Parnes</I> has been appointed to serve on our board of directors upon completion of this offering. Mr. Parnes co-founded and served as
a chief executive officer and president (2016-2020) of Zuta-Core Ltd. from 2016 to 2020. Prior to that, Mr. Parnes co-founded and served
as a chief executive officer of HQL Pharmaceuticals Ltd. from 2010 to 2015.&nbsp; Mr. Parnes also served as chief operating officer of
Silynx Communications Inc. from 2007 to 2009, served as a vice president of operations of Wavion Inc. from 2005 to 2006 and Atrica Ltd.
2002-2004. Between 1999 to 2001, Mr. Parnes also served as a chief financial officer and business development director of Printlife Ltd.
Mr. Parnes holds a B.A. in Economics and History from Tel Aviv University. We selected Mr. Parnes to serve as a director due to his broad
experience in bringing technology companies to market, both from a management and a business development perspective.&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Scientific Advisory Board</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have a Scientific Advisory Board of four
active physicians and experts in the field(s) of: respiratory disease, pulmonary diseases, cardiac disease and laboratory animal science.
The Scientific Advisory Board consults and assists us in the aforementioned fields by conducting clinical research and participating
in pre-clinical studies. The members of our Scientific Advisory Board receive compensation in the form of cash payments or option grants.
All members of the Scientific Advisory Board provided us with their consents to be named in this prospectus and any materials related
hereto. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white"><I>Prof.
Eli Gabbay, </I>M.D., MBBS, FRACP, is a respiratory physician and a specialist of respiratory disease. Prof. Gabbay is Professor of Respiratory
Medicine at the University of Notre Dame (Australia) Medical School and The University of Western Australia Medical School. He is also
Adjunct Professor at Curtin University School of Physiotherapy. Prof. Gabbay also serves as a Deputy Director Clinical Services, Director
of Post Graduate Education and Physician Training, Head of Department of Respiratory Medicine, Head of Respiratory Research and Chair,
Bendat Respiratory Research and Development Fund at St John of God Subiaco Hospital, Western Australia.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="text-indent: 0.5in; margin: 0pt 0"> Dr. Yigal Kassif <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is a cardiac surgeon
at the <FONT STYLE="background-color: white">Chaim Sheba Medical Center at Tel HaShomer </FONT>in Ramat Gan, Israel. Dr. Kassif has been
a senior surgeon since 1995, specializing in adult cardiac surgery, heart Transplantation and assist devices. Dr. Kassif has been serving
as the director of the ECMO program in the <FONT STYLE="background-color: white">Chaim Sheba Medical Center at Tel HaShomer</FONT> since
2019, and in September 2019, he was appointed the first chairman of the Israel ECMO Society. In 2008, Dr. Kassif was one of the entrepreneurs
of Leviticus Cardio Ltd., a start-up company that developed wireless technology for Left Ventricular Assist Device. From 2018 to 2020,
Dr. Kassif served as a consultant in Serenno Medical, a start-up company that developed electronic urine output and abdominal pressure
measurement for the purpose of &ldquo;no touch technique&rdquo; in the ICU environment.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white"><I>Dr.
Avraham Abutbul, M.D.,</I> has held numerous positions at the Hadassah Medical Center in Jerusalem, Israel, since 2008. Currently, Dr.
Abutbul has served a senior physician the Hadassah Medical Center&rsquo;s Medical Intensive Care Unit and its Pulmonology Institute since
2017, in addition to leading the Hadassah Medical Center&rsquo;s nationwide research of chronic obstructive pulmonary disease. Prior
to his current roles, Dr. Abutbul completed fellowship at the Institute of Pulmonology in 2016 and the General Intensive Care Unit in
2014. Dr. Abutbul also completed residency at the Department of Internal Medicine in 2012. Dr. Abutbul is a lecturer at the Hebrew University
of Jerusalem, Israel and at the Hadassah Medical School, Jerusalem, Israel. Dr. Abutbul received his B.Med.Sc. from the The Ruth and
Bruce Rappaport Faculty of Medicine in Haifa, Israel.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="background-color: white"><I>Dr.
Orit Cohen Jacob</I></FONT> is veterinary surgeon with a unique certified speciality in laboratory animal medicine. Dr. Jacob held numerous
positions at the Israel Institute for Biological Research in Ness Ziona, Israel, for 16 years, while leading the establishment of the
biggest pre-clinical animal facility and laboratories in Israel. At the Israel Institute for Biological Research, Dr. Jacob founded a
GMP stable facility, for anti-serum production for the State of Israel. Dr. Jacob participated as a surgeon and advisor, in her field
of expertise, in a wide variety of research studies, related to homeland security from 1999 to 2015. Dr. Jacob was a member of the national
animal experimentation council of the ministry of health, and head of the national ethics committee for animal experimentations from
2013 to 2018. Currently, Dr. Jacob is the co-owner and chief executive officer of SeruMed GMP Ltd., which has been the sole manufacturer
and provider of the anti-venom serum against viper and echis snakes to the Ministry of Health of Israel since 2016. Furthermore, Dr.
Jacob is the owner of BioSphera Consulting Ltd., through which she has been providing knowledge to bio-tech companies in all aspects
of pre-clinical research, facility establishment, GMP regulations, ethics and science since 2016. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>Family Relationships</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">There are no family relationships between
any members of our executive management and our directors.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>Arrangements for Election of
Directors and Members of Management</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">There are no arrangements
or understandings with major shareholders, customers, suppliers or others pursuant to which any of our executive management or
our directors were selected. See &ldquo;Related Party Transactions&rdquo; for additional information. </P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>Compensation </I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table presents in the aggregate
all compensation we paid to all of our directors and senior management as a group for the year ended December 31, 2020. The table
does not include any amounts we paid to reimburse any of such persons for costs incurred in providing us with services during this
period.&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All amounts reported in the table below
reflect our cost, in thousands of U.S. dollars. Amounts paid in NIS are translated into U.S. dollars at the rate of NIS 3.44 =
U.S. $1.00, based on the average representative rate of exchange between the NIS and the U.S. dollar as reported by the Bank of
Israel during such period of time.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Salary, bonuses and</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Related</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Benefits</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pension,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Retirement</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and Other</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Similar</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Benefits</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share<BR> Based<BR> Compensation<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">All directors and senior management as a group, consisting of four persons as of December&nbsp;31, 2020.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">652,976</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">143,712</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,804,993</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based compensation
    includes options to purchase 285,763 Ordinary Shares, at exercise price ranging between NIS 0.37 (approximately $0.12) to NIS 0.97
    (approximately $0.29) per share, granted on April 20, 2020 and exercisable for 10 years from the date of the grant. </FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">For so long as
we qualify as a foreign private issuer, we will not be required to comply with the proxy rules applicable to U.S. domestic companies
regarding disclosure of the compensation of certain executive officers on an individual basis. Pursuant to the Companies Law,
we will be required, after we become a public company, to disclose the annual compensation of our five most highly compensated
officers on an individual basis. This disclosure will not be as extensive as that required of a U.S. domestic issuer. We intend
to commence providing such disclosure, at the latest, in the annual proxy statement for our first annual meeting of shareholders
following the closing of this offering, which will be filed under cover of a report on Form 6-K.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>Employment Agreements with Executive Officers </I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="text-indent: 0.5in; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"> We have entered into
written employment agreements with each of our executive officers. All of these agreements contain customary provisions regarding noncompetition,
confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited
under applicable law. In addition, we intend to enter into indemnification agreements, subject to the listing of our securities on the
Nasdaq Capital Market, with each executive officer and director pursuant to which we will indemnify each of them up to a certain amount
and to the extent that these liabilities are not covered by directors and officers insurance. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">For a description
of the terms of our options and option plans, see &ldquo;Management&mdash;Equity Incentive Plan<FONT STYLE="font-variant: small-caps">&rdquo;
</FONT>below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>Directors&rsquo; Service Contracts</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Other than with respect to our directors
that are also executive officers, we do not have written agreements with any director providing for benefits upon the termination
of his employment with our company.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>Differences between the Companies
Law and Nasdaq Requirements</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The Sarbanes-Oxley Act, as well as related
rules subsequently implemented by the SEC, require foreign private issuers, such as us, to comply with various corporate governance
practices. In addition, following the listing of the Ordinary Shares on Nasdaq, we will be required to comply with the Nasdaq
Stock Market rules. Under those rules, we may elect to follow certain corporate governance practices permitted under the Companies
Law in lieu of compliance with corresponding corporate governance requirements otherwise imposed by the Nasdaq Stock Market rules
for U.S. domestic issuers.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">In accordance with Israeli law and practice
and subject to the exemption set forth in Rule&nbsp;5615 of the Nasdaq Stock Market rules, we have elected to follow the provisions
of the Companies Law, rather than the Nasdaq Stock Market rules, with respect to the following requirements:</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Quorum</I>. While the Nasdaq Stock Market rules
        require that the quorum for purposes of any meeting of the holders of a listed company&rsquo;s ordinary voting stock,
        as specified in the company&rsquo;s bylaws, be no less than 33 1/3% of the company&rsquo;s outstanding ordinary voting
        stock, under Israeli law, a company is entitled to determine in its articles of association the number of shareholders
        and percentage of holdings required for a quorum at a shareholders meeting. Our amended and restated articles of association
        provide that a quorum of two or more shareholders holding at least 25% of the voting rights in person or by proxy is required
        for commencement of business at a general meeting. However, the quorum set forth in our amended and restated articles
        of association with respect to an adjourned meeting consists of at least one shareholders present in person or by proxy.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Compensation of officers.</I>&nbsp;Israeli law and
        our amended and restated articles of association do not require that the independent members of our board of directors
        (or a compensation committee composed solely of independent members of our board of directors) determine an executive
        officer&rsquo;s compensation, as is generally required under the Nasdaq Stock Market rules with respect to the chief executive
        officer and all other executive officers. Instead, compensation of executive officers is determined and approved by our
        compensation committee and our board of directors, and in certain circumstances by our shareholders, either in consistency
        with our office holder compensation policy or, in special circumstances in deviation therefrom, taking into account certain
        considerations stated in the Companies Law. See &ldquo;Management&mdash;Board Practices&mdash;Approval of Related Party
        Transactions under Israeli Law&rdquo; for additional information.</P></TD></TR>
</TABLE>

<P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Shareholder approval.</I>&nbsp;We will seek shareholder
        approval for all corporate actions requiring such approval under the requirements of the Companies Law, rather than seeking
        approval for corporation actions in accordance with Nasdaq Listing Rule&nbsp;5635. In particular, under this Nasdaq Stock
        Market rule, shareholder approval is generally required for: (i)&nbsp;an acquisition of shares/assets of another company
        that involves the issuance of 20% or more of the acquirer&rsquo;s shares or voting rights or if a director, officer or
        5% shareholder has greater than a 5% interest in the target company or the consideration to be received; (ii)&nbsp;the
        issuance of shares leading to a change of control; (iii)&nbsp;adoption/amendment of equity compensation arrangements (although
        under the provisions of the Companies Law there is no requirement for shareholder approval for the adoption/amendment
        of the equity compensation plan); and (iv)&nbsp;issuances of 20% or more of the shares or voting rights (including securities
        convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales by directors/officers/5%
        shareholders) if such equity is issued (or sold) at below the greater of the book or market value of shares. By contrast,
        under the Companies Law, shareholder approval is required for, among other things: (i)&nbsp;transactions with directors
        concerning the terms of their service or indemnification, exemption and insurance for their service (or for any other
        position that they may hold at a company), for which approvals of the compensation committee, board of directors and shareholders
        are all required, (ii)&nbsp;extraordinary transactions with controlling shareholders of publicly held companies, which
        require the special approval, and (iii)&nbsp;terms of employment or other engagement of the controlling shareholder of
        us or such controlling shareholder&rsquo;s relative, which require special approval. In addition, under the Companies
        Law, a merger requires approval of the shareholders of each of the merging companies.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Approval of Related Party Transactions</I>. All
        related party transactions are approved in accordance with the requirements and procedures for approval of interested
        party acts and transaction as set forth in the Companies Law, which requires the approval of the audit committee, or the
        compensation committee, as the case may be, the board of directors and shareholders, as may be applicable, for specified
        transactions, rather than approval by the audit committee or other independent body of our board of directors as required
        under the Nasdaq Stock Market rules. See &ldquo;Management&mdash;Board Practices&mdash;Approval of Related Party Transactions
        under Israeli Law&rdquo; for additional information.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Annual Shareholders Meeting.&nbsp;</I> As opposed
        to the Nasdaq Stock Market Rule 5620(a), which mandates that a listed company hold its annual shareholders meeting within
        one year of the company&rsquo;s fiscal year-end, we are required, under the Companies Law, to hold an annual shareholders
        meeting each calendar year and within 15 months of the last annual shareholders meeting.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Distribution of periodic reports to shareholders;
    proxy solicitation.</I>&nbsp;As opposed to the Nasdaq Stock Market rules, which require listed issuers to make such reports
    available to shareholders in one of a number of specific manners, Israeli law does not require us to distribute periodic reports
    directly to shareholders, and the generally accepted business practice in Israel is not to distribute such reports to shareholders
    but to make such reports available through a public website. In addition to making such reports available on a public website,
    we currently make our audited consolidated financial statements available to our shareholders at our offices and will only
    mail such reports to shareholders upon request. As a foreign private issuer, we are generally exempt from the SEC&rsquo;s
    proxy solicitation rules.</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Board Practices</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Introduction</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Upon the consummation of this offering, our
board of directors will consist of six members. We believe that Prof. Benad Goldwasser, Limor Rozen and Tal Parnes are &ldquo;independent&rdquo;
for purposes of the Nasdaq Stock Market rules. We intend to appoint an additional &ldquo;independent&rdquo; director following the consummation
of this offering, so that our board of directors will have a majority of &ldquo;independent&rdquo; directors. Our amended and restated
articles of association provide that the number of board of directors&rsquo; members shall be set by the general meeting of the shareholders
provided that it will consist of not less than two and not more than nine. Pursuant to the Companies Law, the management of our business
is vested in our board of directors. Our board of directors may exercise all powers and may take all actions that are not specifically
granted to our shareholders or to management. Our executive officers are responsible for our day-to-day management and have individual
responsibilities established by our board of directors. Our Chief Executive Officer is appointed by, and serves at the discretion of,
our board of directors, subject to the employment agreement that we have entered into with him. All other executive officers are appointed
by our Chief Executive Officer. Their terms of employment are subject to the approval of the board of directors&rsquo; compensation committee
and of the board of directors, and are subject to the terms of any applicable employment agreements that we may enter into with them. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Each director, except external directors
that may be required to be appointed under the Companies Law under certain circumstances, will hold office until the next annual
general meeting of our shareholders following his or her appointment, or until he or she resigns or unless he or she is removed
by a majority vote of our shareholders at a general meeting of our shareholders or upon the occurrence of certain events, in accordance
with the Companies Law and our amended and restated articles of association. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In addition, under certain circumstances,
our amended and restated articles of association allow our board of directors to appoint directors to fill vacancies on our board
of directors or in addition to the acting directors (subject to the limitation on the number of directors), until the next annual
general meeting or special general meeting in which directors may be appointed or terminated. External directors may be elected
for up to two additional three-year terms after their initial three-year term under the circumstances described below, with certain
exceptions as described in &ldquo;External Directors&rdquo; below. External directors may be removed from office only under the
limited circumstances set forth in the Companies Law. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Under the Companies Law, any shareholder
holding at least one percent of our outstanding voting power may nominate a director. However, any such shareholder may make such
a nomination only if a written notice of such shareholder&rsquo;s intent to make such nomination has been given to our board of
directors. Any such notice must include certain information, including the consent of the proposed director nominee to serve as
our director if elected, and a declaration that the nominee signed declaring that he or she possesses the requisite skills and
has the availability to carry out his or her duties. Additionally, the nominee must provide details of such skills, and demonstrate
an absence of any limitation under the Companies Law that may prevent his or her election, and affirm that all of the required
election-information is provided to us, pursuant to the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Under the Companies Law, our board of directors
must determine the minimum number of directors who are required to have accounting and financial expertise. In determining the
number of directors required to have such expertise, our board of directors must consider, among other things, the type and size
of the company and the scope and complexity of its operations. Our board of directors has determined that the minimum number of
directors of our company who are required to have accounting and financial expertise is two.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The board of directors must elect one director
to serve as the chairman of the board of directors to preside at the meetings of the board of directors, and may also remove that
director as chairman. Pursuant to the Companies Law, neither the chief executive officer nor any of his or her relatives is permitted
to serve as the chairman of the board of directors, and a company may not vest the chairman or any of his or her relatives with
the chief executive officer&rsquo;s authorities. In addition, a person who reports, directly or indirectly, to the chief executive
officer may not serve as the chairman of the board of directors; the chairman may not be vested with authorities of a person who
reports, directly or indirectly, to the chief executive officer; and the chairman may not serve in any other position in the company
or a controlled company, but he or she may serve as a director or chairman of a controlled company. However, the Companies Law
permits a company&rsquo;s shareholders to determine, for a period not exceeding three years from each such determination, that
the chairman or his or her relative may serve as chief executive officer or be vested with the chief executive officer&rsquo;s
authorities, and that the chief executive officer or his or her relative may serve as chairman or be vested with the chairman&rsquo;s
authorities. Such determination of a company&rsquo;s shareholders requires either: (1) the approval of at least a majority of
the shares of those shareholders present and voting on the matter (other than controlling shareholders and those having a personal
interest in the determination) (shares held by abstaining shareholders shall not be considered); or (2) that the total number
of shares opposing such determination does not exceed 2% of the total voting power in the company. Currently, we have a separate
chairman and chief executive officer.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The board of directors may, subject to
the provisions of the Companies Law, delegate any or all of its powers to committees of the board, and it may, from time to time,
revoke such delegation or alter the composition of any such committees, subject to certain limitations. Unless otherwise expressly
provided by the board of directors, the committees shall not be empowered to further delegate such powers. The composition and
duties of our audit committee, financial statement examination committee and compensation committee are described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The board of directors oversees how management
monitors compliance with our risk management policies and procedures, and reviews the adequacy of the risk management framework
in relation to the risks faced by us. The board of directors is assisted in its oversight role by an internal auditor. The internal
auditor undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported
to our audit committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>External Directors</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Under the Companies
Law, except as provided below, companies incorporated under the laws of the State of Israel that are publicly traded, including
Israeli companies with shares listed on the Nasdaq, are required to appoint at least two external directors who meet the qualification
requirements set forth in the Companies Law. The definitions of an external director under the Companies Law and independent director
under Nasdaq Stock Market rules are similar such that it would generally be expected that our two external directors will also
comply with the independence requirement under Nasdaq Stock Market rules. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Pursuant to
regulations under the Companies Law, the board of directors of a company such as us is not required to have external directors
if: (i) the company does not have a controlling shareholder (as such term is defined in the Companies Law); (ii) a majority of
the directors serving on the board of directors are &ldquo;independent,&rdquo; as defined under Nasdaq Rule 5605(a)(2); and (iii)
the company follows Nasdaq Rule 5605(e)(1), which requires that the nomination of directors be made, or recommended to the board
of directors, by a Nominating Committee of the board of directors consisting solely of independent directors, or by a majority
of independent directors. The Company meets all these requirements. Our board of directors has resolved to adopt the corporate
governance exemption set forth above, and accordingly we will not have external directors as members of our board of directors. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B>&nbsp;&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Alternate Directors</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">Our amended and
restated articles of association provide, as allowed by the Companies Law, that any director may, subject to the conditions set
thereto including approval of the nominee by our board of directors, appoint a person as an alternate to act in his place, to
remove the alternate and appoint another in his place and to appoint an alternate in place of an alternate whose office is vacated
for any reason whatsoever. Under the Companies Law, a person who is not qualified to be appointed as a director, a person who
is already serving as a director or a person who is already serving as an alternate director for another director, may not be
appointed as an alternate director. Nevertheless, a director who is already serving as a director may be appointed as an alternate
director for a member of a committee of the board of directors so long as he or she is not already serving as a member of such
committee, and if the alternate director is to replace an external director, he or she is required to be an external director
and to have either &ldquo;financial and accounting expertise&rdquo; or &ldquo;professional expertise,&rdquo; depending on the
qualifications of the external director he or she is replacing. A person who does not have the requisite &ldquo;financial and
accounting experience&rdquo; or the &ldquo;professional expertise,&rdquo; depending on the qualifications of the external director
he or she is replacing, may not be appointed as an alternate director for an external director. A person who is not qualified
to be appointed as an independent director, pursuant to the Companies Law, may not be appointed as an alternate director of an
independent director qualified as such under the Companies Law. Unless the appointing director limits the time or scope of the
appointment, the appointment is effective for all purposes until the appointing director ceases to be a director or terminates
the appointment.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Committees of the Board of Directors </B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Our board of directors has established
two standing committees, the audit committee and the compensation committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Audit Committee</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Under the Companies Law, we will be
required to appoint an audit committee subject to the listing of our Ordinary Shares on the Nasdaq Capital Market. The audit committee
must be comprised of at least three directors, including all of the external directors, if applicable, (one of whom must serve
as chair of the committee). The audit committee may not include the chairman of the board; a controlling shareholder of the company
or a relative of a controlling shareholder; a director employed by or providing services on a regular basis to the company, to
a controlling shareholder or to an entity controlled by a controlling shareholder; or a director who derives most of his or her
income from a controlling shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our audit committee will be comprised of &nbsp;Prof.
Benad Goldwasser, Limor Rozen and Tal Parnes. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Companies Law, our audit committee is
responsible for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether there are deficiencies in
    the business management practices of our company, and making recommendations to the board of directors to improve such practices;
    </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether to approve certain related
    party transactions (including transactions in which an office holder has a personal interest and whether such transaction
    is extraordinary or material under Companies Law) and establishing the approval process for certain transactions with a controlling
    shareholder or in which a controlling shareholder has a personal interest (see &ldquo;Management&mdash;Board Practices&mdash;Approval
    of Related Party Transactions under Israeli law&rdquo;);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining the approval process for transactions
    that are &ldquo;non-negligible&rdquo; (i.e., transactions with a controlling shareholder that are classified by the audit
    committee as non-negligible, even though they are not deemed extraordinary transactions), as well as determining which types
    of transactions would require the approval of the audit committee, optionally based on criteria which may be determined annually
    in advance by the audit committee;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining our internal controls and internal
    auditor&rsquo;s performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities;
    </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</Font></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining the scope of our auditor&rsquo;s work and
        compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending
        on which of them is considering the appointment of our auditor;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures for the handling of
    employees&rsquo; complaints as to deficiencies in the management of our business and the protection to be provided to such
    employees; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the board of directors approves the working
    plan of the internal auditor, examining such working plan before its submission to the board of directors and proposing amendments
    thereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our audit committee may not conduct
any discussions or approve any actions requiring its approval (see &ldquo;Management&mdash;Board Practices&mdash;Approval of Related
Party Transactions under Israeli law&rdquo;), unless at the time of the approval a majority of the committee&rsquo;s members are
present. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Our board of directors intends to adopt
an audit committee charter to be effective upon the listing of our Ordinary Shares on the Nasdaq Capital Market setting forth,
among others, the responsibilities of the audit committee consistent with the rules of the SEC and Nasdaq Listing Rules (in addition
to the requirements for such committee under the Companies Law), including, among others, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversight of our independent registered public
    accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public
    accounting firm to the board of directors in accordance with Israeli law;</FONT></TD></TR>
</TABLE>

<P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the engagement or termination of
    the person filling the office of our internal auditor, reviewing the services provided by our internal auditor and reviewing
    effectiveness of our system of internal control over financial reporting;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the terms of audit and non-audit
    services provided by the independent registered public accounting firm for pre-approval by our board of directors; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and monitoring, if applicable, legal
    matters with significant impact, finding of regulatory authorities&rsquo; findings, receive reports regarding irregularities
    and legal compliance, acting according to &ldquo;whistleblower policy&rdquo; and recommend to our board of directors if so
    required.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Nasdaq Stock Market Requirements for Audit Committee</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Under the Nasdaq Stock Market rules, we
are required to maintain an audit committee consisting of at least three members, all of whom are independent and are financially
literate and one of whom has accounting or related financial management expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As noted above, the members of our audit committee
will include Prof. Benad Goldwasser, Tal Parnes and Limor Rozen. Tal Parnes will serve as the chairman of our audit committee. All members
of our audit committee meet the requirements for financial literacy under the Nasdaq Stock Market rules. Our board of directors has determined
that each member of our audit committee is an audit committee financial expert as defined by the SEC rules and has the requisite financial
experience as defined by the Nasdaq Stock Market rules.&nbsp; </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Under the Companies Law, our audit committee
also carries out the duties of a financial statement examination committee. As such, the audit committee is responsible for: (i)
estimations and assessments made in connection with the preparation of financial statements; (ii) internal controls related to
the financial statements; (iii) completeness and propriety of the disclosure in the financial statements; (iv) the accounting
policies adopted and the accounting treatments implemented in material matters of the company; and (v) value evaluations, including
the assumptions and assessments on which evaluations are based and the supporting data in the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Compensation Committee</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Under the Companies Law, the board of
directors of any public company must establish a compensation committee. The compensation committee must be comprised of at least
three directors, including all of the external directors (if any). The compensation committee is subject to the same Companies
Law restrictions as the audit committee as to: (a) who may not be a member of the committee; and (b)&nbsp;who may not be present
during committee deliberations as described above. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our compensation committee, acting pursuant
to a written charter, will consist of Prof. Benad Goldwasser, Limor Rozen and Tal Parnes. Our compensation committee complies with the
provisions of the Companies Law, the regulations promulgated thereunder, and our amended and restated articles of association, on all
aspects referring to its independence, authorities and practice. Our compensation committee follows home country practice as opposed
to complying with the compensation committee membership and charter requirements prescribed under the Nasdaq Stock Market rules. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Our compensation committee reviews and
recommends to our board of directors: with respect to our executive officers&rsquo; and directors&rsquo;: (1) annual base compensation
(2) annual incentive bonus, including the specific goals and amounts; (3) equity compensation; (4) employment agreements, severance
arrangements, and change in control agreements and provisions; (5) retirement grants and/or retirement bonuses; and (6) any other
benefits, compensation, compensation policies or arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The duties of the compensation committee
include the recommendation to the company&rsquo;s board of directors of a policy regarding the terms of engagement of office holders,
to which we refer as a compensation policy. Such policy must be adopted by the company&rsquo;s board of directors, after considering
the recommendations of the compensation committee. The compensation policy is then brought for approval by our shareholders, which
requires a special majority (see &ldquo;Management&mdash;Board Practices&mdash;Approval of Related Party Transactions under Israeli
law&rdquo;). Under the Companies Law, the board of directors may adopt the compensation policy if it is not approved by the shareholders,
provided that after the shareholders oppose the approval of such policy, the compensation committee and the board of directors
revisit the matter and determine that adopting the compensation policy would be in the best interests of the company. Under the
Companies Law, we are required to adopt an office holder compensation policy no later than 9 months from the consummation of this
offering. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The compensation policy must serve as the
basis for decisions concerning the financial terms of employment or engagement of executive officers and directors, including
exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement.
The compensation policy must relate to certain factors, including advancement of the company&rsquo;s objectives, the company&rsquo;s
business and its long-term strategy, and creation of appropriate incentives for executives. It must also consider, among other
things, the company&rsquo;s risk management, size and the nature of its operations. The compensation policy must furthermore consider
the following additional factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the education, skills, expertise and accomplishments
    of the relevant director or executive;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the director&rsquo;s or executive&rsquo;s roles
    and responsibilities and prior compensation agreements with him or her;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between the cost of the terms
    of service of an office holder and the average median compensation of the other employees of the company (including those
    employed through manpower companies), including the impact of disparities in salary upon work relationships in the company;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility of reducing variable compensation
    at the discretion of the board of directors; and the possibility of setting a limit on the exercise value of non-cash variable
    compensation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as to severance compensation, the period of
    service of the director or executive, the terms of his or her compensation during such service period, the company&rsquo;s
    performance during that period of service, the person&rsquo;s contribution towards the company&rsquo;s achievement of its
    goals and the maximization of its profits, and the circumstances under which the person is leaving the company.</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The compensation policy must also include
the following principles:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with the exception of office holders who report
    directly to the chief executive officer, the link between variable compensation and long-term performance and measurable criteria;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between variable and fixed
    compensation, and the ceiling for the value of variable compensation at the time of its grant;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the conditions under which a director or executive
    would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation
    was based was inaccurate and was required to be restated in the company&rsquo;s financial statements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the minimum holding or vesting period for variable,
    equity-based compensation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maximum limits for severance compensation.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The compensation policy must also consider
appropriate incentives from a long-term perspective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The compensation committee is responsible
for: (1) recommending the compensation policy to a company&rsquo;s board of directors for its approval (and subsequent approval
by the shareholders); and (2) duties related to the compensation policy and to the compensation of a company&rsquo;s office holders,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending whether a compensation policy should
    continue in effect, if the then-current policy has a term of greater than three years (approval of either a new compensation
    policy or the continuation of an existing compensation policy must in any case occur every three years);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the board of directors periodic
    updates to the compensation policy;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing implementation of the compensation
    policy;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether the terms of compensation
    of certain office holders of the company need not be brought to approval of the shareholders; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether to approve the terms of
    compensation of office holders that require the committee&rsquo;s approval.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our compensation policy will be designed
to promote our long-term goals, work plan and policy, retain, motivate and incentivize our directors and executive officers, while
considering the risks that our activities involve, our size, the nature and scope of our activities and the contribution of an
officer to the achievement of our goals and maximization of profits, and align the interests of our directors and executive officers
with our long-term performance. To that end, a portion of an executive officer compensation package is targeted to reflect our
short and long-term goals, as well as the executive officer&rsquo;s individual performance. On the other hand, our compensation
policy will include measures designed to reduce the executive officer&rsquo;s incentives to take excessive risks that may harm
us in the long-term, such as limits on the value of cash bonuses and equity-based compensation, limitations on the ratio between
the variable and the total compensation of an executive officer and minimum vesting periods for equity-based compensation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our compensation policy will also address
our executive officer&rsquo;s individual characteristics (such as his or her respective position, education, scope of responsibilities
and contribution to the attainment of our goals) as the basis for compensation variation among our executive officers, and considers
the internal ratios between compensation of our executive officers and directors and other employees. For example, the compensation
that may be granted to an executive officer may include: base salary, annual bonuses, equity-based compensation, benefits and
retirement and termination of service arrangements. All cash bonuses are limited to a maximum amount linked to the executive officer&rsquo;s
base salary. In addition, our compensation policy will provide for maximum permitted ratios between the total variable (cash bonuses
and equity-based compensation) and non-variable (base salary) compensation components, in accordance with an officer&rsquo;s respective
position with the company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">An annual cash bonus may be awarded to
executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may be
granted to executive officers other than our chairman or Chief Executive Officer may be based entirely on a discretionary evaluation.
Our Chief Executive Officer will be entitled to recommend performance objectives to such executive officers, and such performance
objectives will be approved by our compensation committee (and, if required by law, by our board of directors).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The performance measurable objectives of
our chairman and Chief Executive Officer will be determined annually by our compensation committee and board of directors. A less
significant portion of the chairman&rsquo;s and/or the Chief Executive Officer&rsquo;s annual cash bonus may be based on a discretionary
evaluation of the chairman&rsquo;s or the Chief Executive Officer&rsquo;s respective overall performance by the compensation committee
and the board of directors based on quantitative and qualitative criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The equity-based compensation under
our compensation policy for our executive officers (including members of our board of directors) will be designed in a manner
consistent with the underlying objectives in determining the base salary and the annual cash bonus, with its main objectives being
to enhance the alignment between the executive officers&rsquo; interests with our long-term interests and those of our shareholders
and to strengthen the retention and the motivation of executive officers in the long term. Our compensation policy will provide
for executive officer compensation in the form of share options or other equity-based awards, such as restricted shares and phantom,
options, in accordance with our equity incentive plan then in place. Share options granted to executive officers shall be subject
to vesting periods in order to promote long-term retention of the awarded executive officers. The equity-based compensation shall
be granted from time to time and be individually determined and awarded according to the performance, educational background,
prior business experience, qualifications, role and the personal responsibilities of the executive officer. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In addition, our compensation policy
will contain compensation recovery provisions which allows us under certain conditions to recover bonuses paid in excess, will
enable our Chief Executive Officer to approve an immaterial change in the terms of employment of an executive officer (provided
that the changes of the terms of employment are in accordance our compensation policy) and will allow us to exculpate, indemnify
and insure our executive officers and directors subject to certain limitations set forth thereto. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our compensation policy will also provide
for compensation to the members of our board of directors either: (i) in accordance with the amounts provided in the Companies
Regulations (Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations
(Relief for Public Companies Traded in Stock Exchange Outside of Israel) of 2000, as such regulations may be amended from time
to time; or (ii) in accordance with the amounts determined in our compensation policy. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Internal Auditor </I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Under the Companies Law, the board of
directors of an Israeli public company must appoint an internal auditor nominated by the audit committee. We intend to appoint
our internal auditor within 90 days following the consummation of this offering. The role of the internal auditor is to examine,
among other things, whether a company&rsquo;s actions comply with the law and proper business procedure. The audit committee is
required to oversee the activities, and to assess the performance of the internal auditor as well as to review the internal auditor&rsquo;s
work plan. An internal auditor may not be an interested party or office holder, or a relative of any interested party or office
holder, and may not be a member of the company&rsquo;s independent accounting firm or its representative. The Companies Law defines
an interested party as a holder of 5% or more of the outstanding shares or voting rights of a company, any person or entity that
has the right to appoint at least one director or the general manager of the company or any person who serves as a director or
as the general manager of a company. Our internal auditor is not our employee, but partner of a firm which specializes in internal
auditing. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Remuneration of Directors</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Under the Companies Law, remuneration of
directors is subject to the approval of the compensation committee, thereafter by the board of directors and thereafter, unless
exempted under the regulations promulgated under the Companies Law, by the general meeting of the shareholders. In case the remuneration
of the directors is in accordance with regulations applicable to remuneration of the external directors then such remuneration
shall be exempt from the approval of the general meeting. Where the director is also a controlling shareholder, the requirements
for approval of transactions with controlling shareholders apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Fiduciary Duties of Office Holders</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The Companies Law imposes a duty of care
and a duty of loyalty on all office holders of a company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The duty of care requires an office holder
to act with the level of care with which a reasonable office holder in the same position would have acted under the same circumstances.
The duty of care of an office holder includes a duty to use reasonable means to obtain:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information on the advisability of a given action
    brought for his approval or performed by him by virtue of his position; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all other important information pertaining to
    these actions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The duty of loyalty of an office holder
requires an office holder to act in good faith and for the benefit of the company, and includes a duty to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any conflict of interest between
    the performance of his duties in the company and his performance of his other duties or personal affairs;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any action that is competitive
    with the company&rsquo;s business;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from exploiting any business opportunity
    of the company to receive a personal gain for himself or others; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose to the company any information or documents
    relating to the company&rsquo;s affairs which the office holder has received due to his position as an office holder.</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Insurance</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Under the Companies Law, a company may
obtain insurance for any of its office holders against the following liabilities incurred due to acts he or she performed as an
office holder, if and to the extent provided for in the company&rsquo;s articles of association:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">breach of his or her duty of care to the company
    or to another person, to the extent such a breach arises out of the negligent conduct of the office holder;</FONT></TD></TR>
</TABLE>

<P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of his or her duty of loyalty to the
    company, provided that the office holder acted in good faith and had reasonable cause to assume that his or her act would
    not prejudice the company&rsquo;s interests; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed upon him or her
    in favor of another person.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">We currently have directors&rsquo; and
officers&rsquo; liability insurance, providing total coverage of $2 million for the benefit of all of our directors and officers,
in respect of which we paid a twelve-month premium of approximately $907, which expires on April 14, 2021. We intend to purchase
additional insurance coverage prior to the consummation of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Indemnification</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The Companies Law and the Israeli Securities
Law, 5728-1968, or the Securities Law, provide that a company may indemnify an office holder against the following liabilities
and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance
of an event or following an event, provided its articles of association include a provision authorizing such indemnification:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed on him or her
    in favor of another person by any judgment concerning an act performed in his or her capacity as an office holder, including
    a settlement or arbitrator&rsquo;s award approved by a court;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&rsquo;
    fees, expended by the office holder (a) as a result of an investigation or proceeding instituted against him or her by an
    authority authorized to conduct such investigation or proceeding, provided that (1) no indictment (as defined in the Companies
    Law) was filed against such office holder as a result of such investigation or proceeding; and (2) no financial liability
    as a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such
    investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does
    not require proof of criminal intent; or (b) in connection with a monetary sanction; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&rsquo;
    fees, expended by the office holder or imposed on him or her by a court: (1) in proceedings that the company institutes, or
    that another person institutes on the company&rsquo;s behalf, against him or her; (2) in a criminal proceeding of which he
    or she was acquitted; or (3) as a result of a conviction for a crime that does not require proof of criminal intent; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred by an office holder in connection
    with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&rsquo;
    fees. An &ldquo;Administrative Procedure&rdquo; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the
    Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1
    (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The Companies Law also permits a company
to undertake in advance to indemnify an office holder, provided that if such indemnification relates to financial liability imposed
on him or her, as described above, then the undertaking should be limited and shall detail the following foreseen events and amount
or criterion:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to events that in the opinion of the board of
    directors can be foreseen based on the company&rsquo;s activities at the time that the undertaking to indemnify is made; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in amount or criterion determined by the board
    of directors, at the time of the giving of such undertaking to indemnify, to be reasonable under the circumstances.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">We have entered into indemnification agreements
with all of our directors and with all members of our senior management. Each such indemnification agreement provides the office
holder with indemnification permitted under applicable law and up to a certain amount, and to the extent that these liabilities
are not covered by directors and officers insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Exculpation</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Under the Companies Law, an Israeli company
may not exculpate an office holder from liability for a breach of his or her duty of loyalty, but may exculpate in advance an
office holder from his or her liability to the company, in whole or in part, for damages caused to the company as a result of
a breach of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such exculpation
is included in its articles of association. Our amended and restated articles of association provide that we may exculpate, in
whole or in part, any office holder from liability to us for damages caused to the company as a result of a breach of his or her
duty of care, but prohibit an exculpation from liability arising from a company&rsquo;s transaction in which our controlling shareholder
or officer has a personal interest. Subject to the aforesaid limitations, under the indemnification agreements, we exculpate and
release our office holders from any and all liability to us related to any breach by them of their duty of care to us to the fullest
extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Limitations</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The Companies Law provides that we may
not exculpate or indemnify an office holder nor enter into an insurance contract that would provide coverage for any liability
incurred as a result of any of the following: (1) a breach by the office holder of his or her duty of loyalty unless (in the case
of indemnity or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable basis to believe
that the act would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried out
intentionally or recklessly (as opposed to merely negligently); (3) any act or omission committed with the intent to derive an
illegal personal benefit; or (4) any fine, monetary sanction, penalty or forfeit levied against the office holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Under the Companies Law, exculpation, indemnification
and insurance of office holders in a public company must be approved by the compensation committee and the board of directors
and, with respect to certain office holders or under certain circumstances, also by the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Our amended and restated articles of association
permit us to exculpate (subject to the aforesaid limitation), indemnify and insure our office holders to the fullest extent permitted
or to be permitted by the Companies Law.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The foregoing descriptions summarize the
material aspects and practices of our board of directors. For additional details, we also refer you to the full text of the Companies
Law, as well as of our amended and restated articles of association, which are exhibits to this registration statement of which
this prospectus forms a part, and are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">There are no service contracts between
us or our Subsidiary, on the one hand, and our directors in their capacity as directors, on the other hand, providing for benefits
upon termination of service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Approval of Related Party Transactions
under Israeli Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>General</I></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">Under the Companies
Law, we may approve an action by an office holder from which the office holder would otherwise have to refrain, as described above,
if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder acts in good faith and the
    act or its approval does not cause harm to the company; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder disclosed the nature of his
    or her interest in the transaction (including any significant fact or document) to the company at a reasonable time before
    the company&rsquo;s approval of such matter.</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Disclosure of Personal Interests of an Office Holder</I></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">The Companies
Law requires that an office holder disclose to the company, promptly, and, in any event, not later than the board meeting at which
the transaction is first discussed, any direct or indirect personal interest that he or she may have and all related material
information known to him or her relating to any existing or proposed transaction by the company. If the transaction is an extraordinary
transaction, the office holder must also disclose any personal interest held by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder&rsquo;s relatives; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any corporation in which the office holder or
    his or her relatives holds 5% or more of the shares or voting rights, serves as a director or general manager or has the right
    to appoint at least one director or the general manager.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">An office holder
is not, however, obliged to disclose a personal interest if it derives solely from the personal interest of his or her relative
in a transaction that is not considered an extraordinary transaction. Under the Companies Law, an extraordinary transaction is
a transaction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not in the ordinary course of business;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not on market terms; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that is likely to have a material effect on
    the company&rsquo;s profitability, assets or liabilities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">The Companies
Law does not specify to whom within us nor the manner in which required disclosures are to be made. We require our office holders
to make such disclosures to our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">Under the Companies
Law, once an office holder complies with the above disclosure requirement, the board of directors may approve a transaction between
the company and an office holder, or a third party in which an office holder has a personal interest, unless the articles of association
provide otherwise and provided that the transaction is in the company&rsquo;s interest. If the transaction is an extraordinary
transaction in which an office holder has a personal interest, first the audit committee and then the board of directors, in that
order, must approve the transaction. Under specific circumstances, shareholder approval may also be required. Generally, a person
who has a personal interest in a matter which is considered at a meeting of the board of directors or the audit committee may
not be present at such a meeting unless the chairman of the audit committee or board of directors (as applicable) determines that
he or she should be present in order to present the transaction that is subject to approval. A director who has a personal interest
in a transaction, which is considered at a meeting of the board of directors or the audit committee, may not be present at this
meeting or vote on this matter, unless a majority of members of the board of directors or the audit committee, as the case may
be, has a personal interest. If a majority of the board of directors has a personal interest, then shareholder approval is generally
also required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Disclosure of Personal Interests of a Controlling Shareholder</I></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">Under the Companies
Law, the disclosure requirements that apply to an office holder also apply to a controlling shareholder of a public company. Extraordinary
transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private
placement in which a controlling shareholder has a personal interest, as well as transactions for the provision of services whether
directly or indirectly by a controlling shareholder or his or her relative, or a company such controlling shareholder controls,
and transactions concerning the terms of engagement and compensation of a controlling shareholder or a controlling shareholder&rsquo;s
relative, whether as an office holder or an employee, require the approval of the audit committee or the compensation committee,
as the case may be, the board of directors and a majority of the shares voted by the shareholders of the company participating
and voting on the matter in a shareholders&rsquo; meeting. In addition, the shareholder approval must fulfill one of the following
requirements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least a majority of the shares held by shareholders
    who have no personal interest in the transaction and are voting at the meeting must be voted in favor of approving the transaction,
    excluding abstentions; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the shares voted by shareholders who have no
    personal interest in the transaction who vote against the transaction represent no more than 2% of the voting rights in the
    company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">In addition, any
extraordinary transaction with a controlling shareholder or in which a controlling shareholder has a personal interest with a
term of more than three years requires the abovementioned approval every three years; however, such transactions not involving
the receipt of services or compensation can be approved for a longer term, provided that the audit committee determines that such
longer term is reasonable under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">The Companies
Law requires that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction
with a controlling shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest
in the vote in question. Failure to so indicate will result in the invalidation of that shareholder&rsquo;s vote.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">The term &ldquo;controlling
shareholder&rdquo; is defined in the Companies Law as a shareholder with the ability to direct the activities of the company,
other than by virtue of being an office holder. A shareholder is presumed to be a controlling shareholder if the shareholder holds
50% or more of the voting rights in a company or has the right to appoint 50% or more of the directors of the company or its general
manager. In the context of a transaction involving a shareholder of the company, a controlling shareholder also includes a shareholder
who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in
the company. For this purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Approval of the Compensation of Directors and Executive
Officers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The compensation of, or an undertaking
to indemnify, insure or exculpate, an office holder who is not a director requires the approval of the company&rsquo;s compensation
committee, followed by the approval of the company&rsquo;s board of directors, and, if such compensation arrangement or an undertaking
to indemnify, insure or exculpate is inconsistent with the company&rsquo;s stated compensation policy, or if the said office holder
is the chief executive officer of the company (subject to a number of specific exceptions), then such arrangement is subject to
the approval of our shareholders, subject to a special majority requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>Directors</I>. Under the Companies Law,
the compensation of our directors requires the approval of our compensation committee, the subsequent approval of the board of
directors and, unless exempted under the regulations promulgated under the Companies Law, the approval of the general meeting
of our shareholders. If the compensation of our directors is inconsistent with our stated compensation policy, then, provided
that those provisions that must be included in the compensation policy according to the Companies Law have been considered by
the compensation committee and board of directors, shareholder approval by a special majority will be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>Executive officers other than the chief
executive officer.</I>&nbsp;The Companies Law requires the approval of the compensation of a public company&rsquo;s executive
officers (other than the chief executive officer) in the following order: (i) the compensation committee, (ii) the company&rsquo;s
board of directors, and (iii) only if such compensation arrangement is inconsistent with the company&rsquo;s stated compensation
policy, the company&rsquo;s shareholders by a special majority. However, if the shareholders of the company do not approve a compensation
arrangement with an executive officer that is inconsistent with the company&rsquo;s stated compensation policy, the compensation
committee and board of directors may override the shareholders&rsquo; decision if each of the compensation committee and the board
of directors provide detailed reasons for their decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><I>Chief executive officer.</I>&nbsp;Under
the Companies Law, the compensation of a public company&rsquo;s chief executive officer is required to be approved by: (i) the
company&rsquo;s compensation committee; (ii) the company&rsquo;s board of directors, and (iii) the company&rsquo;s shareholders
by a special majority. However, if the shareholders of the company do not approve the compensation arrangement with the chief
executive officer, the compensation committee and board of directors may override the shareholders&rsquo; decision if each of
the compensation committee and the board of directors provides detailed reasons for their decision. In addition, the compensation
committee may exempt the engagement terms of a candidate to serve as the chief executive officer from shareholders&rsquo; approval,
if the compensation committee determines that the compensation arrangement is consistent with the company&rsquo;s stated compensation
policy, that the chief executive officer did not have a prior business relationship with the company or a controlling shareholder
of the company, and that subjecting the approval to a shareholder vote would impede the company&rsquo;s ability to attain the
candidate to serve as the company&rsquo;s chief executive officer (and provide detailed reasons for the latter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The approval of each of the compensation
committee and the board of directors, with regard to the office holders and directors above, must be in accordance with the company&rsquo;s
stated compensation policy; however, under special circumstances, the compensation committee and the board of directors may approve
compensation terms of a chief executive officer that are inconsistent with the company&rsquo;s compensation policy provided that
they have considered those provisions that must be included in the compensation policy according to the Companies Law and that
shareholder approval was obtained by a special majority requirement.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Duties of Shareholders</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 6pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">Under the Companies
Law, a shareholder has a duty to refrain from abusing his power in the company and to act in good faith and in an acceptable manner
in exercising his rights and performing his obligations toward the company and other shareholders, including, among other things,
in voting at general meetings of shareholders (and at shareholder class meetings) on the following matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 6pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendment of the articles of association;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase in the company&rsquo;s authorized share
    capital;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">merger; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval of related party transactions and
    acts of office holders that require shareholder approval.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 6pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">A shareholder
also has a general duty to refrain from oppressing other shareholders. The remedies generally available upon a breach of contract
will also apply to a breach of the above mentioned duties, and in the event of oppression of other shareholders, additional remedies
are available to the injured shareholder.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 6pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">In addition, any
controlling shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any shareholder
that, under a company&rsquo;s articles of association, has the power to appoint or prevent the appointment of an office holder,
or has another power with respect to a company, is under a duty to act with fairness towards the company. The Companies Law does
not describe the substance of this duty except to state that the remedies generally available upon a breach of contract will also
apply in the event of a breach of the duty to act with fairness, taking the shareholder&rsquo;s position in the company into account.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-size: 6pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Equity Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 6pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Our
2019 Plan was adopted by our board of directors on December 2019 (although no options were granted until April 20, 2020). The 2019 Plan
provides for the grant of options to our directors, employees, officers, consultants and service providers who are our employees, officers,
directors or consultants, as well as those of our affiliated companies. As of June 25, 2021, the total number of Ordinary Shares reserved
for the exercise of options granted under our 2019 Plan was 633,357. The shares subject to our 2019 Plan may be either authorized but
unissued Ordinary Shares or reacquired Ordinary Shares, subject to applicable laws.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 6pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">Our 2019 Plan
is administered by the committee, consisting of our board of directors, regarding the granting of options and the terms of option
grants, including exercise price, method of payment, vesting schedule, acceleration of vesting and the other matters necessary
in the administration of this plan. Eligible employees, officers and directors, as well as those of our affiliated companies,
would qualify for provisions of Section 102 of the Israeli Income Tax Ordinance of 1961 (New Version), or the Tax Ordinance. Section&nbsp;102
of the Tax Ordinance allows employees, directors and officers who are not controlling shareholders and are considered Israeli
residents to receive favorable tax treatment for compensation in the form of shares or options. Section&nbsp;102 includes two
alternatives for tax treatment involving the issuance of options or shares to a trustee for the benefit of the grantees and also
includes an additional alternative for the issuance of options or shares directly to the grantee. Section&nbsp;102(b)(2) of the
Ordinance, the most favorable tax treatment for the grantee, permits the issuance to a trustee under the &ldquo;capital gain track.&rdquo;
However, under this track we are not allowed to deduct an expense with respect to the issuance of the options or shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 6pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">Our consultants
and those of our affiliated companies and our employees, directors and/or officers and those of our affiliated companies who are
controlling shareholders prior to and/or after the issuance of Ordinary Shares underlying the options may only be granted options
under section&nbsp;3(i) of the Tax Ordinance, which does not provide for similar tax benefits. In addition, the committee may,
in its sole discretion, grant restricted shares to our service providers, subject to terms and conditions of our 2019 Plan and
the applicable restricted shares agreement between the service provider and us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 6pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">As a default,
our 2019 Plan provides that upon termination of a service provider&rsquo;s engagement for any reason, other than in the event
of death, disability or cause, all unvested options will terminate and the underlying Ordinary Shares will revert to our 2019
Plan, and all vested options will generally be exercisable for 90 days following such termination, subject to the terms of the
2019 Plan and the governing option agreement. Notwithstanding the foregoing, in the event the engagement is terminated for cause
(including, inter alia, due to dishonesty toward us or our affiliate, substantial malfeasance or nonfeasance of duty and conduct
substantially prejudicial to our or our affiliate&rsquo;s business; or any substantial breach by the optionee of his or her service
agreement) all options granted to such service provider, whether vested or unvested, will not be exercisable and will terminate
on the date of the termination of his service agreement. If a service provider&rsquo;s engagement with us is terminated six months
following any exercise, payment or delivery pursuant to an option or restricted share, the service provider shall pay to us the
amount of any gain realized or payment received as a result of the rescinded exercise, payment or delivery. Upon termination of
a service agreement due to death or disability, all the options vested at the time of termination and within 60 days after the
date of such termination, will generally be exercisable for 12 months, or such other period as determined by the plan administrator,
subject to the terms of the 2019 Plan and the governing option agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 6pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;If we are
party to a merger, acquisition, reorganization or consolidation in which we are not the surviving entity or the sale, transfer,
exchange or other disposition of all or substantially all of our shares or assets, outstanding options and shares acquired under
the 2019 Plan will be subject to the agreement of merger or consolidation, which will provide for one or more of the following:
(i)&nbsp;the assumption of such options by the surviving corporation or its parent, (ii)&nbsp;the substitution by the surviving
corporation or its parent of new options, or (iii)&nbsp;in the event that the successor entity neither assumes nor substitutes
all outstanding options, then the option shall terminate as of the date of a merger, acquisition, reorganization or consolidation
in which we are not the surviving entity or the sale, transfer, exchange or other disposition of all or substantially all of our
shares or assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 6pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 7pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B><A NAME="i_013"></A>BENEFICIAL
OWNERSHIP OF PRINCIPAL SHAREHOLDERS AND MANAGEMENT </B></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> The following table
sets forth information regarding beneficial ownership of our Ordinary Shares as of June 25, 2021 by: </P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person, or group of affiliated persons,
    known to us to be the beneficial owner of more than 5% of our outstanding ordinary shares;</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: top">
    <TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our directors and executive officers;
    and</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: top">
    <TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all of our directors and executive officers
    as a group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 7pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Beneficial
ownership is determined in accordance with the rules of the SEC, and includes voting or investment power with respect to Ordinary Shares.
Ordinary Shares issuable under share options or warrants that are exercisable within 60 days after June 25, 2021, are deemed outstanding
for the purpose of computing the percentage ownership of the person holding the options or warrants but are not deemed outstanding for
the purpose of computing the percentage ownership of any other person. IML&rsquo;s pre-offering holdings in the beneficial ownership
table below include 756,333 Ordinary Shares and options to purchase 169,019 Ordinary shares that are exercisable within 60 days, at an
exercise price equal to the offering price per share, issued to IML in connection with the Termination Agreement, discussed further below
in &ldquo;Related Party Transactions &ndash; Shareholders Loans&rdquo;. Percentage of shares beneficially owned before this offering
is based on 4,542,317 shares outstanding on June 25, 2021. The number of Ordinary Shares deemed outstanding after this offering is based
on 6,843,902 Ordinary Shares outstanding after the offering, assuming the sale of 2,307,692 Ordinary Shares in this offering as part
of the Units and Pre-funded Units in this offering, which assumes the exercise of any Pre-Funded Units and does not assume exercise of
the underwriters&rsquo; over-allotment option.</FONT> </P>
<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">We are not controlled
by another corporation, by any foreign government or by any natural or legal persons except as set forth herein, and there are
no arrangements known to us which would result in a change in control of our company at a subsequent date. Except as indicated
in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with respect
to all shares shown to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise
noted below, each beneficial owner&rsquo;s address is: c/o Inspira Technologies Oxy B.H.N. Ltd., 2 Ha-Tidhar St., Ra&rsquo;anana,
4366504 Israel.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No.&nbsp;of&nbsp;Shares<BR>
    Beneficially<BR>
    Owned<BR>
    Prior to this<BR>
    Offering </B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Percentage</B> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Owned<BR>
    Before&nbsp;this<BR>
    Offering</B> </P></TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage
    Owned<BR>
    After this Offering </B></FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Holders of more than 5% of our voting securities:
    </B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 64%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon (1) * </FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">683,898 </FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.87 </FONT> </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.90 </FONT> </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Udi Nussinovitch (2) </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">683,898 </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.87 </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.90 </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joe Hayon (3) * </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">683,898 </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.87 </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.90 </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IML (4) </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">925,349 </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.64 </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- </FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors and senior management who are not 5%
    holders: </B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tal Parnes (5) * </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,834</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">** </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">** </FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avi Shabtai (6) </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90,477 </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.95 </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.30 </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limor Rozen (7) * </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,481 </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">** </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">** </FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benad Goldwasser (8) * </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,803 </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">** </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">** </FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>
        <P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All
        directors and senior management as a group (7 persons) </B></FONT> </P></TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2,159,289 </B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>43.3 </B></FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>% </B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30 </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates director of the Company.</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: top">
    <TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less than 1%.</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: top">
    <TD STYLE="font-size: 7pt"> &nbsp; </TD>
    <TD STYLE="font-size: 7pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 57,159&nbsp;Ordinary
    Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 57,159&nbsp;Ordinary
    Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 57,159&nbsp;Ordinary
    Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 756,333 Ordinary Shares and options to
    purchase 169,016 Ordinary shares that are exercisable within 60 days, at an exercise price equal to the offering price per share,
    issued to IML in connection with the Termination Agreement. After IML&rsquo;s distribution of the shares to individual shareholders
    upon this offering, none of the individual shareholders will beneficially own 5% or more of our Ordinary Shares.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 7,834 Ordinary Shares
    that are exercisable within 60 days (subject to the director nominee&rsquo;s appointment to our board of directors), at an exercise
    price of NIS 0.37 (approximately $0.12) per share.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 57,144 Ordinary Shares
    that are exercisable within 60 days, at an exercise price of NIS 0.97 (approximately $0.29) per share and options to purchase 33,333
    Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share.</FONT> </TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"> (7) </TD>
    <TD STYLE="font-size: 10pt"> Includes options to purchase 2,481 Ordinary Shares that are exercisable within 60 days (subject to
    the director nominee&rsquo;s appointment to our board of directors), at an exercise price of NIS 0.37 (approximately $0.12) per share. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We granted Prof. Goldwasser
    options to purchase 81,633 Ordinary Shares at an exercise price of NIS 0.37 (approximately $0.12) per share in February 2021. The
    options vest on a quarterly basis for three years 6,803 of the options are not exercisable within 60 days.</FONT> </TD></TR>
</TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Record Holders</I></B></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of June 25, 2021, there were nine shareholders
of record of our Ordinary Shares, which were located in Israel. </P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B><A NAME="i_014"></A>RELATED PARTY
TRANSACTIONS</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Employment and Service Agreements</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">We have entered
into written employment agreements with each of our executive officers. All of these agreements contain customary provisions regarding
noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition
provisions may be limited under applicable law. In addition, we have entered into agreements with each executive officer and director
pursuant to which we have agreed to indemnify each of them up to a certain amount and to the extent that these liabilities are
not covered by directors and officers insurance. Members of our senior management are eligible for bonuses each year. The bonuses
are payable upon meeting objectives and targets that are set by our Chief Executive Officer and approved annually by our board
of directors that also set the bonus targets for our Chief Executive Officer. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Options </I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">Since our inception,
we have granted options to purchase our Ordinary Shares to our officers and certain of our directors. Such option agreements may
contain acceleration provisions upon certain merger, acquisition, or change of control transactions. We describe our option plans
under &ldquo;Management&mdash;Equity Incentive Plan.&rdquo; If the relationship between us and an executive officer or a director
is terminated, except for cause (as defined in the various option plan agreements), options that are vested will generally remain
exercisable for three months after such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Founders
Agreement</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white">Two
of our shareholders, who also serve as officers and directors of our company, Dagi Ben-Noon and Udi Nussinovitch, or the Initial
Founders, have entered into a founders agreement, or the Founders Agreement, dated February 19, 2018. Pursuant to the Founders
Agreement, there was an opportunity for one or more founders to join our company and approximately 47.87% of the then issued and
outstanding shares of our company were earmarked for additional founders. The parties have agreed that for a period of four years
commencing on August 1, 2017 with respect to Dagi Ben-Noon and any additional founders, and for a period of four years commencing
on February 19, 2018 with respect to Udi Nussinovitch, the parties&rsquo; shares shall be subject to repurchase right by other
founders who are engaged with us then. Upon the termination or resignation of one of the Initial Founders, the other founders
that engage with us at such point will have the right to repurchase the shares for no consideration within 180 days from the termination
or resignation of another Initial Founder. The parties also agreed to restrict the transfer of each of the Initial Founders&rsquo;
shares (i) to any beneficiary designation or by intestate will succession of the founder; or (ii) to the members of the founder&rsquo;s
immediate family; or (iii) to any corporation or other entity wholly owned by the founder. In addition, such transferee has to
abide by the provisions of the Founders Agreement. In December 2018, Joe Hayon entered into a co-founder agreement with the Initial
Founders. We expect that the Founders Agreement will be terminated in connection with this offering. </P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Shareholders
Loans</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"> On
March 1, 2018, we entered into a shareholder loan agreement with Dagi Ben-Noon. Pursuant to this shareholder loan agreement, Dagi Ben-Noon
undertook to provide to us, upon our request, funds up to an aggregate amount of up to 50,000 NIS (approximately $14,347) as a loan,
in one or more tranches. The loan amount did not accrue any interest but was linked to the Consumer Price Index of the Central Bureau
of Statistics in Israel. Dagi Ben-Noon provided a loan in the amount of NIS 200,000 (approximately $57,389). We repaid the entire loan
amount to Dagi Ben-Noon in April 2020. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white"> On
May 20, 2019, we entered into an initial public offering implementation deed, or the IPO Deed, with InSense Medical Pty Ltd., or IML,
the Founders and Newburyport Partners Pty Ltd., or Newburyport. Despite the similarity between our company&rsquo;s name and IML&rsquo;s
name, IML was not and has never been our subsidiary. IML was a newly formed corporation under the laws of the State of Victoria, Australia,
incorporated for the purpose of facilitating an initial public offering on the Australian Securities Exchange, or ASX. Pursuant to the
IPO Deed, we agreed to pursue an initial public offering on the ASX, and Newburyport agreed to fund such initial public offering on the
ASX as well as our operations by selling IML&rsquo;s ordinary shares to private investors for proceeds in a minimum aggregate amount
of A$5 (approximately $3.357) million and a maximum aggregate of A$5.5 (approximately $3.692) million and advance the proceeds of such
sale to us as a convertible loan. Within six weeks from May 20, 2019 and subject to successful fundraising by IML, we and our shareholders
would exchange all of our shares and rights to purchase our shares for shares and rights to purchase shares of IML. Pursuant to the IPO
Deed, we were allowed to use the proceeds of the convertible loan to develop our technology and pay for accrued expenses, administration
consultant costs in Australia and the costs associated with the initial public offering on the ASX. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white"> On
July 1, 2019, we entered into a convertible bridge loan agreement, or the 2019 CLA, with IML, according to which we were to receive a
loan in the minimum amount of $2.44 million and the maximum amount of up to $2.79 million. The 2019 CLA did not include an option of
cash repayment. As of December 31, 2020, we received from IML approximately $2.374 million (A$3.536), out of which we returned $377,000
(A$559,000) to IML for fundraising expenses. The loan bore interest of 2.56% and was provided in Australian dollars. Pursuant to the
2019 CLA, we agreed to repay the loan by converting the principal amount and accrued interest amount to our Ordinary Shares at a price
per share of A$5.15 (approximately $3.45) or A$5.9 (approximately $3.91) upon the earlier of (i) an initial public offering on the ASX;
or (ii) a merger, an acquisition or passage of twelve months from July 1, 2019. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white">On
July 18, 2019, we modified the IPO Deed, or the Deed of Variation, to reduce the amount that Newburyport had to raise to a minimum
aggregate amount of A$3.5 (approximately $2.35) million and a maximum aggregate amount of A$4 (approximately $2.68) million. Subject
to Newburyport securing the initial commitments in the minimum amount of A$3.5 million by July 26, 2019, the Deed of Variation
specified that the timing to receive the funds from the private placement of IML&rsquo;s shares would be as provided in the budget
of the 2019 CLA. </P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> When we were considering pursuing an initial
public offering on the ASX, we were focused on another type of product &ndash; an intravenous oxygenation device. However, the development
of this product did not progress as quickly as we planned. On the other hand, we progressed with our ART500 ahead of our plans, reducing
the time to market by approximately two years. As we are focusing on the commercialization of our ART500 in the U.S. market, we decided
to pursue an initial public offering on Nasdaq rather than the ASX. Therefore, on November 27, 2020, we entered into an agreement, or
the Termination Agreement, with IML, the Founders and Newburyport to terminate the IPO Deed, the Deed of Variation and the 2019 CLA,
or the Previous Agreements. Pursuant to the Termination Agreement, we agreed to convert the loan amount and the interest accrued under
the 2019 CLA as of November 27, 2020, into 676,061 of our Ordinary Shares, at price per share of A$5.15 (approximately $3.45) or A$5.88
(approximately $3.91), and to issue to Newburyport or its affiliates 80,273 of our Ordinary Shares as promoter shares, and options to
purchase 28,572 of our Ordinary Shares, to Daniel Goldstein, who promoted our contract with IML, at an exercise price of NIS 0.37 (approximately
$0.12 per share. We also issued 169,019 warrants to IML, exercisable upon our initial public offering on the Nasdaq Capital Market. IML&rsquo;s
warrants are exercisable for three years. IML has advised us that it expects to distribute its holdings of our shares as a dividend to
its shareholders upon our initial public offering on the Nasdaq Capital Market. Each party to the Termination Agreement agreed to release
each other party to the Termination Agreement from all the claims related to the IPO Deed, Deed of Variation and CLA. In addition, we
agreed to hire Newburyport and Peter Marks, another affiliate of IML, as our business developers to identify, introduce and promote us
to potential investors, approved by us in writing at our sole discretion. We promised to pay cash commission in the amount of 7% from
the net proceeds of received by us from an investment consummated within 12 months of our introduction to the investor by Newburyport
or Peter Marks. As of June 25, 2021, we have paid Newburyport and Peter Marks A$253,000 (approximately $197,000) each, as cash commission
for investor introductions. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B><A NAME="i_015"></A>DESCRIPTION OF SHARE CAPITAL</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B><I>General</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">As
of </FONT>June 25<FONT STYLE="background-color: white">, 2021, our authorized share capital consisted of 8,435,375 Ordinary Shares, no
par value, of which </FONT>4,542,317 <FONT STYLE="background-color: white">Ordinary Shares were issued and outstanding as of such date.
All of our outstanding Ordinary Shares have been validly issued, fully paid and non-assessable. Our Ordinary Shares are not redeemable
and are not subject to any preemptive right.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Since our incorporation in February 2018, we
have issued the following Ordinary Shares: (i) an aggregate of 1,904,762 Ordinary Shares for no consideration to our founders and certain
advisors; (ii) and an aggregate of 756,333 Ordinary Shares to Inspira Technologies Limited (formerly known as IML), which was issued
pursuant to the Termination Agreement. The aforementioned amounts do not include Ordinary Shares to be issued under SAFEs and convertible
loan agreements and Ordinary Shares to be issued to financial advisors, which shares are included in the 4,542,317 issued and outstanding
Ordinary Shares set forth above. See above &ldquo;Related Party Transactions &ndash; Shareholders Loans&rdquo; for additional information
regarding the Termination Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In addition to Ordinary Shares, in the last
three years, we have granted options to purchase an aggregate of 633,358 Ordinary Shares to directors, officers and employees with exercise
prices ranging between NIS 0.37 (approximately $0.12) to NIS 0.97 (approximately $0.29) per share under our Global Plan. The exercise
prices of the Ordinary Shares underlying such options range between $0.00368 to $4.199. As of June 25, 2021, 6,111 options granted under
the Global Plan were exercised, and 67,335 options were cancelled, forfeited, expired, or were otherwise not granted, such that the total
outstanding amount of options under the Global Plan as of June 1, 2021 is 559,912. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Our
registration number with the Israeli Registrar of Companies is 515806495.&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B><I>Purposes
and Objects of the Company</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Our
purpose is set forth in Article 3(b) of our amended and restated articles of association and includes every lawful purpose.&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B><I>Simple
Agreements for Future Equity</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2020 through March 2021,
we entered into certain equity investment agreements, which we refer to as Simple Agreements for Future Equity, or SAFEs, for
aggregate proceeds of $5,414,593. Out of the amounts we received under the SAFEs, $2,803,844 will be converted into our Ordinary
Shares, at a conversion rate equal to the lower of (i) our company valuation cap of $35,000,000, or (ii) a discount of 30% from
the per share price of our Ordinary Share in the event of an initial public offering, merger, acquisition or other liquidity event.
However, if an initial public offering, merger, acquisition, other liquidity event or dissolution event does not take place within
24 months from December 2020, then the subscription amount under such SAFEs will convert into our Ordinary Shares as follows:
(i) investors representing an aggregate of $1,426,155 of the SAFEs will convert at a conversion price reflecting a company valuation
of $17,500,000, and (ii) investors representing an aggregate of $1,377,689 of the SAFEs will convert at a conversion price reflecting
a company valuation of $35,000,000. In addition, if the subscription amounts under the SAFEs is converted to Ordinary Shares in
connection with an initial public offering, then we will issue the SAFE investors warrants to purchase our Ordinary Shares with
an exercise price equal to the public offering price in such offering, as follows: (i) investors representing an aggregate of
$1,426,155 of the SAFEs shall receive 75% warrant coverage with a four year warrant, and (ii) investors representing an aggregate
of $1,377,689 of the SAFEs shall receive 50% warrant coverage with a three year warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The remaining $2,610,749 we received
under the SAFEs will be converted into our Ordinary Shares, at a conversion rate equal to the lower of (i) our company valuation
cap of $70,000,000, or (ii) a discount of 30% from the per share price of our Ordinary Share in the event of an initial public
offering, merger, acquisition or other liquidity event. However, if an initial public offering, merger, acquisition, other liquidity
event or dissolution event does not take place within 24 months from December 2020, then the subscription amount under such SAFEs
will convert into our Ordinary Shares at a conversion price reflecting a company valuation of $70,000,000. In addition, if the
subscription amounts under the SAFEs is converted to Ordinary Shares in connection with an initial public offering, then we will
issue the SAFE investors warrants to purchase our Ordinary Shares with an exercise price equal to the public offering price in
such offering with 50% warrant coverage with a three year warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B><I>Convertible
Loan Agreements </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In January through March 2021, we entered
into convertible loan agreements for the aggregate amount of $3,484,113. These convertible loan agreements had a maturity date of
May 31, 2021 and bear interest at the rate of 5.0% per year accrued quarterly. Upon completion of this offering, the loan amount
under the convertible loan agreements will convert to Ordinary Shares at a conversion rate equal to a discount of 20% from the per
share price of our Ordinary Shares in this offering. Additionally, the investors will receive warrants to purchase our Ordinary
Shares with an exercise price equal to the public offering price in such offering with 50% warrant coverage with a three-year
warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In May 2021, we offered an extension with a maturity date of July 15, 2021
for the convertible loan agreements. The convertible loan agreements in the aggregate amount of $3,053,920 were extended. We repaid $430,193
plus interest of 5% per year (approximately $7,000) to the investors who did not agree to the extension. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Equity Compensation to Financial Advisors</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have agreed to issue to Exchange Listing,
LLC, in consideration for their advisory and consulting services, 73,321 Ordinary Shares upon our initial public offering on the Nasdaq
Capital Market. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In addition, we have agreed to issue to Peregrine
Corporate Limited, in consideration for their advisory and consulting services, 24,440 Ordinary Shares upon our initial public offering
on the Nasdaq Capital Market. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B><I>The
Powers of the Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Our
Board of Directors shall direct our policy and shall supervise the performance of our Chief Executive Officer and his actions.
Our Board of Directors may exercise all powers that are not required under the Companies Law or under our amended and restated
articles of association to be exercised or taken by&nbsp;our shareholders.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B><I>Rights
Attached to Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Our
Ordinary Shares shall confer upon the holders thereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">equal right to attend and to vote at all of our general
meetings, whether regular or special, with each Ordinary Share entitling the holder thereof, which attend the meeting and participate
at the voting, either in person or by a proxy or by a written ballot, to one vote;</P></TD></TR>
</TABLE>



<P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 48px">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">equal right to participate in distribution of dividends,
if any, whether payable in cash or in bonus shares, in distribution of assets or in any other distribution, on a per share pro
rata basis; and</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">equal right to participate, upon our dissolution, in the distribution of our assets legally available for distribution, on a per share pro rata basis.</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B><I>Election
of Directors</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Pursuant
to our amended and restated articles of association, our directors are elected at an annual general meeting and/or a special meeting
of our shareholders and serve on the board of directors until the next annual general meeting (except for external directors) or
until they resign or until they cease to act as board members pursuant to the provisions of our amended and restated articles of
association or any applicable law, upon the earlier. Pursuant to our amended and restated articles of association, other than the
external directors, for whom special election requirements apply under the Companies Law, the vote required to appoint a director
is a simple majority vote of holders of our voting shares, participating and voting at the relevant meeting. In addition, our amended
and restated articles of association allow our Board of Directors to appoint directors to fill vacancies and/or as an addition
to the Board of Directors (subject to the maximum number of directors) to serve until the next annual general meeting. External
directors are elected for an initial term of three years, may be elected for additional terms of three years each under certain
circumstances, and may be removed from office pursuant to the terms of the Companies Law. See &ldquo;Management&mdash;Board Practices&mdash;External
Directors.&rdquo;&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B><I>Annual
and Special Meetings</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Under
the Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year, at such time and
place which shall be determined by our Board of Directors, that must be no later than 15 months after the date of the previous
annual general meeting. All meetings other than the annual general meeting of shareholders are referred to as special general meetings.
Our Board of Directors may call special meetings whenever it sees fit and upon the request of </FONT>any shareholder or shareholders
holding at least five percent (5%) or a higher percent of our voting rights<FONT STYLE="background-color: white">.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Subject
to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote
at general meetings are the shareholders of record on a date to be decided by the board of directors, which may be between four
and twenty one days prior to the date of the meeting. Resolutions regarding the following matters must be passed at a general meeting
of our shareholders:</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">amendments to our amended and restated articles of
association;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">the exercise of our Board of Director&rsquo;s powers
by a general meeting if our Board of Directors is unable to exercise its powers and the exercise of any of its powers is required
for our proper management;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">appointment or termination of our auditors;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">appointment of directors, including external directors;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">approval of acts and transactions requiring general
meeting approval pursuant to the provisions of the Companies Law (mainly certain related party transactions) and any other applicable
law;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">increases or reductions of our authorized share capital;
and</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a merger (as such term is defined in the Companies Law).&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B><I>Notices</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
Companies Law and our amended and restated articles of association require that a notice of any annual or special shareholders
meeting be provided at least 21 days prior to the meeting, and if the agenda of the meeting includes the appointment or removal
of directors, the approval of transactions with office holders or interested or related parties, approval of the company&rsquo;s
general manager to serve as the chairman of the board of directors or an approval of a merger, notice must be provided at least
35 days prior to the meeting.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B><I>Quorum</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">As
permitted under the Companies Law, the quorum required for our general meetings consists of at least two shareholders present in
person, by proxy, written ballot or voting by means of electronic voting system, who hold or represent between them at least 25%
of the total outstanding voting rights. If within half an hour of the time set forth for the general meeting a quorum is not present,
the general meeting shall stand adjourned the same day of the following week, at the same hour and in the same place, or to such
other date, time and place as prescribed in the notice to the shareholders and in such adjourned meeting, if no quorum is present
within half an hour of the time arranged, any number of shareholders participating in the meeting, shall constitute a quorum.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">If
a special general meeting was summoned following the request of a shareholder, and within half an hour a legal quorum shall not
have been formed, the meeting shall be canceled.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B><I>Adoption
of Resolutions</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Our
amended and restated articles of association provide that all resolutions of our shareholders require a simple majority vote, unless
otherwise required under the Companies Law or our amended and restated articles of association. A shareholder may vote in a general
meeting in person, by proxy, by a written ballot.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B><I>Changing
Rights Attached to Shares</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Unless
otherwise provided by the terms of the shares and subject to any applicable law, any modification of rights attached to any class
of shares must be adopted by the holders of a majority of the shares of that class present a general meeting of the affected class
or by a written consent of all the shareholders of the affected class.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
enlargement of an existing class of shares or the issuance of additional shares thereof, shall not be deemed to modify the rights
attached to the previously issued shares of such class or of any other class, unless otherwise provided by the terms of the shares.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B><I>Limitations
on the Right to Own Securities in Our Company</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">There
are no limitations on the right to own our securities. &nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B><I>Provisions
Restricting Change in Control of Our Company</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">There
are no specific provisions of our amended and restated articles of association that would have an effect of delaying, deferring or preventing
a change in control of our company or that would operate only with respect to a merger, acquisition or corporate restructuring involving
us (or our Subsidiary). However, as described below, certain provisions of the Companies Law may have such effect.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">The
Companies Law includes provisions that allow a merger transaction and requires that each company that is a party to the merger have the
transaction approved by its board of directors and, unless certain requirements described under the Companies Law are met, a vote of
the majority of shareholders, and, in the case of the target company, also a majority vote of each class of its shares.&nbsp;&nbsp;For
purposes of the shareholder vote of each party, unless a court rules otherwise, the merger will not be deemed approved if shares representing
a majority of the voting power present at the shareholders meeting and which are not held by the other party to the merger (or by any
person or group of persons acting in concert who holds 25% or more of the voting power or the right to appoint 25% or more of the directors
of the other party) vote against the merger.&nbsp;If, however, the merger involves a merger with a company&rsquo;s own controlling shareholder
or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same Special Majority
approval that governs all extraordinary transactions with controlling shareholders.&nbsp;Upon the request of a creditor of either party
to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that as a result
of the merger the surviving company will be unable to satisfy the obligations of any of the parties to the merger, and may further give
instructions to secure the rights of creditors.&nbsp;If the transaction would have been approved by the shareholders of a merging company
but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still
approve the merger upon the petition of holders of at least 25% of the voting rights of a company. For such petition to be granted, the
court must find that the merger is fair and reasonable, taking into account the value of the parties to the merger and the consideration
offered to the shareholders.&nbsp;In addition, a merger may not be completed unless at least (1) 50 days have passed from the time that
the requisite proposals for approval of the merger were filed with the Israeli Registrar of Companies by each merging company and (2)
30 days have passed since the merger was approved by the shareholders of each merging company.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
Companies Law also provides that, subject to certain exceptions, an acquisition of shares in an Israeli public company must be
made by means of a &ldquo;special&rdquo; tender offer if as a result of the acquisition (1) the purchaser would become a controlling
shareholder if there is no controlling shareholder in the company or (2) the purchaser would become a holder of 45% or more of
the voting rights in the company, unless there is already a holder of more than 45% of the voting rights in the company. These
requirements do not apply if, in general, the acquisition (1) was made in a private placement that received shareholders&rsquo;
approval, subject to certain conditions, (2) was from a controlling shareholder in the company which resulted in the acquirer becoming
a controlling shareholder in the company, or (3) was from a holder of more than 45% of the voting rights in the company which resulted
in the acquirer becoming a holder of more than 45% of the voting rights in the company. A &ldquo;special&rdquo; tender offer must
be extended to all shareholders. In general, a &ldquo;special&rdquo; tender offer may be consummated only if (1) at least 5% of
the voting power attached to the company&rsquo;s outstanding shares will be acquired by the offeror and (2) the offer is accepted
by a majority of the offerees who notified the company of their position in connection with such offer (excluding the offeror,
controlling shareholders, holders of 25% or more of the voting rights in the company or anyone on their behalf, or any person having
a personal interest in the acceptance of the tender offer). If a special tender offer is accepted, then the purchaser or any person
or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent
tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period
of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger
in the initial special tender offer.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">If,
as a result of an acquisition of shares, the acquirer will hold more than 90% of an Israeli company&rsquo;s outstanding shares
or of certain class of shares, the acquisition must be made by means of a tender offer for all of the outstanding shares, or for
all of the outstanding shares of such class, as applicable. In general, if less than 5% of the outstanding shares, or of applicable
class, are not tendered in the tender offer and more than half of the offerees who have no personal interest in the offer tendered
their shares, all the shares that the acquirer offered to purchase will be transferred to it by operation of law. However, a tender
offer will also be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share
capital of the company or of the applicable class of shares. Any shareholders that was an offeree in such tender offer, whether
such shareholder accepted the tender offer or not, may request, by petition to an Israeli court, (i) appraisal rights in connection
with a full tender offer, and (ii) that the fair value should be paid as determined by the court, for a period of six months following
the acceptance thereof. However, the acquirer is entitled to stipulate, under certain conditions, that tendering shareholders will
forfeit such appraisal rights.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Lastly,
Israeli tax law treats some acquisitions, such as stock-for-stock exchanges between an Israeli company and a foreign company, less
favorably than U.S. tax laws. For example, Israeli tax law may, under certain circumstances, subject a shareholder who exchanges
his Ordinary Shares for shares in another corporation to taxation prior to the sale of the shares received in such stock-for-stock
swap.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B><I>Changes
in Our Capital</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
general meeting may, by a simple majority vote of the shareholders attending the general meeting:</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">increase our registered share capital by the creation
of new shares from the existing class or a new class, as determined by the general meeting;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">cancel any registered share capital which have not
been taken or agreed to be taken by any person;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">consolidate and divide all or any of our share capital
into shares of larger nominal value than our existing shares;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">subdivide our existing shares or any of them, our share
capital or any of it, into shares of smaller nominal value than is fixed; and</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce our share capital and any fund reserved for capital redemption in any manner, and with and subject to any incident authorized, and consent required, by the Companies Law.</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B><A NAME="i_015a"></A>Description
of SECURITIES WE ARE Offering</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Units</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are offering the Units at the initial assumed
public offering price of $6.50 per Unit. Each Unit consists of one share of Ordinary Share and a Warrant to purchase one Ordinary Share
at an exercise price equal to $6.50 (based on an assumed public offering price of $6.50 per Unit, the midpoint of the range set forth
on the cover page of this prospectus), which is 100% of the public offering price of the Units. The Ordinary Shares and Warrants may
be transferred separately immediately upon issuance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Pre-funded Units</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are offering the Pre-funded Units at a price
equals to the price per Unit, minus $0.01, and the exercise price of each Pre-funded Warrant included in the Pre-funded Unit will be
$0.01 per Ordinary Share. Each Pre-funded Unit consists of one Pre-funded Warrant to purchase one Ordinary Share and one Warrant to purchase
one Ordinary Share. The Pre-funded Warrants and Warrants may be transferred separately immediately upon issuance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Ordinary Shares</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The material terms and provisions of our Ordinary
Shares are described under the caption &ldquo;Description of Share Capital&rdquo; in this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Warrants</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>Pre-funded Warrants Included in the
Pre-funded Units</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The following summary
of certain terms and provisions of the Pre-funded Warrants offered hereby is not complete and is subject to, and qualified in its entirety
by, the provisions of the warrant agent agreement between us and VStock Transfer, LLC, as warrant agent, and the form of Pre-funded Warrant,
both of which are filed as exhibits to the registration statement of which this prospectus is a part. Prospective investors should carefully
review the terms and provisions set forth in the warrant agent agreement, including the annexes thereto, and form of Pre-funded Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The term &ldquo;pre-funded&rdquo;
refers to the fact that the purchase price of our Ordinary Shares in this offering includes almost the entire exercise price that will
be paid under the Pre-funded Warrants, except for a nominal remaining exercise price of $0.01. The purpose of the Pre-funded Warrants
is to enable investors that may have restrictions on their ability to beneficially own more than 4.99% (or, upon election of the holder,
9.99%) of our outstanding Ordinary Shares following the consummation of this offering the opportunity to make an investment in the Company
without triggering their ownership restrictions, by receiving Pre-funded Warrants in lieu of our Ordinary Shares which would result in
such ownership of more than 4.99% (or 9.99%), and receive the ability to exercise their option to purchase the shares underlying the
Pre-funded Warrants at such nominal price at a later date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <I>Exercise of Warrants</I>.
Each Pre-funded Warrant is exercisable for one Ordinary Share, with an exercise price equal to $0.01&nbsp;per Ordinary Share, at any
time that the Pre-funded Warrant is outstanding. There is no expiration date for the Pre-funded Warrants. The holder of a Pre-funded
Warrant will not be deemed a holder of our underlying Ordinary Shares until the Pre-funded Warrant is exercised. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Subject to limited exceptions,
a holder of Pre-funded Warrants will not have the right to exercise any portion of its Pre-funded Warrants if the holder (together with
such holder&rsquo;s affiliates, and any persons acting as a group together with such holder or any of such holder&rsquo;s affiliates)
would beneficially own a number of Ordinary Shares in excess of 4.99% (or, at the election of the purchaser prior to the date of issuance,
9.99%) of the Ordinary Shares then outstanding after giving effect to such exercise. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The exercise price and
the number of Ordinary Shares issuable upon exercise of the Pre-funded Warrants is subject to appropriate adjustment in the event of
recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting
our Ordinary Shares. The Pre-funded Warrant holders must pay the exercise price in cash upon exercise of the Pre-funded Warrants, unless
such Pre-funded Warrant holders are utilizing the cashless exercise provision of the Pre-funded Warrants. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Upon the holder&rsquo;s
exercise of a Pre-funded Warrant, we will issue the Ordinary Shares issuable upon exercise of the Pre-funded Warrant within two trading
days following our receipt of a notice of exercise, provided that payment of the exercise price has been made (unless exercised to the
extent permitted via the &ldquo;cashless&rdquo; exercise provision). Prior to the exercise of any Pre-funded Warrants to purchase Ordinary
Shares, holders of the Pre-funded Warrants will not have any of the rights of holders of Ordinary Shares purchasable upon exercise, including
the right to vote, except as set forth therein. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Pre-funded Warrant
holders must pay the exercise price in cash upon exercise of the Pre-funded Warrants unless there is not an effective registration statement
covering the issuance of the shares underlying the Pre-funded Warrants (in which case, the Pre-funded Warrants may only be exercised
via a &ldquo;cashless&rdquo; exercise provision). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <I>Fundamental Transaction</I>.
In the event of a fundamental transaction, as described in the Pre-funded Warrants and generally including any reorganization, recapitalization
or reclassification of our Ordinary Shares, the sale, transfer or other disposition of all or substantially all of our properties or
assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding Ordinary Shares,
or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding Ordinary Shares, the holders
of the Pre-funded Warrants will be entitled to receive upon exercise of the Pre-funded Warrants the kind and amount of securities, cash
or other property that the holders would have received had they exercised the Pre-funded Warrants immediately prior to such fundamental
transaction without regard to any limitations on exercised contained in the Pre-funded Warrants. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Warrant Agent</I>. The Pre-funded Warrants
will be issued in registered form under a warrant agent agreement between VStock Transfer, LLC, as warrant agent, and us. The Pre-Funded
Warrants shall initially be represented only by one or more global warrants deposited with the warrant agent, as custodian on behalf
of The Depository Trust Company, or DTC, and registered in the name of Cede &amp; Co., a nominee of DTC, or as otherwise directed by
DTC </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp;<I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <I>Exchange Listing</I>.
We do not intend to apply for listing of the Pre-funded Warrants on any securities exchange or other trading system. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Warrants Included in the Units and Pre-funded Units</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following summary of certain terms and
provisions of the Warrants offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the
warrant agent agreement between us and VStock Transfer, LLC, as warrant agent, and the form of Warrant, both of which are filed as exhibits
to the registration statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions
set forth in the warrant agent agreement, including the annexes thereto, and form of Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Exercisability</I>. The Warrants are exercisable
at any time after their original issuance and at any time up to the date that is five years after their original issuance. The Warrants
will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and, at any
time a registration statement registering the issuance of the Ordinary Shares underlying the warrants under the Securities Act is effective
and available for the issuance of such shares, by payment in full in immediately available funds for the number of Ordinary Shares purchased
upon such exercise. If a registration statement registering the issuance of the Ordinary Shares underlying the Warrants under the Securities
Act is not effective or available the holder may, in its sole discretion, elect to exercise the Warrant through a cashless exercise,
in which case the holder would receive upon such exercise the net number of Ordinary Shares determined according to the formula set forth
in the Warrant. No fractional shares will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, we will
pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Exercise Limitation</I>. A holder will not
have the right to exercise any portion of the warrant if the holder (together with its affiliates) would beneficially own in excess of
4.99% of the number of Ordinary Shares outstanding immediately after giving effect to the exercise, as such percentage ownership is determined
in accordance with the terms of the Warrants. However, any holder may increase or decrease such percentage to any other percentage not
in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days following notice from the holder
to us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Exercise Price</I>. The exercise price per
whole Ordinary Share purchasable upon exercise of the Warrants is $ per share, which is 100% of the public offering price of the Units.
The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock
combinations, reclassifications or similar events affecting our Ordinary Shares and also upon any distributions of assets, including
cash, stock or other property to our stockholders. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Transferability</I>. Subject to applicable
laws, the Warrants may be offered for sale, sold, transferred or assigned without our consent. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Exchange Listing</I>. We have applied to
list our Ordinary Shares and Warrants on the Nasdaq Capital Market, or Nasdaq, under the symbols &ldquo;IINN&rdquo; and &ldquo;IINNW,&rdquo;
respectively. No assurance can be given that our application will be approved or that a trading market will develop. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Warrant Agent</I>. The Warrants will be
issued in registered form under a warrant agent agreement between VStock Transfer, LLC, as warrant agent, and us. The Warrants shall
initially be represented only by one or more global warrants deposited with the warrant agent, as custodian on behalf of The Depository
Trust Company, or DTC, and registered in the name of Cede &amp; Co., a nominee of DTC, or as otherwise directed by DTC. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Fundamental Transactions.</I> In the event
of a fundamental transaction, as described in the Warrants and generally including any reorganization, recapitalization or reclassification
of our Ordinary Shares, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation
or merger with or into another person, the acquisition of more than 50% of our outstanding Ordinary Shares, or any person or group becoming
the beneficial owner of 50% of the voting power represented by our outstanding Ordinary Shares, the holders of the Warrants will be entitled
to receive upon exercise of the Warrants the kind and amount of securities, cash or other property that the holders would have received
had they exercised the Warrants immediately prior to such fundamental transaction without regard to any limitations on exercised contained
in the Warrants. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Rights as a Stockholder</I>. Except as otherwise
provided in the Warrants or by virtue of such holder&rsquo;s ownership of our Ordinary Shares, the holder of a Warrant does not have
the rights or privileges of a holder of our Ordinary Shares, including any voting rights, until the holder exercises the Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>Governing
Law.</I> The Warrants and the warrant agent agreement are governed by New York law. Representative&rsquo;s Warrants. see &ldquo;Underwriting
&mdash; Underwriters&rsquo; Warrants&rdquo; for a description of the warrants we have agreed to issue to the representative of the underwriters
in this offering, subject to the completion of the offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="i_016"></A>SHARES ELIGIBLE FOR FUTURE SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">In
connection with this offering, we have applied to list our Ordinary Shares and Warrants on Nasdaq, under the symbols &ldquo;IINN&rdquo;
and &ldquo;IINNW,&rdquo; respectively. No assurance can be given that our application will be approved. Sales of substantial amounts
of our Ordinary Shares in the public market, or the perception that such sales could occur, could adversely affect prevailing market
prices of our Ordinary Shares. Upon completion of this offering, we will have outstanding Ordinary Shares, assuming the underwriters
do not exercise their over-allotment option. All of the Ordinary Shares sold in this offering will be freely transferable without restriction
or further registration under the Securities Act by persons other than by our affiliates.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B>Lock-up
Agreements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">We
and our executive officers, directors, and certain shareholders have agreed not to offer, sell, agree to sell, directly or indirectly,
or otherwise dispose of any Ordinary Shares or any other securities convertible into or exchangeable for Ordinary Shares except
for the Ordinary Shares offered in this offering without the prior written consent of the representative for a period of 180 days
after the consummation of this offering. After the expiration of such day period, the Ordinary Shares held by our directors, executive
officers or certain of our other existing shareholders may be sold outside of the United States subject to the restrictions under
applicable Israeli securities laws or by means of registered public offerings.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B>Rule
144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">In
general, under Rule 144 under the Securities Act as in effect on the date hereof, beginning 90 days after the date hereof, a person
who holds restricted Ordinary Shares (assuming there are any restricted shares) and is not one of our affiliates at any time during
the three months preceding a sale, and who has beneficially owned these restricted shares for at least six months, would be entitled
to sell an unlimited number of our Ordinary Shares, provided current public information about us is available. In addition, under
Rule 144, a person who holds restricted shares in us and is not one of our affiliates at any time during the three months preceding
a sale, and who has beneficially owned these restricted shares for at least one year, would be entitled to sell an unlimited number
of shares immediately upon the closing of this offering without regard to whether current public information about us is available.
Beginning 90 days after the date hereof, our affiliates who have beneficially owned our Ordinary Shares for at least six months
will be entitled to sell within any three-month period a number of shares that does not exceed the greater of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">1% of the number of Ordinary Shares then outstanding;
or</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the average weekly trading volume of our or Ordinary Shares on Nasdaq during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale; provided that current public information about us is available and the affiliate complies with the manner of sale requirements imposed by Rule 144.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Affiliates
are also subject to additional restrictions on the manner of sales under Rule 144 and notice filing requirements. We cannot estimate
the number of our Ordinary Shares that our existing shareholders will elect to sell.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B>Regulation
S</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Regulation
S under the Securities Act provides that securities owned by any person may be sold without registration in the United States,
provided that the sale is effected in an offshore transaction and no directed selling efforts are made in the United States (as
these terms are defined in Regulation S), subject to certain other conditions. In general, this means that our Ordinary Shares
may be sold in some manner outside the United States without requiring registration in the United States.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B>Rule
701</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">In
general, under Rule 701 of the Securities Act as currently in effect, each of our employees, consultants or advisors who purchases
our Ordinary Shares from us in connection with a compensatory share plan or other written agreement executed prior to the completion
of this offering is eligible to resell such Ordinary Shares in reliance on Rule 144, but without compliance with some of the restrictions,
including the holding period, contained in Rule 144.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">THE
DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL SHARE TRANSFER RESTRICTION MATTERS THAT MAY BE OF IMPORTANCE TO A
PROSPECTIVE INVESTOR. EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN LEGAL ADVISOR REGARDING THE PARTICULAR SECURITIES LAWS AND
TRANSFER RESTRICTION CONSEQUENCES OF PURCHASING, HOLDING, AND DISPOSING OF THE ORDINARY SHARES, INCLUDING THE CONSEQUENCES OF ANY
PROPOSED CHANGE IN APPLICABLE LAWS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><A NAME="i_017"></A>TAXATION</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">The
following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition
of our Ordinary Shares and Warrants. You should consult your own tax advisor concerning the tax consequences of your particular situation,
as well as any tax consequences that may arise under the laws of any state, local, foreign, including Israeli, or other taxing jurisdiction.</FONT> </P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ISRAELI TAX CONSIDERATIONS AND GOVERNMENT PROGRAMS</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
following is a description of the material Israeli income tax consequences of the ownership of our Ordinary Shares. The following
also contains a description of material relevant provisions of the current Israeli income tax structure applicable to companies
in Israel, with reference to its effect on us. To the extent that the discussion is based on new tax legislation which has not
been subject to judicial or administrative interpretation, there can be no assurance that the tax authorities will accept the views
expressed in the discussion in question. The discussion is not intended, and should not be taken, as legal or professional tax
advice and is not exhaustive of all possible tax considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition
of our Ordinary Shares. Shareholders should consult their own tax advisors concerning the tax consequences of their particular
situation, as well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>General Corporate Tax Structure in Israel</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Israeli
companies are generally subject to corporate tax. As of January 2016, the corporate tax rate was 25%. As of January 1, 2017, the
corporate tax rate was reduced to 24% and as of January 1, 2018, the corporate tax rate is 23%. However, the effective tax rate
payable by a company that derives income from a Preferred Enterprise (as discussed below) may be considerably less. Capital gains
derived by an Israeli company are generally subject to the prevailing corporate tax rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Capital
gains derived by an Israeli resident company are subject to tax at the prevailing corporate tax rate. Under Israeli tax legislation,
a corporation will be considered as an &ldquo;Israeli resident company&rdquo; if it meets one of the following: (i) it was incorporated
in Israel; or (ii) the control and management of its business are exercised in Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Law for the Encouragement of Industry (Taxes), 5729-1969</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several
tax benefits for &ldquo;Industrial Companies.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
Industry Encouragement Law defines an &ldquo;Industrial Company&rdquo; as an Israeli resident-company, of which 90% or more of
its income in any tax year, other than income from defense loans, is derived from an &ldquo;Industrial Enterprise&rdquo; owned
by it. An &ldquo;Industrial Enterprise&rdquo; is defined as an enterprise whose principal activity in a given tax year is industrial
production.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
following corporate tax benefits, among others, are available to Industrial Companies:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amortization of the cost of purchased a patent, rights to use a patent, and know-how, which are used for the development or advancement of the company, over an eight-year period, commencing on the year in which such rights were first exercised;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">under limited conditions, an election to file consolidated tax returns with related Israeli Industrial Companies; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses related to a public offering are deductible in equal amounts over three years.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Eligibility
for benefits under the Industry Encouragement Law is not contingent upon approval of any governmental authority.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Tax Benefits and Grants for Research and Development</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Under
the Israeli Encouragement of Research, Development and Industrial Initiative Technology Law, 5744-1984, as amended, and related
regulations, or the Research Law, research and development programs which meet specified criteria and are approved by the IIA are
eligible for grants of up to 50% of the project&rsquo;s expenditure, as determined by the research committee, in exchange for the
payment of royalties from the revenues generated from the sale of products and related services developed, in whole or in part
pursuant to, or as a result of, a research and development program funded by the IIA. The royalties are generally at a range of
3.0% to 5.0% of revenues until the entire IIA grant is repaid, together with an annual interest generally equal to the 12 months
London Interbank Offered Rate applicable to dollar deposits that is published on the first business day of each calendar year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
terms of the Research Law also require that the manufacture of products developed with government grants be performed in Israel.
The transfer of manufacturing activity outside Israel may be subject to the prior approval of the IIA. Under the regulations of
the Research Law, assuming we receive approval from the Chief Scientist to manufacture our IIA-funded products outside Israel,
we may be required to pay increased royalties. The increase in royalties depends upon the manufacturing volume that is performed
outside of Israel as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid">Manufacturing Volume Outside of Israel</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Royalties to <BR>
the Chief <BR>
Scientist as&nbsp;a <BR>
Percentage <BR>
of Grant</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Up to 50%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">120</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Between 50% and 90%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">90% and more</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>


<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">If
the manufacturing is performed outside of Israel by us, the rate of royalties payable by us on revenues from the sale of products
manufactured outside of Israel will increase by 1% over the regular rates. If the manufacturing is performed outside of Israel
by a third party, the rate of royalties payable by us on those revenues will be equal to the ratio obtained by dividing the amount
of the grants received from the Office of the Chief Scientist and our total investment in the project that was funded by these
grants. The transfer of no more than 10% of the manufacturing capacity in the aggregate outside of Israel is exempt under the Research
Law from obtaining the prior approval of the IIA. A company requesting funds from the IIA also has the option of declaring in its
IIA grant application an intention to perform part of its manufacturing outside Israel, thus avoiding the need to obtain additional
approval. On January 6, 2011, the Research Law was amended to clarify that the potential increased royalties specified in the table
above will apply even in those cases where the IIA approval for transfer of manufacturing outside of Israel is not required, namely
when the volume of the transferred manufacturing capacity is less than 10% of total capacity or when the company received an advance
approval to manufacture abroad in the framework of its IIA grant application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
know-how developed within the framework of the Chief Scientist plan may not be transferred to third parties outside Israel without
the prior approval of a governmental committee charted under the Research Law. The approval, however, is not required for the export
of any products developed using grants received from the Chief Scientist. The IIA approval to transfer know-how created, in whole
or in part, in connection with an IIA-funded project to third party outside Israel where the transferring company remains an operating
Israeli entity is subject to payment of a redemption fee to the IIA calculated according to a formula provided under the Research
Law that is based, in general, on the ratio between the aggregate IIA grants to the company&rsquo;s aggregate investments in the
project that was funded by these IIA grants, multiplied by the transaction consideration. The transfer of such know-how to a party
outside Israel where the transferring company ceases to exist as an Israeli entity is subject to a redemption fee formula that
is based, in general, on the ratio between the aggregate IIA grants to the total financial investments in the company, multiplied
by the transaction consideration. According to the January 2011 amendment, the redemption fee in case of transfer of know-how to
a party outside Israel will be based on the ratio between the aggregate IIA grants received by the company and the company&rsquo;s
aggregate R&amp;D expenses, multiplied by the transaction consideration. According to regulations promulgated following the 2011
amendment, the maximum amount payable to the IIA in case of transfer of know how outside Israel shall not exceed 6 times the value
of the grants received plus interest, and in the event that the receiver of the grants ceases to be an Israeli corporation such
payment shall not exceed six times the value of the grants received plus interest, with a possibility to reduce such payment to
up to three times the value of the grants received plus interest if the R&amp;D activity remains in Israel for a period of three
years after payment to the IIA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Transfer
of know-how within Israel is subject to an undertaking of the recipient Israeli entity to comply with the provisions of the Research
Law and related regulations, including the restrictions on the transfer of know-how and the obligation to pay royalties, as further
described in the Research Law and related regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">These
restrictions may impair our ability to outsource manufacturing, engage in change of control transactions or otherwise transfer
our know-how outside Israel and may require us to obtain the approval of the IIA for certain actions and transactions and pay additional
royalties to the IIA. In particular, any change of control and any change of ownership of our Ordinary Shares that would make a
non-Israeli citizen or resident an &ldquo;interested party,&rdquo; as defined in the Research Law, requires a prior written notice
to the IIA in addition to any payment that may be required of us for transfer of manufacturing or know-how outside Israel. If we
fail to comply with the Research Law, we may be subject to criminal charges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Tax Benefits for Research and Development</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Israeli
tax law allows, under certain conditions, a tax deduction for expenditures, including capital expenditures, for the year in which
they are incurred. Expenditures are deemed related to scientific research and development projects, if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expenditures are approved by the relevant Israeli government ministry, determined by the field of research;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The research and development must be for the promotion of the company; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The research and development is carried out by or on behalf of the company seeking such tax deduction.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
amount of such deductible expenses is reduced by the sum of any funds received through government grants for the finance of such
scientific research and development projects. No deduction under these research and development deduction rules is allowed if such
deduction is related to an expense invested in an asset depreciable under the general depreciation rules of the income Tax Ordinance,
1961. Expenditures not so approved are deductible in equal amounts over three years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">From
time to time we may apply the Office of the Chief Scientist for approval to allow a tax deduction for all research and development
expenses during the year incurred. There can be no assurance that such application will be accepted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Law for the Encouragement of Capital Investments, 5719-1959</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
Law for the Encouragement of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives
for capital investments in production facilities (or other eligible assets).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Tax Benefits</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
Investment Law grants tax benefits for income generated by a &ldquo;Preferred Company&rdquo; through its &ldquo;Preferred Enterprise&rdquo;
(as such terms are defined in the Investment Law) The definition of a Preferred Company includes a company incorporated in Israel
that is not fully owned by a governmental entity, and that has, among other things, Preferred Enterprise status and is controlled
and managed from Israel. A Preferred Company is entitled to a reduced corporate tax rate of 16% with respect to its income derived
by its Preferred Enterprise, unless the Preferred Enterprise is located in a specified development zone, in which case the rate
will be 9%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Dividends
paid out of income attributed to a Preferred Enterprise are generally subject to withholding tax at source at the rate of 20% or
such lower rate as may be provided in an applicable tax treaty. However, if such dividends are paid to an Israeli company, no tax
is required to be withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Taxation of our Shareholders</I></B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Capital
Gains Taxes Applicable to Non-Israeli Resident Shareholders. A non-Israeli resident who derives capital gains from the sale of
shares in an Israeli resident company will be exempt from Israeli tax so long as the shares were not held through a permanent establishment
that the non-resident maintains in Israel. However, non-Israeli corporations will not be entitled to the foregoing exemption if
Israeli residents: (i) have a controlling interest of 25% or more in such non-Israeli corporation or (ii) are the beneficiaries
of, or are entitled to, 25% or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Additionally,
a sale of securities by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable
tax treaty. For example, under Convention Between the Government of the United States of America and the Government of the State
of Israel with respect to Taxes on Income, as amended, or the United States-Israel Tax Treaty, the sale, exchange or other disposition
of shares by a shareholder who is a United States resident (for purposes of the treaty) holding the shares as a capital asset and
is entitled to claim the benefits afforded to such a resident by the U.S.-Israel Tax Treaty, or a Treaty U.S. Resident, is generally
exempt from Israeli capital gains tax unless: (i) the capital gain arising from such sale, exchange or disposition is attributed
to real estate located in Israel; (ii) the capital gain arising from such sale, exchange or disposition is attributed to royalties;
(iii) the capital gain arising from the such sale, exchange or disposition is attributed to a permanent establishment in Israel,
under certain terms; (iv) such Treaty U.S. Resident holds, directly or indirectly, shares representing 10% or more of the voting
capital during any part of the 12-month period preceding the disposition, subject to certain conditions; or (v) such Treaty U.S.
Resident is an individual and was present in Israel for 183 days or more during the relevant taxable year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">In
some instances where our shareholders may be liable for Israeli tax on the sale of their Ordinary Shares, the payment of the consideration
may be subject to the withholding of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from
tax on their capital gains in order to avoid withholding at source at the time of sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Taxation
of Non-Israeli Shareholders on Receipt of Dividends. Non-Israeli residents are generally subject to Israeli income tax on the receipt
of dividends paid on our Ordinary Shares at the rate of 25%, which tax will be withheld at source, unless relief is provided in
a treaty between Israel and the shareholder&rsquo;s country of residence. With respect to a person who is a &ldquo;substantial
shareholder&rdquo; at the time of receiving the dividend or on any time during the preceding twelve months, the applicable tax
rate is 30%. A &ldquo;substantial shareholder&rdquo; is generally a person who alone or together with such person&rsquo;s relative
or another person who collaborates with such person on a permanent basis, holds, directly or indirectly, at least 10% of any of
the &ldquo;means of control&rdquo; of the corporation. &ldquo;Means of control&rdquo; generally include the right to vote, receive
profits, nominate a director or an executive officer, receive assets upon liquidation, or order someone who holds any of the aforesaid
rights how to act, regardless of the source of such right. However, a distribution of dividends to non-Israeli residents is subject
to withholding tax at source at a rate of 20% if the dividend is distributed from income attributed to a Preferred Enterprise,
unless a reduced tax rate is provided under an applicable tax treaty. For example, under the United States-Israel Tax Treaty, the
maximum rate of tax withheld at source in Israel on dividends paid to a holder of our Ordinary Shares who is a Treaty U.S. Resident
is 25%. However, generally, the maximum rate of withholding tax on dividends, not generated by a Preferred Enterprise, that are
paid to a United States corporation holding 10% or more of the outstanding voting capital throughout the tax year in which the
dividend is distributed as well as during the previous tax year, is 12.5%, provided that not more than 25% of the gross income
for such preceding year consists of certain types of dividends and interest. Notwithstanding the foregoing, dividends distributed
from income attributed to an Preferred Enterprise are not entitled to such reduction under the tax treaty but are subject to a
withholding tax rate of 15% for a shareholder that is a U.S. corporation, provided that the condition related to our gross income
for the previous year (as set forth in the previous sentence) is met. If the dividend is attributable partly to income derived
from a Preferred Enterprise, and partly to other sources of income, the withholding rate will be a blended rate reflecting the
relative portions of the two types of income. We cannot assure you that we will designate the profits that we may distribute in
a way that will reduce shareholders&rsquo; tax liability.<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="background-color: white"><B>U.S.
FEDERAL INCOME TAX CONSIDERATIONS</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> THE FOLLOWING SUMMARY IS INCLUDED HEREIN FOR
GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR TAX ADVICE. EACH U.S. HOLDER SHOULD CONSULT
WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND SALE OF ORDINARY
SHARES, <FONT STYLE="text-transform: uppercase">the Warrants, the Pre-funded Warrants and the Ordinary Shares issued or issuable upon
exercise of the Warrants and Pre-funded Warrants</FONT>, INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS
AND POSSIBLE CHANGES IN THE TAX LAWS. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Subject to the limitations described in the
next two paragraphs, the following discussion summarizes the material U.S. federal income tax consequences to a &ldquo;U.S. Holder&rdquo;
arising from the purchase, ownership and sale of the Ordinary Shares, the Warrants, the Pre-funded Warrants and the Ordinary Shares issued
or issuable upon exercise of the Warrants and Pre-funded Warrants, collectively, the &ldquo;securities&rdquo;. For this purpose, a &ldquo;U.S.
Holder&rdquo; is a holder of securites that is: (1) an individual citizen or resident of the United States, including an alien individual
who is a lawful permanent resident of the United States or meets the substantial presence residency test under U.S. federal income tax
laws; (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) or a partnership (other than a partnership
that is not treated as a U.S. person under any applicable U.S. Treasury regulations) created or organized under the laws of the United
States or the District of Columbia or any political subdivision thereof; (3) an estate, the income of which is includable in gross income
for U.S. federal income tax purposes regardless of source; (4) a trust if a court within the United States is able to exercise primary
supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of
the trust; or (5) a trust that has a valid election in effect to be treated as a U.S. person to the extent provided in U.S. Treasury
regulations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> This summary is for general information purposes
only and does not purport to be a comprehensive description of all of the U.S. federal income tax considerations that may be relevant
to a decision to purchase our securities. This summary generally considers only U.S. Holders that will own our securities as capital
assets. Except to the limited extent discussed below, this summary does not consider the U.S. federal tax consequences to a person that
is not a U.S. Holder, nor does it describe the rules applicable to determine a taxpayer&rsquo;s status as a U.S. Holder. This summary
is based on the provisions of the Internal Revenue Code of 1986, as amended, or the Code, final, temporary and proposed U.S. Treasury
regulations promulgated thereunder, administrative and judicial interpretations thereof, and the U.S./Israel Income Tax Treaty, all as
in effect as of the date hereof and all of which are subject to change, possibly on a retroactive basis, and all of which are open to
differing interpretations. We will not seek a ruling from the IRS with regard to the U.S. federal income tax treatment of an investment
in our securities by U.S. Holders and, therefore, can provide no assurances that the IRS will agree with the conclusions set forth below. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> This discussion does not address all of the
aspects of U.S. federal income taxation that may be relevant to a particular U.S. holder based on such holder&rsquo;s particular circumstances
and in particular does not discuss any estate, gift, generation-skipping transfer, state, local, excise or foreign tax considerations.
In addition, this discussion does not address the U.S. federal income tax treatment of a U.S. Holder who is: (1) a bank, life insurance
company, regulated investment company, or other financial institution or &ldquo;financial services entity;&rdquo; (2) a broker or dealer
in securities or foreign currency; (3) a person who acquired our securities in connection with employment or other performance of services;
(4) a U.S. Holder that is subject to the U.S. alternative minimum tax; (5) a U.S. Holder that holds our securities as a hedge or as part
of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction transaction for U.S. federal income tax purposes;
(6) a tax-exempt entity; (7) real estate investment trusts or grantor trusts; (8) a U.S. Holder that expatriates out of the United States
or a former long-term resident of the United States; or (9) a person having a functional currency other than the U.S. dollar. This discussion
does not address the U.S. federal income tax treatment of a U.S. Holder that owns, directly or constructively, at any time, securities
representing 10% or more of our voting power. Additionally, the U.S. federal income tax treatment of partnerships (or other pass-through
entities) or persons who hold securities through a partnership or other pass-through entity are not addressed. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Each prospective investor is advised to consult
his or her own tax adviser for the specific tax consequences to that investor of purchasing, holding or disposing of our securities,
including the effects of applicable state, local, foreign or other tax laws and possible changes in the tax laws. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Tax Treatment of the Pre-Funded Warrants</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> We intend to treat our
pre-funded warrants as a class of Ordinary Shares stock for U.S. federal income tax purposes. However, our position is not binding on IRS
and the IRS may treat the pre-funded warrants as warrants to acquire our Ordinary Shares. Accordingly, you should consult your tax adviser
regarding the U.S. federal tax consequences of an investment in the pre-funded warrants. The following discussion assumes our pre-funded
warrants are properly treated as a class of our Ordinary Shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="background-color: white"><B><I>Taxation
of Dividends Paid on Ordinary Shares</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We do not intend to pay dividends in the foreseeable
future. In the event that we do pay dividends, and subject to the discussion under the heading &ldquo;Passive Foreign Investment Companies&rdquo;
below and the discussion of &ldquo;qualified dividend income&rdquo; below, a U.S. Holder, other than certain U.S. Holders that are U.S.
corporations, will be required to include in gross income as ordinary income the amount of any distribution paid on securities (including
the amount of any Israeli tax withheld on the date of the distribution), to the extent that such distribution does not exceed our current
and accumulated earnings and profits, as determined for U.S. federal income tax purposes. The amount of a distribution which exceeds
our earnings and profits will be treated first as a non-taxable return of capital, reducing the U.S. Holder&rsquo;s tax basis for the
securities to the extent thereof, and then capital gain. We do not expect to maintain calculations of our earnings and profits under
U.S. federal income tax principles and, therefore, U.S. Holders should expect that the entire amount of any distribution generally will
be reported as dividend income. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">In general, preferential tax rates for &ldquo;qualified
dividend income&rdquo; and long-term capital gains are applicable for U.S. Holders that are individuals, estates or trusts. For
this purpose, &ldquo;qualified dividend income&rdquo; means, inter alia, dividends received from a &ldquo;qualified foreign corporation.&rdquo;
A &ldquo;qualified foreign corporation&rdquo; is a corporation that is entitled to the benefits of a comprehensive tax treaty with
the United States which includes an exchange of information program. The IRS has stated that the Israel/U.S. Tax Treaty satisfies
this requirement and we believe we are eligible for the benefits of that treaty.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In addition, our dividends will be qualified
dividend income if our securities are readily tradable on the Nasdaq Capital Market or another established securities market in the United
States. Dividends will not qualify for the preferential rate if we are treated, in the year the dividend is paid or in the prior year,
as a PFIC, as described below under &ldquo;Passive Foreign Investment Companies.&rdquo; A U.S. Holder will not be entitled to the preferential
rate: (1) if the U.S. Holder has not held our securities for at least 61 days of the 121 day period beginning on the date which is 60
days before the ex-dividend date, or (2) to the extent the U.S. Holder is under an obligation to make related payments on substantially
similar property. Any days during which the U.S. Holder has diminished its risk of loss on our securities are not counted towards meeting
the 61-day holding period. Finally, U.S. Holders who elect to treat the dividend income as &ldquo;investment income&rdquo; pursuant to
Code section 163(d)(4) will not be eligible for the preferential rate of taxation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The amount of a distribution with respect to
our securities will be measured by the amount of the fair market value of any property distributed, and for U.S. federal income tax purposes,
the amount of any Israeli taxes withheld therefrom. Cash distributions paid by us in NIS will be included in the income of U.S. Holders
at a U.S. dollar amount based upon the spot rate of exchange in effect on the date the dividend is includible in the income of the U.S.
Holder, and U.S. Holders will have a tax basis in such NIS for U.S. federal income tax purposes equal to such U.S. dollar value. If the
U.S. Holder subsequently converts the NIS into U.S. dollars or otherwise disposes of them, any subsequent gain or loss in respect of
such NIS arising from exchange rate fluctuations will be U.S. source ordinary exchange gain or loss. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <FONT STYLE="background-color: white"><B><I>Taxation
of the Disposition of Securities</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Except as provided under the PFIC rules described
below under &ldquo;Passive Foreign Investment Companies,&rdquo; upon the sale, exchange or other disposition of our securities, a U.S.
Holder will recognize capital gain or loss in an amount equal to the difference between such U.S. Holder&rsquo;s tax basis for the securities
in U.S. dollars and the amount realized on the disposition in U.S. dollar (or its U.S. dollar equivalent determined by reference to the
spot rate of exchange on the date of disposition, if the amount realized is denominated in a foreign currency). The gain or loss realized
on the sale, exchange or other disposition of securities will be long-term capital gain or loss if the U.S. Holder has a holding period
of more than one year at the time of the disposition. Individuals who recognize long-term capital gains may be taxed on such gains at
reduced rates of tax. The deduction of capital losses is subject to various limitations. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"></P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="background-color: white"><B><I>Passive
Foreign Investment Companies</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Special U.S. federal income tax laws apply
to U.S. taxpayers who own shares of a corporation that is a PFIC. We will be treated as a PFIC for U.S. federal income tax purposes
for any taxable year that either:</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75% or more of our gross income (including our pro rata share of gross income for any company, in which we are considered to own 25% or more of the shares by value), in a taxable year is passive; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At least 50% of our assets, averaged over the year and generally determined based upon fair market value (including our pro rata share of the assets of any company in which we are considered to own 25% or more of the shares by value) are held for the production of, or produce, passive income.</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">For this purpose, passive income generally
consists of dividends, interest, rents, royalties, annuities and income from certain commodities transactions and from notional
principal contracts. Cash is treated as generating passive income.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We believe that we will not be a PFIC for the
current taxable year, although we have not determined whether we will be a PFIC in the foreseeable future. The tests for determining
PFIC status are applied annually, and it is difficult to make accurate projections of future income and assets which are relevant to
this determination. In addition, our PFIC status may depend in part on the market value of our securities. Accordingly, there can be
no assurance that we currently are not or will not become a PFIC. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> If we currently are or become a PFIC, each
U.S. Holder who has not elected to mark the shares to market (as discussed below), would, upon receipt of certain distributions by us
and upon disposition of our securities at a gain:&nbsp;(1) have such distribution or gain allocated ratably over the U.S. Holder&rsquo;s
holding period for the securities, as the case may be; (2) the amount allocated to the current taxable year and any period prior to the
first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of
the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year,
and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other
taxable year. In addition, when shares of a PFIC are acquired by reason of death from a decedent that was a U.S. Holder, the tax basis
of such shares would not receive a step-up to fair market value as of the date of the decedent&rsquo;s death, but instead would be equal
to the decedent&rsquo;s basis if lower, unless all gain were recognized by the decedent. Indirect investments in a PFIC may also be subject
to these special U.S. federal income tax rules. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">&nbsp;&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The PFIC rules described above would not apply
to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has held the securities while we are a PFIC, provided
that we comply with specified reporting requirements. Instead, each U.S. Holder who has made such a QEF election is required for each
taxable year that we are a PFIC to include in income such U.S. Holder&rsquo;s pro rata share of our ordinary earnings as ordinary income
and such U.S. Holder&rsquo;s pro rata share of our net capital gains as long-term capital gain, regardless of whether we make any distributions
of such earnings or gain. In general, a QEF election is effective only if we make available certain required information. The QEF election
is made on a shareholder-by-shareholder basis and generally may be revoked only with the consent of the IRS. We do not intend to notify
U.S. Holders if we believe we will be treated as a PFIC for any tax year. In addition, we do not intend to furnish U.S. Holders annually
with information needed in order to complete IRS Form 8621 and to make and maintain a valid QEF election for any year in which we or
any of our Subsidiaries are a PFIC. Therefore, the QEF election will not be available with respect to our securities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In addition, the PFIC rules described above
would not apply if we were a PFIC and a U.S. Holder made a mark-to-market election. A U.S. Holder of our securities which are regularly
traded on a qualifying exchange, including the Nasdaq Capital Market, can elect to mark the securities to market annually, recognizing
as ordinary income or loss each year an amount equal to the difference as of the close of the taxable year between the fair market value
of the securities and the U.S. Holder&rsquo;s adjusted tax basis in the securities. Losses are allowed only to the extent of net mark-to-market
gain previously included income by the U.S. Holder under the election for prior taxable years. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> U.S. Holders who hold our securities during
a period when we are a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC. U.S. Holders are strongly urged to
consult their tax advisors about the PFIC rules. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>Tax
on Net Investment Income</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> U.S. Holders who are individuals, estates or
trusts will generally be required to pay a 3.8% Medicare tax on their net investment income (including dividends on and gains from the
sale or other disposition of our securities), or in the case of estates and trusts on their net investment income that is not distributed
to beneficiaries of the estate or trust. In each case, the 3.8% Medicare tax applies only to the extent the U.S. Holder&rsquo;s total
adjusted income exceeds applicable thresholds. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B><I>Information
Reporting and Withholding</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> A U.S. Holder may be subject to backup withholding
at a rate of 24% with respect to cash dividends and proceeds from a disposition of securities. In general, backup withholding will apply
only if a U.S. Holder fails to comply with specified identification procedures. Backup withholding will not apply with respect to payments
made to designated exempt recipients, such as corporations and tax-exempt organizations. Backup withholding is not an additional tax
and may be claimed as a credit against the U.S. federal income tax liability of a U.S. Holder, provided that the required information
is timely furnished to the IRS. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to recently enacted legislation, a
U.S. Holder with interests in &ldquo;specified foreign financial assets&rdquo; (including, among other assets, our securities, unless
such securities are held on such U.S. Holder&rsquo;s behalf through a financial institution) may be required to file an information report
with the IRS if the aggregate value of all such assets exceeds $50,000 on the last day of the taxable year or $75,000 at any time during
the taxable year (or such higher dollar amount as may be prescribed by applicable IRS guidance); and may be required to file a Report
of Foreign Bank and Financial Accounts, or FBAR, if the aggregate value of the foreign financial accounts exceeds $10,000 at any time
during the calendar year. You should consult your own tax advisor as to the possible obligation to file such information report. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Exercise of Pre-Funded Warrants</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"> Under current law, (1) a U.S. Holder will
not be required to recognize income, gain or loss upon the exercise of a pre-funded warrant, (2) a U.S. Holder&rsquo;s basis in an
Ordinary Share received upon exercise will be equal to the sum of&thinsp; (x) the U.S. Holder&rsquo;s basis in the pre-funded
warrant and (y) the exercise price of the pre-funded warrant and (3) a U.S. Holder&rsquo;s holding period in the Ordinary share received upon exercise will include the holding period in the pre-funded warrants exchanged therefor. However, under a
proposed regulation (which is proposed to have retroactive effect), a U.S. Holder would recognize gain if the pre-funded warrant was
treated as stock of a PFIC with respect to a U.S. Holder at the time of the exercise of the pre-funded warrants and the stock
received upon the exercise was not treated as stock of a PFIC for the taxable year in which the exercise occurs. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="i_018"></A>UNDERWRITING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Aegis Capital Corp. (&ldquo;Aegis&rdquo;)
is acting as the representative of the underwriters and the book-running manager of this offering. Under the terms of an underwriting
agreement, which is filed as an exhibit to the registration statement, each of the underwriters named below has severally agreed to purchase
from us the respective number of Units and Pre-funded Units shown opposite its name below: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; padding-bottom: 8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriter</B></FONT> </TD>
    <TD STYLE="padding-bottom: 8pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; padding-bottom: 8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Units</B></FONT> </TD>
    <TD STYLE="padding-bottom: 8pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 8pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; padding-bottom: 8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Pre-funded Units</B></FONT> </TD>
    <TD STYLE="padding-bottom: 8pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 46%; padding-bottom: 8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aegis Capital
    Corp.</FONT> </TD>
    <TD STYLE="width: 1%; padding-bottom: 8pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; padding-bottom: 8pt"> &nbsp; </TD>
    <TD STYLE="width: 24%; padding-bottom: 8pt; text-align: right"> &nbsp; </TD>
    <TD STYLE="width: 1%; padding-bottom: 8pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; padding-bottom: 8pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; padding-bottom: 8pt"> &nbsp; </TD>
    <TD STYLE="width: 24%; padding-bottom: 8pt; text-align: right"> &nbsp; </TD>
    <TD STYLE="width: 1%; padding-bottom: 8pt"> &nbsp; </TD></TR>
  <TR>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">The
underwriting agreement</FONT> provides that <FONT STYLE="font-family: Times New Roman, Times, Serif">the underwriters&rsquo; </FONT>obligation
to purchase Units <FONT STYLE="font-family: Times New Roman, Times, Serif">and </FONT>Pre-Funded Units depends on the satisfaction of
the conditions <FONT STYLE="font-family: Times New Roman, Times, Serif">contained in the underwriting agreement</FONT> including: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            representations and warranties made by us to the underwriters are true;</FONT> </TD>
</TR></TABLE>

<P STYLE="margin: 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
                                            is no material change in our business or the financial markets; and</FONT> </TD>
</TR></TABLE>

<P STYLE="margin: 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            deliver customary closing documents to the underwriters.</FONT> </TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>Underwriting Commissions and Discounts
and Expenses</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table shows the </FONT>per Unit and total underwriting discounts and commissions we will pay to Aegis. These amounts are shown
assuming both no exercise and full exercise of the underwriters&rsquo; option to purchase additional securities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Total </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Per Unit </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Per Pre-funded Unit </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> No Exercise </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Full Exercise </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%"> Public offering price </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Underwriting discounts and commissions to be paid by us (8%): </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Non-accountable expense allowance (1%) (1) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Proceeds, before expenses, to us </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have agreed to pay a non-accountable expense allowance to the representative equal to 1%
                                            of the gross proceeds we received in this offering.</FONT> </TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We have also agreed to
reimburse the underwriters for certain of their expenses, including &ldquo;roadshow&rdquo;, diligence, and reasonable legal fees and
disbursements, in an amount not to exceed $100,000 in the aggregate. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We estimate that the total
expenses of the offering payable by us, excluding underwriting discounts and commissions, will be approximately $ . </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>Over-Allotment Option</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have granted the representative of the underwriters
an option to purchase from us, up to additional Ordinary Shares and/or Pre-Funded Warrants, and/or up to an additional Warrants, within
45 days from the date of this prospectus to cover over-allotments, if any. The purchase price to be paid per additional Ordinary Share
or Pre-Funded Warrant will be equal to the public offering price of one Unit or Pre-Funded Unit (less $0.001 allocated to the Warrants),
as applicable, less the underwriting discount, and the purchase price to be paid per additional Warrant will be $0.001. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Discretionary Accounts</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The underwriters do not intend to confirm sales
of the securities offered hereby to any accounts over which they have discretionary authority. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Lock-Up Agreements</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to certain &ldquo;lock-up&rdquo; agreements,
the Company, its executive officers, directors and certain holders of the Company&rsquo;s ordinary shares and securities exercisable
for or convertible into its ordinary shares outstanding immediately upon the closing of this offering, have agreed, subject to certain
exceptions, not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise
dispose of, or enter into any swap, hedge or similar agreement or arrangement that transfers, in whole or in part, the economic risk
of ownership of, directly or indirectly, engage in any short selling of any ordinary shares or securities convertible into or exchangeable
or exercisable for any ordinary shares, whether currently owned or subsequently acquired, without the prior written consent of the underwriters,
for a period of 180 days from the closing date of the offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Underwriter Warrants</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The Company has agreed to issue to Aegis or its designees warrants
to purchase up to a total of 5.0% of the Ordinary Shares sold in this offering (including any Ordinary Shares underlying the Pre-Funded
Warrants, but excluding the shares sold through the exercise of the over-allotment option).&nbsp;Such warrants and underlying ordinary
shares are included in this prospectus. The warrants are exercisable at $ per share (125% of the public offering price) commencing on
a date which is six (6) months from the effective date of the offering under this prospectus supplement and expiring on a date which
is no more than five (5) years from the commencement of sales of the offering in compliance with FINRA Rule 5110.&nbsp;The warrants have
been deemed compensation by FINRA and are therefore subject to a 6-month lock-up pursuant to Rule 5110 of FINRA.&nbsp;The underwriters
(or their permitted assignees under the Rule) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities
underlying these warrants, nor will it engage in any hedging, short sale, derivative, put, or call transaction that would result in the
effective economic disposition of the warrants or the underlying securities for a period of 180 days from effectiveness.&nbsp;The warrants
may be exercised as to all, or a lesser number of ordinary shares, and will provide for cashless exercise and will contain provisions
for &ldquo;piggyback&rdquo; registration rights, for a period of no greater than five (5) years from the effective date of the offering
in compliance with FINRA Rule 5110.&nbsp;The Company will bear all fees and expenses attendant to registering the securities issuable
on exercise of the warrants other than underwriting commissions incurred and payable by the holders.&nbsp;The exercise price and number
of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend,
extraordinary cash dividend or the Company&rsquo;s recapitalization, reorganization, merger or consolidation. However, the warrant exercise
price or underlying shares will not be adjusted for issuances of ordinary shares at a price below the warrant exercise price. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left"> We have granted the underwriter
a right of first refusal, for a period of eighteen (18) months from the closing of this offering, to act as sole managing underwriter
and book runner, sole manager, sole placement agent or sole agent at the underwriter&rsquo;s discretion, for each and every future public
and private equity, equity-linked or debt (excluding commercial bank debt) offering, including all equity linked financings during such
eighteen (18) month period, of the Company, or any successor to or subsidiary of the Company. Following such eighteen (18) month period
and for an additional period of eighteen (18) months, the Company shall have the right to bring a tier two or tier one investment bank
to act as lead left book-runner or lead placement agent for 50% of the economics of such transaction and Aegis shall have the right to
act as joint book-running manager or co-placement agent for the balance of the economics. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Offer, Sale and Distribution of Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on the websites maintained by the underwriters, if any, participating in
this offering and the underwriters participating in this offering may distribute prospectuses electronically. The underwriters
may agree to allocate a number of shares for sale to its online brokerage account holders. Internet distributions will be allocated
by the underwriters that will make internet distributions on the same basis as other allocations. Other than the prospectus in
electronic format, the information on these websites is not part of, nor incorporated by reference into, this prospectus or the
registration statement of which this prospectus forms a part, has not been approved or endorsed by us or the underwriters in their
capacity as underwriters, and should not be relied upon by investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stabilization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering
transactions, penalty bids and purchases to cover positions created by short sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing transactions
    permit bids to purchase shares so long as the stabilizing bids do not exceed a specified maximum and are engaged in for the
    purpose of preventing or retarding a decline in the market price of the shares while the offering is in progress.</FONT></TD></TR>
</TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over-allotment transactions
    involve sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase.
    This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered
    short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that they
    may purchase in the over-allotment option. In a naked short position, the number of shares involved is greater than the number
    of shares in the over-allotment option. The underwriters may close out any short position by exercising their over-allotment
    option and/or purchasing shares in the open market.</FONT></TD></TR>
</TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syndicate covering
    transactions involve purchases of shares in the open market after the distribution has been completed in order to cover syndicate
    short positions. In determining the source of shares to close out the short position, the underwriters will consider, among
    other things, the price of shares available for purchase in the open market as compared with the price at which they may purchase
    shares through exercise of the over- allotment option. If the underwriters sell more shares than could be covered by exercise
    of the over-allotment option and, therefore, have a naked short position, the position can be closed out only by buying shares
    in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing
    there could be downward pressure on the price of the shares in the open market that could adversely affect investors who purchase
    in the offering.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalty bids permits
    the underwriters to reclaim a selling concession from a syndicate member when the shares originally sold by that syndicate
    member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> These stabilizing transactions, syndicate covering
transactions and penalty bids may have the effect of raising or maintaining the market price of the Company&rsquo;s ordinary shares or
preventing or retarding a decline in the market price of its ordinary shares. As a result, the price of the Company&rsquo;s ordinary
shares or warrants in the open market may be higher than it would otherwise be in the absence of these transactions. Neither the Company
nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price
of the Company&rsquo;s ordinary shares. These transactions may be effected on the Nasdaq Capital Market, in the over-the-counter market
or otherwise and, if commenced, may be discontinued at any time. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Passive
Market Making</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In connection with this offering, the underwriters
may engage in passive market making transactions in the Company&rsquo;s ordinary shares on The Nasdaq Capital Market in accordance with
Rule 103 of Regulation M under the Exchange Act, during a period before the commencement of offers or sales of the shares and extending
through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent
bid of that security. However, if all independent bids are lowered below the passive market maker&rsquo;s bid, then that bid must then
be lowered when specified purchase limits are exceeded. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters and their respective affiliates may, in the future provide various investment banking, commercial banking and other
financial services for the Company and its affiliates for which they have received, and may in the future receive, customary fees.
However, except as disclosed in this prospectus, the Company has no present arrangements with the underwriters for any further
services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offer
Restrictions Outside the United States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities
offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus
may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in
connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances
that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this
prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution
of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered
by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="i_019"></A>EXPENSES</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Set forth below is an itemization of the total
expenses, excluding underwriting discounts, expected to be incurred in connection with the offer and sale of the securities offered by
us.&nbsp;With the exception of the SEC registration fee and the FINRA filing fee, all amounts are estimates: </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left"> SEC registration fee </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 3,827.17 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Nasdaq listing fee </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 50,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> FINRA filing fee </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 3,268.63 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Transfer agent fees and expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 5,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Printer fees and expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 30,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Legal fees and expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 425,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Accounting fees and expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 76,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"> Miscellaneous </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 6,859.20 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt"> Total </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 600,000 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="i_020"></A>LEGAL MATTERS</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Certain legal matters concerning this offering
will be passed upon for us by Sullivan &amp; Worcester LLP, New York, New York. Certain legal matters with respect to the legality of
the issuance of the securities offered by this prospectus and other legal matters concerning this offering relating to Israeli law will
be passed upon for us by Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), Tel Aviv, Israel. Certain legal matters related to the
offering will be passed upon for the underwriters by Sichenzia Ross Ference LLP, New York, New York. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="i_021"></A>EXPERTS</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in"> The
financial statements as of December 31, 2020 and 2019 and for the years then ended included in this prospectus have been so included
in reliance upon the report of Ziv Haft, a member of BDO, an independent registered public accounting firm, (the report on the financial
statements contains an explanatory paragraph regarding the Company's ability to continue as a going concern) appearing elsewhere herein
[and in the Registration Statement], given on the authority of said firm as experts in auditing and accounting. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="i_022"></A>ENFORCEABILITY OF CIVIL LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">We are incorporated under the laws of the
State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in the registration
statement of which this prospectus forms a part, a substantial majority of whom reside outside of the United States, may be difficult
to obtain within the United States. Furthermore, because substantially all of our assets and a substantial of our directors and
officers are located outside of the United States, any judgment obtained in the United States against us or any of our directors
and officers may not be collectible within the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">We have been informed by our legal counsel
in Israel, Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), that it may be difficult to assert U.S. securities law claims
in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws
because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a
claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the
content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure
will also be governed by Israeli law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Subject to specified time limitations and
legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter which, subject to certain exceptions, is non-appealable,
including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary
or compensatory judgment in a non-civil matter, provided that among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">the judgment is obtained after due process before a
court of competent jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international
law currently prevailing in Israel;</P></TD></TR>
</TABLE>

<P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">the judgment is final and is not subject to any right
of appeal;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">the prevailing law of the foreign state in which the
judgment was rendered allows for the enforcement of judgments of Israeli courts;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">adequate service of process has been effected and the
defendant has had a reasonable opportunity to be heard and to present his or her evidence;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">the liabilities under the judgment are enforceable
according to the laws of the State of Israel and the judgment and the enforcement of the civil liabilities set forth in the judgment
is not contrary to the law or public policy in Israel nor likely to impair the security or sovereignty of Israel;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">the judgment was not obtained by fraud and does not
conflict with any other valid judgments in the same matter between the same parties;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">an action between the same parties in the same matter
is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court; and</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment is enforceable according to the laws of Israel and according to the law of the foreign state in which the relief was granted.</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">If a foreign judgment is enforced by an
Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred
out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the
Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of
the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an
Israeli court stated in Israeli currency ordinarily will be linked to the Israeli CPI plus interest at the annual statutory rate
set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="i_023"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">We have filed with the SEC a registration
statement on Form&nbsp;F-1 under the Securities Act relating to this offering of our Ordinary Shares. This prospectus does not
contain all of the information contained in the registration statement. The rules and regulations of the SEC allow us to omit certain
information from this prospectus that is included in the registration statement. Statements made in this prospectus concerning
the contents of any contract, agreement or other document are summaries of all material information about the documents summarized,
but are not complete descriptions of all terms of these documents. If we filed any of these documents as an exhibit to the registration
statement, you may read the document itself for a complete description of its terms.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">You may read and copy the registration statement,
including the related exhibits and schedules, and any document we file with the SEC without charge at the SEC&rsquo;s public reference
room at 100&nbsp;F Street, N.E., Room&nbsp;1580, Washington, DC 20549. You may also obtain copies of the documents at prescribed
rates by writing to the Public Reference Section of the SEC at 100&nbsp;F Street, N.E., Room&nbsp;1580, Washington, DC 20549. Please
call the SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also maintains an Internet website
that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are
also available to the public through the SEC&rsquo;s website at www.sec.gov.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Upon completion of this offering, we will
be subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under
those requirements are filing reports with the SEC. Those other reports or other information may be inspected without charge at
the locations described above. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the
furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting
and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we are not required under
the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly
as U.S. companies whose securities are registered under the Exchange Act. However, we will file with the SEC, within 120&nbsp;days
after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form&nbsp;20-F containing
financial statements audited by an independent registered public accounting firm, and will submit to the SEC, on Form&nbsp;6-K,
unaudited quarterly financial information.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">We maintain a corporate website at www.inspira-technologies.com.
Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus. We have included
our website address in this prospectus solely as an inactive textual reference. We will post on our website any materials required
to be so posted on such website under applicable corporate or securities laws and regulations, including, posting any XBRL interactive
financial data required to be filed with the SEC and any notices of general meetings of our shareholders.&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B><U><A NAME="toc_01"></A>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>FINANCIAL STATEMENTS AS OF DECEMBER 31,
2020</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 127 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>(FORMERLY: INSENSE MEDICAL LTD.)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TABLE OF CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 93%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 7%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Page</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#a_001">Report of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">F-2</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_002">Statements of financial position</A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">F-3 - F-4</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_003">Statements of comprehensive loss</A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">F-5</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_004">Statements of changes in shareholders&rsquo; deficit</A></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-6</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_005">Statements of cash flows</A></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-7</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_006">Notes to financial statements</A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">F-8 - F-34</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The amounts are stated in thousands of U.S. dollars</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">_______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">____________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 128; Options: NewSection -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B><A NAME="a_001"></A>REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> To The Board of Directors and Stockholders
of INSPIRA TECHNOLOGIES OXY B.H.N. LTD. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>Opinion on the Financial Statements&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-size: 10pt">We have audited
the accompanying statements of financial position of INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (formerly: INSENSE MEDICAL LTD.) (the &ldquo;Company&rdquo;)
as of December 31, 2020 and 2019, the related statements of comprehensive loss, changes in shareholders&rsquo; deficit, and cash flows
for each of the years in the two-year period ended December 31, 2020, and the related notes (collectively, the &ldquo;Financial Statements&rdquo;).
In our opinion, the Financial Statements present fairly, in all material respects, the financial position of the Company as of December
31, 2020 and 2019, and the results of its operations and its cash flows for </FONT>each of the years in the two-year period ended December&nbsp;31,
2020<FONT STYLE="font-size: 10pt">, in conformity with International Financial Reporting Standards as issued by the International Accounting
Standards Board.&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-size: 10pt"><I>Substantial
Doubt About the Company&rsquo;s Ability to Continue as a Going Concern</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The accompanying Financial Statements have
been prepared assuming that the Company will continue as a going concern. As discussed in Note 1(3) to the Financial Statements, the
Company incurred a net loss of $7,228 for the year ended December 31, 2020 and generated $11,836 of accumulated deficit since inception.
These factors, along with other matters, raise substantial doubt on the Company&rsquo;s ability to continue as a going concern. Management&rsquo;s
plans in regard to these matters are also described in Note 1(3). The Financial Statements do not include any adjustments that might
result from the outcome of this uncertainty. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>Basis for Opinion</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> These Financial Statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on these Financial Statements based on our audits. We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to
be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an
understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the
Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Our audits included performing procedures
to assess the risks of material misstatement of the Financial Statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the Financial
Statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well
as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We have served as the Company&rsquo;s auditor
since 2018.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; width: 65%"> <FONT STYLE="font-size: 10pt">Tel-Aviv, Israel</FONT> </TD>
    <TD STYLE="text-align: center; width: 35%"> <FONT STYLE="font-size: 10pt">BDO Ziv haft</FONT> </TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt">April</FONT> 30, 2021, <FONT STYLE="font-size: 10pt">except
    for note 20.5 which is dated June 4, 2021</FONT> </TD>
    <TD STYLE="padding-left: 2.85pt; text-align: center"> <FONT STYLE="font-size: 10pt">Certified Public Accountants (Isr.)</FONT> </TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 2.85pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; padding-left: 2.85pt; text-align: center"> <FONT STYLE="font-size: 10pt">BDO Member Firm</FONT> </TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 129 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B><A NAME="a_002"></A>INSPIRA TECHNOLOGIES
OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>STATEMENTS OF FINANCIAL POSITION</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <B>(US dollars in thousands)</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left"> &nbsp; </TD><TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; text-align: center"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center"> December 31, </TD><TD STYLE="white-space: nowrap; font-weight: bold"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center"> December 31, </TD><TD STYLE="white-space: nowrap; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Note </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2020 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2019 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify"> ASSETS </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"> Current Assets: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 64%; text-align: left"> Cash and cash equivalents </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 11%; text-align: center"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 496 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 96 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"> Other accounts receivable </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt"> 4 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 188 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 86 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Total current assets </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 684 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 182 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"> Non-Current Assets: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left"> Right of use assets, net </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 15 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 258 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 163 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"> Property and equipment, net </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt"> 5 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 45 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 29 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Total non-current assets </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 303 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 192 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt"> Total Assets </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 987 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 374 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>The accompanying notes are an integral part
of the financial statements.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 130 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA
                                            TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>STATEMENTS OF FINANCIAL POSITION</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <B>(US dollars in thousands)</B> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> Note </TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> December
    31, <BR>
    2020 </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> December
    31, <BR>
    2019 </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left"> LIABILITIES AND DEFICIT </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left"> Current Liabilities: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left; padding-left: 11.35pt"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 64%; text-align: left"> Trade accounts payables </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 11%; text-align: center; padding-left: 2.8pt"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 3 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 74 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left"> Other accounts payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-left: 2.8pt"> 6 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 549 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 103 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left"> Lease liabilities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-left: 2.8pt"> 15 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 180 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 125 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left"> Warrants </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-left: 2.8pt"> 7 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 219 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"> Convertible loan </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; padding-left: 2.8pt"> 7 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 4,685 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Total current liabilities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; padding-left: 2.8pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 951 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 4,987 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: right; padding-left: 14.2pt"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"> NON-CURRENT LIABILITIES: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-left: 2.8pt"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left"> Loan from the Israel Innovation Authority </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-left: 2.8pt"> 8 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 372 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left"> Convertible note </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-left: 2.8pt"> 9 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,273 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"> Lease liabilities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; padding-left: 2.8pt"> 15 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 95 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 28 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt"><B>Total non-current liabilities</B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; padding-left: 2.8pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,740 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 28 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: justify; padding-left: 2.8pt"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"> Deficit: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-left: 2.8pt"> 10 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left"> Share capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-left: 2.8pt"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 304 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left"> Premium </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-left: 2.8pt"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,749 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left"> Share base compensation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-left: 2.8pt"> 16 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,714 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left"> Foreign exchange reserve </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center; padding-left: 2.8pt"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (635 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (36 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"> Accumulated deficit </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt; padding-left: 14.2pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (11,836 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (4,608 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Total deficit </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt; padding-left: 14.2pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (1,704 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (4,641 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt; padding-left: 14.2pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt"> Total Liabilities And Deficit </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="text-align: right; padding-bottom: 4pt; padding-left: 14.2pt"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 987 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 374 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE DIR="RTL" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: center; width: 32%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 2%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: center; width: 32%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 2%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 32%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    4, 2021</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon <BR>
    Chief Executive Officer &nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joe Hayon <BR>
    Chief Financial Officer</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of approval of the
    <BR>
    Financial Statements</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>The accompanying notes are an integral part
of the financial statements.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>


<!-- Field: Page; Sequence: 131 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B><A NAME="a_003"></A>INSPIRA TECHNOLOGIES
OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>STATEMENTS OF COMPREHENSIVE LOSS</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-size: 10pt"><B>(US dollars
in thousands</B></FONT><B> except <FONT STYLE="font-size: 10pt">loss per share)</FONT></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<BR> December 31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Year ended<BR> December&nbsp;31, </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2019</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">3,873</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">887</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: justify">General and administrative expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">12</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,447</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">384</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Other income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">51</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-left: 9pt">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,269</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,271</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Finance expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">13</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">959</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,304</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-left: 9pt">Loss before tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,228</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,57</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Taxes on income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">14</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 9pt">Loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,228</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,575</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other comprehensive income (loss), net of tax:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left">Items that will not be reclassified to profit or loss:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Exchange gains (losses) arising on translation to presentation currency</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(599</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(37</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total comprehensive loss for the period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(7,827</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,612</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Basic and diluted loss per share (*)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: center">10</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3.67</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2.401</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"> (*) </TD><TD STYLE="text-align: justify"> Number of shares restated based on Reverse Stock
                                            Splits according to subsequent events note. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>The accompanying notes are an integral part
of the financial statements.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 132 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B><A NAME="a_004"></A>INSPIRA TECHNOLOGIES
OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>STATEMENTS OF CHANGES IN SHAREHOLDERS&rsquo;
DEFICIT</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Share capital </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Premium </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><DIV STYLE="border-bottom: Black 0.5pt solid; margin-right: 0in; margin-left: 2.85pt; padding: 0in 0in 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Adjustments
                                            arising from translating financial operation</B> </P> </DIV></TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Share-based payment reserve </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Accumulated deficit </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Total </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold; text-align: left"> Balance at January 1, 2020 </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; text-align: right"> 3 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; text-align: right"> (36 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; text-align: right"> (4,608 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; text-align: right"> (4,641 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"> Changes during the period: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"> Loss for the year </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; text-align: right"> - </TD><TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; text-align: right"> - </TD><TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; text-align: right"> - </TD><TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (7,228 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (7,228 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify; padding-bottom: 1.5pt"> Other comprehensive loss </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (599 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (599 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"> Total comprehensive loss </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; text-align: right"> - </TD><TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (599 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (7,228 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (7,827 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"> Share split </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 215 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (215 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left"> Share base compensation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,896 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,896 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left"> Share base compensation to exercise </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 839 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (848 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left"> Conversion of convertible loan to shares </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 77 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,791 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,868 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt"> Classification of share-based compensation </TD><TD STYLE="font-weight: bold; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 334 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (334 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt"> Balance at December 31, 2020 </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 304 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 7,749 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (635 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 2,714 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (11,836 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (1,704 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Share <BR>
    capital </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Adjustments arising from translating
    financial operation </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Accumulated deficit </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Total </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-weight: bold; text-align: left"> Balance at December 31, 2018 </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 3 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 1 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> (33 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> (29 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"> Changes during the period: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: justify"> Loss for the year </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; text-align: right"> - </TD><TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; text-align: right"> - </TD><TD STYLE="font-weight: bold; text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (4,575 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (4,575 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"> Other comprehensive loss </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (37 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (37 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: justify; padding-bottom: 4pt"> Total comprehensive loss </TD><TD STYLE="font-weight: bold; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (37 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (4,575 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (4,612 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt"> Balance at December &nbsp;&nbsp;31, 2019 </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 3 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (36 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (4,608 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (4,641 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>The accompanying notes are an integral part
of the financial statement</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 133 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B><A NAME="a_005"></A>INSPIRA TECHNOLOGIES
OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>STATEMENTS
OF CASH FLOWS </B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> Year ended<BR>
    December 31, <BR>
    2020 </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> Year ended<BR>
    December 31, <BR>
    2019 </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify"> CASH FLOWS FROM OPERATING ACTIVITIES: </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: justify"> Net loss for the period </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> (7,228 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> (4,575 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"> Adjustments to reconcile net loss to net cash provided
    by operating activities: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"> Depreciation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 203 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 76 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"> Increase in other accounts receivable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (46 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"> Increase in trade payables </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (70 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 72 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"> Increase in other accounts payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 408 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 58 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"> Issuance of warrants </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 204 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"> Change in fair value of convertible loan </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 689 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,295 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"> Share base compensation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,896 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify; padding-bottom: 1.5pt"> Financial expenses </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 12 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 9 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Net cash provided by (used in) operating
    activities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (1,876 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (1,111 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"> CASH FLOWS FROM INVESTING ACTIVITIES: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: justify"> Purchase of property, plant and equipment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (23 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (31 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: justify"> Payment of deposit </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (3 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (35 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"> Lease payment at the commencement date </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (5 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-weight: bold; text-align: justify; padding-bottom: 1.5pt"> Net cash used in investing activities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (26 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (71 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"> CASH FLOWS FROM FINANCING ACTIVITIES: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"> Receipt of short term convertible loan and convertible
    note </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,157 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,355 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"> Receipt loan from the Israel Innovation Authority </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 308 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: justify; padding-bottom: 1.5pt"> Principal paid on lease liabilities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (176 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (88 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: justify; padding-bottom: 1.5pt"> Net cash
    provided by financing activities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2,289 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,267 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Net increase in cash and cash equivalents </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 387 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 85 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Cash and cash equivalents at beginning of the period </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 96 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 8 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Effects of exchange rate changes on cash and cash equivalents </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 13 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 3 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt"> Cash and cash equivalents at the end of the period </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 496 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 96 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: justify"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> Year ended<BR>
    December 31, <BR>
    2020 </TD><TD STYLE="white-space: nowrap; font-weight: bold"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> Year ended<BR>
    December 31,<BR>
    2019 </TD><TD STYLE="white-space: nowrap; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify"> APPENDIX A - AMOUNT PAID DURING THE YEAR FOR: </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; padding-bottom: 4pt"> Interest paid </TD><TD STYLE="width: 1%; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right"> 45 </TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right"> 9 </TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>The accompanying notes are an integral
part of the financial statements.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 134 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B><A NAME="a_006"></A>INSPIRA TECHNOLOGIES
OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"> <B>NOTE 1 &ndash; GENERAL:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> 1. </TD><TD STYLE="text-align: justify"> INSPIRA TECHNOLOGIES OXY B.H.N LTD. (formerly: INSENSE MEDICAL LTD.)
                                 (the &ldquo;Company&rdquo;) was incorporated in Yokneam, Israel and commenced its operations on February
                                 27, 2018. In July 2020, the Company moved to 2 Ha-Tidhar St., Ra&rsquo;anana, Israel. (On July 30, 2020,
                                 the Company change its name from INSENSE MEDICAL LTD. to INSPIRA TECHNOLOGIES OXY B.H.N LTD.). The Company&rsquo;s
                                 functional currency is NIS. The Company operates in the medical technology industry and is developing
                                 a proprietary respiratory support device named &ldquo;ART system&rdquo;. Subject to regulatory approval,
                                 this device will be used to prevent the need for mechanical ventilation in supporting the lungs as well
                                 as to wean patients off mechanical lung ventilation faster, thus reducing hospital days and patient
                                 exposure to medical complications. </TD></TR><TR STYLE="vertical-align: top">
<TD> &nbsp; </TD><TD STYLE="text-align: justify"> &nbsp; </TD></TR>
                                   </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> 2. </TD><TD STYLE="text-align: justify"> The Company expects to raise funds during 2021 through an initial
                                 public offering on Nasdaq (the &ldquo;NASDAQ IPO&rdquo;). </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in; background-color: white"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> 3. </TD><TD><P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"> The Company did not generate
                                     any revenue since its inception, the Company is still at the development stage of its products.
                                     The Company incurred a net loss of 7,228 for the year ended December 31, 2020 and generated 11,836
                                     of accumulated deficit since the inception. </P>
                                                                    <P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"> &nbsp; </P>
                                                                    <P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"> The
                                            management of the Company intends to seek additional funding through public offerings, which
                                            will be utilized to fund product development and continue operations. The Company does not
                                            have any material financial obligations as of the balance date, the simple agreement for
                                            future equity (the &ldquo;SAFE&rdquo;) could not be redeemed in cash according to its terms
                                            (see note 7). </P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in; background-color: white"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> 4. </TD><TD STYLE="text-align: justify"> Infection of the Company&rsquo;s workforce with COVID-19 could result
                                 in a temporary disruption in the Company&rsquo;s business activities, including manufacturing, and other
                                 functions. Based on guidelines provided by the Israeli government, employers (including the Company)
                                 are also required to increase as much as possible the capacity and arrangement for employees to work
                                 remotely. In that regard, while the Company continued to operate almost fully including carrying out
                                 the studies in compliance with all applicable Israeli rules and guidelines on COVID-19, the employees
                                 worked remotely when full lockdowns were enforced. The spread of an infectious disease, including COVID-19,
                                 may also result in the inability of the manufacturers to deliver components or finished products on
                                 a timely basis and may also result in the inability of the Company&rsquo;s suppliers to deliver the
                                 parts required by the manufacturers to complete manufacturing of components or finished products. Since
                                 March 2020, the Company has experienced delays in supply of some components of the products from abroad.
                                 Ecmo systems and oxygenators which were needed for research were also unavailable to purchase. In addition,
                                 governments may divert spending from other budgeted resources as they seek to reduce and/or stop the
                                 spread of an infectious disease, such as COVID-19. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 135 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"> <B>NOTE 1 &ndash; GENERAL (CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"> Such events may result in a period
of business and manufacturing disruption and in reduced operations, any of which could materially affect the Company&rsquo;s business,
financial condition and results of operations. The extent to which COVID-19 impacts the Company&rsquo;s business will depend on future
developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity
of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> 5. </TD><TD STYLE="text-align: justify"> A 12.5:1 reverse stock split of the Company&rsquo;s ordinary shares
                                 was effected on March 18, 2021 and additional 2.94:1 reverse stock split of the Company&rsquo;s ordinary
                                 shares was affected on June 1, 2022 (the &ldquo;Reverse Stock Split&rdquo;). All share and per share
                                 information has been retroactively adjusted to give effect to the Reverse Stock Split for all periods
                                 presented, unless otherwise indicated. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"> <B>NOTE 2 &ndash; SIGNIFICANT ACCOUNTING POLICIES:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; background-color: white"> The principal accounting
policies adopted in the preparation of the financial statements are set out below. The policies have been consistently applied to all
the years presented, unless otherwise stated. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"> <B>Basis of preparation</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> These financial statements
have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standard
Board (IASB). The financial statements have been prepared under the historical cost convention except of the convertible loan, convertible
note and warrants that was measured at fair value through profit or loss, share based compensation that was measured at fair value according
to IFRS2 and governments grants that were measured at amortized cost. The Company has elected to present the statement of comprehensive
loss using the function of expense method. In addition, these financial statements are presented in the U.S. dollars. All currency amounts
have been recorded to the nearest thousand, unless otherwise indicated. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"> <B>Use of estimates and assumptions in the
preparation of the financial statements</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> The preparation of
financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during
the reporting periods. Actual results could differ from those estimates. See also Note 3. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 136 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"> <B>NOTE 2 &ndash; SIGNIFICANT ACCOUNTING POLICIES
(CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <B>Cash and cash equivalents</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> Cash equivalents are
considered by the Company to be highly-liquid investments, including, inter alia, short-term deposits with banks, the maturity of which
does not exceed three months at the time of deposit and which are not restricted. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"> <B>Loss per share</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> Basic and diluted loss
per share is calculated as net loss attributed to the Company, divided by the weighted average number of ordinary shares, adjusted for
any bonus element. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"> <B>Functional and foreign currency</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> The Company&rsquo;s
operational currency is NIS. However, the presentation currency is the U.S. dollars (&ldquo;USD&rdquo;). Transactions and balances in
foreign currencies are converted into USD in accordance with the principles set forth by International Accounting Standard (IAS) 21 &ldquo;The
Effects of Changes in Foreign Exchange Rates&rdquo;. Accordingly, transactions and balances have been converted as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
                                            and liabilities items were reported at closing rate of exchange at the statements of financial
                                            position date.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -0.25in; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            comprehensive income items were reported at annual average rate of exchange at the statements
                                            of financial position date.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -0.25in; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
                                            capital, capital reserve and other capital movement items were at rate of exchange as of
                                            the date of recognition of those items.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -0.25in; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
                                            deficit was based on the opening balance for the beginning of the reporting period in addition
                                            to the movements mentioned above.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -0.25in; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rate
                                            of exchange rate differentials created was recognized in other comprehensive income and accumulated
                                            in equity.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -0.25in; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 137 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -0.25in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -0.25in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <B>NOTE 2 &ndash; SIGNIFICANT
ACCOUNTING POLICIES (CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"> <B>Fair value measurement</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> Fair value is the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the
measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability
takes place either: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> A. </TD><TD STYLE="text-align: justify"> In the principal
                                            market for the asset or liability, or </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify; text-indent: -0.25in; background-color: white"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> B. </TD><TD STYLE="text-align: justify"> In the absence of
                                            a principal market, in the most advantageous market for the asset or liability. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify; text-indent: -0.25in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> The principal or the
most advantageous market must be accessible by the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 7.1pt; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> The fair value of an
asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming
that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a
market participant&rsquo;s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another
market participant that would use the asset in its highest and best use. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> When there are no quoted
prices in active markets for identical assets or liabilities, the Company uses valuation techniques that are appropriate in the circumstances
and for which sufficient data is available to measure fair value, maximizing the use of relevant observable inputs and minimizing the
use of unobservable inputs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"> <U>Classification by fair value hierarchy</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; background-color: white"> Assets and liabilities
measured in the statement of financial position at fair value are grouped into classes with similar characteristics using the following
fair value hierarchy which is determined based on the source of input used in measuring fair value: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; width: 0.5in"> Level&nbsp;1&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Quoted prices (unadjusted) in active markets for identical assets
    or liabilities.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; text-align: justify"> <FONT STYLE="font-size: 10pt">Level&nbsp;2&nbsp;-</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Inputs other than quoted prices included within Level 1 that are
    observable either directly or indirectly.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; white-space: nowrap; text-align: left"> <FONT STYLE="font-size: 10pt">Level&nbsp;3&nbsp;-</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Inputs that are not based on observable market data (valuation techniques
    that use inputs that are not based on observable market data).</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 138 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <B>NOTE 2 &ndash; SIGNIFICANT
ACCOUNTING POLICIES (CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <B>Financial instruments</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"> 1. </TD><TD STYLE="text-align: justify"> <U>Financial assets</U> </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; background-color: white"> The
Company classifies its financial assets into one of the following categories, based on the business model for managing the financial
asset and its contractual cash flow characteristics. The Company&rsquo;s accounting policy for the relevant category is as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; background-color: white"> Amortized
cost: other types of financial assets where the objective is to hold these assets in order to collect contractual cash flows and the
contractual cash flows are solely payments of principal and interest. They are initially recognized at fair value including direct transaction
costs and are subsequently carried at amortized cost using the effective interest rate method, less provision for impairment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -0.25in; background-color: white"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"> 2. </TD><TD STYLE="text-align: justify"> <U>Financial Liabilities</U> </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; background-color: white"> The
Company classifies its financial liabilities, including trade accounts payable and other accounts payable, which are initially recognized
at fair value and subsequently carried at amortized cost using the effective interest method. The convertible loan (see also Note 7),
convertible note (see also Note 8) and warrants (see also Note 7) are measured at fair value through profit or loss. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -0.25in; background-color: white"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"> 3. </TD><TD STYLE="text-align: justify"> <U>De-recognition</U> </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            assets - The Company derecognizes a financial asset when the contractual rights to the cash
                                            flows from the financial asset expire or it transfers the rights to receive the contractual
                                            cash flows.</FONT> </TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            Liabilities - The Company derecognizes a financial liability when its contractual obligations
                                            are discharged or cancelled, or expire.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"> 4. </TD><TD STYLE="text-align: justify"> <U>Impairment of financial assets</U> </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; background-color: white"> The
Company recognizes an allowance for expected credit losses (ECL) for all debt instruments not held at fair value through profit or loss.
ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the
Company expects to receive, discounted at an approximation of the original effective interest rate. ECLs are recognized in two stages.
For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided
for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures
for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses
expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). Cash and cash equivalents
are subject to the impairment requirements of IFRS 9, the identified impairment loss was immaterial. </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 139 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <B>NOTE 2 &ndash; SIGNIFICANT
ACCOUNTING POLICIES (CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"> <B>Property, plant and equipment</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> Items of property,
plant and equipment are initially recognized at cost including directly attributable costs. Depreciation is calculated on a straight
line basis, over the useful lives of the assets at annual rates as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: justify"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> Annual<BR>
    depreciation<BR>
    rate (%) </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> Main annual<BR>
    depreciation<BR>
    rate (%) </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify"> Computers </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 33 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 33 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"> Laboratory equipment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 20 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 20 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"> Furniture and office equipment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">6-15</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"> Leasehold improvements </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> Subsequent costs are
included in the asset&rsquo;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future
economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount
of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit
or loss during the reporting period in which they are incurred. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> The assets&rsquo; residual
values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset&rsquo;s carrying amount
is written down immediately to its recoverable amount if the asset&rsquo;s carrying amount is higher than its estimated recoverable amount. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> Gains and losses on
disposals are determined by comparing proceeds with carrying amount. These are included in profit or loss.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <B>Impairment of non-financial
assets</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> Non-financial assets
are subject to impairment test whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.
Where the carrying value of the non-financial asset exceeds its recoverable amount (i.e. the higher of value in use and fair value less
costs to dispose), the asset is written down and impairment charge is recognized accordingly. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> Where it is not possible
to estimate the recoverable amount of an individual asset, the impairment test is carried out on the asset&rsquo;s cash-generating unit
(i.e. the smallest group of assets to which the asset belongs that generates cash inflow that is largely independent of cash inflows
from other assets). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> An impairment loss
allocated to asset, is reversed only if there have been changes in the estimates used to determine the asset&rsquo;s recoverable amount
since the last impairment loss was recognized. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 140 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <B>NOTE 2 &ndash; SIGNIFICANT
ACCOUNTING POLICIES (CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <B>Impairment of non-financial
assets (cont.)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> Reversal of an impairment
loss, as above, is limited to the lower of the carrying amount of the asset that would have been determined (net of depreciation or amortization)
had no impairment loss been recognized for the asset in prior years and the asset&rsquo;s recoverable amount. After an impairment of
non-financial asset is recognized, the Company examines at each reporting date whether there are indications that the impairment which
was recognized in the past no longer exists or should be reduced. The reversal of impairment loss of an asset is recognized in profit
or loss. Impairment charges are included in general and administrative expenses. During the years ended December 31, 2020 and 2019, no
impairment charges of non-financial assets were recognized. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <B>Research and development
costs</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> Expenditure on research
activities is recognized in profit or loss as incurred. Development expenditures is recognized as an intangible asset when the Company
can demonstrate: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            product is technically and commercially feasible.</FONT> </TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company intends to complete the product so that it will be available for use or sale.</FONT> </TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has the ability to use the product or sell it.</FONT> </TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has the technical, financial and other resources to complete the development and
                                            to use or sell the product.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 21.3pt; text-indent: -0.25in; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company can demonstrate that the product will generate future economic benefits.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 21.3pt; text-indent: -0.25in; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company is able to measure reliably the expenditure attributable to the product during the
                                            development.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 3.3pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> During the reported
years the expenses were not capitalized, as they do not meet the criteria set forth in IAS 38. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 141 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 2 &ndash; SIGNIFICANT ACCOUNTING POLICIES
(CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Share based payment</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The Company measures the share based expense
and the cost of equity-settled transactions with employees and service providers by reference to the fair value of the equity instruments
at the date at which they are granted. The fair value is determined using an accepted options pricing model. The model is based on share
price, grant date and on assumptions regarding expected volatility, expected life of the options, expected dividend, and a no risk interest
rate.<BR>
<BR>
The Company selected the Black-Scholes model as the Company&rsquo;s option pricing model to estimate the fair value of the company&rsquo;s
options awards. The option-pricing model requires a number of assumptions: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <I>Expected dividend yield</I> - The expected
dividend yield assumption is based on the Company&rsquo;s historical experience and expectation of no future dividend payouts. The Company
has not historically paid cash dividends and has no foreseeable plans to pay cash dividends in the future. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <I>Volatility</I>&nbsp;- The expected volatility
is based on similar companies&rsquo; stock volatility. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <I>Risk free interest rate</I>&nbsp;- The risk-free
interest rate is based on the yield of governmental bonds with equivalent terms. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <I>Contractual term</I>&nbsp;- An option&rsquo;s
contractual term is the amount of time the holder has to exercise the option, per the contract. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The granted options are settled in equity instruments
method and not in cash, the fair value of the options at the date of grant is charged to the statement of comprehensive loss over the
vesting period. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at
each reporting date so that, ultimately, the cumulative amount recognized over the vesting period is based on the number of options that
eventually vest. Non-vesting conditions and market vesting conditions are factored into the fair value of the options granted. As long
as all other vesting conditions are satisfied, a charge is made irrespective of whether the market vesting conditions are satisfied.
The cumulative expense is not adjusted for failure to achieve a market vesting condition or where a non-vesting condition is not satisfied.
Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately
before and after the modification, is also charged to the statement of comprehensive income over the remaining vesting period. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 142 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 2 &ndash; SIGNIFICANT ACCOUNTING POLICIES
(CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Government grants</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> Government grants received for the use of research
and development activities, for which the Company undertook to pay royalties to the state, contingent on future sales arising from this
financing, were treated as forgivable loans. The grant was recognized as a liability in the financial statements, except when there is
reasonable assurance that the Company will comply with the conditions for the forgiveness of the loan, then it would be recognized as
a government grant. When the loan bears a below-market rate of interest, the liability is recognized at its fair value in accordance
with the market interest rate prevailing at the time of receiving the grant. The difference between the consideration received and the
liability recognized at inception was treated as a government grant and recognized as a reimbursement of research expenses or a reduction
in capitalized development costs. The repayment of the liability to the state is reviewed every reporting period, with changes in the
liability resulting from a change in the expected royalties recognized in profit or loss. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Current taxes</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The current tax liability is measured using
the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required in connection
with the tax liability in respect of previous years. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Deferred tax</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> Significant management judgment is required
to determine the amount of deferred tax assets that can be recognized, based upon the estimated timing and level of future taxable profits
together with future tax planning strategies. Deferred taxes are recognized in respect of temporary differences between the carrying
amounts of assets and liabilities in the financial statements and the amounts attributable for tax purposes. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <BR>
Deferred taxes are measured at the tax rates that are expected to apply in the period when the temporary differences are reversed based
on tax laws that have been enacted or substantively enacted at the end of the reporting period. Deferred taxes are recognized in profit
or loss, except when they relate to items recognized in other comprehensive income or directly in equity. Deferred tax assets are reviewed
at the end of each reporting period and reduced to the extent that it is not probable that they will be utilized. In addition, temporary
differences (such as carry forward losses) for which deferred tax assets have not been recognized are reassessed and deferred tax assets
are recognized to the extent that their recoverability is probable. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 143 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 2 &ndash; SIGNIFICANT ACCOUNTING POLICIES
(CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Deferred tax (cont.)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> Any resulting reduction or reversal is recognized
on &ldquo;income tax&rdquo; within the statement of comprehensive income. All deferred tax assets and liabilities are presented in the
statement of financial position as non-current items, respectively. Deferred taxes are offset in the statement of financial position
if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to
the same taxpayer and the same taxation authority. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Employee benefits</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The Company has several employee benefit plans
as to Israeli employees: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> 1. </TD><TD STYLE="text-align: justify"> Short-term employee
                                            benefits: Short-term employee benefits include salaries, paid annual leave, paid sick leave,
                                            recreation and social security contributions and are recognized as expenses as the services
                                            are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
                                            when the Company has a legal or constructive obligation to make such payment as a result
                                            of past service rendered by an employee and a reliable estimate of the amount can be made. </TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> 2. </TD><TD STYLE="text-align: justify"> Post-employment
                                            benefits: The plans are normally financed by contributions to insurance companies and classified
                                            as defined contribution plans. The Company has contributed for all of its employees&rsquo;
                                            contribution plans pursuant to Section 14 to the Severance Pay Law since 2018 under which
                                            the Company pays fixed contributions and will not have any legal or constructive obligation
                                            to pay further contributions if the fund does not hold sufficient amounts to pay all employee
                                            benefits relating to employee service in the current and prior periods. </TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 144 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; background-color: white"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 3 &ndash; CRITICAL ACCOUNTING ESTIMATES
AND JUDGEMENTS:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The convertible loan, convertible note and warrants
were designated to be measured at fair value through profit or loss. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <BR>
The fair value of convertible loan, convertible note and warrants was estimated by using a Monte-Carlo simulation approach, which was
aimed to model the value of the Company&rsquo;s assets over time. The simulation approach was designed to take into account the terms
and conditions of the convertible loan, convertible note and warrants which are described in Note 7 and Note 9, as well as the capital
structure of the Company and the volatility of its assets. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <BR>
The valuation was performed based on management&rsquo;s assumptions and projections.<BR>
<BR><B>NOTE 4 &ndash; OTHER ACCOUNT RECIVABLE:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; white-space: nowrap; text-align: justify; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> December
    31,<BR>
    2020 </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> December
    31, <BR>
    2019 </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; width: 76%; text-align: justify; text-indent: 0pt"> Institutions </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 43 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 51 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> Deposits </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 45 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 35 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> Others </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 100 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: 0pt"> <B>Total</B> </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 188 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 86 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>NOTE 5 &ndash; PROPERTY AND EQUIPMENT, NET:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <U>For the year ended December 31, 2020:</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Computers </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Leasehold improvements </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Laboratory equipment </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Furniture and office equipment </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Total </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify"> Cost </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold; text-align: justify"> At January 1, 2020 </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 17 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 4 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 10 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 31 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"> Additions </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 23 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0in; font-weight: bold; text-align: justify"> At December 31, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 22 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 19 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 54 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify"> Accumulated depreciation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"> At January 1, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"> Depreciation </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 5 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><P STYLE="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> * </P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 7 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0in; font-weight: bold; text-align: justify"> At December 31, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"> Net book value: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"> As of December 31, 2020 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 15 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 7 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 5 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 18 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 45 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; width: 0.25in"> * </TD>
  <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt"> Less than thousand dollars </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 145 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>NOTE 5 &ndash; PROPERTY AND EQUIPMENT, NET
(CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <U>For the year ended December 31, 2019:</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Computers </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> leasehold improvements </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Laboratory equipment </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Furniture and office equipment </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Total </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify"> Cost </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"> At January 1, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: justify; padding-bottom: 1.5pt"> Additions </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"> 17 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"> - </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"> 4 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"> 10 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"> 31 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0in; font-weight: bold; text-align: justify"> At December 31, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 17 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 31 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify"> Accumulated depreciation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"> At January 1, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"> Depreciation </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><P STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> * </P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><P STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> * </P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0in; font-weight: bold; text-align: justify"> At December 31, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"> Net book value: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"> As of December 31, 2019 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 15 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 4 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 10 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 29 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; width: 0.25in"> * </TD>
  <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt"> Less than thousand dollars </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 6 &ndash; OTHER ACCOUNTS PAYABLE:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> December
    31, 2020 </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> December
    31, 2019 </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; width: 76%; text-align: justify; text-indent: 0pt"> Employees, salaries and related liabilities </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 295 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 99 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> Accrued expenses </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 148 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> Related parties </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 98 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 4 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> Other </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 8 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: 0pt"> <FONT STYLE="font-size: 10pt"><B>Total</B></FONT> </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 549 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 103 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B></B> </P>

<!-- Field: Page; Sequence: 146 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 7 &ndash; CONVERTIBLE LOAN:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> On July 1, 2019, the Company signed an agreement
with a lender, according to which the Company will receive a loan in the amount of 2,440 (AUD 3,500,000) up to 2,790 (AUD 4,000,000).
The total amount the Company received from the lender was approximately 2,374 (AUD 3,535,750). The loan bears interest of 2.56%. The
loan was provided in AUD, USD and NIS. The repayment will be by converting the principal amount and accrued interest amount to ordinary
shares of the Company at a price per share of AUD 5.15 or AUD 5.9. The repayment of the loan will be upon the earlier of: (i) initial
public offering, (ii) a merger or, an acquisition, or (iii) twelve months from the date of the agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> In July 2020, the Company signed an extension
to the conversion period so the conversion&nbsp;period was extended to&nbsp;November 2020, instead of 12 months from the date of signing
the agreement. There is no option of cash repayment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> On November 27, 2020, the Company, the lender
of the convertible loan , the founders of the Company, and the advisors entered into an agreement (the &ldquo;Separation Agreement&rdquo;)
which includes: (i) a full termination of all previous agreements, (ii) a settlement of all cash obligations between the parties, (iii)
a settlement of all equity (share and option) obligations between the parties, with a commitment by the lender not to distribute the
shares of the Company it holds, until the earlier of the Company&rsquo;s initial public offering or 18 months, (iv) an agreement for
the advisors to continue assisting the Company with fundraising in return for a 7% cash commission, and (v) a full release and waiver
of claims between the parties to the agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-size: 10pt">On December, 2020,
the Company&rsquo;s board of directors approved as part of the Separation Agreement the Company&rsquo;s issuance to the lender of the
convertible loan of (i) 597,938 ordinary shares (at a price per share of AUD 5.15), (ii) 78,123 ordinary shares (at a price per share
of AUD 5.88), (iii) 80,273 ordinary shares (issued as promoter shares to the advisors), and (iv) </FONT>w<FONT STYLE="font-size: 10pt">arrants
of the convertible loan to purchase an additional 169,019 ordinary shares upon consummation of an initial public offering on the Nasdaq.
The </FONT>w<FONT STYLE="font-size: 10pt">arrants will be converted into ordinary shares of the Company an exercise price equal to the
initial public offering price, and be exercisable for three years after the initial public offering.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The convertible note and the warrants were designated
to be measured at fair value through profit or loss. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 147 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 8 &ndash; LOAN FROM ISRAEL INNOVATION
AUTHORITY:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The Company received the approval of the Israel
Innovation Authority (the &ldquo;IIA&rdquo;) for its participation in certain development expenses carried out by the Company, within
the framework of determined budgets and time periods. The total amount of the IIA grant will be up to 847 (NIS 2,928,000). The total
amount the Company received during 2020 was 678 (NIS 2,377,000). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> In accordance with its commitment, the Company
is obliged to pay the IIA royalties of 3% of sales, constituting the revenues derived from sales of the Company&rsquo;s ART system that
was financed by the IIA, up to the total amount of the grant actually received, all linked to the exchange rate of the USD and bears
an annual interest linked to the LIBOR. Therefore, the total amount of the grants that will be repaid through royalties and will increase
until repayments begin. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The difference between the consideration received
and the liability recognized at inception (present value) was treated as a government grant according to IAS20 and recognized as a reimbursement
of research expenses or a reduction in capitalized development costs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 9 &ndash; CONVERTIBLE NOTE:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> In December 2020 through March 2021, Company
entered into certain equity investment agreements, by means of SAFE for aggregate proceeds of 5,415. Out of the amounts received under
the SAFE, 2,804 will be converted into ordinary shares of the Company according to the lower of: (i) a Company valuation cap of 35,000
(including only securities currently issued by the Company), or (ii) a discount of 30% from the price of an initial public offering,
merger and acquisition or other liquidity event. If the subscription amounts under the SAFE is converted to ordinary shares in connection
with an initial public offering, then the Company will issue the SAFE investors warrants to purchase ordinary shares with an exercise
price equal to the public offering price in such offering, as follows: (i) investors representing an aggregate of 1,426 of the SAFE will
receive 75% warrant coverage, such that each investor will receive options to purchase 3 additional ordinary shares for every 4 shares
issued upon conversion of the SAFE, which will be exercisable for 4 years after the initial public offering, and (ii) investors representing
an aggregate of 1,378 of the SAFE will receive 50% warrant coverage, such that each investor will receive options to purchase 2 additional
ordinary shares for every four shares issued upon conversion of the SAFE, which will be exercisable for three years after the initial
public offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 148 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 9 &ndash; CONVERTIBLE NOTE (CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> If an initial public offering, merger and acquisition
or other liquidity event does not take place within 24 months from December 2020, then the subscription amount under the SAFE will convert
into ordinary shares of the Company as follows: (i) investors representing an aggregate of 1,426 of the SAFEs will convert at a conversion
price reflecting a company valuation of 17,500, and (ii) investors representing an aggregate of 1,378 of the SAFE will convert at a conversion
price reflecting a company valuation of 35,000. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The terms for the remaining amounts of 2,611
that the Company received under the SAFE are described in Note 20.2. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The convertible note was designated to be measured
at fair value through profit or loss. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <BR>
The total amount that was received by December 31, 2020 was 1,273. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 10 &ndash; EQUITY (DEFICT):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>A. Share capital:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Number of shares as of December
    31, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Number of shares as of December
    31, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2020 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2019 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Authorized </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Issued and outstanding </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Authorized </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Issued and outstanding </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 52%; text-align: right; padding-left: 2.8pt"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> &nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> &nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> &nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> &nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Ordinary shares </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 8,435,375 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2,661,095 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 18,802,157 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,904,762 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> Since the company&rsquo;s incorporation in February
2018, the company issued the following ordinary shares: (i) an aggregate of 27,566 ordinary shares for no consideration to the Company&rsquo;s
founders and certain advisors; (ii) 1,877,196 ordinary shares as bonus shares for no consideration to existing shareholders; (iii) and
an aggregate of 756,333 ordinary shares to Insense Medical Pty Ltd. See note 7. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The authorized share capital of the Company
following the reverse stock split is NIS 310,000,000 divided into 8,435,375 Shares. See note 10.5. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 149 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 10 &ndash; EQUITY (DEFICT) (CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>B. Loss per share:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> Loss per share has been calculated using the
weighted average number of shares in issue during the relevant financial periods, the weighted average number of equity shares in issue
and profit for the period as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> Year ended<BR>
    December 31,<BR> 2020 </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> Year ended<BR>
    December 31,<BR> 2019 </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt"> Loss for the period </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 7,228 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 4,575 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"> Weighted average number of ordinary shares before issuing
    bonus shares to Company&rsquo;s&nbsp;&nbsp;shareholders </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,013,055 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,013,055 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0pt"> Issuance of bonus shares to Company&rsquo;s shareholders </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 68,986,945 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 68,986,945 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"> Conversion of convertible loan to
    shares </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 27,795,209 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"> Total number of ordinary shares after
    issuing bonus shares to Company&rsquo;s shareholders </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 97,795,209 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 70,000,000 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"> Weighted average number of ordinary
    shares after issuing bonus shares to Company&rsquo;s shareholders </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 72,316,267 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 70,000,000 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"> Total number of ordinary shares after
    the Reverse Stock Splits (*) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2,661,095 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,904,762 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"> Weighted average number of ordinary shares
    after the Reverse Stock Splits (*) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 1,967,790 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 1,904,762 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"> Basic and diluted loss per share after
    issuing bonus shares to Company&rsquo;s shareholders </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD
                                            (0.1&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD
                                            (0.065&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"> Basic and diluted loss per share after
    the Reverse Stock Splits (*) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD
                                            (3.67 </FONT> </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD
                                            (2.401&nbsp;</FONT> </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"> Anti-dilutive potentially dilutive securities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 12,503,056 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 14,564,925 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"> Anti-dilutive potentially dilutive securities
    after the Reverse Stock Splits (*) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 340,219 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 396,324 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; width: 0.25in"> (*) </TD>
  <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt"> Number of shares restated based on Reverse Stock Splits according
  to subsequent events note. </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 150 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 11 &ndash; RESEARCH AND DEVELOPMENT
EXPENSES:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; white-space: nowrap; text-align: justify; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> Year
    ended<BR>
    December 31,<BR>
    2020 </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding: 0pt; text-align: center; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
    ended<BR>
    December 31,<BR>
    </B>&nbsp;<B>2019 </B></FONT> </TD><TD STYLE="padding: 0pt; white-space: nowrap; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; width: 76%; text-align: justify; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"></TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-indent: 0pt"> Share based payment </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 2,230 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Salary and related expenses </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 1,237 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 493 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Materials and related expenses </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 440 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 132 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-indent: 0pt"> Depreciation </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 196 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 74 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-indent: 0pt"> Subcontractors </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 125 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 105 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Office maintenance </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 28 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 47 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Travel abroad </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 36 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> IIA participation </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> (383 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT> </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 3,873 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 887 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 12 &ndash; GENERAL AND ADMINISTRATIVE
EXPENSES:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; white-space: nowrap; text-align: justify; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> Year
    ended<BR>
    December 31,<BR>
    2020 </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding: 0pt; text-align: center; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
    ended<BR>
    December 31,<BR>
    </B>&nbsp;<B>2019 </B></FONT> </TD><TD STYLE="padding: 0pt; white-space: nowrap; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; width: 76%; text-align: left; text-indent: 0pt"> Related NASDAQ IPO expenses </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 1,235 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 185 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-indent: 0pt"> Share based payment </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 818 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Professional fees </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 154 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 90 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Salary and related expenses </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 140 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 67 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Rent and office maintenance </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 77 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 23 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Travel abroad </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 12 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 15 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-indent: 0pt"> Depreciation </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 7 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 2 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-indent: 0pt"> Others </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 4 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 2 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT> </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 2,447 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 384 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 151 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>NOTE 13 &ndash; FINANCIAL EXPENSES:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; white-space: nowrap; text-align: justify; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> Year
    ended<BR>
    December 31, <BR>
    2020 </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding: 0pt; text-align: center; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
    ended<BR>
    December 31, <BR>
    2019 </B></FONT> </TD><TD STYLE="padding: 0pt; white-space: nowrap; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; width: 76%; text-align: left; text-indent: 0pt"> Evaluation of convertible loan </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 689 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 3,295 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Warrants evaluation </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 204 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Lease liabilities </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 5 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 9 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-indent: 0pt"> Others </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 61 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT> </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 959 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 3,304 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>NOTE 14 &ndash; TAXES ON INCOME:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> Taxes on income: </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-weight: normal">Israeli corporate
tax rate is 23% in 2020 and 2019</FONT>. </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Net operating
losses carry forwards</B></FONT>: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> As of December 31, 2020, the Company has carried
forward tax losses of approximately 2,323, which may be carried forward and offset against taxable income for an indefinite period in
the future. The Company did not recognize deferred tax assets relating to carry forward losses in the financial statements because their
utilization in the foreseeable future is not probable. As of December 31, 2020, the Company has temporary differences of 3,000 for which
no deferred tax asset was recognized. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Theoretical tax:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; white-space: nowrap; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; white-space: nowrap; font-weight: bold; text-align: center"> Year
    ended<BR>
    December 31,<BR>
    2020 </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
    ended<BR>
    December 31, </B>&nbsp;<B><BR>
    2019 </B></FONT> </TD><TD STYLE="padding: 0pt; white-space: nowrap; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; width: 76%; text-align: left; text-indent: 0pt"> Loss before taxation </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> (7,228 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> ) </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> (4,575 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Theoretical tax credit at applicable statutory rate for 2020 and
    2019: 23% </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> (1,662 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> (1,052 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Non-allowable expenses </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 4,733 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 3,305 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Temporary differences and tax losses for which no Deferred Tax Asset
    is recognized </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> (3,071 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> (2,253 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Income tax benefit </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 152 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 15 &ndash; LEASES:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The Company has lease contracts for office facilities
and vehicles used in its operations. Leases of vehicles generally have lease terms up to three years. Lease of office facility has lease
terms of up to 24 months (July 14, 2022). There is an extension option until July 14, 2023. The Company does not expect to exercise the
option. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> Set out below are the carrying amounts of right-of-use
assets recognized and the movements during the period: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center"> Office facility </TD><TD STYLE="padding: 0pt; font-weight: bold"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center"> Vehicles </TD><TD STYLE="padding: 0pt; font-weight: bold"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center"> Total </TD><TD STYLE="padding: 0pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; width: 64%; font-weight: bold; text-align: left"> At January 1, 2020 </TD><TD STYLE="padding: 0pt; width: 1%"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right"> 106 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right"> 57 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right"> 163 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left"> Additions </TD><TD STYLE="padding: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right"> 207 </TD><TD STYLE="padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right"> 66 </TD><TD STYLE="padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right"> 273 </TD><TD STYLE="padding: 0pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: left"> Exchange rate differences </TD><TD STYLE="padding: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right"> 13 </TD><TD STYLE="padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right"> 5 </TD><TD STYLE="padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right"> 18 </TD><TD STYLE="padding: 0pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left"> Depreciation expense </TD><TD STYLE="padding: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right"> (153 </TD><TD STYLE="padding: 0pt; text-align: left"> ) </TD><TD STYLE="padding: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right"> (43 </TD><TD STYLE="padding: 0pt; text-align: left"> ) </TD><TD STYLE="padding: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right"> (196 </TD><TD STYLE="padding: 0pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; font-weight: bold; text-align: left"> As at December 31, 2020 </TD><TD STYLE="padding: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right"> 173 </TD><TD STYLE="padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right"> 85 </TD><TD STYLE="padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="padding: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right"> 258 </TD><TD STYLE="padding: 0pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> Set out below are the carrying amounts of lease
liabilities and the movements during the period: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> 2020 </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> 2019 </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; width: 76%; font-weight: bold; text-align: left; text-indent: 0pt"> At January 1, 2020 </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 153 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Additions </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 273 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 232 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Accretion of interest </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 5 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 9 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Interest payment </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> (5 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> (9 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Exchange rate differences </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 20 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Principal payment </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> (171 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> (79 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt"> As at December 31, 2020 </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 275 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 153 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The following are the amounts recognized in
profit or loss: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; white-space: nowrap; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> Year
    ended<BR>
    December 31, <BR>
    2020 </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> Year
    ended<BR>
    December 31,<BR>
    2019 </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; width: 76%; text-align: left; text-indent: 0pt"> Depreciation expense of right-of-use assets </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 196 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 74 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Interest expense on lease liabilities </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 5 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 9 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt"> Total amount recognized in profit or loss </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 201 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 83 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The Company had total cash outflows for leases
of 176 in 2020 and 93 in 2019. The Company also had non-cash additions to right-of-use assets and lease liabilities of 273 in 2020 and
232 in 2019. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 153 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 16 &ndash; SHARE BASED PAYMENT </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> On December, 2019, the Company established a
share option plan (the &ldquo;Plan&rdquo;). Under the Plan, on April 20, 2020 a total of 478,747 options to subscribe ordinary shares
have been granted to employees and consultants. The exercise price per share to 123,719 and 355,029 options was USD 0.0029 (AUD 0.052)
and USD 2.67 (AUD 4.2), respectively. The fair value of the options at the grant date, which were measured according to Black-Scholes
model, were USD 6.14 and USD 3.79, to 123,719 and 355,029 options, respectively. The vesting period is up to 3 years from the grant date,
according to the various vesting periods: from an immediate one and up to 3 years. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> Contractual life of the options under the Plan
is 10 years. The options were granted under section 102 of the Israeli Tax Ordinance which enables the employee to pay 25% of capital
gain tax upon exercise. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> In October 2020, 73,380 options were canceled. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> On December 17, 2020, the Israeli Taxes Authority
(ITA) approved a ruling request from the Company for a tax-free amendment of the commercial terms of the outstanding options, including
(i) a reduction of the exercise price to NIS 0.37 per share, and (ii) a shortening of the vesting schedules. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <BR>
The company implemented IFRS 2 on options terms change. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> On December 20, 2020, the board of directors
granted a total of 56,653 options to subscribe ordinary shares to employees and consultants. The vesting period is up to 3 years from
the grant date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The exercise price per share was NIS 0.37. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The fair value of the options at the grant date,
which were measured according to Black-Scholes model, were USD 10.29. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> Contractual life of the options under the Plan
is 10 years. The options were granted under section 102 of the Israeli Tax Ordinance which enables the employee to pay 25% of capital
gain tax upon exercise. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The number of the remaining options as of December
31, 2020, is 462,020. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The number of total unallocated options under
the Plan is 37,412 options as of the balance date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The fair value of all granted options was estimated
by using the Black and Scholes model, which was aimed to model the value of the Company&rsquo;s assets over time. The simulation approach
was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company and
the volatility of its assets, on the date of grant based on certain assumptions. Those conditions are, among others: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (i) </TD><TD STYLE="text-align: left"> the expected volatility is 50%; </TD></TR><TR STYLE="vertical-align: top">
<TD> &nbsp; </TD><TD> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
                                                                                                                                      </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (ii) </TD><TD STYLE="text-align: left"> the dividend rate 0%; and </TD></TR><TR STYLE="vertical-align: top">
<TD> &nbsp; </TD><TD> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
                                                                                                                                 </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (iii) </TD><TD STYLE="text-align: left"> expected term &ndash; three years. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The valuation was performed by an external valuator
based on management&rsquo;s assumptions. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> During the year ended December 31, 2020, the
Company recorded share based payment expenses in the amount of 3,048. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 154 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 16 &ndash; SHARE BASED PAYMENT (CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The options to services providers and advisers
outstanding as of December 31, 2020, as&nbsp;follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
                                            ended<BR>
                                            December 31, 2020</B></FONT> </P></TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Number of options </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Weighted average Exercise price
    NIS </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Outstanding at beginning of year </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%"> Granted </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 230,280 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 0.37 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Expired </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (64,293 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.37 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"> Forfeited </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 1.1pt"> Outstanding at end of period </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 165,987 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 0.37 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"> Exercisable options </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 106,742 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 0.37 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The options to employees outstanding as of December 31, 2020, as&nbsp;follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
                                            ended <BR>
                                            December 31, 2020</B></FONT> </P></TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Number of options </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Weighted average Exercise price
    NIS </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Outstanding at beginning of year </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%"> Granted </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 305,120 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 0.37 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Expired </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (4,701 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.37 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"> Forfeited </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (4,387 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.
                                            37 &nbsp; &nbsp; &nbsp;</FONT> </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 1.1pt"> Outstanding at end of period </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 296,032 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 0.37 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"> Exercisable options </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 233,478 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 0.37 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> In May, 2019, the Company signed an agreement,
pursuant to which it will issue 108,844 ordinary shares (in July 2020 revised to 80,273 ordinary shares) to advisors that assisted with
closing a convertible loan agreement (see note 7). The share grant is conditioned upon completion of a raising of at least AUD 3,500,000
in a few different agreed dates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The agreement also includes the grant of additional
108,844 shares upon initial public offering event according to the agreed timetable. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> In November 2020, the Company signed on an agreement
that canceled the agreement from May 2019. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> According to the new agreement, the Company
issued 80,273 shares to advisors that assisted with raising the convertible loan agreement when they met the raising target on November
2020. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 155 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 17 &ndash; RELATED PARTIES:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>The following transactions arose with related
parties:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Transaction &ndash; expenses (income)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; white-space: nowrap; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> December
    31,<BR>
    2020 </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> December
    31,<BR>
    2019 </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; width: 76%; text-align: left; text-indent: 0pt"> Salary and related expenses </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 795 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 230 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-indent: 0pt"> Share based payment </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 1,805 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Liabilities to related parties</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: left"> Name </TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> Nature of transaction </TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> December
    31,<BR> 2020 </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> December
    31, <BR> 2019 </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; text-align: left"> Related parties </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 30%; text-align: left"> Ongoing transaction </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> (98 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> (4 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 18 &ndash; FINANCIAL INSTRUMENTS AND
RISK MANAGEMENT:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The Company is exposed to a variety of financial
risks, which result from its financing, operating and investing activities. The objective of financial risk management is to contain,
where appropriate, exposures in these financial risks to limit any negative impact on the Company&rsquo;s financial performance and position.
The Company&rsquo;s financial instruments are its cash and other receivables, convertible loan, payables and other payables. The main
purpose of these financial instruments is to raise finance for the Company&rsquo;s operation. The Company actively measures, monitors
and manages its financial risk exposures by various functions pursuant to the segregation of duties and principals. The risks arising
from the Company&rsquo;s financial instruments are mainly credit risk and currency risk. The risk management policies employed by the
Company to manage these risks are discussed below. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Credit risk</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> Credit risk arises when a failure by counterparties
to discharge their obligations could reduce the amount of future cash inflows from financial assets on hand at the balance sheet date.
The Company closely monitors the activities of its counterparties and controls the access to its intellectual property which enables
it to ensure the prompt collection. The Company&rsquo;s main financial assets are cash and cash equivalents as well as other receivables
and represent the Company&rsquo;s maximum exposure to credit risk in connection with its financial assets. Wherever possible and commercially
practical, the Company holds cash with major financial institutions in Israel. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The carrying amount of financial assets represents
the maximum credit exposure. The maximum exposure to credit risk at the reporting date was: </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> December
    31, 2020 </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> December
    31, 2019 </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; width: 76%; text-align: justify; text-indent: 0pt"> Cash and cash equivalents </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 496 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 96 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> Other account receivable </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 145 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 35 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: 0pt"> Total </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 641 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 131 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 156 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 18 &ndash; FINANCIAL INSTRUMENTS AND
RISK MANAGEMENT (CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Currency risk</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> Currency risk is the risk that the value of
financial instruments will fluctuate due to changes in foreign exchange rates. Currency risk arises when future commercial transactions
and recognized assets and liabilities are denominated in a currency that is not the Company&rsquo;s functional currency. The Company
exposed to foreign exchange risk arising from currency exposure primarily with respect to the USD and to the AUD. The Company&rsquo;s
policy is not to enter into any currency hedging transactions. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The carrying amounts of the Company&rsquo;s
foreign currency denominated monetary liability at the reporting date are as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> December
    31,<BR>
    2020 </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> $ </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; padding-bottom: 4pt"> Cash and cash equivalents </TD><TD STYLE="width: 1%; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right"> 85 </TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Assets</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; white-space: nowrap; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> December
    31,<BR>
    2020 </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> $ </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; width: 88%; text-align: justify; text-indent: 0pt"> Convertible note </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 1,273 </TD><TD STYLE="padding: 0pt; white-space: nowrap; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> Warrant </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 219 </TD><TD STYLE="padding: 0pt; white-space: nowrap; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> Total </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 1,492 </TD><TD STYLE="padding: 0pt; white-space: nowrap; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; font-weight: bold; text-align: justify; text-indent: 0pt"> Net Liabilities </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> (1,407 </TD><TD STYLE="padding: 0pt; white-space: nowrap; text-align: left; text-indent: 0pt"> ) </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>Liabilities</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; white-space: nowrap; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> December
    31,<BR>
    2019 </TD><TD STYLE="padding: 0pt; white-space: nowrap; font-weight: bold; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> AUD </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; width: 88%; text-align: justify; text-indent: 0pt"> Convertible loan </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 1,355 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> Total </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 1,355 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 157 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 18 &ndash; FINANCIAL INSTRUMENTS AND
RISK MANAGEMENT (CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Sensitivity analysis</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> A 10% strengthening of the NIS against the following
currencies would have increased (decreased) equity and the income statement by the amounts shown below. This analysis assumes that all
other variables, in particular interest rates, remain constant. For a 10% weakening of the NIS against the relevant currency, there would
be an equal and opposite impact on the profit and other equity. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> Year ended<BR>
    December 31, <BR>
    2020 </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"> Year ended<BR>
    December 31,<BR>
    2019 </TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: left"> USD </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> (141 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"> AUD </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (135 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Liquidity risks</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> Liquidity risk is the risk that arises when
the maturity of assets and the maturity of liabilities do not match. An unmatched position potentially enhances profitability, but can
also increase the risk of loss. The Company has procedures to minimize such loss by maintaining sufficient cash and other highly liquid
current assets and by having available an adequate amount of committed credit facilities. As of the balance sheet date, the Company has
a negative working capital. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The following tables detail the Company&rsquo;s
remaining contractual maturity for its financial liabilities. The tables have been drawn up based on the undiscounted cash flows of financial
liabilities based on the earliest date on which the Company can be required to pay. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 158 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 18 &ndash; FINANCIAL INSTRUMENTS AND
RISK MANAGEMENT (CONT.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Liquidity risks (cont.):</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt"></TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> Up
    to 1 year </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center"> Between <BR>
    1 and 3 years </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center"> More than <BR>
    3 years </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt"> At&nbsp;&nbsp;December &nbsp;31, 2020 </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding: 0pt 0pt 1.5pt; font-weight: bold; text-align: center; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding: 0pt 0pt 1.5pt; font-weight: bold; text-align: center"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding: 0pt 0pt 1.5pt; font-weight: bold; text-align: center"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; width: 64%; text-align: left; text-indent: 0pt"> Trade payables </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 3 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Convertible note </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 1,273 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Related party </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 98 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Loan from the IIA </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 110 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 568 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Warrants </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 219 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Lease liabilities </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 147 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 92 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt"> Total </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 1,740 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 202 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 568 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt"></TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> Up
    to 1 year </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> Between
    <BR>
    1 and 3 years </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt"> At&nbsp;&nbsp;December &nbsp;31, 2019 </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding: 0pt 0pt 1.5pt; font-weight: bold; text-align: center; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding: 0pt 0pt 1.5pt; font-weight: bold; text-align: center; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; width: 76%; text-align: left; text-indent: 0pt"> Trade payables </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> 74 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Convertible loan </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> 1,355 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Lease liabilities </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 135 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 40 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt"> Total </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 1,564 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; padding: 0pt; text-align: right; text-indent: 0pt"> 40 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>


<!-- Field: Page; Sequence: 159 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 19 &ndash; FAIR VALUE MEASUREMENT:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>Fair value hierarchy</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The following table details the Company&rsquo;s
assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is
significant to the entire fair value measurement, being: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; width: 0.25in"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 0.5in; text-align: justify; padding-left: 0pt"> Level&nbsp;1:&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD STYLE="text-align: justify"> Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity
    can access at the measurement date. </TD></TR>

<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify; padding-left: 0pt"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify; padding-left: 0pt"> Level 2: </TD>
    <TD STYLE="text-align: justify"> Inputs other than quoted prices included within Level 1 that are observable for the asset or liability,
    either directly or indirectly. </TD></TR>

<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify; padding-left: 0pt"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify; padding-left: 0pt"> Level 3: </TD>
    <TD STYLE="text-align: justify"> Unobservable inputs for the asset or liability The fair value measurement of the convertible loan
    in the table above was estimated using a discounted cash flows approach (DCF). </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> According to the DCF approach, the value of
a firm is equivalent to the sum of present values, of all future tax-adjusted cash flows. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The cost of capital is equal to 21%. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> Movements in level 3 liability during the current
financial year is set out below: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> Convertible
    loan </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> Convertible
    note </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt"> Warrants </TD><TD STYLE="padding: 0pt; font-weight: bold; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; width: 64%; text-align: justify; text-indent: 0pt"> December 31, 2019 </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> (4,685 </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> ) </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; width: 9%; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> Receipt </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> (1,021 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> (1,236 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> Loss due to change in fair value </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> (689 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> (204 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> Gains recognized in other comprehensive income </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> (473 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> (37 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"> (15 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt"> Conversion to shares </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> 6,868 </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0pt 0pt 4pt; text-align: justify; text-indent: 0pt"> December 31, 2020 </TD><TD STYLE="padding: 0pt 0pt 4pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: left; text-indent: 0pt"></TD><TD STYLE="border-bottom: Black 4pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: right; text-indent: 0pt"> - </TD><TD STYLE="padding: 0pt 0pt 4pt; text-align: left; text-indent: 0pt"> &nbsp; </TD><TD STYLE="padding: 0pt 0pt 4pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: left; text-indent: 0pt"></TD><TD STYLE="border-bottom: Black 4pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: right; text-indent: 0pt"> (1,273 </TD><TD STYLE="padding: 0pt 0pt 4pt; text-align: left; text-indent: 0pt"> ) </TD><TD STYLE="padding: 0pt 0pt 4pt; text-indent: 0pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: left; text-indent: 0pt"></TD><TD STYLE="border-bottom: Black 4pt double; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: right; text-indent: 0pt"> (219 </TD><TD STYLE="padding: 0pt 0pt 4pt; text-align: left; text-indent: 0pt"> ) </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <BR>
There were no transfers between levels during the 2020 financial year. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> The carrying amounts of trade and other receivables
and trade and other payables are assumed to approximate their fair values due to their short-term nature. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 160 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>Notes
to financial statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(US dollars in thousands)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>NOTE 20 &ndash; SUBSEQUENT EVENTS:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> 1. </TD><TD STYLE="text-align: justify"> In January through March 2021, the Company entered into convertible
                                 loan agreements for the aggregate amount of 3,484. These convertible loan agreements have a maturity
                                 date of May 31, 2021 and 5.0% per annum accrued quarterly. Upon completion of the NASDAQ IPO, the loan
                                 amount under the convertible loan agreements will convert to ordinary shares at a conversion rate equal
                                 to a discount of 20% from the per share price of the Company&rsquo;s ordinary Share in the NASDAQ IPO.
                                 Additionally, the investors will receive warrants to purchase the Company&rsquo;s ordinary shares with
                                 an exercise price equal to the public offering price in such offering with 50% warrant coverage with
                                 a three year warrant. </TD></TR><TR STYLE="vertical-align: top">
<TD> &nbsp; </TD><TD STYLE="text-align: justify"> &nbsp; </TD></TR>
                                                                           </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> 2. </TD><TD STYLE="text-align: justify"> The remaining 2,611, the Company received under the SAFE will be
                                 converted into ordinary shares according to the lower of: (i) a company valuation cap of 70,000 , or
                                 (ii) a discount of 30% from the price of ordinary share in the event of an initial public offering,
                                 merger, acquisition or other liquidity event. However, if an initial public offering, merger, acquisition,
                                 other liquidity event or dissolution event does not take place within 24 months from December 2020,
                                 then the subscription amount under such SAFE will convert into ordinary shares at a conversion price
                                 reflecting a company valuation of 70,000. In addition, if the subscription amounts under the SAFE is
                                 converted to ordinary shares in connection with an initial public offering, then the Company will issue
                                 the SAFE investors warrants to purchase ordinary shares with an exercise price equal to the public offering
                                 price in such offering with 50% warrant coverage with a three year warrant. </TD></TR><TR STYLE="vertical-align: top">
<TD> &nbsp; </TD><TD STYLE="text-align: justify"> &nbsp; </TD></TR>
                                                                                                                                                 </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> 3. </TD><TD STYLE="text-align: justify"> On February 21, 2021, the Company&rsquo;s board of directors granted
                                 a total of 35,375 options to subscribe for Ordinary Shares to employees and consultants. The vesting
                                 period is up to three years from the grant date. The exercise price per share was NIS 0.37. The contractual
                                 life of the options under the Plan is ten years. The options were granted under Section 102 of the Israeli
                                 Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise. </TD></TR><TR STYLE="vertical-align: top">
<TD> &nbsp; </TD><TD STYLE="text-align: justify"> &nbsp; </TD></TR>
                                                                                                                       </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> 4. </TD><TD STYLE="text-align: justify"> On March 16, 2021, the Company&rsquo;s board of directors granted
                                 a total of 81,633 options to subscribe for Ordinary Shares to a director. The vesting period is up to
                                 three years from the grant date. The exercise price per share was NIS 0.37. The contractual life of
                                 the options under the Plan is ten years. The options were granted under Section 102 of the Israeli Tax
                                 Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise. </TD></TR><TR STYLE="vertical-align: top">
<TD> &nbsp; </TD><TD STYLE="text-align: justify"> &nbsp; </TD></TR>
                                                                                               </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> 5. </TD><TD STYLE="text-align: justify"> On March 18, 2021, the Company shareholders approved all shares (issued
                                 and unissued) be consolidated on the basis that every <FONT STYLE="font-family: Times New Roman, Times, Serif">12.5
                                 </FONT>shares in the capital of the Company be consolidated into 1 Share, such that the authorized share
                                 capital of the Company following such consolidation is NIS <FONT STYLE="font-family: Times New Roman, Times, Serif">310,000,000
                                 </FONT>divided into <FONT STYLE="font-family: Times New Roman, Times, Serif">24,800,000</FONT> Shares.
                                 On June 01 2021, our shareholders approved an additional reverse split at a ratio of one-for-2.94, pursuant
                                 to which holders of our Ordinary Shares received one Ordinary Share for every 2.94&nbsp;Ordinary Shares
                                 held. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> <B>&nbsp;</B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> 6. </TD><TD STYLE="text-align: justify"> On June 01, 2021 the Company shareholders approved amending the structure
                                 of the Company&rsquo;s share capital (both authorized and issued) by cancelling the par value of the
                                 Company&rsquo;s shares such that each Company share with a current par value of NIS 0.125 will become
                                 one share with no par value. </TD></TR><TR STYLE="vertical-align: top">
<TD> &nbsp; </TD><TD STYLE="text-align: justify"> &nbsp; </TD></TR>
                                                                                                                                          </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> 7. </TD><TD STYLE="text-align: justify"> On June 01,2021 the company shareholders approved an increase the
                                 authorized share capital of the company to 15,000,000 Ordinary Shares of no par value. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> &nbsp; </P>


<!-- Field: Page; Sequence: 161; Options: NewSection; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <B>Up to 2,307,692
Units Each Consisting of</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>One Ordinary Shares and One Warrant to Purchase
One Ordinary Share</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Up to 2,307,692 Pre-Funded Units Each
Consisting of</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>One Pre-Funded Warrant to Purchase One Ordinary
Share and One Warrant to Purchase One Ordinary Share</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 12pt Times New Roman, Times, Serif"><B></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Inspira
Technologies Oxy B.H.N. Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-size: 14pt"><B>Aegis Capital
Corp.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;,
2021</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 162 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item&nbsp;6. Indemnification
of Directors, Officers and Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Indemnification</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Israeli Companies Law 5759-2999, or
the Companies Law, and the Israeli Securities Law, 5728-1968, or the Securities Law, provide that a company may indemnify an office
holder against the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant
to an undertaking made in advance of an event or following an event, provided its articles of association include a provision authorizing
such indemnification:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed on him or her in favor of another person by any judgment concerning an act performed in his or her capacity as an office holder, including a settlement or arbitrator&rsquo;s award approved by a court;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&rsquo; fees, expended by the office holder (a) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (1) no indictment (as defined in the Companies Law) was filed against such office holder as a result of such investigation or proceeding; and (2) no financial liability as a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; or (b) in connection with a monetary sanction; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&rsquo; fees, expended by the office holder or imposed on him or her by a court (1) in proceedings that the company institutes, or that another person institutes on the company&rsquo;s behalf, against him or her; (2) in a criminal proceedings of which he or she was acquitted; or (3) as a result of a conviction for a crime that does not require proof of criminal intent; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred by an office holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&rsquo; fees. An &ldquo;Administrative Procedure&rdquo; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Companies Law also permits a company
to undertake in advance to indemnify an office holder, provided that if such indemnification relates to financial liability imposed
on him or her, as described above, then the undertaking should be limited and shall detail the following foreseen events and amount
or criterion:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to events that in the opinion of the board of directors can be foreseen based on the company&rsquo;s activities at the time that the undertaking to indemnify is made; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in amount or criterion determined by the board of directors, at the time of the giving of such undertaking to indemnify, to be reasonable under the circumstances.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We intend to enter, into indemnification agreements
with all of our directors and with all members of our senior management subject to the listing of our securities on the Nasdaq Capital
Market. Each such indemnification agreement will provide the office holder with indemnification permitted under applicable law and up
to a certain amount, and to the extent that these liabilities are not covered by directors and officers insurance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Exculpation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Under
the Companies Law, an Israeli company may not exculpate an office holder from liability for a breach of his or her duty of loyalty,
but may exculpate in advance an office holder from his or her liability to the company, in whole or in part, for damages caused
to the company as a result of a breach of his or her duty of care (other than in relation to distributions), but only if a provision
authorizing such exculpation is included in its articles of association. Our amended and restated articles of association provide
that we may exculpate, in whole or in part, any office holder from liability to us for damages caused to the company as a result
of a breach of his or her duty of care, but prohibit an exculpation from liability arising from a company&rsquo;s transaction in
which our controlling shareholder or officer has a personal interest. Subject to the aforesaid limitations, under the indemnification
agreements, we exculpate and release our office holders from any and all liability to us related to any breach by them of their
duty of care to us to the fullest extent permitted by law.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 163; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Limitations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
Companies Law provides that the Company may not exculpate or indemnify an office holder nor enter into an insurance contract that
would provide coverage for any liability incurred as a result of any of the following: (1) a breach by the office holder of his
or her duty of loyalty unless (in the case of indemnity or insurance only, but not exculpation) the office holder acted in good
faith and had a reasonable basis to believe that the act would not prejudice us; (2) a breach by the office holder of his or her
duty of care if the breach was carried out intentionally or recklessly (as opposed to merely negligently); (3) any act or omission
committed with the intent to derive an illegal personal benefit; or (4) any fine, monetary sanction, penalty or forfeit levied
against the office holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Under
the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation
committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our amended and restated articles of association
permit us to exculpate (subject to the aforesaid limitation), indemnify and insure our office holders to the fullest extent permitted
or to be permitted by the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item&nbsp;7. Recent Sales of Unregistered
Securities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Set forth below are the sales of all securities
by the Company since the Company&rsquo;s incorporation in February 2018, which were not registered under the Securities Act. The
Company believes that each of such issuances was exempt from registration under the Securities Act in reliance on Section 4(a)(2)
of the Securities Act, Rule 701 and/or Regulation S under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On February 27, 2018, upon our incorporation,
we issued an aggregate of 27,566 Ordinary Shares for no consideration to our Founders and certain advisors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On November 1, 2020, we issued 1,877,193 bonus
shares for no consideration to our existing shareholders. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On December 3, 2020, we issued to IML and its
affiliates, pursuant to the Termination Agreement: (i) 597,938 Ordinary Shares at a price per share of A$5.15 <FONT STYLE="background-color: white">(approximately
$3.45)</FONT> upon the conversion of funds; (ii) 77,911 Ordinary Shares at a price per share of A$5.9 <FONT STYLE="background-color: white">(approximately
$3.92)</FONT> upon the conversion of funds; (iii) 80,273 Ordinary Shares issued to a promoter; and (iv) options to purchase additional
an 169,019 Ordinary Shares at an exercise price equal to the price per Ordinary Share in this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2020 through March 2021, we
entered into certain equity investment agreements, which we refer to as Simple Agreements for Future Equity, or SAFEs, for aggregate
proceeds of $5,414,593. Out of the amounts we received under the SAFEs, $2,803,844 will be converted into our Ordinary Shares,
at a conversion rate equal to the lower of (i) our company valuation cap of $35,000,000, or (ii) a discount of 30% from the per
share price of our Ordinary Share in the event of an initial public offering, merger, acquisition or other liquidity event. However,
if an initial public offering, merger, acquisition, other liquidity event or dissolution event does not take place within 24 months
from December 2020, then the subscription amount under such SAFEs will convert into our Ordinary Shares as follows: (i) investors
representing an aggregate of $1,426,155 of the SAFEs will convert at a conversion price reflecting a company valuation of $17,500,000,
and (ii) investors representing an aggregate of $1,377,689 of the SAFEs will convert at a conversion price reflecting a company
valuation of $35,000,000. In addition, if the subscription amounts under the SAFEs is converted to Ordinary Shares in connection
with an initial public offering, then we will issue the SAFE investors warrants to purchase our Ordinary Shares with an exercise
price equal to the public offering price in such offering, as follows: (i) investors representing an aggregate of $1,426,155 of
the SAFEs shall receive 75% warrant coverage with a four year warrant, and (ii) investors representing an aggregate of $1,377,689
of the SAFEs shall receive 50% warrant coverage with a three year warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The remaining $2,610,749 we received under
the SAFEs will be converted into our Ordinary Shares, at a conversion rate equal to the lower of (i) our company valuation cap
of $70,000,000, or (ii) a discount of 30% from the per share price of our Ordinary Share in the event of an initial public offering,
merger, acquisition or other liquidity event. However, if an initial public offering, merger, acquisition, other liquidity event
or dissolution event does not take place within 24 months from December 2020, then the subscription amount under such SAFEs will
convert into our Ordinary Shares at a conversion price reflecting a company valuation of $70,000,000. In addition, if the subscription
amounts under the SAFEs is converted to Ordinary Shares in connection with an initial public offering, then we will issue the SAFE
investors warrants to purchase our Ordinary Shares with an exercise price equal to the public offering price in such offering with
50% warrant coverage with a three year warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Additionally, we will issue warrants to purchase
2,747 Ordinary Shares, exercisable upon our initial public offering for two year and three years, respectively, to promoters in connection
with the SAFEs, assuming the offering price of $6.50, which is the midpoint of the price range set forth on the cover page of this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In January through March 2021, we entered
into convertible loan agreements for the aggregate amount of $3,484,113. These convertible loan agreements had a maturity date of
May 31, 2021 and bear interest at the rate of 5.0% per year accrued quarterly. Upon completion of this offering, the loan amount
under the convertible loan agreements will convert to Ordinary Shares at a conversion rate equal to a discount of 20% from the per
share price of our Ordinary Shares in this offering. Additionally, the investors will receive warrants to purchase our Ordinary
Shares with an exercise price equal to the public offering price in such offering with 50% warrant coverage with a three year
warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> In May 2021, we offered an extension with a maturity
date of July 15, 2021 for the convertible loan agreements. The convertible loan agreements in the aggregate amount of $3,053,920 were
extended. We repaid $430,193 plus interest of 5% per year (approximately $7,000) to the investors who did not agree to the extension. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 164; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Since February 2018, we have granted to our
directors, officers, employees and other service providers options to purchase an aggregate of 633,358 Ordinary Shares under our 2019
Plan, with an exercise prices ranging between A$0.368 (approximately $0.25) and NIS 0.22 (approximately $0.06) per share. On November
30, 2020, we requested the Israeli Tax Authority to reduce the exercise price of all Ordinary Shares underlying our outstanding options
to NIS 0.37 (approximately $0.12) per share. As of June 25, 2021, 6,111 options granted to our directors, officers and employees and
other service providers under the 2019 Plan were exercised, and 67,335 options were cancelled, forfeited, expired, or were otherwise
not granted, such that the total outstanding amount of options to our directors, officers and employees and other service providers under
the 2019 Plan as of such date is 559,912. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item&nbsp;8. Exhibits and Financial
Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibits:</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 7%; border-bottom: black 1.5pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;<BR>
    Number</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 92%; border-bottom: black 1.5pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;Description</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1**</FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"> <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021031503/ea140235ex1-1_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement by and among Inspira Technologies Oxy B.H.N. Ltd. and the underwriters named therein.</FONT></A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1**</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex3-1_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
    and Restated Articles of Association of Inspira Technologies Oxy B.H.N. Ltd. currently in effect. </FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2**</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex3-2_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
    and Restated Articles of Association of Inspira Technologies Oxy B.H.N. Ltd. to be in effect upon the consummation of this offering.</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"> 4.1* </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"> <A HREF="ea143325ex4-1_inspiratech.htm">Form of Representative&rsquo;s
    Warrant.</A> </TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2**</FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021031503/ea140235ex4-2_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant Agent Agreement.</FONT></A> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3**</FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021031503/ea140235ex4-3_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Pre-funded Warrant</FONT></A> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4**</FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021031503/ea140235ex4-4_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant.</FONT></A> </TD></TR>

<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"> 4.5* </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt"><A HREF="ea143325ex4-5_inspiratech.htm"> Form of Warrant Agent Agreement for Pre-funded Warrants. </A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left; width: 7%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1**</FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left; width: 1%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left; width: 92%"> <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021031503/ea140235ex5-1_inspiratech.htm">
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Sullivan &amp; Worcester Tel Aviv (Har-Even
    &amp; Co.), Israeli counsel to Inspira Technologies Oxy B.H.N. Ltd.</FONT> </A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">5.2*</P></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"><P STYLE="margin: 0pt 0; font-size: 10pt"><A HREF="ea143325ex5-2_inspiratec.htm">Opinion
                                            of Sullivan &amp; Worcester LLP, U.S. counsel to Inspira Technologies Oxy B.H.N. Ltd.</A></P></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1**</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-1_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Indemnification Agreement.</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2**</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-2_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inspira
    Technologies Oxy B.H.N. Option Plan.</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3**
    </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-3_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Public Offering Implementation Deed, dated May 20, 2019, by and among the Company, Insense Medical Pty Ltd., Udi Nussinovitch, Joe
    Hayon, Dagi Ben-Noon and Newburyport Partners Pty Ltd</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4**</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-4_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    Bridge Loan Agreement, dated July 1, 2019, by and between the Company and Insense Medical Pty Ltd.</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5**</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-5_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deed
    of Variation of Initial Public Offering Implementation Deed, dated July 18, 2019, by and among the Company, Insense Medical Pty Ltd.,
    Udi Nussinovitch, Joe Hayon, Dagi Ben-Noon and Newburyport Partners Pty Ltd</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6**</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-6_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement,
    dated November 27, 2020, by and among the Company, Insense Medical Pty Ltd., Udi Nussinovitch, Joe Hayon, Dagi Ben-Noon and Newburyport
    Partners Pty Ltd.</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7**</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-7_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Simple Agreement for Future Equity.</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"> 10.8* </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"> <A HREF="ea143325ex10-8_inspiratec.htm">Shareholder
    Loan Agreement, dated March 1, 2018, by and between the Company and Dagi Ben-Noon.</A> </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9**</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-8_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Convertible Loan Agreement</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt"><A HREF="ea143325ex23-1_inspiratec.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Ziv Haft, a member firm of BDO, independent registered public accounting firm.</FONT> </A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2**</FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"> <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021031503/ea140235ex5-1_inspiratech.htm">
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Sullivan &amp; Worcester Tel Aviv (Har-Even
    &amp; Co.) (included in Exhibit 5.1)</FONT> </A> </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> 23.3* </P></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><A HREF="ea143325ex5-2_inspiratec.htm"> Consent of Sullivan &amp; Worcester (included in Exhibit 5.2) </A></P></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1**</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021016846/ea138125-f1a2_inspiratech.htm#Signature"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
    of Attorney.</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1**</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021013704/ea137084ex99-1_inspiratech.htm">Registrant&rsquo;s
    Representation Pursuant to Requirements of Form 20-F, Item 8.A.4.</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2**</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021016846/ea138125ex99-2_inspiratech.htm">Consent
    of Tal Parnes as Director Nominee.</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3*</FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: left"><A HREF="ea143325ex99-3_inspiratech.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Limor Rozen as Director Nominee.</FONT> </A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD> Filed herewith. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously filed.</FONT> </TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial Statement Schedules:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All financial statement schedules have been
omitted because either they are not required, are not applicable or the information required therein is otherwise set forth in
the Company&rsquo;s financial statements and related notes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 165; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item&nbsp;9. Undertakings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) The undersigned Registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Act or Rule 3-19 of this chapter if such financial statements and information are contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Form F-3.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the registrant is relying on Rule 430B:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 166; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness of the date of the first contract or sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date and underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell securities to such purchaser:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) The undersigned registrant hereby undertakes
to provide to the underwriters at the closing specified in the underwriting agreements, certificates in such denominations and
registered in such names as required by the underwriter to permit prompt delivery to each purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) Insofar as indemnification for liabilities
arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant
to the provisions described in Item&nbsp;6 hereof, or otherwise, the registrant has been advised that in the opinion of the SEC
such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim
for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final
adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) The undersigned registrant hereby undertakes
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(1) That for purposes of determining any liability
under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement
in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or
(4), or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared
effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(2) That for the purpose of determining any liability
under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial&nbsp;<I>bona fide</I>&nbsp;offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 167; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="Signature"></A><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to the requirements of the Securities
Act of&nbsp;1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing
on Form F-1 and has duly caused this registration statement on Form F-1 to be signed on its behalf by the undersigned, thereunto duly
authorized, in&nbsp;Ra&rsquo;anana Israel on&nbsp;June 28, 2021. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 36%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt solid"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">/s/ Dagi Ben-Noon</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned officers and directors of
Inspira Technologies Oxy B.H.N. Ltd. hereby constitute and appoint each of Dagi Ben-Noon and Joe Hayon with full power of substitution,
each of them singly our true and lawful attorneys-in-fact and agents to take any actions to enable the Company to comply with the
Securities Act, and any rules, regulations and requirements of the SEC, in connection with this registration statement on Form
F-1, including the power and authority to sign for us in our names in the capacities indicated below any and all further amendments
to this registration statement and any other registration statement filed pursuant to the provisions of Rule 462 under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Act of 1933, this amendment to the registration statement on Form F-1 has been signed by the following persons in the capacities
and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 225px; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT> </TD>
    <TD STYLE="width: 6px"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT> </TD>
    <TD STYLE="width: 6px"> &nbsp; </TD>
    <TD STYLE="width: 134px; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dagi
    Ben-Noon</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2021</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Joe
    Hayon</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer, President and Director
    </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2021</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joe Hayon</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(Principal Financial and Accounting Officer)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, Chairman of the Board of Directors</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2021</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prof. Benad Goldwasser </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*By:</FONT> </TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;Dagi
    Ben-Noon</FONT> </TD>
    <TD STYLE="width: 60%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</FONT> </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Attorney-in-fact</I></FONT> </TD>
    <TD> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 168; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE OF AUTHORIZED REPRESENTATIVE
IN THE UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to the Securities Act of 1933, as
amended, the undersigned, Puglisi &amp; Associates, the duly authorized representative in the United States of Inspira Technologies Oxy
B.H.N. Ltd., has signed this registration statement on June 28, 2021. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 60%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 40%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Puglisi &amp; Associates</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Authorized U.S. Representative</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">/s/ Donald J. Puglisi</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;&nbsp;Donald J. Puglisi </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Managing Director</FONT></TD></TR>
</TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea143325ex4-1_inspiratech.htm
<DESCRIPTION>FORM OF REPRESENTATIVE'S WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Representative&rsquo;s Warrant Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>THE REGISTERED HOLDER OF THIS PURCHASE WARRANT
BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE, OR BE THE SUBJECT OF ANY HEDGING, SHORT
SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF THIS PURCHASE WARRANT OR THE UNDERLYING
SECURITIES FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS IMMEDIATELY FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) EXCEPT AS HEREIN PROVIDED
AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE, OR BE THE SUBJECT
OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF, THIS PURCHASE
WARRANT OR THE UNDERLYING SECURITIES FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS IMMEDIATELY FOLLOWING THE EFFECTIVE DATE TO ANYONE
OTHER THAN (I) AEGIS CAPITAL CORP OR ANY UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER
OR PARTNER OF AEGIS CAPITAL CORP, OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR
TO [ ] [ ], 2021. VOID AFTER 5:00 P.M., EASTERN TIME, [ ] [ ], 2026.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WARRANT TO PURCHASE ORDINARY SHARES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">Warrant Shares:</TD>
                                                                              <TD STYLE="text-align: right">Initial Issuance Date: [ ] [ ], 2021</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">&nbsp;</TD>
                                                                              <TD STYLE="text-align: right">Initial Exercise Date: [
] [ ], 2021<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">THIS WARRANT TO PURCHASE ORDINARY
SHARES(the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, [______], or its assigns (the &ldquo;<U>Holder</U>&rdquo;),
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
[ ] [ ], 2021<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT> (the &ldquo;<U>Initial Exercise
Date</U>&rdquo;) and prior to [ ] [ ], 2026<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3</SUP></FONT>
at 5:00 p.m. (New York time) (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from INSPIRA
TECHNOLOGIES OXY B.H.N. LTD., an Israeli company (the &ldquo;<U>Company</U>&rdquo;), up to [______]<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>4</SUP></FONT>
ordinary shares par value NIS 0.125 per share (the &ldquo;<U>Ordinary Shares</U>&rdquo;), of the Company (the &ldquo;<U>Warrant Shares</U>&rdquo;),
as subject to adjustment hereunder. The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price,
as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>Section 1. Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided that banks shall not be deemed to be authorized or obligated to be closed due to a &ldquo;shelter
in place,&rdquo; &ldquo;non-essential employee&rdquo; or similar closure of physical branch locations at the direction of any governmental
authority if such banks&rsquo; electronic funds transfer systems (including for wire transfers) are open for use by customers on such
day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
Date that is one hundred eighty (180) days from the effective date of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
</SUP></FONT>Date that is one hundred eighty (180) days from the effective date of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3
</SUP></FONT>Date that is five (5) years from the commencement of sales under the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>4</SUP></FONT>
Amount that is 5% of the Firm Shares and Firm Pre-funded Warrants.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Effective
Date</U>&rdquo; means the effective date of the registration statement on Form F-1, as amended (File No. 333-253920), pursuant to which
this Warrant is initially issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the New York Stock Exchange is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Ordinary Shares are listed or quoted for trading on the
date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New
York Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Ordinary Shares then listed or
quoted on a Trading Market, the daily volume weighted average price of the Ordinary Shares for such date (or the nearest preceding date)
on the Trading Market on which the Ordinary Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from
9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of a share of Ordinary Shares for such date (or the nearest preceding date) on the OTCQB or OTCQX as applicable, (c) if
Ordinary Shares are not then listed or quoted for trading on the OTCQB or OTCQX and if prices for Ordinary Shares are then reported on
the OTC Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price
per Ordinary Share so reported, or (d) in all other cases, the fair market value of the Ordinary Shares as determined by an independent
appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>Section 2. Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">a) Exercise
of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise
Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate
by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed facsimile
copy (or e-mail attachment) of the notice of exercise in the form annexed hereto as Exhibit A (&ldquo;Notice of Exercise&rdquo;). Within
two (2) Trading Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares
specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless
exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case,
the Holder shall surrender this Warrant to the Company for cancellation within five (5) Trading Days of the date the final Notice of Exercise
is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares
available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within two (2) Business
Days of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of
the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">b) <U>Exercise
Price</U>. The exercise price per Ordinary Share under this Warrant shall be $[ ]<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>5</SUP></FONT>,
subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">c) <U>Cashless
Exercise</U>. If at any time on or after the Initial Exercise Date, there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive the number of
Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(A) =</TD><TD STYLE="text-align: left"> &#8239;as applicable: (i) the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section
2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior
to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal
securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding
the date of the applicable Notice of Exercise or (z) the Bid Price of the Ordinary Shares on the principal Trading Market as reported
by Bloomberg L.P. as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed
during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2)
hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the
date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both
executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.5in">(B) =</TD><TD STYLE="text-align: left">the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.5in">(X) =</TD><TD STYLE="text-align: left">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the
terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If Warrant Shares are issued
in such a &ldquo;cashless exercise,&rdquo; the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities
Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised, and the holding period of the Warrants
being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to
this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">d) <U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by its transfer
agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by Holder, or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant
to Rule 144 and, in either case, the Warrant Shares have been sold by the Holder prior to the Warrant Share Delivery Date (as defined
below), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder
or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by
the Holder in the Notice of Exercise by the date that is two (2) Trading Days after the delivery to the Company of the Notice of Exercise
(such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). If the Warrant Shares can be delivered via DWAC, the transfer agent
shall have received from the Company, at the expense of the Company, any legal opinions or other documentation required by it to deliver
such Warrant Shares without legend (subject to receipt by the Company of reasonable back up documentation from the Holder, including with
respect to affiliate status) and, if applicable and requested by the Company prior to the Warrant Share Delivery Date, the transfer agent
shall have received from the Holder a confirmation of sale of the Warrant Shares (provided the requirement of the Holder to provide a
confirmation as to the sale of Warrant Shares shall not be applicable to the issuance of unlegended Warrant Shares upon a cashless exercise
of this Warrant if the Warrant Shares are then eligible for resale pursuant to Rule 144(b)(1)). The Warrant Shares shall be deemed to
have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of
such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by
cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance
of such shares, having been paid. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice
of Exercise by the second Trading Day following the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated
damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Ordinary Shares on
the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after
such liquidated damages begin to accrue) for each Trading Day after the second Trading Day following such Warrant Share Delivery Date
until such Warrant Shares are delivered or Holder rescinds such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>5 </SUP></FONT>
Equal to 125% public offering price</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">iii. <U>Rescission
Rights</U>. If the Company fails to cause its transfer agent to deliver to the Holder the Warrant Shares pursuant to Section 2(d)(i) by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise; <U>provided, however</U>, that the Holder
shall be required to return any Warrant Shares or Ordinary Shares subject to any such rescinded exercise notice concurrently with the
return to Holder of the aggregate Exercise Price paid to the Company for such Warrant Shares and the restoration of Holder&rsquo;s right
to acquire such Warrant Shares pursuant to this Warrant (including, issuance of a replacement warrant certificate evidencing such restored
right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause its transfer agent to transmit to the Holder the Warrant Shares pursuant to an exercise on or before the Warrant
Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise)
or the Holder&rsquo;s brokerage firm otherwise purchases, Ordinary Shares to deliver in satisfaction of a sale by the Holder of the Warrant
Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash
to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the
Ordinary Shares so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required
to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase
obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant
Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number
of Ordinary Shares that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For
example, if the Holder purchases Ordinary Shares having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of Ordinary Shares with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver Ordinary
Shares upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in
the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise
shall be accompanied by the assignment form attached hereto as Exhibit B (&ldquo;Assignment Form&rdquo;) duly executed by the Holder and
the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all transfer agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">viii. <U>Signature</U>.
This Section 2 and the Notice of Exercise set forth the totality of the procedures required of the Holder in order to exercise this Purchase
Warrant. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall any medallion guarantee
(or other type of guarantee or notarization) of any Notice of Exercise be required in order to exercise this Purchase Warrant. No additional
legal opinion, other information or instructions shall be required of the Holder to exercise this Purchase Warrant. The Company shall
honor exercises of this Purchase Warrant and shall deliver Shares underlying this Purchase Warrant in accordance with the terms, conditions
and time periods set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates), would beneficially own in excess of the Beneficial Ownership
Limitation (as defined below). For purposes of the foregoing sentence, the number of Ordinary Shares beneficially owned by the Holder
and its Affiliates shall include the number Ordinary Shares issuable upon exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of Ordinary Shares which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated
in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the
Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act
and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned
by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the
Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining
the number of outstanding Ordinary Shares, a Holder may rely on the number of outstanding Ordinary Shares as reflected in (A) the Company&rsquo;s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company
or (C) a more recent written notice by the Company or the Company&rsquo;s transfer agent setting forth the number of Ordinary Shares outstanding.
Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder the
number of Ordinary Shares then outstanding. In any case, the number of outstanding shares of Ordinary Shares shall be determined after
giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates since
the date as of which such number of outstanding Ordinary Shares was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of Ordinary Shares issuable
upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions
of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of Ordinary Shares outstanding
immediately after giving effect to the issuance of Ordinary Shares upon exercise of this Warrant held by the Holder and the provisions
of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st
day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.
&quot;Common Stock Equivalents&quot; means any rights or warrants or options to purchase any Ordinary Shares or securities convertible
into Ordinary Shares.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>Section 3. Certain Adjustments</U>.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on Ordinary Shares or any other equity or equity equivalent securities payable in Ordinary Shares (which,
for avoidance of doubt, shall not include any Ordinary Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding
Ordinary Shares into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding Ordinary Shares into
a smaller number of shares, or (iv) issues by reclassification of Ordinary Shares and any shares of capital stock of the Company, then
in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Ordinary Shares (excluding
treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of Ordinary Shares
outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall
become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. For the
purposes of clarification, the Exercise Price of this Warrant will not be adjusted in the event that the Company or any Subsidiary thereof,
as applicable, sells or grants any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce
any offer, sale, grant or any option to purchase or other disposition) any Ordinary Shares or Common Stock Equivalents, at an effective
price per share less than the Exercise Price then in effect.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of Ordinary Shares (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable
to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of Ordinary
Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase
Rights, or, if no such record is taken, the date as of which the record holders of Ordinary Shares are to be determined for the grant,
issue or sale of such Purchase Rights (provided, however, to the extent that the Holder&rsquo;s right to participate in any such Purchase
Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in
such Purchase Right to such extent (or beneficial ownership of such Ordinary Shares as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not
result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">c) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other than
cash dividends) or other distribution of its assets (or rights to acquire its assets) to holders of Ordinary Shares, by way of return
of capital or otherwise (including, without limitation, any distribution of shares or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of Ordinary Shares acquirable upon
complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of Ordinary Shares are to be determined for the participation in such Distribution (provided, however,
to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of
any Ordinary Shares as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for
the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">d) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another
Person) is completed pursuant to which holders of Ordinary Shares are permitted to sell, tender or exchange their shares for other securities,
cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary Shares, (iv) the Company, directly or
indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Ordinary Shares
or any compulsory share exchange pursuant to which the Ordinary Shares are effectively converted into or exchanged for other securities,
cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding Ordinary Shares (not
including any Ordinary Shares held by the other Person or other Persons making or party to, or associated or affiliated with the other
Persons making or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of Ordinary Shares of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable by holders of Ordinary Shares as a result of such Fundamental Transaction for each Ordinary Share for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one Ordinary Share in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Ordinary Shares are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all
of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Ordinary Shares acquirable and receivable
upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction,
and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the Ordinary Shares pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares
of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the
consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence
of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of
such Fundamental Transaction, the provisions of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor
Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant
with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">e) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number
of Ordinary Shares (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">f) <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant
Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Ordinary
Shares, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary Shares, (C) the Company
shall authorize the granting to all holders of the Ordinary Shares rights or warrants to subscribe for or purchase any shares of capital
stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Ordinary Shares, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all
of the assets of the Company, or any compulsory share exchange whereby the Ordinary Shares are converted into other securities, cash or
property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the
Company, then, in each case, the Company shall cause to be mailed a notice to the Holder at its last address as it shall appear upon the
Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a
record is not to be taken, the date as of which the holders of the Ordinary Shares of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Ordinary Shares
of record shall be entitled to exchange their Ordinary Shares for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to provide such notice or any defect therein shall
not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided hereunder
constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant
during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise
be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4. Transfer of
Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">a) <U>Transferability</U>.
Pursuant to FINRA Rule 5110(e), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred,
assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result
in the effective economic disposition of the securities by any person for a period of 180 days immediately following the Effective Date
or commencement of sales of the offering pursuant to which this Warrant is being issued, except the transfer of any security:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">i. by
operation of law or by reason of reorganization of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">ii. to
any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject
to the lock-up restriction in this Section 4(a) for the remainder of the time period;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">iii. if
the aggregate amount of securities of the Company held by the Holder or related person do not exceed 1% of the securities being offered;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">iv. that
is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or
otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the equity in the fund;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">v. the
exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this Section 4(a) for
the remainder of the time period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">Subject to the foregoing
restriction, any applicable securities laws and the conditions set forth in Section 4(d), this Warrant and all rights hereunder (including,
without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office
of the Company or its designated agent, together with an Assignment Form duly executed by the Holder or its agent or attorney and funds
sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the
Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this
Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall
not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case,
the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an Assignment Form
to the Company assigning this Warrant full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">b) <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">d) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5.</U> Registration
Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">a) <U>&ldquo;Piggy-Back&rdquo;
Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">i. <U>Grant
of Right</U>. The Holder shall have the right, for a period of no more than three (3) years from the Initial Exercise Date in compliance
with FINRA Rule 5110(g)(8)(D), to include the Registrable Securities as part of any other registration of securities filed by the Company
(other than in connection with a transaction contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8
or any equivalent form); provided, however, that if, solely in connection with any primary underwritten public offering for the account
of the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of Shares which
may be included in the Registration Statement because, in such underwriter(s)&rsquo; judgment, marketing or other factors dictate such
limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such Registration Statement
only such limited portion of the Registrable Securities with respect to which the Holder requested inclusion hereunder as the underwriter
shall reasonably permit. Any exclusion of Registrable Securities shall be made pro rata among the Holders seeking to include Registrable
Securities in proportion to the number of Registrable Securities sought to be included by such Holders; provided, however, that the Company
shall not exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are
not entitled to inclusion of such securities in such Registration Statement or are not entitled to pro rata inclusion with the Registrable
Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">ii. <U>Terms</U>.
The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 5(a)(i) hereof, but
the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent
them in connection with the sale of the Registrable Securities. In the event of such a proposed registration, the Company shall furnish
the then Holders of outstanding Registrable Securities with not less than thirty (30) days written notice prior to the proposed date of
filing of such registration statement. Such notice to the Holders shall continue to be given for each registration statement filed by
the Company during the three (3) year period following the Initial Exercise Date until such time as all of the Registrable Securities
have been sold by the Holder. The holders of the Registrable Securities shall exercise the &ldquo;piggy-back&rdquo; rights provided for
herein by giving written notice within ten (10) days of the receipt of the Company&rsquo;s notice of its intention to file a registration
statement. Except as otherwise provided in this Warrant, there shall be no limit on the number of times the Holder may request registration
under this Section 5(a)(ii); provided, however, that such registration rights shall terminate on the third (3rd) anniversary of the Initial
Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">b) <U>General
Terms</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">i. <U>Indemnification</U>.
The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder and
each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20 (a) of the Exchange
Act against all loss, claim, damage, expense or liability (including all reasonable attorneys&rsquo; fees and other expenses reasonably
incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become subject under the Securities
Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent and with the same effect as the
provisions pursuant to which the Company has agreed to indemnify the Underwriters contained in Section 5(a) of the underwriting agreement,
dated [ ] [ ], 2021, by and between the Company and Aegis Capital Corp., as representative of the underwriters set forth therein (the
&ldquo;Underwriting Agreement&rdquo;). The Holder(s) of the Registrable Securities to be sold pursuant to such registration statement,
and their successors and assigns, shall severally, and not jointly, indemnify the Company, against all loss, claim, damage, expense or
liability (including all reasonable attorneys&rsquo; fees and other expenses reasonably incurred in investigating, preparing or defending
against any claim whatsoever) to which they may become subject under the Securities Act, the Exchange Act or otherwise, arising from information
furnished by or on behalf of such Holders, or their successors or assigns, in writing, for specific inclusion in such registration statement
to the same extent and with the same effect as the provisions contained in Section 6.2 of the Underwriting Agreement pursuant to which
the Underwriters have agreed to indemnify the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">ii. <U>Exercise
of Warrants</U>. Nothing contained in this Warrant shall be construed as requiring the Holder(s) to exercise their Warrants prior to or
after the initial filing of any registration statement or the effectiveness thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">iii. <U>Documents
Delivered to Holders</U>. The Company shall furnish to each Holder participating in any of the foregoing offerings and to each underwriter
of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of counsel to the Company,
dated the effective date of such registration statement (and, if such registration includes an underwritten public offering, an opinion
dated the date of the closing under any underwriting agreement related thereto), and (ii) a &ldquo;cold comfort&rdquo; letter dated the
effective date of such registration statement (and, if such registration includes an underwritten public offering, a letter dated the
date of the closing under the underwriting agreement) signed by the independent registered public accounting firm which has issued a report
on the Company&rsquo;s financial statements included in such registration statement, in each case covering substantially the same matters
with respect to such registration statement (and the prospectus included therein) and, in the case of such accountants&rsquo; letter,
with respect to events subsequent to the date of such financial statements, as are customarily covered in opinions of issuer&rsquo;s counsel
and in accountants&rsquo; letters delivered to underwriters in underwritten public offerings of securities. The Company shall also deliver
promptly to each Holder participating in the offering requesting the correspondence and memoranda described below and to the managing
underwriter, if any, copies of all correspondence between the Commission and the Company, its counsel or auditors and all memoranda relating
to discussions with the Commission or its staff with respect to the registration statement and permit each Holder and underwriter to do
such investigation, upon reasonable advance notice, with respect to information contained in or omitted from the registration statement
as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation shall include access
to books, records and properties and opportunities to discuss the business of the Company with its officers and independent auditors,
all to such reasonable extent and at such reasonable times as any such Holder shall reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">iv. <U>Underwriting
Agreement</U>. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any, selected by the Company,
which managing underwriter shall be reasonably satisfactory to the Holders. Such agreement shall be reasonably satisfactory in form and
substance to the Company, each Holder and such managing underwriters, and shall contain such representations, warranties and covenants
by the Company and such other terms as are customarily contained in agreements of that type used by the managing underwriter. The Holders
shall be parties to any underwriting agreement relating to an underwritten sale of their Registrable Securities and may, at their option,
require that any or all the representations, warranties and covenants of the Company to or for the benefit of such underwriters shall
also be made to and for the benefit of such Holders. Such Holders shall not be required to make any representations or warranties to or
agreements with the Company or the underwriters except as they may relate to such Holders, their Warrant Shares and their intended methods
of distribution, as well as customary agreements regarding indemnification and contribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">v. <U>Documents
to be Delivered by Holder(s)</U>. Each of the Holder(s) participating in any of the foregoing offerings shall furnish to the Company a
completed and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">vi. <U>Damages</U>.
Should the registration or the effectiveness thereof required by Sections 5(a) hereof be delayed by the Company or the Company otherwise
fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to the Holder(s),
be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened breach of such provisions
or the continuation of any such breach, without the necessity of proving actual damages and without the necessity of posting bond or other
security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 6. Miscellaneous</U>.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">a) <U>No
Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as
a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any certificate relating to the Warrant Shares, and in case of
loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">d) <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Ordinary Shares a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Ordinary Shares may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which
results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs
and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the
Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">h) <U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Ordinary Shares or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(<I>Signature Page Follows</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TO:&#9;INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(1) The undersigned hereby elects
to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders
herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(2) Payment shall take the form
of (check applicable box):</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
in lawful money of the United States; or</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(3) Please register and issue
said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp; &nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Warrant Shares shall be delivered to the following DWAC Account
Number or by physical delivery of a certificate to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(4) <U>Accredited Investor</U>.
If the Warrant is being exercised via cash exercise, the undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation
D promulgated under the Securities Act of 1933, as amended</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%">Name of Investing Entity:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 54%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><I>Signature of Authorized Signatory of Investing Entity</I>:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT B</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(To assign the foregoing warrant, execute</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">this form and supply required information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Do not use this form to exercise the warrant.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">FOR VALUE RECEIVED, [____] all
of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_______________________________________________ whose address is</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_______________________________________________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_______________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dated: ______________, _______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">Holder&rsquo;s Signature:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Holder&rsquo;s Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">NOTE: The signature to this Assignment Form must correspond with the
name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever. Officers of corporations and
those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>3
<FILENAME>ea143325ex4-5_inspiratech.htm
<DESCRIPTION>FORM OF WARRANT AGENT AGREEMENT FOR PRE-FUNDED WARRANTS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 4.5</B></FONT></P>

<P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WARRANT
AGENT AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
WARRANT AGENT AGREEMENT (this &ldquo;<U>Warrant Agreement</U>&rdquo;) dated as of [&nbsp;&nbsp;], 2021 (the &ldquo;<U>Issuance Date</U>&rdquo;)
is between Inspira Technologies Oxy B.H.N. Ltd., an Israeli corporation (the &ldquo;<U>Company</U>&rdquo;), and VStock Transfer LLC (the
&ldquo;<U>Warrant Agent</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
pursuant to the terms of that certain Underwriting Agreement (&ldquo;<U>Underwriting Agreement</U>&rdquo;), dated [&nbsp;&nbsp;], 2021,
by and among the Company and Aegis Capital Corp., as the representative (the &ldquo;<U>Representative</U>&rdquo;) of the underwriters
set forth therein, the Company is engaged in a public offering of [&nbsp;&nbsp;] units (each, a &ldquo;<U>Unit</U>&rdquo;), with each
Unit consisting of either: (A) one ordinary share, par value NIS 0.125 per share (each, an &ldquo;<U>Ordinary Share</U>&rdquo;), and
one warrant (each, a &ldquo;<U>Warrant</U>&rdquo;) to purchase one Ordinary Share at an exercise price of $______&nbsp;(representing
100% of the per Unit offering price set forth on the cover page of the Registration Statement); or (B) one pre-funded warrant (each,
a &ldquo;<U>Pre-Funded Warrant&rdquo;)&nbsp;</U>to purchase one Ordinary Share at an exercise price of $0.01 until such time as the Pre-Funded
Warrant is exercised in full, subject to adjustment as provided in the Pre-Funded Warrant, and one Warrant;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company has filed with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) a Registration Statement on Form
F-1 (File No. 333-253920) (as the same may be amended from time to time, the &ldquo;<U>Registration Statement</U>&rdquo;), for the registration
under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), of the Ordinary Shares, Units, Pre-funded Warrants,
Warrants, and shares underlying Pre-funded Warrants and Warrants, and such Registration Statement was declared effective on [], 2021;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in accordance with
the terms set forth in this Warrant Agreement in connection with the issuance, registration, transfer, exchange and exercise of the Pre-Funded
Warrants;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company desires to provide for the provisions of the Pre-Funded Warrants, the terms upon which they shall be issued and exercised,
and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Pre-Funded
Warrants; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
all acts and things have been done and performed which are necessary to make the Pre-Funded Warrants the valid, binding and legal obligations
of the Company, and to authorize the execution and delivery of this Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Appointment of Warrant Agent</U>. The Company hereby appoints the Warrant Agent to act as agent for the Company with respect to the
Pre-Funded Warrants, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the express
terms and conditions set forth in this Warrant Agreement (and no implied terms or conditions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Pre-Funded Warrants</U>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.
<U>Form of Pre-Funded Warrants</U>. The Pre-Funded Warrants shall be registered securities and shall be evidenced by a global pre-funded
warrant (&ldquo;<U>Global Pre-Funded Warrant</U>&rdquo;) in the form of <U>Exhibit A</U> to this Warrant Agreement, which shall be deposited
on behalf of the Company with a custodian for The Depository Trust Company (&ldquo;<U>DTC</U>&rdquo;) and registered in the name of Cede
&amp; Co., a nominee of DTC. The terms of the Global Pre-Funded Warrant are incorporated herein by reference. If DTC subsequently ceases
to make its book-entry settlement system available for the Pre-Funded Warrants, the Company may instruct the Warrant Agent regarding
making other arrangements for book-entry settlement. In the event that the Pre-Funded Warrants are not eligible for, or it is no longer
necessary to have the Pre-Funded Warrants available in, book-entry form, the Company may instruct the Warrant Agent to provide written
instructions to DTC to deliver to the Warrant Agent for cancellation the Global Pre-Funded Warrant, and the Company shall instruct the
Warrant Agent to deliver to DTC separate certificates evidencing Pre-Funded Warrants (&ldquo;Definitive Certificates&rdquo; and, together
with the Global Pre-Funded Warrant, &ldquo;Warrant Certificates&rdquo;) registered as requested through the DTC system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.
<U>Issuance and Registration of Pre-Funded Warrants</U>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.
<U>Warrant Register</U>. The Warrant Agent shall maintain books (&ldquo;<U>Warrant Register</U>&rdquo;) for the registration of original
issuance and the registration of transfer of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.2.
<U>Issuance of Pre-Funded Warrants</U>. Upon the initial issuance of the Pre-Funded Warrants, the Warrant Agent shall issue the Global
Pre-Funded Warrant and deliver the Pre-Funded Warrants in the DTC book-entry settlement system in accordance with written instructions
delivered to the Warrant Agent by the Company. Ownership of security entitlements in the Pre-Funded Warrants shall be shown on, and the
transfer of such ownership shall be effected through, records maintained (i) by DTC and (ii) by institutions that have accounts with
DTC (each, a &ldquo;<U>Participant</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.3.
<U>Beneficial Owner; Holder</U>. Prior to due presentment for registration of transfer of any Pre-Funded Warrant, the Company and the
Warrant Agent may deem and treat the person in whose name that Pre-Funded Warrant shall be registered on the Warrant Register (the &ldquo;<U>Holder</U>&rdquo;)
as the absolute owner of such Pre-Funded Warrant for purposes of any exercise thereof, and for all other purposes, and neither the Company
nor the Pre-Funded Warrant Agent shall be affected by any notice to the contrary. Notwithstanding the foregoing, nothing herein shall
prevent the Company, the Warrant Agent or any agent of the Company or the Warrant Agent from giving effect to any written certification,
proxy or other authorization furnished by DTC governing the exercise of the rights of a holder of a beneficial interest in any Pre-Funded
Warrant. The rights of beneficial owners in a Pre-Funded Warrant evidenced by the Global Pre-Funded Warrant shall be exercised by the
Holder or a Participant through the DTC system, except to the extent set forth herein or in the Global Pre-Funded Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.4.
<U>Delivery of Warrant Certificate</U>. A Holder has the right to elect at any time or from time to time a Warrant Exchange (as defined
below) pursuant to a Warrant Certificate Request Notice (as defined below). Upon written notice by a Holder to the Warrant Agent for
the exchange of some or all of such Holder&rsquo;s Global Pre-Funded Warrants for a Warrant Certificate evidencing the same number of
Pre-Funded Warrants, which request shall be in the form attached hereto as <U>Exhibit B</U> (a &ldquo;<U>Warrant Certificate Request
Notice</U>&rdquo; and the date of delivery of such Warrant Certificate Request Notice by the Holder, the &ldquo;<U>Warrant Certificate
Request Notice Date</U>&rdquo; and the deemed surrender upon delivery by the Holder of a number of Global Pre-Funded Warrants for the
same number of Pre-Funded Warrants evidenced by a Warrant Certificate, a &ldquo;<U>Warrant Exchange</U>&rdquo;), the Warrant Agent shall
promptly effect the Warrant Exchange and shall promptly issue and deliver to the Holder a Warrant Certificate for such number of Pre-Funded
Warrants in the name set forth in the Warrant Certificate Request Notice. Such Warrant Certificate shall be dated the date of issuance
of the Warrant Certificate, shall include the initial exercise date of the Pre-Funded Warrants, shall be executed by an authorized signatory
of the Company and shall be reasonably acceptable in all respects to such Holder. In connection with a Warrant Exchange, the Company
agrees to deliver, or to direct the Warrant Agent to deliver, the Warrant Certificate to the Holder within three (3) Business Days of
the Warrant Certificate Request Notice pursuant to the delivery instructions in the Warrant Certificate Request Notice (&ldquo;<U>Warrant
Certificate Delivery Date</U>&rdquo;). If the Company fails for any reason to deliver to the Holder the Warrant Certificate subject to
the Warrant Certificate Request Notice by the Warrant Certificate Delivery Date, the Company shall pay to the Holder, in cash, as liquidated
damages and not as a penalty, for each $1,000 of Ordinary Shares issuable upon exercise of the Pre-Funded Warrants (the &ldquo;<U>Warrant
Shares</U>&rdquo;) evidenced by such Warrant Certificate (based on the VWAP (as defined in the Pre-Funded Warrants) of the Ordinary Shares
on the Warrant Certificate Request Notice Date), $10 per Business Day for each Business Day after such Warrant Certificate Delivery Date
until such Warrant Certificate is delivered or, prior to delivery of such Warrant Certificate, the Holder rescinds such Warrant Exchange.
The Company covenants and agrees that, upon the date of delivery of the Warrant Certificate Request Notice, the Holder shall be deemed
to be the holder of the Warrant Certificate and, notwithstanding anything to the contrary set forth herein, the Warrant Certificate shall
be deemed for all purposes to contain all of the terms and conditions of the Pre-Funded Warrants evidenced by such Warrant Certificate
and the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.5.
<U>Execution</U>. The Warrant Certificates shall be executed on behalf of the Company by any authorized officer of the Company (an &ldquo;<U>Authorized
Officer</U>&rdquo;), which need not be the same authorized signatory for all of the Warrant Certificates, either manually or by facsimile
signature. The Warrant Certificates shall be countersigned by an authorized signatory of the Warrant Agent, which need not be the same
signatory for all of the Warrant Certificates, and no Warrant Certificate shall be valid for any purpose unless so countersigned. In
case any Authorized Officer of the Company that signed any of the Warrant Certificates ceases to be an Authorized Officer of the Company
before countersignature by the Warrant Agent and issuance and delivery by the Company, such Warrant Certificates, nevertheless, may be
countersigned by the Warrant Agent, issued and delivered with the same force and effect as though the person who signed such Warrant
Certificates had not ceased to be such officer of the Company; and any Warrant Certificate may be signed on behalf of the Company by
any person who, at the actual date of the execution of such Warrant Certificate, shall be an Authorized Officer of the Company authorized
to sign such Warrant Certificate, although at the date of the execution of this Warrant Agreement any such person was not such an Authorized
Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.6.
<U>Registration of Transfer</U>. At any time at or prior to the Expiration Date (as defined below), a transfer of any Pre-Funded Warrants
may be registered and any Warrant Certificate or Warrant Certificates may be split up, combined or exchanged for another Warrant Certificate
or Warrant Certificates evidencing the same number of Pre-Funded Warrants as the Warrant Certificate or Warrant Certificates surrendered.
Any Holder desiring to register the transfer of Pre-Funded Warrants or to split up, combine or exchange any Warrant Certificate shall
make such request in writing delivered to the Warrant Agent, and shall surrender to the Warrant Agent the Warrant Certificate or Warrant
Certificates evidencing the Pre-Funded Warrants the transfer of which is to be registered or that is or are to be split up, combined
or exchanged and, in the case of registration of transfer, shall provide a signature guarantee. Thereupon, the Warrant Agent shall countersign
and deliver to the person entitled thereto a Warrant Certificate or Warrant Certificates, as the case may be, as so requested. The Company
and the Warrant Agent may require payment, by the Holder requesting a registration of transfer of Pre-Funded Warrants or a split-up,
combination or exchange of a Warrant Certificate (but, for purposes of clarity, not upon the exercise of the Pre-Funded Warrants and
issuance of Warrant Shares to the Holder), of a sum sufficient to cover any tax or governmental charge that may be imposed in connection
with such registration of transfer, split-up, combination or exchange, together with reimbursement to the Company and the Warrant Agent
of all reasonable expenses incidental thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.7.
<U>Loss, Theft and Mutilation of Warrant Certificates</U>. Upon receipt by the Company and the Warrant Agent of evidence reasonably satisfactory
to them of the loss, theft, destruction or mutilation of a Warrant Certificate, and, in case of loss, theft or destruction, of indemnity
or security in customary form and amount, and reimbursement to the Company and the Warrant Agent of all reasonable expenses incidental
thereto, and upon surrender to the Warrant Agent and cancellation of the Warrant Certificate if mutilated, the Warrant Agent shall, on
behalf of the Company, countersign and deliver a new Warrant Certificate of like tenor to the Holder in lieu of the Warrant Certificate
so lost, stolen, destroyed or mutilated. The Warrant Agent may charge the Holder an administrative fee for processing the replacement
of lost Warrant Certificates, The Warrant Agent may receive compensation from the surety companies or surety agents for administrative
services provided to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.8.
<U>Proxies</U>. The Holder of a Warrant may grant proxies or otherwise authorize any person, including the Participants and beneficial
holders that may own interests through the Participants, to take any action that a Holder is entitled to take under this Agreement or
the Pre-Funded Warrants; <U>provided</U>, <U>however</U>, that at all times that Pre-Funded Warrants are evidenced by a Global Pre-Funded
Warrant, exercise of those Pre-Funded Warrants shall be effected on their behalf by Participants through DTC in accordance the procedures
administered by DTC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Terms and Exercise of Pre-Funded Warrants</U>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.
<U>Exercise Price</U>. Each Pre-Funded Warrant shall entitle the Holder, subject to the provisions of the applicable Warrant Certificate
and of this Warrant Agreement, to purchase from the Company the number of Ordinary Shares stated therein, at the price of $[&nbsp;&nbsp;]
per whole share, subject to the subsequent adjustments provided in the Global Pre-Funded Warrant. The term &ldquo;<U>Exercise Price</U>&rdquo;
as used in this Warrant Agreement refers to the price per share at which Ordinary Shares may be purchased at the time a Pre-Funded Warrant
is exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.
<U>Duration of Pre-Funded Warrants</U>. A Pre-Funded Warrant may be exercised only during the period (&ldquo;<U>Exercise Period</U>&rdquo;)
commencing on the date of issuance and ending on the Termination Date. For purposes of this Warrant Agreement, the &ldquo;<U>Termination
Date</U><B>&rdquo; </B>shall have the meaning set forth in the Global Pre-Funded Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.
<U>Exercise of Pre-Funded Warrants</U>.</FONT></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.1.
<U>Exercise</U>. Subject to the provisions of the Global Pre-Funded Warrant, a Holder (or a Participant or a designee of a Participant
acting on behalf of a Holder) may exercise Pre-Funded Warrants by delivering to the Warrant Agent, (i) not later than 5:00 P.M., Eastern
Standard Time, on any business day during the Exercise Period a notice of exercise of the Pre-Funded Warrants to be exercised (A) in
the form attached to the Global Pre-Funded Warrant or (B) via an electronic warrant exercise through the DTC system (each, an &ldquo;<U>Election
to Purchase</U>&rdquo;) and (ii) within one (1) Trading Day of the Date of Exercise, Pre-funded Warrants to be exercised by (A) surrender
of the Warrant Certificate evidencing the Pre-funded Warrants to the Warrant Agent at its office designated for such purpose or (B) delivery
of the Warrants to an account of the Warrant Agent at DTC designated for such purpose in writing by the Warrant Agent to DTC from time
to time. Partial exercises of a Pre-funded Warrant resulting in purchases of a portion of the total number of Warrant Shares available
thereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the
applicable number of Warrant Shares purchased. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender a Warrant Certificate until the Holder has purchased all of the Warrant Shares available thereunder and the Pre-funded Warrant
has been exercised in full, in which case, the Holder shall surrender such Pre-funded Warrant to the Company for cancellation within
three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company.. All other requirements for the exercise
of a Pre-Funded Warrant shall be as set forth in the Pre-Funded Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.2.
The Warrant Agent shall, by 5:00 p.m., New York City time, on the Trading Day following the Exercise Date of any Pre-Funded Warrant,
advise the Company, the transfer agent and registrar for the Company&rsquo;s Ordinary Shares, in respect of (i) the number of Warrant
Shares indicated on the Notice of Exercise as issuable upon such exercise with respect to such exercised Pre-Funded Warrants, (ii) the
instructions of the Holder or Participant, as the case may be, provided to the Warrant Agent with respect to the delivery of the Warrant
Shares and the number of Pre-Funded Warrants that remain outstanding after such exercise and (iii) such other information as the Company
or such transfer agent and registrar shall reasonably request. The Company shall issue the Warrant Shares in compliance with the terms
of the Pre-Funded Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.3.
<U>Valid Issuance</U>. All Warrant Shares issued by the Company upon the proper exercise of a Pre-Funded Warrant in conformity with this
Warrant Agreement shall be validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.4.
<U>No Fractional Exercise</U>. Notwithstanding any provision contained in this Warrant Agreement to the contrary, no fractional shares
or scrip representing fractional shares shall be issued upon the exercise of the Pre-Funded Warrants. As to any fraction of a share which
the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment
in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole
share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.5.
<U>No Transfer Taxes</U>. The Company shall not be required to pay any stamp or other tax or governmental charge required to be paid
in connection with any transfer involved in the issue of the Warrant Shares upon the exercise of Pre-Funded Warrants; and in the event
that any such transfer is involved, the Company shall not be required to issue or deliver any Warrant Shares until such tax or other
charge shall have been paid or it has been established to the Company&rsquo;s satisfaction that no such tax or other charge is due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.6.
<U>Date of Issuance</U>. The Company will treat an exercising Holder as a beneficial owner of the Warrant Shares as of the Exercise Date,
and for purposes of Regulation SHO, a holder whose interest in the Pre-Funded Warrant is a beneficial interest in certificate(s) representing
the Pre-Funded Warrant held in book-entry form through DTC shall be deemed to have exercised its interest in the Pre-Funded Warrant upon
instructing its broker that is a DTC participant to exercise its interest in the Pre-Funded Warrant, except that, if the Exercise Date
is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares
at the open of business on the next succeeding date on which the stock transfer books are open.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Adjustments</U>. Upon every adjustment of the Exercise Price or the number of Warrant Shares issuable upon exercise of a Pre-Funded
Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Exercise Price resulting from
such adjustment and the increase or decrease, if any, in the number of Warrant Shares purchasable at such price upon the exercise of
a Pre-Funded Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based.
Upon the occurrence of any event specified in Section 3 of the Pre-Funded Warrant, then, in any such event, the Company shall give written
notice to the Warrant Agent. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event.
The Warrant Agent shall be entitled to rely conclusively on, and shall be fully protected in relying on, any certificate, notice or instructions
provided by the Company with respect to any adjustment of the Exercise Price or the number of shares issuable upon exercise of a Pre-Funded
Warrant, or any related matter, and the Warrant Agent shall not be liable for any action taken, suffered or omitted to be taken by it
in accordance with any such certificate, notice or instructions or pursuant to this Warrant Agreement. The Warrant Agent shall not be
deemed to have knowledge of any such adjustment unless and until it shall have received written notice thereof from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Restrictive Legends; Fractional Pre-Funded Warrants</U>. In the event that a Warrant Certificate surrendered for transfer bears a
restrictive legend, the Warrant Agent shall not register that transfer until the Warrant Agent has received an opinion of counsel for
the Company stating that such transfer may be made and indicating whether the Pre-Funded Warrants must also bear a restrictive legend
upon that transfer. The Warrant Agent shall not be required to effect any registration of transfer or exchange which will result in the
transfer of or delivery of a Warrant Certificate for a fraction of a Pre-Funded Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Other Provisions Relating to Rights of Holders of Pre-Funded Warrants</U>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.
<U>No Rights as Stockholder</U>. Except as otherwise specifically provided herein, a Holder, solely in its capacity as a Holder of Pre-Funded
Warrants, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose,
nor shall anything contained in this Warrant Agreement be construed to confer upon a Holder, solely in its capacity as the registered
holder of Pre-Funded Warrants, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any
corporate action (whether any reorganization, issue of stock, reclassification of share capital, consolidation, merger, conveyance or
otherwise), receive notice of meetings, receive dividends or subscription rights or rights to participate in new issues of shares, or
otherwise, prior to the issuance to the Holder of the Warrant Shares which it is then entitled to receive upon the due exercise of Pre-Funded
Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2.
<U>Reservation of Ordinary Shares</U>. The Company shall at all times reserve and keep available a number of its authorized but unissued
Ordinary Shares that will be sufficient to permit the exercise in full of all outstanding Pre-Funded Warrants issued pursuant to this
Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Concerning the Warrant Agent and Other Matters</U>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.
Any instructions given to the Warrant Agent orally, as permitted by any provision of this Warrant Agreement, shall be confirmed in writing
by the Company as soon as practicable. The Warrant Agent shall not be liable or responsible and shall be fully authorized and protected
for acting, or failing to act, in accordance with any oral instructions which do not conform with the written confirmation received in
accordance with this Section 7.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2.
(a) Whether or not any Pre-Funded Warrants are exercised, for the Warrant Agent&rsquo;s services as agent for the Company hereunder,
the Company shall pay to the Warrant Agent such fees as may be separately agreed between the Company and Warrant Agent and the Warrant
Agent&rsquo;s out of pocket expenses in connection with this Warrant Agreement, including, without limitation, the fees and expenses
of the Warrant Agent&rsquo;s counsel. While the Warrant Agent endeavors to maintain out-of-pocket charges (both internal and external)
at competitive rates, these charges may not reflect actual out-of-pocket costs, and may include handling charges to cover internal processing
and use of the Warrant Agent&rsquo;s billing systems. (b) All amounts owed by the Company to the Warrant Agent under this Warrant Agreement
are due within 30 days of the invoice date. Delinquent payments are subject to a late payment charge of one and one-half percent (1.5%)
per month commencing 45 days from the invoice date. The Company agrees to reimburse the Warrant Agent for any attorney&rsquo;s fees and
any other costs associated with collecting delinquent payments. (c) No provision of this Warrant Agreement shall require Warrant Agent
to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties under this Warrant
Agreement or in the exercise of its rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3.
As agent for the Company hereunder the Warrant Agent: (a) shall have no duties or obligations other than those specifically set forth
herein or as may subsequently be agreed to in writing by the Warrant Agent and the Company; (b) shall be regarded as making no representations
and having no responsibilities as to the validity, sufficiency, value, or genuineness of the Pre-Funded Warrants or any Warrant Shares;
(c) shall not be obligated to take any legal action hereunder; if, however, the Warrant Agent determines to take any legal action hereunder,
and where the taking of such action might, in its judgment, subject or expose it to any expense or liability it shall not be required
to act unless it has been furnished with an indemnity reasonably satisfactory to it; (d) may rely on and shall be fully authorized and
protected in acting or failing to act upon any certificate, instrument, opinion, notice, letter, telegram, telex, facsimile transmission
or other document or security delivered to the Warrant Agent and believed by it to be genuine and to have been signed by the proper party
or parties; (e) shall not be liable or responsible for any recital or statement contained in the Registration Statement or any other
documents relating thereto; (f) shall not be liable or responsible for any failure on the part of the Company to comply with any of its
covenants and obligations relating to the Pre-Funded Warrants, including without limitation obligations under applicable securities laws;
(g) may rely on and shall be fully authorized and protected in acting or failing to act upon the written, telephonic or oral instructions
with respect to any matter relating to its duties as Warrant Agent covered by this Warrant Agreement (or supplementing or qualifying
any such actions) of officers of the Company, and is hereby authorized and directed to accept instructions with respect to the performance
of its duties hereunder from the Company or counsel to the Company, and may apply to the Company, for advice or instructions in connection
with the Warrant Agent&rsquo;s duties hereunder, and the Warrant Agent shall not be liable for any delay in acting while waiting for
those instructions; any applications by the Warrant Agent for written instructions from the Company may, at the option of the Agent,
set forth in writing any action proposed to be taken or omitted by the Warrant Agent under this Warrant Agreement and the date on or
after which such action shall be taken or such omission shall be effective; the Warrant Agent shall not be liable for any action taken
by, or omission of, the Warrant Agent in accordance with a proposal included in such application on or after the date specified in such
application (which date shall not be less than five business days after the date such application is sent to the Company, unless the
Company shall have consented in writing to any earlier date) unless prior to taking any such action, the Warrant Agent shall have received
written instructions in response to such application specifying the action to be taken or omitted; (h) may consult with counsel satisfactory
to the Warrant Agent, including its in- house counsel, and the advice of such counsel shall be full and complete authorization and protection
in respect of any action taken, suffered, or omitted by it hereunder in good faith and in accordance with the advice of such counsel;
(i) may perform any of its duties hereunder either directly or by or through nominees, correspondents, designees, or subagents, and it
shall not be liable or responsible for any misconduct or negligence on the part of any nominee, correspondent, designee, or subagent
appointed with reasonable care by it in connection with this Warrant Agreement; (j) is not authorized, and shall have no obligation,
to pay any brokers, dealers, or soliciting fees to any person; and (k) shall not be required hereunder to comply with the laws or regulations
of any country other than the United States of America or any political subdivision thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4.
(a) In the absence of gross negligence or willful or illegal misconduct on its part, the Warrant Agent shall not be liable for any action
taken, suffered, or omitted by it or for any error of judgment made by it in the performance of its duties under this Warrant Agreement.
Anything in this Warrant Agreement to the contrary notwithstanding, in no event shall Warrant Agent be liable for special, indirect,
incidental, consequential or punitive losses or damages of any kind whatsoever (including but not limited to lost profits), even if the
Warrant Agent has been advised of the possibility of such losses or damages and regardless of the form of action. Any liability of the
Warrant Agent will be limited in the aggregate to the amount of fees paid by the Company hereunder. The Warrant Agent shall not be liable
for any failures, delays or losses, arising directly or indirectly out of conditions beyond its reasonable control including, but not
limited to, acts of government, exchange or market ruling, suspension of trading, work stoppages or labor disputes, fires, civil disobedience,
riots, rebellions, storms, electrical or mechanical failure, computer hardware or software failure, communications facilities failures
including telephone failure, war, terrorism, insurrection, earthquakes, floods, acts of God or similar occurrences. (b) In the event
any question or dispute arises with respect to the proper interpretation of the Pre-Funded Warrants or the Warrant Agent&rsquo;s duties
under this Warrant Agreement or the rights of the Company or of any Holder, the Warrant Agent shall not be required to act and shall
not be held liable or responsible for its refusal to act until the question or dispute has been judicially settled (and, if appropriate,
it may file a suit in interpleader or for a declaratory judgment for such purpose) by final judgment rendered by a court of competent
jurisdiction, binding on all persons interested in the matter which is no longer subject to review or appeal, or settled by a written
document in form and substance satisfactory to Warrant Agent and executed by the Company and each such Holder. In addition, the Warrant
Agent may require for such purpose, but shall not be obligated to require, the execution of such written settlement by all the Holders
and all other persons that may have an interest in the settlement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5.
The Company covenants to indemnify the Warrant Agent and hold it harmless from and against any loss, liability, claim or expense (&ldquo;<U>Loss</U>&rdquo;)
arising out of or in connection with the Warrant Agent&rsquo;s duties under this Warrant Agreement, including the costs and expenses
of defending itself against any Loss, unless such Loss shall have been determined by a court of competent jurisdiction to be a result
of the Warrant Agent&rsquo;s gross negligence or willful misconduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6.
Unless terminated earlier by the parties hereto, this Agreement shall terminate 90 days after the earlier of the Expiration Date and
the date on which no Pre-Funded Warrants remain outstanding (the &ldquo;<U>Agreement Termination Date</U>&rdquo;). On the business day
following the Agreement Termination Date, the Agent shall deliver to the Company any entitlements, if any, held by the Warrant Agent
under this Warrant Agreement. The Agent&rsquo;s right to be reimbursed for fees, charges and out- of-pocket expenses as provided in this
Section 8 shall survive the termination of this Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7.
If any provision of this Warrant Agreement shall be held illegal, invalid, or unenforceable by any court, this Warrant Agreement shall
be construed and enforced as if such provision had not been contained herein and shall be deemed an Agreement among the parties to it
to the full extent permitted by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8.
The Company represents and warrants that: (a) it is duly incorporated and validly existing under the laws of its jurisdiction of incorporation;
(b) the offer and sale of the Pre-Funded Warrants and the execution, delivery and performance of all transactions contemplated thereby
(including this Warrant Agreement) have been duly authorized by all necessary corporate action and will not result in a breach of or
constitute a default under the articles of association, bylaws or any similar document of the Company or any indenture, agreement or
instrument to which it is a party or is bound; (c) this Warrant Agreement has been duly executed and delivered by the Company and constitutes
the legal, valid, binding and enforceable obligation of the Company; (d) the Pre-Funded Warrants will comply in all material respects
with all applicable requirements of law; and (e) to the best of its knowledge, there is no litigation pending or threatened as of the
date hereof in connection with the offering of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.9.
In the event of inconsistency between this Warrant Agreement and the descriptions in the Pre-Funded Warrant, as it may from time to time
be amended, the terms of this Warrant Agreement shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10.
Set forth in <U>Exhibit C</U> hereto is a list of the names and specimen signatures of the persons authorized to act for the Company
under this Warrant Agreement (the &ldquo;<U>Authorized Representatives</U>&rdquo;). The Company shall, from time to time, certify to
you the names and signatures of any other persons authorized to act for the Company under this Warrant Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.11.
Except as expressly set forth elsewhere in this Warrant Agreement, all notices, instructions and communications under this Agreement
shall be in writing, shall be effective upon receipt and shall be addressed, if to the Company, to its address set forth beneath its
signature to this Agreement, or, if to the Warrant Agent, to VStock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598, or to such
other address of which a party hereto has notified the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.12.
(a) This Warrant Agreement shall be governed by and construed in accordance with the laws of the State of New York. All actions and proceedings
relating to or arising from, directly or indirectly, this Warrant Agreement may be litigated in courts located within the Borough of
Manhattan in the City and State of New York. The Company hereby submits to the personal jurisdiction of such courts and consents that
any service of process may be made by certified or registered mail, return receipt requested, directed to the Company at its address
last specified for notices hereunder. Each of the parties hereto hereby waives the right to a trial by jury in any action or proceeding
arising out of or relating to this Warrant Agreement. (b) This Warrant Agreement shall inure to the benefit of and be binding upon the
successors and assigns of the parties hereto. This Warrant Agreement may not be assigned, or otherwise transferred, in whole or in part,
by either party without the prior written consent of the other party, which the other party will not unreasonably withhold, condition
or delay; except that (i) consent is not required for an assignment or delegation of duties by Warrant Agent to any affiliate of Warrant
Agent and (ii) any reorganization, merger, consolidation, sale of assets or other form of business combination by Warrant Agent or the
Company shall not be deemed to constitute an assignment of this Warrant Agreement. (c) No provision of this Warrant Agreement may be
amended, modified or waived, except in a written document signed by both parties. The Company and the Warrant Agent may amend or supplement
this Warrant Agreement without the consent of any Holder for the purpose of curing any ambiguity, or curing, correcting or supplementing
any defective provision contained herein or adding or changing any other provisions with respect to matters or questions arising under
this Agreement as the parties may deem necessary or desirable and that the parties determine, in good faith, shall not adversely affect
the interest of the Holders. All other amendments and supplements shall require the vote or written consent of Holders of at least 50.1%
of the then outstanding Pre-Funded Warrants, provided that adjustments may be made to the Pre-Funded Warrant terms and rights in accordance
with Section 4 without the consent of the Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.13.
<U>Payment of Taxes</U>. The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company or
the Warrant Agent in respect of the issuance or delivery of Warrant Shares upon the exercise of Pre-Funded Warrants, but the Company
may require the Holders to pay any transfer taxes in respect of the Pre-Funded Warrants or such shares. The Warrant Agent may refrain
from registering any transfer of Pre-Funded Warrants or any delivery of any Warrant Shares unless or until the persons requesting the
registration or issuance shall have paid to the Warrant Agent for the account of the Company the amount of such tax or charge, if any,
or shall have established to the reasonable satisfaction of the Company and the Warrant Agent that such tax or charge, if any, has been
paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.14.
<U>Resignation of Warrant Agent</U>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.14.1.
<U>Appointment of Successor Warrant Agent</U>. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and
be discharged from all further duties and liabilities hereunder after giving thirty (30) days&rsquo; notice in writing to the Company,
or such shorter period of time agreed to by the Company. The Company may terminate the services of the Warrant Agent, or any successor
Warrant Agent, after giving thirty (30) days&rsquo; notice in writing to the Warrant Agent or successor Warrant Agent, or such shorter
period of time as agreed. If the office of the Warrant Agent becomes vacant by resignation, termination or incapacity to act or otherwise,
the Company shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such
appointment within a period of 30 days after it has been notified in writing of such resignation or incapacity by the Warrant Agent,
then the Warrant Agent or any Holder may apply to any court of competent jurisdiction for the appointment of a successor Warrant Agent
at the Company&rsquo;s cost. Pending appointment of a successor to such Warrant Agent, either by the Company or by such a court, the
duties of the Warrant Agent shall be carried out by the Company. Any successor Warrant Agent (but not including the initial Warrant Agent),
whether appointed by the Company or by such court, shall be a person organized and existing under the laws of any state of the United
States of America, in good standing, and authorized under such laws to exercise corporate trust powers and subject to supervision or
examination by federal or state authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers,
rights, immunities, duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent
hereunder, without any further act or deed, and except for executing and delivering documents as provided in the sentence that follows,
the predecessor Warrant Agent shall have no further duties, obligations, responsibilities or liabilities hereunder, but shall be entitled
to all rights that survive the termination of this Warrant Agreement and the resignation or removal of the Warrant Agent, including but
not limited to its right to indemnity hereunder. If for any reason it becomes necessary or appropriate or at the request of the Company,
the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor
Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant
Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting
in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.14.2.
<U>Notice of Successor Warrant Agent</U>. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof
to the predecessor Warrant Agent and the transfer agent for the Ordinary Shares not later than the effective date of any such appointment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.14.3.
<U>Merger or Consolidation of Warrant Agent</U>. Any person into which the Warrant Agent may be merged or converted or with which it
may be consolidated or any person resulting from any merger, conversion or consolidation to which the Warrant Agent shall be a party
or any person succeeding to the shareowner services business of the Warrant Agent or any successor Warrant Agent shall be the successor
Warrant Agent under this Warrant Agreement, without any further act or deed. For purposes of this Warrant Agreement, &ldquo;person&rdquo;
shall mean any individual, firm, corporation, partnership, limited liability company, joint venture, association, trust or other entity,
and shall include any successor (by merger or otherwise) thereof or thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Miscellaneous Provisions</U>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.
<U>Persons Having Rights under this Warrant Agreement</U>. Nothing in this Warrant Agreement expressed and nothing that may be implied
from any of the provisions hereof is intended, or shall be construed, to confer upon, or give to, any person or corporation other than
the parties hereto any right, remedy, or claim under or by reason of this Warrant Agreement or of any covenant, condition, stipulation,
promise, or agreement hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.
<U>Examination of the Warrant Agreement</U>. A copy of this Warrant Agreement shall be available at all reasonable times at the office
of the Warrant Agent designated for such purpose for inspection by any Holder. Prior to such inspection, the Warrant Agent may require
any such holder to provide reasonable evidence of its interest in the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3.
<U>Counterparts</U>. This Warrant Agreement may be executed in any number of original, facsimile or electronic counterparts and each
of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one
and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.
<U>Effect of Headings</U>. The Section headings herein are for convenience only and are not part of this Warrant Agreement and shall
not affect the interpretation thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Certain Definitions</U>. As used herein, the following terms shall have the following meanings:</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&ldquo;<U>Trading Day</U>&rdquo; means any day on which the Ordinary Share is traded on the Trading Market, or, if the Trading Market
is not the principal trading market for the Ordinary Share, then on the principal securities exchange or securities market in the United
States on which the Ordinary Share is then traded, provided that &ldquo;Trading Day&rdquo; shall not include any day on which the Ordinary
Share is are scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Ordinary Share is suspended from
trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the
closing time of trading on such exchange or market, then during the hour ending at 4:00 P.M., Eastern Standard Time).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
&ldquo;<U>Trading Market</U>&rdquo; means NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select
Market or the New York Stock Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, this Warrant Agent Agreement has been duly executed by the parties hereto as of the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INSPIRA TECHNOLOGIES
    OXY B.H.N. LTD.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VSTOCK TRANSFER
    LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
A</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GLOBAL
PRE-FUNDED WARRANT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
B</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WARRANT
CERTIFICATE REQUEST NOTICE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:<U>____________</U>as
Warrant Agent for<U>____________</U>(the &ldquo;Company&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned Holder of Ordinary Shares Purchase Pre-Funded Warrants (&ldquo;Pre-Funded Warrants&rdquo;) in the form of Global Pre-Funded
Warrants issued by the Company hereby elects to receive a Warrant Certificate evidencing the Pre-Funded Warrants held by the Holder as
specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Holder
    of Pre-Funded Warrants in form of Global Pre-Funded Warrants:&nbsp;____________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Holder
    in Warrant Certificate (if different from name of Holder of Pre-Funded Warrants in form of Global Pre-Funded Warrants):&nbsp;____________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Pre-Funded Warrants in name of Holder in form of Global Pre-Funded Warrants:&nbsp;____________</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Pre-Funded Warrants
    for which Warrant Certificate shall be issued: ____________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Pre-Funded Warrants
    in name of Holder in form of Global Pre-Funded Warrants after issuance of Warrant Certificate, if any:&nbsp;___________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.</FONT></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Certificate shall be delivered to the following address:</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby acknowledges and agrees that, in connection with this Warrant Exchange and the issuance of the Warrant Certificate,
the Holder is deemed to have surrendered the number of Pre-Funded Warrants in form of Global Pre-Funded Warrants in the name of the Holder
equal to the number of Pre-Funded Warrants evidenced by the Warrant Certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: <U>______________________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: <U>________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: <U>__________________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ___________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
<U>______________________________________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBITC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUTHORIZED
REPRESENTATIVES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name</FONT></TD>
  <TD STYLE="padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
  <TD STYLE="padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joe Hayon</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">13</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>4
<FILENAME>ea143325ex5-2_inspiratec.htm
<DESCRIPTION>OPINION OF SULLIVAN & WORCESTER LLP, U.S. COUNSEL TO INSPIRA TECHNOLOGIES OXY B.H.N. LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex5-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">June 28, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inspira Technologies Oxy B.H.N. Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2 Ha-Tidhar St.,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ra&rsquo;anana, 4366504 Israel&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration Statement on Form F-1</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion is furnished
to you in connection with the Registration Statement on Form F-1 (Registration No. 333-253920) (as amended to date, the &ldquo;Registration
Statement&rdquo;) filed by Inspira Technologies Oxy B.H.N. Ltd., an Israeli company (the &ldquo;Company&rdquo;), with the Securities and
Exchange Commission (the &ldquo;Commission&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), for
the registration (including in connection with an over-allotment option granted to the Underwriter (as defined below)) and proposed maximum
aggregate offering price by the Company of up to $35,491,875 of (A) units (the &ldquo;Units&rdquo;), with each unit consisting of either
(1) (i) one ordinary share, no par value, of the Company (the &ldquo;Ordinary Shares&rdquo;) and (ii) a warrant (the &ldquo;Regular Warrant&rdquo;)
to purchase one Ordinary Share, or (2) (i) a pre-funded warrant (the &ldquo;Pre-Funded Warrant&rdquo; and together with the Regular Warrants,
the &ldquo;Warrants&rdquo;) to purchase one Ordinary Share and (ii) a Regular Warrant, and (B) warrants (the &ldquo;Underwriter Warrants&rdquo;
and together with the Units, the &ldquo;Securities&rdquo;) to purchase Ordinary Shares issued to the Underwriters (as defined below).
The Securities are being registered by the Company, which has engaged Aegis Capital Corp. (the &ldquo;Underwriter&rdquo;) to act as the
underwriter in connection with a public offering of the Company&rsquo;s Units (the &ldquo;Offering&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are acting as U.S. securities
counsel for the Company in connection with the Registration Statement. We have examined signed copies of the Registration Statement and
have also examined and relied upon minutes of meetings of the Board of Directors of the Company as provided to us by the Company, the
articles of association of the Company, as restated and/or amended to date, and such other documents as we have deemed necessary for purposes
of rendering the opinion hereinafter set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our examination of the
foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals,
the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents
and the legal competence of all signatories to such documents. Other than our examination of the documents indicated above, we have made
no other examination in connection with this opinion. Because the Warrants contain provisions stating that they are to be governed by
the laws of the State of New York, we are rendering this opinion as to New York law. We are admitted to practice in the State of New York,
and we express no opinion as to any matters governed by any law other than the law of the State of New York. With respect to the Ordinary
Shares and the Ordinary Shares underlying the Warrants being duly and validly issued, fully paid and non-assessable, we have relied on
the opinion of Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.) filed as an exhibit to the Registration Statement as filed with
the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon and subject to
the foregoing, we are of the opinion that, when the Registration Statement has become effective under the Securities Act, (i) each of
the Units and each of the Warrants comprising the Units, if and when issued and paid for in accordance with the terms of the Offering,
will be valid and binding obligations of the Company enforceable against the Company in accordance with their terms and (ii) the Underwriter
Warrants, if and when issued and paid for in accordance with the terms of the Offering, will be valid and binding obligations of the Company
enforceable against the Company in accordance with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The opinion set forth herein is rendered as of
the date hereof, and we assume no obligation to update such opinion to reflect any facts or circumstances which may hereafter come to
our attention or any changes in the law which may hereafter occur (which may have retroactive effect). In addition, the foregoing opinion
is qualified to the extent that (a) enforceability may be limited by and be subject to general principles of equity, regardless of whether
such enforceability is considered in a proceeding in equity or at law (including, without limitation, concepts of notice and materiality),
and by bankruptcy, insolvency, reorganization, moratorium and other similar laws affecting creditors&rsquo; and debtors&rsquo; rights
generally (including, without limitation, any state or federal law in respect of fraudulent transfers); and (b) no opinion is expressed
herein as to compliance with or the effect of federal or state securities or blue sky laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion is rendered to
you in connection with the Registration Statement. This opinion may not be relied upon for any other purpose, or furnished to, quoted
or relied upon by any other person, firm or corporation for any purpose, without our prior written consent, except that (A) this opinion
may be furnished or quoted to judicial or regulatory authorities having jurisdiction over you, and (B) this opinion may be relied upon
by purchasers and holders of (i) the Units (including the underlying Warrants) and (ii) the Underwriter Warrants, currently entitled to
rely on it pursuant to applicable provisions of federal securities law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to the filing
of this opinion as Exhibit 5.2 to the Registration Statement and to the reference to this firm under the caption &ldquo;Legal Matters&rdquo;
in the Registration Statement and in any Registration Statement pursuant to Rule 462(b) under the Securities Act. In giving such consent,
we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and
regulations of the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sullivan &amp; Worcester LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sullivan &amp; Worcester LLP</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>5
<FILENAME>ea143325ex10-8_inspiratec.htm
<DESCRIPTION>SHAREHOLDER LOAN AGREEMENT, DATED MARCH 1, 2018, BY AND BETWEEN THE COMPANY AND DAGI BEN-NOON
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.8</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SHAREHOLDER
LOAN AGREEMENT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SHAREHOLDER LOAN AGREEMENT (this &#8220;<B>Agreement</B>&#8221;) is made as of the 01 day of March 2018 (&#8220;<B>Effective Date</B>&#8221;),
by and among ClearX Medical Ltd. an Israeli company with registration number 51-580649-5 (the &#8220;<B>Company</B>&#8221;) and Mr. Dagi
Ben-Noon ID 033420969 (the &#8220;<B>Lender</B>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 10%"><B>WHEREAS</B>,</TD>
  <TD STYLE="width: 90%">the Company requires funds for its operation;
and</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><B>WHEREAS</B>, </TD>
  <TD STYLE="text-align: justify">the Company has applied to Lender for a loan,
the details of which are set forth herein, and Lender is willing to extend such loan to the Company, all pursuant to the terms and subject
to the conditions set forth herein</TD>
  </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the mutual agreements herein contained, and intending to be legally bound, Lender and the Company
agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Credit
                                            Framework.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
Upon the terms and conditions set forth in this agreement, and subject to any required corporate approvals, the Lender, at its sole discretion,
has provided and/or may provide to the Company, upon the Company&#8217;s request, funds up to an aggregate amount of up to 50,000 NIS
(the &#8220;<B>Loan Amount</B>&#8221;) as a loan, in one or more tranches.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
The Loan Amount shall not accrue any interest but shall be linked to the Consumer Price Index (CPI) of the Central Bureau of Statistics
in Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3
The Company shall utilize the Loan Amount for its ongoing business, as determined by its Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4
The Company shall not declare or pay any dividend or repay any loan or capital note to any third party, including Company&#8217;s shareholders,
before the full repayment of the Loan Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Repayment.</U></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
The Company may repay the Loan Amount hereunder to Lender at any time at its sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
Without derogating the above, upon the occurrence of any of the following events (each a &#8220;<B>Default Event</B>&#8221;), the entire
Loan Amount linked to the Consumer Price Index shall become immediately due and payable to the Lender:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.35pt"></TD><TD STYLE="width: 31pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
                                            the closing of a Qualified Financing. &#8220;<B>Qualified Financing</B>&#8221; shall mean
                                            a transaction or series of transactions in which the Company issues shares of the Company
                                            in consideration for an aggregate investment amount of no less than US$ 500,000.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.3pt"></TD><TD STYLE="width: 31pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Company earns a profit in the amount of no less than US$ 500,000 during 36 Month since
                                            the Effective Date.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
In the event of dissolution or liquidation, voluntary or otherwise, of the Company, the Lender shall be entitled to receive, without
any demand and prior to the distribution of any assets of the Company, an amount equal to the outstanding Loan Amount, linked to the
CPI for the period commencing on the disbursement date of each portion of the Loan Amount and until completion of payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4
The Loan Amount shall only be convertible upon the mutual agreement of the parties, and under such terms as mutually agreed between the
parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U>.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
Each party represents to the other that this Agreement, when executed and delivered by both parties, shall constitute the valid and
binding obligation of the representing party, and shall not (i) require the consent of any entity which has not been obtained, (ii)
create any third-party rights, or (iii) violate any agreement or instrument to which the representing party is a party, or its
incorporation documents as currently in effect, or any applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
Each party shall solely bear its expenses in connection with the execution of this Agreement and the transactions contemplated herein,
including (but not limited to) applicable taxes, fees and legal expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
Each of the parties hereto shall not assign or transfer any of its rights or obligations hereunder absent the consent of the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
This Agreement may not be amended, supplemented, discharged, terminated or altered except by a writing signed by the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5
The Preamble to this Agreement constitutes an integral part hereof. This Agreement constitutes the full and entire understanding and
agreement between the parties with regard to the subject matter hereof and supersedes all prior agreements between the parties hereof
with regard to such subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6
No failure or delay by any party to this Agreement to enforce at any time any of the provisions hereof, or to exercise any power or right
hereunder, shall operate as or be construed to be, a waiver of any such provision, power or right. Any waiver of any provision hereof
or any power or right hereunder shall be in writing and shall be effective only in the specific instance and for the purpose for which
given.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7
This Agreement shall be governed for all purposes by the laws of the State of Israel and the competent courts of Tel-Aviv shall have
exclusive jurisdiction over any dispute arising from or related to the performance or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8
If any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable under applicable law, then such provision
shall be excluded from this Agreement and the remainder of this Agreement shall be interpreted as if such provision were so excluded
and shall be enforceable in accordance with its terms, provided, however, that in such event this Agreement shall be interpreted so as
to give effect, to the greatest extent consistent with and permitted by applicable law, to the meaning and intention of the excluded
provision as determined by such court of competent jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original and enforceable against the parties
actually executing such counterpart, and all of which together shall constitute one and the same instrument. Signatures by facsimile
or signatures which have been scanned and transmitted by electronic mail shall be deemed valid and binding for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, this Agreement has been executed by the parties hereto as of the day and year first hereinabove written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 36%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <FONT STYLE="font: 10pt Times New Roman, Times, Serif">ClearX Medical Ltd.</FONT></FONT></TD>
  <TD STYLE="width: 28%"></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
  dagi ben-noon</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ClearX Medical Ltd.</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DAGI BEN-NOON</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: Udi Nussinovitch, Director</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ea143325ex23-1_inspiratec.htm
<DESCRIPTION>CONSENT OF ZIV HAFT, A MEMBER FIRM OF BDO, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right; text-indent: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0">&nbsp;<IMG SRC="ex23-1_001.jpg" ALT=""></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><U>INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM&rsquo;S CONSENT</U></P>

<P STYLE="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;&nbsp;</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0">We hereby consent to the use in this Registration
Statement on Form F-1 of INSPIRA TECHNOLOGIES OXY B.H.N LTD. of our report dated April 30, 2021, except for note 20.5, which is
dated June 4, 2021, included in the Prospectus. Our report contains an explanatory paragraph regarding the Company&rsquo;s ability
to continue as a going concern.</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0">We also consent to the reference to us under the caption &ldquo;Experts&rdquo;
in the Registration Statement.</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; width: 60%; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; width: 40%; text-align: center; text-indent: 0">/s/ Ziv Haft</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Certified Public Accountants (Isr.) &nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">BDO Member Firm</TD></TR>
  </TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0">Tel Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0">June 28, 2021</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>7
<FILENAME>ea143325ex99-3_inspiratech.htm
<DESCRIPTION>CONSENT OF LIMOR ROZEN AS DIRECTOR NOMINEE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
99.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">CONSENT
OF DIRECTOR NOMINEE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">I hereby
consent, pursuant to Rule 438 under the Securities Act of 1933, as amended, to being named as a nominee to the board of directors of
Inspira Technologies Oxy B.H.N. Ltd. in its Registration Statement on Form F-1, and any amendments or supplements thereto, and to the
filing or attachment of this consent with such Registration Statement and any amendment or supplement thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Limor Rozen</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limor Rozen</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 27, 2021</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !U / # 2(  A$! Q$!_\0
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M*]&UW1+/XT^ M)NM%U&&/4["/#02'HV &5AU'(&#7A?B+P1XB\*S%-6TR:%
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M(-LGE'+LO]WT ^E>644 %>^^(O\ DUK2/]Z+_P!&-7@5>^^(O^36M(_WHO\
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M(_(+AL%@>#FG<\[$8.=2M[2,K:6\^J_7O\CHK33=%@LH[J_@A NI'1@&=O*
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M%##*LRLS<E1U6@2":Y#W3,5/WB.M#6DR6J71 \MC@'-.DF-[<1^84C& N0.
M/6@",1-)(XA5F49/X4GF#R#'L&<YW=Z>^;>XD2"4L.FY>XI(S"() ZL93]PC
MH* $>+RXTD#J2W.!U%(&#R[I22#UH\B00";;^[)QFE>3SY5W[4& ,@4 -"%R
MVP$@<_A2;ODVX'UIS+LE9(WW#ID=Z0%!&P93O['TH 0KM (;.:3ZTXQLL:R<
M8)XI,[WRQQ0 W'&:*7!).W)%)0 4444 %%%% !1110!TES#)X0URUDMY5G<1
M"4>8G'S#IBJ+S-<S/-(!ND8L<# R:** -"]MK6/PY8W$<)6Y>1@\F[.X#VJI
MI=F=;URWM+B>3][D%\Y. />BB@"M-/<:7-?6-O.PB=S')Q]\ U UGLTZ.\#\
MLY7;CICWHHH ==7L^JW<;7#+NVB,%5Q@"DM[V;3GN(X=A$BF-BRYXHHH A$.
M;5IMW1@N,5)+=SWWV>&9P5C 1,#H*** )+E)=)U!D@F;<H^^!CJ*?I]BE[;7
MDTCMNB3<,=S[T44 9^XXQDX]*LW;1&*W\N$1G9\Q!SN/K110!%!.]K,)(\;A
MZC-36EL+UIV9RI52_ ZFBB@"KN;;MW';UQ4TQ0P0[8PK8Y.>M%% $:.T,@9#
MR*FMH1<&4N3D+NXHHH K4]F\S:-H7'''>BB@!9%,4A4-2 #RV..:** &>]+U
..-%% "4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #Y F@# 2(  A$! Q$!_\0
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M,]S<S101QL%/FR*K;><?LN/^#>G_ (+(M MP/V)O$X5H5G$9^)OP36X"M&)
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MHUWJ>A?LH>#]0E@:Z6*V?XK:Y&9_LHGE;!7P,[ -;6L\H;:5+&*)69S(L?\
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M;JNE6'BO2-9C\+RW-X=5TV\T&\TOQ3:#[),SZ%=Z=X@2+^S+BUO7_.KXU_\
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MKK>G"6>^\.Q2XO[>S@20K\TQ_LA_M8^#[+]L#P-\(_C1\&/!O@_X\^.OBO\
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M$/A[0]5T_0-'&F>(?$.H>'[?6=!EO^P_X;9_8CUCX>CXR-^T]^SGJ/PS\/\
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M_>GR?^EQA^9\X45T6N^$/%OA=VC\2>%O$6@,N=S:OHVH6,. <9%Q/;I;L,\
MI*P/8FN;5E<;D964]"I# _B"17#*$X2<)PG":WA.,H37K&<827_@)TQE&2O&
M49)[.+4E]\6U^(ZMG0/$.K^%]235]$N%M[V."XMR)8EGM[BWN8S'/;75O)\D
MT$JX#(V""%965E!K&HI)N+3BVFG=-.S36S3[H&DTTTFGHT]4T?L[\(?%.C^)
M/A=H8N;I9Y&TJ:VO(;B2[,$>G^((EFLYTM;>3S/)L[]'C+KN\F?30DF$DV5T
M7PVNKC2;F\\/R6]C8Z@FJ2&2+3 @D>R$$CL%N) "B2M+ RLB))MP \L3,LGQ
M%^R+<^*=9?5=.TV>66T\+%+B9$@:=[?0-3$[7]JZ)()+FUN+H2&*%55K.=_M
M$;X&8OT2LKC2='U/2+J'PR-8M+;[0+B\US59DU:[,\3>39LNG"+3_-M;<&>V
MED+@PB)#/(T1 ^RP55XBA0JM<KC%0;:;4K6A)JUWHXN[NDNSO9?-8FFJ-6K3
M^*[YDDTN5ZRC>]EL^MV^FQ\]7UVU@BVTZ1"&VL+Y+>WU((]NK65S*(%D=4$@
M2X-WY6PL>0KLDK[67NK0V/AOPD]Q//':2Q1.;.TM'N8?M&NZE:R:=I<2^8L:
M2P65NWG2!8 5:XF+D>3D=K)X=;7K#3[N/1- TC3GCNXI]3NM3NI6MGO+@#[1
M%:VXE-S.LL<$2(X8AF$B1ML9:^>_VI[77/!/P^_M;1=2FET>![;1K.]=5D>S
MU:[6VM[MA(YB^T75Q&\ZQ74,6VR%N(VBCG_=O52^'IU:[3G&%-M65FE9-NS:
M=EIJM$[*VXH6JSIT[\KE4L[NZ;3:M=75V[Z:NU[=#\YOB'XTU/Q3J]S9RW2R
M:)H^J:G'HT,42PAXVN&B-]=,&=[F[GCB4>=(YVQ?)&%#.6\^H_SZ_P Z*^,G
M*4Y.<FW*3NVVWWLE?HEHET21]+"*A%1BDDET[]7ZMW;]0HHHJ2@HHHH ****
M "BBB@ HHHH _P!RBBBBOGST HHHH **** "BBB@ HHHH **** "BBB@ K\]
MO"G[<WAR'XJ?$;X5^*;;Q)K^L:3\4OVF/#WAZZT;P;I7A[3=&T#]G#X9_!OX
MA>(-&U&YN?B!KUUXDU"^M?BK9IH?B:*P\.QZM=K=V%_X:\/PZ9;ZEK/Z$U^7
M&G?\$U-"\=Z=XSUKX\_$'Q1:_$WQ;^T5\;/C5!XH_9R\5^,O@\V@^$?C)X1\
M*?#'Q%\(UU8:QJ>NZSX8\6?#_P  ^$IO'%Q/+87\GBZ ZIX2G\-'2M(GC &>
M&/\ @JK\+O''Q&^!?@#P?\(/BQK,'QN3X1P+XFEU3X0Z1!X$UCXQ_L[7G[4N
M@:9XE\)ZI\3;;XA:I9Z3\(K&6^U_Q7X-\)>)?!EMXD=/"MEX@OM6@U".QH?$
M;_@H[IVN>!_@_>?!G0]>T'Q/\6?!'[#OQ]TZ[\=Z)H]WI-G\&OVGOVLOA7\"
M]8\-ZC#IOB*YFM_'UOH/B_5Y";47FCZ7,]MJ%MJ>I2V_V.7@/AU_P2_\>_!?
M]JW0OBS\(OC%X:\+?"'2(_A/X;;0[_P@GB'XA7'P6^%OP2\'?!8? 6^OM9AO
M-,U31O$UCX$T76M2^)+:CI_BJTN;B:.#1I[NQ@U.X]\^'?\ P2W_ &:/AM<Q
MW.F:O\;/$ TW2O@WX5\)6OC7XO\ B?Q78^ ?A]^S[\<= _:!^#GPU\$6>J-)
M!H?@GP/X[\-Z9;65B$N-3U/PNA\/Z_JVK6T5I); '.?$#_@JE\(?A;XM^/G@
MGQK\+/BU!XG^!/@>'XCOX=\-7WP=\>>)_'GA)OBKX1^#DKZ'X;\$_%?7=6\(
M^(Y?%_CGPM/H_A#XJP> ?$.O:#K$&IZ=9/-9ZS8Z5](>+_VL= ^%D'P(F^-/
MP]\<?"3_ (7>OQ"M9I?$EYX%U;3/A;X@^'GPR\4_%Z\\-?$37?"/C'Q!HD>I
M:WX&\"^,]1T&X\*:AXGTNYNO#MWI]Q?VMU/9I<?/FD?\$F_V4-&U'QS>6[?%
MBXLO&^C:_P"&QX?O/B3J<VA>$_#OB?X[>%_VD-<TCPG;+:QW5NM_\6/"6F:W
M/JNMWNNZ^]A)=Z$^KMI#6UI;?4W[4W[*_P 'OVQOA1-\&?C?I.L:IX,E\4^$
MO&$9\/>(-2\+:[9ZSX/UNVU>S-CKVCRP:A9VFKVL=]X9\26L,JQZYX1U[Q!X
M>N\V6K7((!\'0_\ !8OX!:]XTTWX7Z3X5^)&@^,=?\*Z&3<:QIO@?4[KP#\1
MO&GP'C_:#\+^#/&GP]L?B';^/)ELO NH:&/$WBC3-,?X?:)XLUBP\':MXVTV
M].IWND]9X#_X*>>$]3U+X9>%=5^$GQK\1VNJZ/\ L?6/Q)^.VD^%?A_X;^%?
MA+Q;^V3X2\/ZA\(QJ'AZ^^+.K^.8UU[Q/KVFZ)XATGPGIGCR#X=OK6E7.N>(
M+S0Y/[=?Z7O_ -C#X83_ !,^(/Q'T?Q7\7/"%G\6H9Y?BC\+?"/Q$U+1O@_X
M[\0W'P]@^%;^,M;\#"WGMX?$S^!=.\/:+=3:->:5I6J'PKX:U+6-)U'5=,6^
MDQ-"_8$_9[\.:)-X?TVQ\8KIT^I?LHZK(L_B_49IOM?[&,?A.+X)%9F7<([1
M/!>B?\)1&./$Q2Z-]M^U/@ ^U:*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K_.$_P"#O7_E)#\'?^S.OA__ .K>^.=?Z/=?YPG_  =Z_P#*2'X.
M_P#9G7P__P#5O?'.NK!_QU_@G^2,JWP/UC^;/Y=O!GC#Q+\//&/A'X@^"]6G
MT#QEX#\4>'_&GA'7;:*VFN-%\4>%M6M-<T#5H(+R&YLYIM.U6QM+R.&[M[BU
ME>$)/!+$SHW4?&?XQ_$O]H7XK^/OCA\9?%5WXX^*?Q0\17/BKQQXKOK>QLI]
M9UJYA@MC,MAIEM9Z9IUK;6=K:6-AIVFV=I86%C:V]K:V\442K7F=%>M97O97
MM:_6V]K]KZG(>^?\-1?'X?L^>&?V51\2M7_X9_\ !OQA;X^>%OAR;/1VL=#^
M+364MA_PEMCJKZ<VOQLL5Q=3II!U1M#2_O;W41IOVR[FF;+_ &B/VAOC%^U?
M\8O&?Q]_: \8R_$'XL_$!](?Q;XJGTK1M%_M,:#H6F^&=(B32/#]AIFBV,%E
MH>D:?8QPV-A;QNL!FE5YY99'\7HI*,4[I)/76VOO--_>TF^]D%WW?_#;?==V
M]7W/=?C#^TS\=OC_ .&/@AX-^,GQ&U?Q[X=_9P^'*_"3X+V6KV^FK-X+^'L=
MY'>0^'8]1M+*WU'68K<V]C9VUYKMUJ5_;:7IFF:9#<I9V4,0BT/]I'XU^&OV
M>?B!^RGHGCBXL?@#\4OB'X5^*WCOP NEZ++#KOCSP5:167AS6CK<^GR>(+%+
M."WLS/INGZG;:;?S:?I\][:S2VJ,?#Z*.6-DK*R=TK*R=V[I=[MN_=W#^OPM
M^6A[W^S3^U!\>?V//BUI7QS_ &;?B'??##XJ:-I&N:!8>*K#2]"UITT7Q);1
MVFMZ9<:7XETS6-'N[6_AA@+BYL))(IH()[>2*:)7'U[^T%_P69_X*>?M2?#+
M7O@U\;OVNO'7B;X8^*[<V7BSPCHNA>!? MGXJTQF5Y=&\17O@?PMX?U?5=#N
M61/MNBW&H'3-00&&_M;JW9HC^8]%)P@VI.,7);-I-JVJLVNG0=VE9-V>ZN[?
M<?5/[*?[<'[6G[#WB?7/%W[*/QU\9_!C5O%%K:67BNUT!M+U+PYXJMM.:=M-
M'B3PEXDT[6?#.L7&F&YN?[,O[K2FU'3UN;F*SO(8;B>.3*_:B_;%_:@_;5\=
M6'Q(_:H^-7C'XT>+='TR31- N?$TMA:Z1X8T:><75SIGA?PQH5CI/AKP]:7E
MTJ7.H?V5I5M/J=Q'#-J,]W)!"T?S713Y8\W-RQYMN:RO]]K_ (BN[6N[;VN[
M?=>WX'Z2_ S_ (+!_P#!3/\ 9K^$=C\"?@I^V#\3/!GPJT:PETKPSX7DM/"'
MB=O!VES&1CIG@W6_%WAO7=?\,Z; TLC6&G:7J<-CI18C2[>S7"C\\_$?B/Q#
MXQ\0Z]XN\7:]K/BKQ9XIUC4?$/B;Q/XBU*\UG7_$.O:O=2WVJZUK6KZA-<7V
MI:GJ-Y-+<W=Y=S2S32R,S-C &-10HQ3;48IO=I)-^K2U&VW:[;MM=MV] KV+
MX)?!O7/C3XM?0]/N8M'T+1[0ZMXO\47?EK8^']&03/O>2=X[87MXEM=&T%Q+
M':VUM::CJ]_)'INE7CCQMFVJS$,=JEMJ@LS8!.%49+,<850"6)  )(K[S^+K
M#]G?]GSP;\#=,9;7X@_%JR/C;XN7L("W<&A22)!'X:DF!$BPW>I68\-/$=O_
M !+?"&M?*L7BF\6;T,!AZ51U\3B4WA,%3C5K04N65>I.7L\-A(2WB\16TG)>
M]"A3KSC[W*UR8JK.*IT:+2KXB3A"35U3C%<U6LULU3AK%/1U)4T]+G&>,OVC
M;7P5IS_#7]FN)?!O@S3W>"^\?P0*?&7C>]0&*XUBUO[R)KG1].N6#&SO'C'B
M2\MS',;O1K1XM&MODW5-2U+7+J2^UO4M1UJ]F9GEO-8O[O5;N1V.69[G4)KB
M9BQ.3E^:IT5CB<9B,7).M/W(Z4J$/<PU""^&G0H1:ITX15DK1<Y6YJE2<Y2D
M]*.'I4%[D?>>LZDO>JU)=93J-<TF_516T8Q22(1;VXY$$(/J(T!'T(7(KI]%
M\7^+O#<D<OAWQ;XHT"2)@T9T;Q#K&F*A'3$=E>0Q$>S(01D8P2#SU%<\92@[
MPE*#6SA*4&K;6<)1:MZFK2DK22DNTDFON::_ ^C-%_:R^/6D)!;WGC5?%MA!
M)YG]G>-]%TGQ);RY5T*37-Q:PZJZ$.2!_:(PP5QRHQU#?M#?"_Q86_X6E^S=
MX(U.ZE"^=KW@#4;OP?J[.O'FBWECNT9F!)9?[4A4GDGBODNBN^&:YA&/)+$S
MKT_^?6+C3QE/:WP8NGB+:?RS@UT:W.:6"PS?,J2IR_GHN="7WT9TT]==8R7=
M'UF/#W['?C'/]C^/OB5\)+Z0D):>,=#'B318V<9 ?4M*&K2K#&WRF2:\MSL^
M8E2"3R/B']GN^CDM'^&OQ!\!?&*TN[.2\:/PCJ]O:ZY8&.25#9WNA:C<+*UR
MR1>?']ENI]\3IOCA<[*^>JWO#WAOQ!XBO$'A_3[NXGA=6-_ 3;06+ @K++J1
M:*.U9<;@5F$W&45C@4WBJ%?W:N6X=3;7[S NOA*OG:E&>)PK;\Z$%W:6R]C4
MI7E#%U>5+X<1[.M'R7.XTJJ7I.3?F?9?[)%QXL\!:_XSLCHE[:ZKJLNF^'K_
M $?5(YM-G\H6U[=_:(I)%2:TN-/9OMD5_&&@,"RY>2(MCZEA\=:;/);6]OXD
M.C7:WWGW%G/(;=)I-DES:RRWJJ;6Z#1RK"2RF6,$V^X-N<W/AAH6N>%O@[I7
MB#QIK</C+Q-'H/B&W34IED-SH-OXDLY=)T2!=2?%SJUW%;32VCR7:;IUNH)R
M6GL8YF]<MK2+2-/M+?3/#_AZPN%M;8RW>J6 OM2F:2)93YOE2>6JAG)^5U=\
M[C@DU]!AL/4H1HTH5&J#PZKQ52*]M&56M+FIS]C/E4X6][EER23C.*5Y0CYV
M)E0G0>(:YL5/&5*$N635)4:.'@XS2J4_?52I.7*_B@H.#3?O/PZX\:6ME;6T
M.J>.D?3?LTLS:7:2-J2W%Q;S9M@;*W5H_,D$LP5KEF5-ID&W;QX9^T+\0;[Q
MK\++_2(A<QZ3I']D7P$L@GN+JXM[^T1I)64"*.RM]SM'%;C;NS,Q+'"_?UMX
M<U'Q-$QO;;PJ]N"P1#I$@D9L;2P\R<XV\C?YT9!X49&:\N\5_L[VOBCPOKMK
M+90Z?#?G7- &J::C)<6VH(OEPIJ.G%S:SVT<LMK<1R))#=O"4=77=DZ8C#8B
MI1J0IRO&I3G&S4DY>[HN:4Y:7MI:*UU.2C6HPJ0G.-G"<7=.+2][=)1B]K]W
MV['X@45V?BCX?^*/",TZ:G8//;6\LD+ZE8K)/9[X7:-Q. OGV3AE8-'=QQ;2
M"%=P-QXL$$9!!!Z$<@_C7QDHRA)QG%QDMU)6?_!]4VO,^FC*,DG%J2?5._\
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MY72?X,^*:*.M%>$>L%%%% !1110!_N44445\^>@%%%% !1110 4444 %%%%
M!1110 4444 %%%% !7E_Q$UG7/#JKK=S966K_#>ST?4H_&.BV.C:MK?C34;F
M]EM;+2H] LK)Q:36:O<2-JRW2YCLQ-,&"(TD7J%%=>!Q-/"8JG7JX:GBZ4;Q
MJT*DI0<J<^53="O!\^%Q4(IRPN,IQJ5,)7Y,1"C5E!0?A<2Y1BL]R;%9=@<W
MQ>18V?)6P6986G2Q,*.+P_MJF&AF66UTL/G>25JU2%/.N'\57P>%SW+56RO$
MX_ T,34Q,?,[[Q'JUI)'I"37A?Q"GB"]TWQ<GAN+_A&? 5K865G<6.G>,Q<:
MY;R?;F:=X[?<UF;Z97@EAL?)+O1\/W_B/Q!XG:[T2VO?"7A7P]X@\4Z3XMTG
MQ%X56TN_'.H?9+3^S?$_A;54OY -$>[D:9+[R2-02*6$Q'<DL%._^#VDR7UU
MIVEPZ+8_#_Q;J?B77?BCX1N=+N+^;QMKNMPVGV74X]8EU%;C19+2]LX;N2.Q
M1(93&$2)&821^O6EK;V-K;65I"EO:6=O#:VL$8Q'!;V\:PPPH.<)'&BHHR<*
MH%>YBL9E.&PJ6 IT\5B<70E&<Z]!1CAH3BZ52IB,,U*A_:#7/2P]*E.MA,#3
MI83/,+BEG.8YC@L'^<Y)D/'.;YU.7$^*Q6391D>94ZV'HY?F,ZM;.:^'JT\=
M@\-EF<0E3S)\*0FZ&-S7&XZAEV>\28S'9[X;9WDK\/>$N$.(N(+%%%%?,'[&
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_G"?\'>O_*2'X._]
MF=?#_P#]6]\<Z_T>Z_SA/^#O7_E)#\'?^S.OA_\ ^K>^.==6#_CK_!/\D95O
M@?K'\V?RI4445ZQR!1110![/\"_@CXG^._CG3/!OAZYL=)AN;E(]2\0:LTJZ
M9I,&QII)9A;Q3W$KK#&S^7#"^Q</(54KN_H<_9W_ &%OA;\'M(L3XC\<_#+Q
MEJ]O-;WL4-QKFLQ^'(=1= R:@=);PL[:IJ(PL0N-3>\-M-$\<:Q1>6H_-3]B
MO4/#7A3P+?ZS-::%>:E-;0+YUY=7L4]O/?7=Y/=[6L]0LBLQCBL[2X5MVR&U
MB5<!V8_=UK\2XKQ3.EOX-W[EW/(VM(8Q)$'CBB_XJ)M_R%6D<!1(Y+MN8@#]
M0X7RS 87"T,;6I1KXVO'VBE)WC1IM^[&$'S0YM$Y2<9-O31)(^.SG%8JO6J8
M>E.5.A3?(U%).<EO)S^*VMK+E2[W;/N;7?!GAF6.ZU75?B%\,;*&RM;B6;RM
M=U1GBMXG=L2*GA=D9E&(K:U@5F>1HXXPTCJ#Q\?PELM5C6YU#XD^ =!TN^CB
ME30H/$&HQ^)+EI(E AU6[@\-2+I[X""6RTN0R1@^7<Z@K!XU^,]=\>P&?0[.
M6V\%F"?4S?W86;666:+1;6;4TBGWZZP,;W<-HS*?G=HPN<;@=B'XAQ.IF%OX
M-\Z60%G>76L@%5DV*?[>R%0#:JC&=S%B6YKZ]XVE*33C91:3][6[5W?1:6:7
M+=7>[Z'AJA5C%6FU>Z^%-);*RL]6T]=6O74^U;/X.^&[ 0Q0_$#X9V5NL4B0
MV%OKM_M4L\3&2;;X5/F71((+;G9@Q+R2,2U?+7Q<\6V_AN#4M)\$>*?#,T=O
M>W&D6?B>S:?6XM1U:.X\G47T6WN=+LK:R\/Z#,US!JOBO5(+FW>^MIK'0=-O
M#')J,/FGC#XJ2:-X3\3ZO;P^#_M6G:!JMQ:O'+K+3)="SE2UDB4ZX<R1W#Q2
M)A6&Y!D$5X%')XI\)6^AI=0^&]1L+JYLM%,ICO)=40BRF^QNLTLXMTMXVM9?
M.A54!:YEF4O-N#\N+S"*2I4TZ:<'*=2+;<8N:IQ2Y+<O-*_O+X;+L[[4,/-M
MSJ2YM;1A*R4FES2W5G9;)W6^^ENUG73-'TW69Y9WU'6M:03ZWJVHRQZK+?6J
M7$;/J.G:Q/))?7"6<$F^'0U)AM%'VJ.>9&WKZ7XX^"OAKQS::@D&KO>.MH7T
M[6D@MCIMI>;'FLKZ/4+EX8TMIHY(8KNV+2EXO-A=1*H*?/&J>*/"*:/?VD[:
M?++!=:;?Z59:E;/!9I_::VLHTZ"VC19;Y5>XOK5(Y)X8O(ECA"^4J@>G^'-8
MUV_T#2+&[NYWM].8V5I]J91&L,$H"-%86[+"K'<^UY&1MA7<'.:\USHU>?#3
MI0J0E!2MS.33YZD9*3TO)M\W.VY-I/1W.Q4ZL>6K&3A*+:3:\HV:6W2W+HDK
MIZ61\A?$[X26I^'U[?6]V=5TU_#6KZOJ37MF+$6%]H\$TI?2)&!^UO:7,$BI
M,$CR5,<;RI,:^5OV3/B1#\//C%H(U00R^&/',)\$>)K*[9187%OK;I%IIO1)
M^[^S?VFT.GW;R JFE:IJ8;*NP/W?XH@C;X4^()9-TTP\*?$,"68[V4*=4 "+
M@1Q  D8C13C ).!C\>DSY2;69&V*5=#M=& !5T8<JZ-AD8<JP##! -?!YQ)9
M?F& Q6&BHSIQ5;E;O&7)4BG"5[WA4A*K3E%N2<:LT]'RGT>"B\3A\51JRYHR
M;@G:S7-&5G_BC)0:>C]Q>IZG\:/AO+\)/BCXQ\ 'S7T_1=3$_ARZF!#W_A+5
MX(M6\*WK%@"TKZ)>6<%X<#;J-O>Q$!HF4>85]K?M$W"_%;X.?!;X]QJ'UR"R
MD^&?CUHUY.HVD]_<V%U.0Q(QK=IXF:,O\YM-?TB+Y8XXEKXIKQLQP]/#XNI&
MC_NU54\5A'WPN*@J]!/SIJ<Z$NTL.T]3OPE656A!U-*L'*C67_3VC)TYOTDX
MJHM-JBL>\?L^VRR>+-9NV4XLO#LP5\9"O=WUI'@L"-I98F !#*PW#Y2 :]WD
M<.\I;[KRNS8QTYZC!;!9E!(  )&[ ((\B_9^ME2W\9ZF5RR1Z78*_7:"+RY=
M?N\9/E%B&/&T,@RK'UK=A0 I))8GT(8%>A91QG!*[W&5RA6NO"JV&I?WI59O
MYS45^$3EQ#O7J>2A'[HW?YG1:'(MG!J6H.>+&PN+@GL/+B>9LG( ^6(\E@,9
M)(ZU\Q_L\I_;7QD\,Z?<W#V]IXENK^QU2X3:'AM-0CDN9)4#':&6Z2W"9!"%
M@^"J,#[[XFNQI?PV\7WY.QY-,N;6(C&3)=HMD@!(P<M<'CDX^Z. 1\N?!V58
M/B)X?RR(TJZC;Q2,&!CF?3;EHGA964QS;HPL4A)5&;E6.!4XB5L1@8](U(S:
M[\U6,;/UC%Q?DV.E&]'%/JXN*?:T&[_)M/Y'[F67A?2]$T/^RM,MK"V2!IX;
MRW=%EGF4LWDW]TRA2&FC.YVN&61+A)0H/ KSF[U)893'-!:)/&K1M) Q"DJ2
MHV@^4_SCYP"I(SACTR[PE\24\8:(UG?ZB;;Q/9V]I;W]G+]G4ZQ!"2$U?3)B
ML<CSL$5-2L=\DJL_G1H\).VOJT:3/(4ND6<*!^^L1\Q'9VBE;<3V81JP((.>
ME?4<T91BZ=N6VEDM%VY5LULUIKM=.[\)1E&4E4O=O5N^M^J?5-;/73TLLAM1
MM9IX_.N(XXXS<I&6,H#S,Z@C$9<+M0/MW\LS'8>#EJZC;FXE<W"LL<:PJ5:4
M@DMYDN %X*XB7/.<,IY6N?O(+M5NE>:-,8FC,4 =F=PH5@)0BJWG*,'#!202
M!FJZ6=RFQ#J-U\N[.([%0S,26<G[(3DL68D$;B><UCSR3MR[.[O97>VJO\_\
MS7EBU>_2W>U]=-/D=/-J%L%242H#!*DN6$F0GS1RE<KPPBDD)(Z@'UP727UF
MDL4RW4;,GFF58WE#F!DPS*SA8P5D6-E#$>9@A>>:P!;2@#;?W8&W!5H[&16]
M"?,M&8<=0I .?PJJ+.[431Q70F)D2(I/!$&>.55V*7B5<*D;LJ*(\ *QW$DX
M'.7\JU^=K;=>OZ H1[O2_P!SWZ>O_ /2K*+2[Y8O)U"1V4(6C=UBDC( YV-(
M6*]%!4, 0"0 :],\#Z5I]L]_>:BB7EL()ENK>6V%U:7+7;!%MRS*RLGEC8([
MB.-MH:1,JIQX3;6&JLX*RQ188 -';EV51C.69X5'''/RC@G/2O7=(\0:?X"\
M-7>I:SJRR7$LA>TTJ PR:EJLUNI6&TMU?>MO;/+)(^HWPA$-O;Q[$DDGDCC;
M>FTGS32BHIMN5E';JFW]WR2=[&4TVK1=VVDDKM]][+^MWI<_-;]MS1K#PYXL
M\,Z7HQ==+U"TU'79;8Y"6&H320VRV<(8"3R$M%$UNCKNBBN A8@I7A?P/OO+
MUS6]+8C;J.C+<(N<$RZ;<JQV@D MY%W,>A(56Q@9-=C^T[KU]XA\1:+J6ISQ
MSZAJ7]MZI<$*P>(3W=M!! ASL2UBB@\FWB"(P2'<S/D!?&OAOJ TWQQX<G9@
ML4]\=.F+$!?*U*&6R.<D#AYD8 G&0.#TKY#$U(_VE.<=(NM%6[1E&,&O2T[V
MZ7MTT^BH0?U*,6[R4)-ONU)ROY[6OULGU/K:53R,'C(W9X&>G'JW7/\ LX)S
MBK-E"MW!>V+DNEY9W%JQ)P<7,,ENW)XX\PX(X QC&,5'<*49E.01SWZ#@YZ9
M&,\G !P>H%/TV0Q7$3 XYX'?*MN.<^O.![]>@KT%NK[;/T>C_!LY#X+,;0LT
M+@AX6:%P>"&B8QL#D \,IZ@'U /%)74^.+#^R_&/B>Q PD6M7LD7H8;J3[9$
M1WQLN%'/)QGO7+5\_*/+*47O&4H_^ MQ_0]>+YHQEW2?WI/]0HHHI#"BBB@#
M_<HKQGQ5^T;^SWX%^(>B?"/QM\=O@YX/^*OB6/2Y?#OPT\4?$SP7H'C_ %V/
M7+JZL=$DT?P?JNM6GB#4DUF^L;ZSTEK/3YAJ5W97=O9>?-;3(GLU?A-^V?X'
M\7>(?BS_ ,%#_AC%^R7\5/CM>?M;?LC? KX6?!#7=(^'NGZC\*E^(VBZ;^TA
MHQN?&/Q8UV\L/#7PO3X>>(_&O@WQA>Z]J=]:ZSHUO%;ZWX1MM5\16NGV,GSY
MZ!^[-<GXH\=^#O!5SX2L_%OB32/#UUX]\66G@3P9!JMW':R^)O&-_I6L:Y9^
M&](60@WFKW.C^'M;U&&TCS(]II=[,!MA;'X>6MS^W3X*^*'A[X.7'@3]JGXE
M7_@7]K+QA\3=;^)6EZZFB?![XA_ :7]@CQ;X>\'^$]/^(VK^)A9V47B;]HV'
M3K6#P;<:+>0> O'4MKXS\2Z?IUBFDZMJGC_[-/@C]LSQK\0_ >I_$7X6?M Z
M-\-?#?[;?[+?Q7\+>'/BGJ?Q<\62_#O3)_V8?VB-"^-][:^)OCWXN\3_ !,U
M/1M%^(.J>$-%\2:N[Z'X-U/Q/J2Z[X%\(:3I&OS3W@!_1+I_CCPAJOC#Q+\/
MM.\1Z3>^-O!VC>%_$/BGPO;W<<FLZ#H?C6?Q%;>$M5U.R!\VULO$-QX2\30Z
M5/( MU)H>I+&2;9\=57XV_M->%_VAO!W[2'QQ^./PV\!_%[6/"NF:O\ \$P=
M:UG_ (55;W-SXG^(GPW^%WQF_:-O/C[X3\*:+87]G?>.9=!\(^,M"U'Q5X(M
M]]SKFBZC'9V%EJU[-#I\OR1XO^&/[=OQA^'_ ,5?%<Q_;A^&^MZ5\#O^"G7Q
M3^"7A31_BEXF\">)8?C5<_M5)XJ_8IT3Q/I?A'QC>:5X@UG2_AC]F;P#\-M=
MU#7/ T?AB6^\*>(M'U#3HFTR  _I)HK^=SXT?!_]M7P2/&WP^\#>*?VM-0_9
MYA_:;^#?BOQ7KLVK_%[X\?%>^^'OBO\ 94U8^.X_!4WAKXR_"[XUZSX#A_:G
M'AG5O'OA+X<?$C0_^$1NKS4IO#?A:3X>0:]X87:T7X'?MHV=V?'E]\3?VS/B
M!XM^$EG_ ,$SK3X4ZGK?B?Q7\-M#\?VUW\4)-)_:NU_XB? C2/&NK>#?$'B"
M7X2:K-IGQ9L/'%UXPN-.MM/M?$%I>Q>-()];< _H)HK\P_VAM-^(\W[<_P '
M+WQ9X:_:U\2_ '_A7'A&#X82_LW^+?%6A_#[PS^T1!\5]3N?'&L_M&:3X'\7
M^%;C4_"DWP[;P'%X?F^)D'B'X7?V);?$S2Y-+/B'4[6"_P#S-@TC_@H;\0/%
M?[2MII7@;]L+X'^%_'GAWX)VTFBV7Q.^+OB'7/"_Q LOV[/!=A\1-1^'OQ/^
M(?BG5-*&K_\ #-]SXDU;4]7^ OAKP?\ "#_A OLVG6%AX@N_#Z30@']-U%?S
M^ZC^S/\ M1Z]XRN/@W>>+OVUM,^ O@'QS^WU+X&UC1/VA/BQI'BG6?#EQ\.?
MV==?_9OL_$?Q=MO&/_"T?&FCZ?\ $O5_BV_PR'B3Q5?W:7&@R^']3NKWPQIT
MFCW]/0M?_P""@-OXJ^%W@OQCX"_:NU3Q+\2_BA_P2T^*^O\ CC1RD/PR\%_#
M[PMX+^%6C?MB>'?&^K6?B33].\'7DWCK0/&TOQ"^&&GZ3)<>)[;Q!'KMOI&I
MZ#<:U?:2 ?O#X$\>^#/B?X2T3Q[\/?$ND>,?!GB2VDO-!\2Z#>1W^D:M:Q7,
M]G)<6-Y$3'/$EU;3P,R$@2Q.O533/'_Q!\$_"OPCK'CWXC>*-&\%^"_#Z6DF
MM^)O$%[%I^CZ6E_J%II5D]Y>3$1PK<ZE?6=E"6/SW%S#&/F<5_-[I_A#]MOX
M?>"/V#_AYX#^"/[17@[Q-\.!^S;?ZSXJ\.^)/BT_A8:)K7[6NN+^T#X+\5_#
MGPEXPT/X)Z&_AWX+'^T_&>O?&_2?'E]XP\)>+-.LOA9H6FZ_X3N]7A]P_P""
MJ'PK_:$^*WC_ .*/A#2_A_\ M9?$CPYXD^$'[/4/[,]C\!_$FLZ7\%-'\;^'
M_CKJ^O?M(C]H#1-/\6Z%X9U?4+_P5;?#FZT6+XE:)XDL=5\)Z?K6C_#&*V\;
M#5DN@#^@*BOY[/C;\._VI_#GPL^+>MVW@_\ ;(^)/CSXR_M>?M8:?%J>D_'?
M]H>*Q^#_ ,)O"_C+XQ7W[,-QX*^$WP6^(/@W7/\ A!?$-K/X;L_#,N@ZOX7T
M.PO-9T7Q-\5-<U#PQH&B:'9\;XG7_@J)X.@^%7B*P\/_ +2'CZ?PG\"OV6_V
M\?B+HNFZO#!?>/\ XT_"[X0^&/@=^T%^P<]C%JD.E6NK?%NYN[KXUCP?:P0^
M$KKX@Z=JFLVUU;7IG,X!_2+7':+\0O!'B-_'$>@^*=&U9_AIXBNO"/C];&]B
MG/A'Q/9>'=#\6W>A:[M)^P:E;>&?$WA_7)K:7#IIVL6%R1LN$)_'[X'>!/VJ
M_A7^U)^RKIGCAOVAOCC!?_ ;P[I'QNU?QIXA^)^E_"KX/^.K[PG\0O&/Q!^)
MWAGQCI7Q#?X2?%27Q+\0M>L_AIJ/PC^)OP^O_B-X5M[;P+XG^&/B:R\%^%[K
M3X/&M6^%?[16E?MO_%R\\!?#S]KO1]7\>?MSV'CR?Q?%XFUFS_8X\2?LAO\
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MDW9JRBEJEM%].[3T^9R]PND!4\VRM9BCA@7DO S;3D!O+O K NJR$!0-RJ,
M"LY[NPX4:5IY&25(FO5)]<YNSZ],_G3+I-1=F/DQ#<>@BE"XR3\I;)(![],
M].T*6%QSO1">,\%<D],?*3P/4<GVI.[?NQ^?*OQ;&K):RO?^\]/2S37];&I#
M<V)P#I-@,@CYY[XJ,].!= G';YL$>U78O[*+^8MAIL;E F6GU!AN!8J^W[8P
M# ,4./E*'!!)S6<;"X"@")>5'.9"<XZ#C&?T/':H197@8#;&3CC<' 'IR3P?
MIGOBJU6\+_)"TZ3:\K_U^9T\>FP:AF/^TXK42#:$AOIX"%P<*KHGFJ<G);S&
MDR2 PXQU4GP \--H?VB+Q#J5KJ4UE]H6?[8NL6\\DQ) D6\A@NU"2M\VRX*!
M6)#$;2?/K9H=-83ZIJ.G6,*?-OGN?( *]]\P0*,#@KO)(X%>@>+_ (\Z+I>C
M26OA-(]?O3ID=C'?2I<II]M(RLTK(TPB-VT0:'RA%$(G(;,X7(JKT.63K*.B
M=DVW+6^T5*_;5)="?WMTJ;EJ]6EI\VU;[VS\??VC[>?2_B?J'AN>9+D^&M/L
MM-%S"6\BY,S3:@T\*,S&-'%V@9,\2*X.6!)\,@G>TG@NX_\ 66D\-U'SC]Y;
M2I,G3G[R#ISZ5W_Q:U2[UGXE>,;Z]G:YN3K$MM),W\36<<=NV!LCV*)$?"!
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MBJ^:YW1KY-EU-1E+%YI0KX*GR5*;J2[&BBBN0]P**** "BBB@ HHHH ****
M"BBB@!KJKJR.JNCJ5=' 965@0RLI!#*P)!!!!!((Q3J** "BBB@ HHHH *_S
MA/\ @[U_Y20_!W_LSKX?_P#JWOCG7^CW7^<)_P '>O\ RDA^#O\ V9U\/_\
MU;WQSKJP?\=?X)_DC*M\#]8_FS^5*BBBO6.0**** /U,_93)U#X8^49HX[:R
M6TADCVRF26=Q>E1O5 D60X7>[,J @K\^2GU9IUC#"L2EDE8Q6\CE"67=+!&S
M D@,1DX!XXXVC'/R7^R-.I^&%QDKM.JV<!!!S^X6[^\<X(9UW 8&%(4[L9/U
MKIKAK:>4D'$,*+Q\HVVT8Z]=QVYQ]!UK]<R;7*\ ^^&@ONNOR25OU/B<<_\
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M>*Y_ 7A%-;\6V>G265W;KXOUV32A?:];6,NE:==0C6KJ[BM9--LIDV-9P-&
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MM<;4-.L;Z[L[6"XD]MK)T+0-"\+Z18Z!X9T72?#N@Z9";?3=$T+3;/2-(TZ
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MJOCFY\1^$?!">!/@_IMAHGA73_!%E>>'+I=,UAK>T\(^$G[$_P 6(?AK\)O
M^B^$?VU?A#XB_9]^ _\ P4\T/4=8T'XG_%OP9K-_\==4^*'P/\2?!"W\)_$
M^++W5_%'P[\96^BIXM\#Z1X6UN#X=^-]=\-ZG/XGTG59H?$6DWG]+GA'X:_#
MGX?SZ]=> O '@GP1<^*;\ZKXGN/"/A70O#<_B/5#)<2G4M>FT:PLI-7OS+=W
M4AO-0:XN/,N;A_,W32%NUH _!#X0>&OVZO$_[9?@OQ9\:?B1^TAX!M+;5O@?
MXBT+PQX?^$'CGQ#\$O%GPDF_9D\)0_$WP-X]\5Z?\9-+^"'@+Q!=_'6;XDW?
MC"'Q9\%;[XN:/XBTWPE-X'\27OA.\T:&P]!^*7@_]L/7/^"CNH:E/\3/V@O
MGP@TOQ9\ M6^!ME\.OA?X[\=_!OQ3\-M-\,(_P ;_!GQ(\1Z!\8?#/PF\%:C
MXK\9KXKTWQ-J'Q@^%/BSQ=I_ARX\!Z[\*];;4K"WL=+_ &NHH _FU\-? _\
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M,0JHT5FZNQ.%0LW:OUC\2^-?%UK]D\2:CX:LX=0U*YAL=/\ $=M>?:=)1[2
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M+ 5>),ZPTHT<2L/CL;E?#W!&8\'\=9)GN9<;<0<2<!<)==1117RY^SA1110
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M,/=-#;HK$M*54&OD[XA_%#7/']SY,A?2_#T#8L]#@E8QN%X6YU.12!?797
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M-'^:/?XEM>U]^^GKIN&O9_<_\B[15&QU*QU&6YAL[A99+.Y>UN5 (*2(0I8
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M^+/#WQ7T'X,^"M7\3^/V\:Z?XBU+XO?"_P 1>/=%TS_A -:^&.L7!2RL]/\
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MPU_\,QXH_P#FYK^]ZBCZW7_G7_@,?\@]C3[/[V?P0_\ $&M\8?\ H^;X:_\
MAF/%'_S<T?\ $&M\8?\ H^;X:_\ AF/%'_S<U_>]11];K_SK_P !C_D'L:?9
M_>S^"'_B#6^,/_1\WPU_\,QXH_\ FYH_X@UOC#_T?-\-?_#,>*/_ )N:_O>H
MH^MU_P"=?^ Q_P @]C3[/[V?P0_\0:WQA_Z/F^&O_AF/%'_S<T?\0:WQA_Z/
MF^&O_AF/%'_S<U_>]11];K_SK_P&/^0>QI]G][/X(?\ B#6^,/\ T?-\-?\
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MYK^]ZBCZW7_G7_@,?\@]C3[/[V?P0_\ $&M\8?\ H^;X:_\ AF/%'_S<T?\
M$&M\8?\ H^;X:_\ AF/%'_S<U_>]11];K_SK_P !C_D'L:?9_>S^"'_B#6^,
E/_1\WPU_\,QXH_\ FYHK^]ZBCZW7_G7_ (#'_(/8T^S^]G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $9 C<# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#_ #_Z***
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M;7P=+)/IO]CW$6JV%IIFL:/.ES8L3_@GSXL\2_M)^&/"R?M)>)=>^*\&@_\
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M?3W+76HZ!H']N _;U6;\ZO%?QC^(OC;P?I7@+Q+X@_M'PIHOCKQU\2M,TO\
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M'QAP!EE>G#AC-,PX3K<0<8Y3CL]X:]ID6(X7RW,,;EN;?47[67[('PJ_9_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HI0K'H":>(9#T0_I0!'14XMISTB8CUXQ^>:* (**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ4_9%\<7MYHME<2#$=S?_!CXC27^AKIEO+A[J+0]9&HR6V^.V'FB//+?$_\
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MF]-ZG,=U9W41EL]1L+E9;/4M/N+K3[V&>TN9X7_HU^._[5NF>+/@[\&OVS_
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MVG^(==\,OI>I>%-3T_Q!#LOM/U%$;2;Z*[AO8Y--O+B*\L8[FW59KFQFGBC
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M%CP4W#CZ?IZ>G6B@#6_XAV/^"U'_ $8#\5__  H?A;_\WU'_ !#L?\%J/^C
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M/_X+*LH-Q^P=\5XV R<:_P##%CGGIM\=G)_'V'K7^P[#_K8O^NB?^A"M>?\
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ML/%.G6LGF#3-550]OH_C?2K9HAKFA&5XYU\O6=$EOM#O;>Y72\&:O;:-# L
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MGW;HJ^;>V&DV5G#J4QS]HU<ZE=Y+7+$_8=K_ ,?$?_ __0&JO5BU_P"/B/\
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MF)_[ZW''^>YI%'[D^)OC]^S?8PFVTGQ98Z2J+L"Z!X.\'L4"@8$9U;2;^,8
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M!VTG4KRVO&N_"?@JYEQY;IXAU*PDO=;B/$7@S1/$]TS))';K+_L0^!_".F>
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MA_AO+Z=3$XK,"K%K_P ?$?\ P/\ ] :J]6+7_CXC_P"!_P#H#5YQ^@&A=?\
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M?+<[R/-\NQ.7YSP_G^4XB7UK*<^R+-,KS?+<1>IA<:H5,3A<;_F4_P#!0?\
MX-,_VD?@MJNM^,/V2M=M_B/X$,UQ=6O@SQ=>K!JMA 9)I%M=)\=P6L6CWL*)
MY45O%XVL/!MS"B[9=6U>4FYD_FC^+/[$'[7WP-O)[3XJ?LW_ !?\*) 7#:I+
MX)UG5?#D@C;:SVOBG0K?5/#=Y&&X$MIJL\;=58CFO]S,$CI_^OV/J/:O-O$7
MP>^%?BR1Y_$/P_\ "NHW4I8R7ITBVM+]RWWB]]8K:W;$GG<TQ.><U[LLPX5S
M+W\QR;'9-BY:U,1PSB,-4R^K-[S>1YTY+".3NW3R[.%AU>U*A1C:$?RZEPGX
M[<&I8;@_Q%X6\1\BI>[A,I\:LJSO!<68.A'2GAEXG>&U.C4SZ-*"C3IXSB[P
MZGFU2,(RQV:9A6=7$U_\(1M"UM+@VCZ/JJ70;8;9M/NUN _]TPF$2!O]G;GV
MKW_X6?L;_M7?&R]@L?A7^SO\8/&;7! 6^TSP'X@BT2(%@H>[\17UE::#8Q98
M9FO=2MXAG)< $U_M:M^R)^S>]V+]_A5HIN@P?S?M^O?>!R25_M7:<GD@C'MR
M:] \/?!7X2^%I4GT+X>>%;.YC*F*[ETN'4+R)E^ZT5YJ7VRYC<<_.DJMR>>:
MQ=+@RE[WU[BK&I.ZH0RO(\M<O[LL36S7,U#SE3PLVMXQ;T-I8[Z36-2P]'A?
MP!X:E)<LLUQG'/BMQI&C?1UJ.197P'P34Q$EK*%#%Y_A:<FE"M7C!RFO\T#]
M@#_@U*_:Q_: U31?%'[3FI0?"'X?M-!<7OAOPU>6FK>*+ZV!B>6UOO&#P7G@
M[0@Z,R/)X?\ ^$]U)"&1].M'*S)_H!?L%_\ !,_]F+_@GU\.M)\#_!7P'H>F
M75C'')<:S'9%[N?4FMU@NM5FOKV2[U;5];ND'E77B/7;Z^UB6 "UM)--TT1Z
M;%^AG0 #@* % X"@< *!P !P   !P**PQ&=PC0JX/)L!2R;"5X.EB9PKU,9F
MN-I.W-2QF:UH4JOU>=DZF"P&'R_!5+)5H8N,8Q-\F\')XS.\LXN\6.+\P\5N
M)\EQ=/,>'<#C,KP/#/AOP=F=)25',^%/#?*\3F&72SW"JI.."XMXTSCCCBO
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MXL_";]N'XM6NM> O"?B?XH^"?V@[/Q'X<_9I\=W7CGX>:'\/?!LVE>)/C/\
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M^*;J7Q!)W?CG]@/X?^/_ (7>%/A'K/BW6(/"WA7XJ?M-?%.!=.T/1[61[_\
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MDO?B+\19?A]HWB=-4\72?$#4+CPKH,'PWUO1?"*Z5-97UYKY\5WU[H_ 6?\
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M *$:HWO^N'^XO\VJ];?ZB/Z'_P!"-4;W_7#_ '%_FU %2BBB@ HHHH ****
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MUFG? G]J2RNL:G^T#9>,;?6/A?\ &WPQXN'BR379] O/'7C75=9G^&WBC0?
MNC:?HMGI&E^&=*GT'2M:TF3Q'<VL&F6%_8^&["UU2^O/$^I?<U% 'YC?!_\
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ME-8BTZPAL[&749)M8UI]+&C:'%-:PR_89-9O[%-2N5^PZ<;J^*VQY&3]M;X
MQ^))O#C^(]9L'L!I#ZMJ/B3P=XS\(6MN/$?A#5_&7ARVT2U\3^'=,U/QCK>L
MV&D26<'A?PO9:CXFCOKJSA?26-Q$) #ZQHKY[TS]JS]GO6M6_L+1_B58ZIK/
M]E1ZN=,L- \87=ZD3_8S+ITEO!X=>2/Q)8QWL=QJ_A%POBK1;2#4;S5M&LK7
M2=4FL_H4C!(/4'![]/<<'\* $HHHH **** )(?\ 6Q?]=$_]"%:\_P#J9?\
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M--%\4:3XGT!X=;U6;1UTGPQXT;P5<>+;+2XO"G]B16^H^+-5^'GA'Q%XE\1
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MA>W-O9Z?9VLU]>7]W/%;65I96\1GGO+J[F=+>WM((%:>:YFD2&*%6ED=8P6
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MT'2[B^U%S::CI'FEI_P39T_3M7.MVGQ>U2Y>#2O"=MIWASQ!HWB+Q!X&M_\
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M?&L/PEU&YM3O\-V/A7P[XAM+;4]1M([>']3,(H"QHL<:@+'&@"I'&H"I&BJ
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MCU&[BBN))C',490/1:** +UC]^3_ '1_.M*LVQ^_)_NC^=:5 !1110 4444
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MT_588+RUAU&RM;Z*VU"UELK^WCNH5F6&]LY@LUI=1*VRXMY0)()5>-P&4UH
M@].: H5Z.*H4,5AZD:N'Q-"CB:%6*DHU:&(HTJ]"K%3ITIJ-2C7I5(J=*E-1
MFE.E3FITZ>%Y<G_/-_\ OEO\*/+D_P">;_\ ?+?X5NTF?K^7OC_/XT&IA^7)
M_P \W_[Y;_"CRY/^>;_]\M_A6YD9QGD_THS_ )[]<9H P_+D_P">;_\ ?+?X
M4>7)_P \W_[Y;_"MS(Y]N>A],_R[=:7- &%Y<G_/-_\ OEO\*/+D_P">;_\
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M #S?_OEO\*/+D_YYO_WRW^%;M% &%Y<G_/-_^^6_PH\N3_GF_P#WRW^%;M%
M&%Y<G_/-_P#OEO\ "CRY/^>;_P#?+?X5NT4 9]DK*[[E9<J,94CO[BM"BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,#&/Y\_KUI:
M* #%&/\ /^?I110 F!Z=\_CS_C2_Y_S^=%% "8'/O_AC^5+C-%% "8'7_/8_
MS'^<FEQSGVQ110 8'\OT.12  =!CO2T4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" #F FP# 2(  A$! Q$!_\0
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M4FON9Z'16!HNNF=EMKP_O#PDG][V/O6_46L?68;%4\3352F] HHHH.@****
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M<YHN2Z%%*_.:W3H2#ZBNTT6_-_8*SD>:GRO]?6N+K;\+3%;R:+/#INQ]#_\
M7H9Z&08F5+$^SZ2_,ZFBDI:@^Z"BLKQ+<3VNB22VI(F$D07#;<YD48SVSG%8
M#^)-5M+NXA-NAN'N&VQO)N10J*=@/')S^% ':45Q=QXEN+Z[EM8VC5!)$T;I
MD%2)55E;GGGZ56@US5HDMKQ[FWG:.VE><$$*0)<8 !^]CN: .]HKE)?%%R+&
MXN1+9HQF,4$)5F=2"1\_/?&>W6H_^$LOVLWNU@MQ#M@4#DD/( 2QY VC/XT
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MSJ54#YB,$_7'>K5(.G/6EH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAE8^R&M2R\-W,Y#71$,?H.6/^%%DBZ-+&XE\L8Z>FA1T_3Y-1N1%'D*/OO\
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M\*Q>7+YEU-)+,N)9" "S;P^<=N@%5[CPF\^INPNW2SE5O.4 9D+.&*^PXZT
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M 1VEN%Q,0L8Z0QG"CZGN:E2.0*!&I5>P7Y1^5;NF>&Y)B'FX%=-#HUM%&%V
MX]: -2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I*1F"*68@*!DD]JY/5M<DO&:*W8I;
MCC(X+_\ UJ:5SBQN.I8.'/4^2[FY=Z[96C%3)YCC^&,9Q6>WBL9^2U;'^TPK
MG.G2EJK'RE;B'$S?N6BOO.DC\5QD_O;:11ZJ0:U;/4[6^_U$H+?W3P?RKAJ
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M)I+E_.N ;A&3AA\FY@Q(.,]5&,YQTH 6X\7Z?:W#P/'=F1"5(6 D;@ Q7/J
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M110 5\Y:XGEZ]J<6,;;N3^=?1M<%XW^'EKJANM7LYI+:\6,NZJ,K*0.X]>*
M/(MJE<@\]Q71_!__ )&6^_Z]S_Z%7*6TTUQ*(E@=Y3T5!D_E78_"B!X/$&H.
MT3JJVY#%AC!+9P<T"1[)HPQHUG_UR7^57:J:2I32;16!!$2Y!^E6Z!A1110
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MT -" =J=110 44M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%K>\*SD33P$\, X^O0_TH9[/#^+E3K^Q>TOS.FHJGJM^-+TV:\,;2^4 =BD
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MOINGVZQ,@ED8Y+NQRQ!)X&>.IX%67\/Z=)+;R-;C=;A5CPQ& IRH//.#R,T
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,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $J G # 2(  A$! Q$!_\0
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M\[Y]BA28PHZYZ<\<U:?Q#KL6AR:H]ZDGVG4C8Q(D2J+=!*R[B3U; QSQR*]
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M.)-E8V]N2""8XPIP><4 ><RZR1XM_P"$H$5[]F2^_L\S;?\ 1_LOW"V[./\
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MN)',IBDW,W4CE>1]:PU\'^(+J._DNO+^T7%E%;YDN=^YUDW$_= 5?0"O2J*
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MU-2:?A]3OGC_ -7E5R.Y YJI*ZUW,X-J2Y=F:E%%%9'6%%%% !1110 4444
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M4444 %%%% &;-X?TJXM+FUFLHWANIC/*IS\TG'S9Z@\#D5 /"FB_V<U@;+=
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M<(CO9M1GARS 9MI@HW_\!8!@/8U/'X7O++43':V9%G%JMK)$=P_U20!2WYT
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M'IC(/UK8T72I[+6HMX<K!8+'+*W_ "TE=RS8/L<_G0!TU%%% !1110 4444
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M&=I]1Z&GT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>;'(9E\_[.3"I?:^=I!QTP>I[4 7**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ H) &2< 49KD88)?%]W<37,TD>DPR&**&-
MMOG$=6)':@#JHYXI21'*CD==K XJ2N<G\&Z;M#V!ELKI/]7-%(>#[@GFK7AW
M4Y[ZUFM[T 7MI(89L=&QT8?6@#9HHHH **** "BBB@ HHHH **** "BBB@ J
M-YX8B%DE1">@9@*QO$>I7-O]ET[3R!?7KE$<_P#+-1]YOPJ*#P9I2H3=B6[G
M;[\TLC9)_/B@#HA@C(HKDGAE\(WML\$\LND7$@B>*1MQA8]"#Z5UM !1110
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MGW)Z"KOA[2YM.M)9+MP][=2&:<CH">P]A6LL:)G8BKGK@8IU !1110 4444
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M <XQ0!V0((!!R#2UCZ:]Q#J+VDMRTZ&W24%E *DD@@8[<5L4 %%%% !1110
M4444 %%%% !1110 4SS8RI;S%V@XSGC-//0UPGS6>E*0&:WOIQ[[)5E_D0/T
MH [>2>**2.-W >4X0?WCC-/5U;.U@<'!P>AK$N+I5O[R^?F+3X=B>\C#)_\
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M*X&2*P%\/W6ZWDWHL\$3/'(#D+*7W8QW')%;"PW#K]I?>)C'S;&3]WNQTZ4
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M2,8HB%\W^%F[@>N/6K=9VEVD^GF2TP&M%^:!L\J#U4_3L:T: "BBB@ HHHH
M*0  8  'M2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &' C0# 2(  A$! Q$!_\0
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M0L(]02Y=KVUCM=N%VJY._"@9Y&.U:0Q3BM")/4@-E;-UA ^A(IITRT/17'_
MZMYI.M.Q-V5DL(T.4EG7VW5:12BX,C/[MUQ12YIV!ML6DXHR**!!2TE H :U
M1V!^>Y'^T#^E2-T-16)_TFY'LII] 6YH#K3A30:4=JDU)%J4=!4*]:E4\"@!
MQY5A[5Y)XET^>Z\3W32RE;9),QI@L,XY./6O7#]T_0UYGXEU2_T_Q%=16UW+
M$AVD*N,9(^E:4W9F-:/,C.TRVFMPR0RP+GJ&<EF_WCC]!5TZG;VX!FN]/!/4
M!VS6<_BG644G^T)/^!(A_I3?^$JUIR=]S Z>DELA_I6W/Y'+[%]S7&O:>P!\
M^$_1C0NJ6@<2"6%!Z^=M!^OK68OBF^"@/'IKCT:S7'Z5&=;BD;=+HVB2-G.3
M9\_SH4D)TI=S=L[NSMU)M(;=0W4QG.ZMK3KAIKIHV*C$0?:%QCG%<E#XF:+(
MCTK3E&.!'$R8_6M?P_JKW>I2+'I]O;EX]TLH=V) /0 FE)IHN$))[FOXG&[P
MW/[3*?U%<"!7H/B(9\-7GLZ']17 'K7D8OXSU:'PFC9]JV[8<"L*T[5NVW05
MC J1I1#@5?B&47'I6?$0!UJ_&Z"-<L!]371%&39...HHR*/RI<$]JL0"G8I
MISTIX]Z % ^84H'-"XR*7'-#0T(:5.E!Z4J]JS:+1*.AJ&&".;5+H31K)&L,
M957Y /M4ZCBFVK;=5NP#C]Q&?YU5->\)[%KR8(U*I!$BKS@(.IJJ2PC4QX_
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MGL5(K.[3-59ZV/+DOULOBIX3UL'$-_"BNWKN4H?YBO>R^UBK=N,U\P:A,_\
MP@WAK4AGSM-NS;L?0JV1_*OI2UO$O;."[B(*3QK*#]1DT2W&BV#\M-*EFX'%
M1JS-G':IXG!&<4ADD<009/6JFIR;8,9QFKA.!65J[_/$F>V328%)>.:F0XP,
M CT/>H4!/:ITC;^Z:S;&D<'K?AWQDES)%H]W)>:*\J,\2W$:7NSDNB.P 4=
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M]0.#5N_7S1$Q!&,]?2MKW1RR5G8;:S?NL9Y6K:7"!E,A( [BLN(F-]U6MPD
M/>JB[HAFF;Q'7$3 ^],C#*WF/\S'IZ"J*D' Z&K"LV.>GO5 6MYY8]35&\;E
M3[U8W$BJE[P%X_B%)@*N6(YXK1M6YZUF(W3FKUH>:E;CZ"W0_P!)8CO2H_R]
M:2Z_UH/J*8IQGUI]1="]:2;HG4_PM^AK-UY\0(N>K<<XR>PJY9G;OSW%8_B&
M-;M(H)"0KMC<IY!QP1[]ZIO0#B]3LHI=7#R(/.50'V.=A';*]FIT&FVZL&CC
MCBQR/D&<U>OK.2)5GD<&5GVRL!S(<<-^G-11Y"__ %\5*=R9*PZ-4@.%(QG)
M[D^]3E$G0X&<>U,"/@'Y?Q-)ODA96.-IX)[T_(+=>I7"-;2E2#CM5]"[K@2^
M7]!_6G.@FCSE21TQ4#/Y2D;0W?!Z4E3LP=2Z,_4@1=JCMO+1 J2<G@G(JE-=
MK"?+!)/?TIWB*X3R+28*4E#,JM'P<8S6 UX6) 1<8ZN=Q_H*\C$TK56>_A)\
MU%,UUGCF8LK#Y>#FJEPB3HTLBD L #MZ'TK/-[)&69IMBD8P, &JLFHH[(BL
M\FYL;B< 9K.-%O8WE5C'=G:^#+B33M1>&"4BUVAS'V!/!QZ5Z?#=*W/?U[&O
M+-%@-L8V4'!7<2?U%=]9.)K5)%;:V-IY]*]6E>,$F>%B)*51M'0*0PR.#Z45
MFQ7#1D9<$#MZU:6[B?\ Y: 'T)P:W3,;$QQZ#%(<=,5$;B%>2X)^M.\Z,GAA
M0(?D[NIP*>..M1>?& <M4,MV""$Z^M,0YGYYZBF/-[U59N?OYIC3(#R: )I)
M< LQ./YU@Z^]O)I^V]EGCCEE15:!B&1MPVD_[.[&<\=<UKM'+(P^3'&0N><>
MM<IXEU!GC:VB?RU:-O.D/&V+O^!YS[ ^M)[-A&[J1BEN_P #C+W7;9]-FN?$
M44TVK(CI;RPRE4!YVL0.,D]>V*S])N'^S1V\EP"CG*NYRL<_]T_[+9 /YUC:
MNXU&1IU3/F.(XXG&%5 .">Y)]*L:2%AA"LA6%@5N5/*K@<.OH .OM7')<RL?
M248>R]Y=3W#P[=Z?=Z9%=6EA;V<BDQSQ)$H,,@^\I./Q!]*J^*M$FU:RFNK"
M3RM32!D24#(=>NU@.H]/3)KA-,UF_P!#EF>W$4TKQ;-LQ.R4+]TDCDLO3/\
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ML 5/7'>FV61?V?'3/_H--T&".UT[7[>W0)#&-L:KT48/ I]E_P A"V![ _\
MH-8/XD:]"W?JSJ!M!XKB];\.I=QDJNU^JL."#7=W#QK]]U&/>N:U77K.SO8K
M,VTTKR[?G4J%7)QSDY_*M+V(L>;H\EM,UK<C;(OJ,9]Q5D.Z'*L01R#GD>E=
M%K^FV^K*YA9%N8N0RGDX[UR$$\B I/&Z[3@OM.W\ZZZ=3F5F83A9W1Z1X=O'
M\0C^S[1XH-02'S"LS[0X7J4P#D\=*LQZQJ<T\D273Y1MK%0",]ZX33;R:PU"
MVO;=]L]O('1A^1'T(R/QKJO"DOVBRFN#UDGD/_CXK*K"SN739VUOX7UJ]M8I
MQX@2-94#A?()(!_&G/X$OI2?.\3W !_YYP ']375Z;_R"K+_ *X+_*K)-)01
M+FS(\/\ ARS\.6<D%K)-*\K;I9IFRSFM/OBG4SO^-6E8S;NRYWIC'Y&/L:4G
M%,<_NW^A_E69L(G_ ![1?[JTXGK3!_Q[Q?[JTI- &W%_JD^@HHB_U*?[HHK%
MFR.&\;9^V/@ E8D;]36382# ]^:VO%:[]9*D<&%?YM7,V!>$B)R2R?*3ZTV]
M!$]S%MN&'KR*JABDF1VK5N4$BJQ )QC-9\MN0<J::9+)1*K@$<&F[VC;<#^-
M51O0U,LH88:@#0AO<X#'Z&N9\30J_C/3)"/W6J6$^GRGL6 ++6JP/45S_BV5
MXM(M-0R=VFWT-SG_ &2P5OT-%@N)\&+LKI^L:/*2'MK@.OM_"?U%>E,"@PPR
MI[UY+X5E&C?&+4K('$5]&[(.@.1O']:]=1]P_P D&HDM2D85R\FD:C'?*I>#
M.) .ZGKFMIFDF<2@AHF&5([J>E-GM?-C9$ 8,.8V_I6;I,S1.^DNS1NF6A5_
M[O=1]*E:#>IH2+L.[JO>G+@=R0>E2*OR^6S GL1Z5%@Q'@9!IIV8B3'<5(C<
M'))I@.>1TIPR:UN23QGZFH+SH/J*52V[:*;=Y"J".:3 :I&,8J]:FL]>HJW;
M/A\5"W'T+-P0<'T-1@=Z6=L"D1LJ"/Q%5(2+-N.M<YX@E$FJ:=;%G5=TCG8V
M"1@#G\ZZ2+C/':O.?%.IM;>-X(S@PK"(LYY#L=WY=*&WRC6YM:C;&+3K@;Y'
MP%/SMG&#VK$ )&<9_"NM4+=V70$21G(/TKBO[8C"A5M\$<9=L?R%*"N*<N4T
M$9@,9P/0BI6*LI7D]QZUSMWK4T<XB6'YCRNU<9]\FH"VM7WRBX^S1G_GD?G_
M .^O\!6\8=SGE4UT-Z2Y-H-QD6,@=7('\ZJG58&(=YO,;/2)2<UCP>"KB1A,
MUY(SGD^9R?SKH;+07MH\22,1W++G]:SE-K9&L*<7K)G.:U/=WLD2VNG2;(P<
M&9]NXGU Z5RU_;>*K7=-+IJ2VJ#<WV,G*CU]?TKV>WTN!L9 -77TNUDB:)I&
MC++]Z)MC@>H/:N1T^:5V>A'$<D5&.QX5I2V.JRJ S+*_1)FR6^AZ&NIM_#%K
M(</&2?J13_'/P]GM2^M:(#.#AKJV2/!]Y5 _4#OSQG%1^"_&7VB>+3]6N%"'
M"Q3S*&VGLKG@X]#VZ&GRV&[SCS1.FATO5$5?LUQ ^.TT63^8-7HQK</RR6L6
M/]D, ?RKHX4CCXV1AA_=J5]0M[=@LDJ*3T%:HY)'/1SZID;+>V'J&E?_  K4
M@M[J;!9(U/H7S_2KIO[!N7EC7W)%317UC(VR*XA>3^X' -421QVDRKPL9/N_
M'\JC,&I9.V"T/O\ :#_\35B>_$"M_H[[AT#<9K('B9/,*2Q&)LXZYIBNC0-E
MJLB#;/9V[^\9E&/S%/\ [,O2G-_$7_ZY8'\Z@35@X!#9!J<7^[&"?SIBT(3I
M%]N)>\@V^P(J6/2I4 Q- Y!S@-UK(\47TR:7$58J3=Q+^!)!%<LDS0^./#[A
MV&ZYF##/!PIQD>U TKGJ$\D8!9@@9E)*%NO'KZ>]>#>+KN\N(WEEC9%DG/G.
MO10/^6?L/\*]<LY#>ZC]OD&Y8P8X\\\]S]!_6L7Q=H5O(@NH5\FWE(2X5$&V
M-S]UR.X)X(_6E5C961OEU:+GS->AQP\!)?>$;;7&U5H;BX#38= T: C:.^01
MCK7(^<MY<O+OVLY".%SM; P3^./UJ_JM]J-CIUQH$UW/%:QR$?98AE0#V'?:
M<YQ6+% ML@$LD\0"DA7A*GCIQ[]*YY6Z'NT8S5W)W3V.ATB_CN=NGS-LF _<
M2;<YV_U'3W'%+<^5'*Z2+8N"<N6&\GCH#_=J XT'3?.&4O[R,J%<Y>%#UR1_
MG)]JU/#6D:#?^'HKJ^T^26Z'+R-*VULN0H !&, "E'GYOW;LQU*E*G2YJT>:
M-]%^I0GU1R(4%\8DB "K$/E..F0:O#Q'D6MRY&UPP?ONQQ5+Q9X6+26EMX>T
MN1[J261'6WWMP,#)!)P.>O%63X(UW3-,MY)X/M..)8X&$C0^Y _IFM:<9IMM
MGG8RO0JTXJG&P\>(;JYN8[>Q#&65MJ *!D_4]L59_M&/SA+=^(1)"  (;>#
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M:K]^ZC)]%)8U0G\1L&(ALIY40J7=OE!4GG:.I('--(#;MW0GQ*8$5(LKM0=
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M0\D(0Q_E74FUCM?$^MQHF%4;T&.BN0P_]"KGG.4W>3-8Q459%*^0_P#"02N
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MS"0 !VZ5@WEVV@^.+B>SA!:,&Y>V/S+)'(/WT8QUR/G ^M6(/"VHJ X1X?\
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M]BHKM]=UN^TW2U70C;W&JFYX@E3>IBP<L?3G'-<-?S*^NV6BZ;#<6Z0/)<W
MEA$?F3#Y058$Y7!XY[]*T?!^HQ:D]Y'<071NP\A9V4^2%'&2W\3DGIS34>@I
M/J3:0LRZ9K"7(59Q,HF"G(#]P/:K?]KV>@Z@=1OIO)B1V5'\LR'>1P H[]:I
M:(2=+U8L<DW R?6I[NTANX-26>,2"*VFG0$='5?E/X5BE[]C9_".L[O2[O4K
MB[TU;E&GN-]SYH 4N4/*+V]Z72F\Q)_4,P_6DM[>S@L[*^MD*&[VF3=QDJA
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M,6Y; Z3KT#8_O+W^H-8UV/\ B5PL3_K$B/U[5>\=Z:^E:JFMZ<2J*PMIR/\
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MITK@HI-1U-O^)?IEQ.#T=P2/SZ5JV=E?:$)KS69(462/"1*X)7##DXZ=<46
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M[@@&#MR>,Y%3:9I.FZ'<2W%C 6N90 \UPV\G!SPO05%XGUM_#4D,,NG-++<
M&)S)B-OFP1D<[AU(J;3+F>^DMI)5C"O*1M087 ..]$F^HDM-" ZEK6I:K=)-
M)+)9H-B1@_+G_=' KH$A7[,BG@A0K8[<5=*X!"X"]@.*B,8YX'-2/0H2P#81
M&0,_WNP]JL6.(@X9E!8#OUIY4$'J"*0("#G#>F14NXU8M9)Y'2H6;_21_N5
MR$'*@#Z'!J,B4.&WL& QDC/%1J.Q>@;,0'?)J4D!3ZXZUR&K6NMR3I-I6JO9
MD [UP&5S[@U2&K>.+-&\VWTZ_4#KM,;'\CBJN*Q]#V/_ "#[?_KFO\J*AT>2
M2;1;&26,1R/ C,@.=I(&1104>5_%NPT_5;N[LGA?^T&M8VAF'16!<@'V/(KG
M/!#7LOA*RBO8P@AW+&<\M'G@-Z$<CFNS\=Z=#=>+=\L1?-M&.7( Y;M69.1#
M$(U&"1C\*ZJ$+NYC4ET*TK>;*<<=A27D5Q+$D-MY0P?G9VQCZ8ZTL?R@R'G'
M3'>F1C6KH#R-,B@']^XER?R%/$3Z(FG$@3296QYUZ0#VACZ_B?\ "I1IFFH^
M)&:0CM-+_ABK/]D:D1F\UE+=<?=@4+^IR:@72?#UN1YLTMTX/<EJY=36Z#[;
MI%GPLMLA](AN;].:Z32Y\A3U!Y%8*ZCI]I_QYZ7&N.C/@?RJ[I=\+HM*-BD/
MAE0\"AJPT[D>K:;JEW<75G;QVD=G)QYK;F<@\],X%9B>%+& 9OM4SCJJD#^5
M:?C27[+IMM?%97C#B*14;'7H37$MK4V\1Q1Q1<J-[Y;:#W-5&]M"96OJ=9%:
M^';3_5027##N1Q^M3_V[%:D?9[.VA4?\]#N_05Y]_:=^\SB:[!7!V[4V@$4^
M.<2 %@>><]15J%]R'*PWQ-+]FBT+7(CN;3[R2T=EX^4.)(__ !UB/PK>UGQ
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MIIG+)7D5+CQ';Z?K2Z5$RB\$/F$R %,=@#G[V.QJ&X\2.V?,O7;_ &8Q_A7
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M*0SU?3O^0;;?]<E_E11IW_(-MO\ KDO\J*DL\^\</!:Z])>74HCABMXR68\
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M&=(G,+%<,X'7#+_$OZ\&MFU\5P/Q<VQ1^A,+9'_?)P1]*9HUO_9FGQH-PGE
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M\9:+;C(Q63+ID4CDE5)SSCO4N1<4>5207B,I+O( ?NENHK<T?5HK>$VERVP
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M+#C\.+O_ *"<!XYS;G_XJG#X<W(Z:G#CT\@X_P#0J**=PL!^'-T?^8I"0/6
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*R!C.!1110,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #G 9L# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPK/K'@;Q$T5Q_8^LHA:UO;>]T'51!JVG3I)]XT %%%% !1110 4444 %%%%
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M]?GU"Y;W]?6OZT/^"CO_  2;\2?LB_ 3X@_M"_L1?%CXI^!/#GPZC@U_Q_\
M GQ'?_\ "=>"I? -[=)I7B+5_ 5]?QZM_8FK>%TOH-;2 #2G;3;2_DCA26WC
M%?R7:=;7)CM+,1337LC+ (5#27$UU+(0(UZM)-+(^#G+.[$D]: /WV_X-O?
M>J^+?^"E'A/6K&.8V/A'P9JTVJSQQ[TA@\0:WX?T !V)"HQ6^>1<_>6)P"&"
MY_T^*_C?_P"#8']B;4OAQX>UWX^^+M*-OKGC>)-6L'E!#6WAC3XKW2]!B=&&
MYHM>U?4-1U?3I>(YK?PK;WJ;A-"P_L@H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH _R1O^"I:!_^"F?_  4#/I^UY\; >N?^1MNB1SC/!XYQZ5\*X(54
M,SA"P.QW<H&Z*P4LRELG (&>2 >>?N'_ (*@7T3_ /!4#_@H9I[X29?VOOC8
M\#/RDN?$TSM&",8=,[@O\:9P<J:^7K;Q)IVFV+V.D>&]-1YK>XBFU34\:IJI
MGNH'MI9[>4QP06:QVTUS#!#;P@*MPTDKRS1Q.FE.,).7/5=**72,I.;Z12BT
MM[7<FDD[V9M0P]&M)NM7HT(PBY*52$ZDY2L[1A&$)2NVK.3E%1NFVT<'%"[.
M!%O=^2"BN2-H+$A4#-\H&YB V "QP!QJRW]W<E&GER8E"*0WE_*I)4 @*203
MD$C)/KR3;WPQ:I%<Z;9-:1)/;O;6<E[-=E2OEC8]X&M)W$T@9F DA>-9/*64
M!!(=G7M%MM,NKJ!4F6>WMHFF2>.[L[I;I[B!9I[NUOXY08Y'FEAA73[Z[A9H
MA>"XV.T5$:M6G%J$Y1BY<LE%V3:O*-UUZNZVM=@\#"MAJF*:C+ZO5C3ES);5
M4^5TV]V^5\R_ELTGK;(&L7!T^>QQO6XX=FDY5=Z2D1HI4(&EBC=\J?,(.[JM
M9 1@A4K@,589(QE2W8=OF..U>@^#_AWK?C-X9-/DL8-.&J+I>HZC=7<44>C[
MM/N=3^W:C$29;?3WM[2:&"[=1#/?^78HWGR*IYB5+?[#8K$+9IA/?M.Z0SI=
MB/? MM]IF>0P3PLHDDM5ABCD@S*L[/OCVU4KUJZ4YU'/D;H)\R=N5)NFU?F5
ME*+U5G=6;V0\GKX'#4,9/!SH8?'RG5P]6<>6.)]G:,ZM)7]^G%KD=2*Y5-2@
MVIIH^:_B$NU_'O0YTA.?^X#:#GL,8[G^M?*=J.5^H['W_P ?\Y%?6/Q)7$WC
MP9_Y@L)/;@Z+:CW_ #KY1M^OX_U6L3$_M+_X-V1M_94\;G^_\<-8YZ9QX2\*
M#!'K_/\ "OZS?!!_XIZR)QR\^/8;Q@''J>_T'<D?R(?\&[WC+PN?@/XW^'!U
MBUB\=1^/[WQZ/#5P7@U&\\&W^DZ+X?B\1Z8DRHFJ:9!K6CWVF:C-8/.=+O%@
MBOQ ;NV\W^N[P0?^*<T\CN;C/?D2L,XSTXZ YQTZT >F:/@+.<@<K]#PQY]A
MC)K8SCG.2.3W[]1Z=<<=O0\5BZ3]R;GG<G\FY_PKX@_X*)_MN>'?V(?@1?\
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M\$/A]JDL9U&(*3%!?_$/7'N?$<LW!ENO$.A+)NCT6()_4U_P51_: N/V:O\
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M=<THW_O1DX27RE%KU1VVB#_2(<C_ ):QXX[[EZXY['WXQTK_ $FO^"&2[?\
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MVB-W63.-K,F"IR0/T>^,_P"Q[\ ]"\7^)O"MY>?'']G3Q?H^J7=IJ'@'XO\
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M>?7_ #[\5#0!6<\,?7/ZG_Z]5).WX_TJ\Z<GC@YZ#I_ABJSQ_B!W'X_7CWH
MS90>>.^?PYYJA(I.?J2/?_.?SK9>(G/!X[CJ.>A'7KV_^O59X<YX[\C&?P(]
M?I[T <]+&V2<''?U&<G\_P#ZV,]LNXCP"2<ACQQDGJ,>^1[?GS74R0YR ,D<
M9/(7@\'C.1GI^?4&J;6())8$D]^F1QP!SC& 1@9SUH X*ZA=M^4XP00>.,8
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ME].>%]._([?4G\Z /EF#P,5'$9QZX]0<$9Y/?D@YSU(ZZT/A C'[HC &?E(
MXX/)R._'3'!P*^C/^$;0'[F#CW) Z8X]LBC_ (1\ @;3QV]OS]OK@YR.X!X/
M%X89<$Q%1QU''/4YQSSCH0#CVQ6A'H++T3ID9 XQTXQG'7./E[=37LYT,#D(
M1[_,/\:0Z+@?=RO3VX]R,$<4 >5PZ2R8&T@\$#'8#N,?U[=/32AL&&<+C'<X
MQV)&>G?V/7M7H0TEA_"?R)_D<=/K2_V;_L_I0!QT5F>!C\.N.>G'X\GCN>I-
M:,5J>/EQW.>2#T_#ZY]\UTR:?G^'GJ>._P#7'2I18[<9 'N<# ^F* ,.*W(
MXS_/O_DXS^'%7HXCQQ_^KCC';GU'UQTK66SP.0,=0<8!]^1@\CMTZ]:G6TZ8
M''OU_0;<9R>G&?R ,Z.,Y^G Y' QW]?PY]JMHAQCWY/;_.*NI:GTSC\<#\/Z
M@_X3+;X'3IZ\_P R/Y4 5D4\>@QS]/3K_A5E <Y[?SJ98#UZ^O&?TQ_6IEB/
M&>?K@>W(Z_YX% #$&.?7@?U_E_GBK* XSV/3\/\ /^>X(R<9R?0#/KZ^GKTJ
M8(?8?Y]J $4'.1C_ "1GG/H?0^W-34@ ' _SP*<%8]C^/^<4 2(>"/0_Y_K3
MZ0#  ]*=@^A_(T :S=#]#_*H*L4UE!]CZT 5V7/3J/UJ(@CJ*M%".G/T_P _
MRS3"/4?F/\: *;)GD=>X_P .GZU&R]0?\^XJZ4!Z<?R_^M_GBFF,^H(]_P#)
MH SRA]C_ )]ZC:/KP1].G^'?_P#5S6B8_5?R_P#K4PQX]1]1_P#JH S2A'3G
M]/ZTPQYZK^(_^M_6M(Q9ZA3G_/I33%CH ?Q/^?T- &48@<_U'/YBH3 6 [ =
M1QN/?J1@#G!Q@\#OG&UY'.>?P(./IG!'Z9Q2&W!Z _DO]#Z9_GVH Q#; #A<
M =@/Z GKWX[DU&;7/\)_#C'Y@?UK=^S>W^?^^J0P'/W1^&?Z<4 <^UIGMR?7
M _4DG^55I=/5U(*@@C&, _X?D3C-=/\ 9SZ$?G_4&C[.3V(]N?\  _SH \J\
M2_#SP[XNTF]T+Q%HNFZYH^HQF*^TO5["VU+3KN/DA;BRO(Y8)"A^:-V7?$_S
MQNCA6'S6/V6]5\#2RS_!CQSJ?A&T9_,'@OQ-"WCOP)A>5@M++5KRW\1:'"!\
MJ+I?B+R($XM[,+MC/W3]E)[$_AG_ -EH-J1GY1Z8./Z#(^HY'6@#XDO+OXV:
M=9OI7CCX0:3X_P!'"NLLG@SQ-IVKV5Q%R"7\&?$RTL41G0J&MH-:O$4,\:N5
M4-)YS<Z3^S^MT;GQ%^SSKG@F_#73-?VOP=\1^&2C#Y;J4:S\*WDM2LS8=;A;
MDBX7$B9ZG](A:#V'UY'UZGKWX'3K3A9*>=H(SS\I(_SU.,]S0!^:7V_]G*R@
M@ELOB-X_\)VL;#R%?XP_M!>&858-N\MK?7]8>VVKR!$\+*%RH3: *W%\?_"4
M&);?X\:\8B5&S_A<FN.DBXQMEGG@^T $'#/YP?J-P%?HBVFPRY\V&.0>KHK>
M_(8'KCU_E48T6PSDV5H3P 6MX6/'0#Y2?Z<4 ?G2WB3X(W][YLGQ<\6ZI<A3
MNL[#XX?%R^B<=\Z;X?U5(Y"<<XC)STP6&<][']GC6EN2? WC3XAM/<0">*3P
M_P#'KQU%+<(=L),7B"ZFTT$$DLQ5(#G,KGM^F$>FP18\JWBC([I&B=>I&!Q^
M!SCWS5L6V<;B2!TR23W[Y/KZ>M 'Y\^'=%TC3I3/\._V1KK2[MI+@KJ=]X"^
M&_P^EDE C$DLFH:O<2:[LNAM"RFV8W&PAR2HSZ?_ &'^T/XB"QR6?@'P1:[=
MJ?VCJFM^.;^*,,R*5L;6/P]HJ,L0A=5%S*H^:' "*Q^NEM5'11@^V?UP/Y@=
M:E6V4=0/QQ_]?U/3'6@#Y1M_V>KO5L-X\^('BSQ3$Q)?2+.>/PIX=96W?NWT
MOPXME<7"*I";;W5+I'VAW4E@$];\-_"_PMX6LUL-"T;3]*M %)M["T@M(9&&
M2))5@C07$O.XS3^9(Q.2Y/3U@0*,<=>@&>=W<9.#^6?2I5A'92>,^@[>X!],
M]>?;% '+PZ/!" $C4  850,#' &.WMC/4#L0;Z6*C@* !GVQZ8SCIVY]/QW/
M)'!.!CZ^G/3D]<<CGFG>4H^O8@ ?_7_E0!C?9!CH/K@9_GC]*/L8//'IC []
MNF.<?_JK:V#U/.._I^ _$<@]3ST<(QZ$^_/]* ,+[$#U7/3G SWYX(]_;-,-
MBI!RH_$]?T[=>HKH1'Z+^?\ ]>CRO]G]?_KT <T=.4=A_/\ E_.HVL W5,>_
MX]R1QU_SS74>3GJN/HY_Q%(81_=_( _T- ')G3U7^'/7I@_R_P GM43V"^G/
M\OH/?U-=>81UP1CV_P#U#\ZC-NO;'3Z<_B#0!R0L%X^49]<,/Z\4&S [?Y^C
M']<?CUKJS;*?3)/((R/P]/R'M[Q_90>V/7@?U)_3@^] '+_9!_D+2BU [#Z\
M<?D:Z4VPSC&?P'OZ ^G/Y>M(;7'3&/\ :'/^>/\ /< YX6P^OY_R(/ZTOD <
MC],?X#C\:W_L_NOY4?9AUXR/R/\ P'I^= &&(1_=!/H2WZ8/-.$)&./T/\^/
M\]ZV?LY]!^0_QI/L_MTZ=.?_ ![G\: ,D0GOD_D*<(?;'L3_ /K/YFM7[/Z@
M?DH_QIP@ [$#VV__ %J ,M8O3] 3^O6GB$^_\OYUH^2??\Q2^3[Y_$_T H H
M"(CM^)(_SW[4_P OW_3_ .O5WR1[?F:7RO9?R_\ K4 2E0>H%-*#MD?K_G\Z
M** $\OW_ $_^O2;#ZC]?\***  HWL?Q_QQ33&3U4?IG\\T44 -,6.H(_'_\
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+%'DGW_,444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "J 58# 2(  A$! Q$!_\0
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M?6C<?6DI: #<?6C<?6DHH =N/K1N/K3:6@!=Q]:3<?6DI: #<?4T;CZTE+0
MNX^M&3ZTE% "[CZT;CZTE+0 ;CZT;CZT4E "[CZT;CZTA%% "[CZT!CZTE%
M"[CZT;CZTE+0 ;CZTNX^M)10 ;CZT;CZTUV6--TC*J],L<9JE+>O_=,,;':"
MP^=C["@"_O.2-W(ZBEW'UJA:0312G$:PP]6W-NDD/J3VJ]0 ;CZTNX^M-HH
M=N/K2;CZTE+0!?A_U0HHA_U0HH H-]XTE*WWC24 %%%)0 M)12T %)110 44
M4M "4M)2T )2TE+0 4E%% !2T4M "8I:2B@!:2BB@ HI:2@ HI:2@ HI:2@
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MA11!_JA10!0;[QI*5OO&FT +2&EHH 2BEHH *6DHH *6BB@!*6DI: "BBDH
M6D-%% "44M% !1110 4"BEH **2EH 2DD=(HVDE=4C7JS' %<]KGC'3M(BD$
M<B7-ROR[%;@'T)']*\LUKQ;J?B.4^4\J21](4Z*?0]@* .\U[XB6MMYMMI;!
M[E>/,<=/<#T]Z\\DN-8\6W#&..66Z#8#*25!]O4?I71>'_AS=ZFUM?:JPAB
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M2T4 -*$]2<?6@(,8[>@Z4^DH **6DH ***#0 444M "4M%)0 4444 +1244
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M\N/*;_FVG/49Z5V74T 5+#3;33(BEK$%+??<\N_U-6J6DH **7M10 44E+0
M4E+24 %+2=J.XH 6BDHH *6BB@!*6DI: $HH[4O>@!**7M24 !HHI* %HH[F
MD[&@ HI:2@!:**!WH 2EI*!0 M)2]J2@!:2CUHH 6DH_PI: -"#_ %0HH@_U
%0HH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #N G # 2(  A$! Q$!_\0
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M2'P8X_YG;Q]^'B(__(>*ZTR'T ^O^133+[@?3G_&@#DCX-D[>-?'P]SXC_\
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M\*7=U!%8^(;B4)I%S=[7*_"7[8G[*OQI^./BK]LU/ ^DP0V?Q1_9@_94\*^
M]4O-?TG2;3Q=XN^#GQW^+OQ-\9?#UYYQJ4NAG7O#FIZ+X>_MK7=#N/#:-XLC
M>ZCU*RLM7M(\VQ_9.D_:#\+?M(KXV\+_ +5_A'X@_$WX!Z9\'=(\=?M->-/@
MQJSZ7JGA[Q+K_C_P!/X3T3X*:WJ4;R?"_P")=U;^,M.\4ZU;6TDMQ?/;Z#<3
M0->+%9S'Z6>,?CG\(/ $OC"W\;?$KP;X6F^'_AG0/&/C6+6]=L=/?PQX:\5Z
MKJFA>%M5UG[1*GV.+Q/K6BZKI'AZ&3%UKFIV4MAI=O=76R)OGGXC?MB>$1X
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MZ_CP 7K_ %2UTC3;_5KUVCLM,LKO4;N14:1X[:R@DN;AA&@+.5BB=@B@LQ&
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MN#]J;QOX_P#''B32=8^(G@CQ_:/K%AXEUK3+37->U>\\2?\ ",W;^'M:NHR
M?O@]Q''M\QD3>ZQIO=5WR.<(B[L;G8\*HRS'H#7SO\5/VA1\/?BK\)/@OX>^
M'7BOXE>/OBM8^+/%*V/AS4?"6C6'A#X<^ =3\&:/XS\<>(-3\7:_H<,\.EZA
MX^\,VVGZ!HJ:EKFM27-Y]DM46RD9_P \/VEX_@/#^US\4;K]NOPEJWBWX.ZA
M\ OAGIO[+T.I>#/'WC;P7'XA_MCXE'XZ:7X1LO!VF:I::=\=-3NI?ALVEW-O
M';?$&Z\/0Z-'X2O8[>UOE'G/[.O[/>O:A\=/^"<?BG]I+X8-XA^,7AK]A[XJ
MWOC/Q?XVT6;5O%6C>./!?Q!_9VG^$Q\9^(9XY0/B3X4\.:AJ]NT^H7#ZNNLR
M^*9S)-<&YF4 _=B2=$4M(X5<J-SL$4%F"*,L0 68A5'=B .34,EQ&KI&\B(\
MN[RXRRAY-@W/L4D,^U>6V@@#DX%?E+^VF/AG%^U#\#M3_:ST&Z\1?LD1?!;X
MMZ?I5KJ7A;Q3XS^&ME^T?>^*OAZ=!NO'6A>&-+UBW_MZY^&D/C"Q^&E_XFLI
M+*WU"3Q-;^'VA\1WEHS?G]^VYKWAG6F^(^E?#'X,6/@'QA\./AC^SMJ7[/GB
M[Q5\+OV@O%7[3_CK0;/1O#7BC1_$/P6USS=-?X-Z/\,H1-X6\;R^(6UO6UU[
M0?%3?$S1;%+VU_M8 _I%UO5X=%TG4]6N%=X=,T^^U!X8BGGSI86DUY)% '9%
M,KQ0/L!95R,LP4$CSCX+?%C2/CA\'_A;\8]!TW4]%T;XK?#OP;\1](T76OL@
MUK3-)\:Z#9>(--M-56QN+NT%Y#;7J0SM:7-Q:O-%(;>>:,!S^?\ X0^#?AKQ
M/^V3^WO\6_&'A'4M9\4> [KX26WP:UWQ!'K5QI'A<ZE^S#H%KXHU7X>6-U_Q
M)8M9UBXF?1?$VN:-!/J-Y;V-KH5W.D=H]J_PK^QKH'P^M+K_ ()O:;^S]X$\
M?>%?VD?"'@#4$_:[U#Q#X1^)7ARZLOA]/^SCX@LY]+^,.J>*K:TL]9T#5OC$
M_P +[GX+Z0]SJ=I8:79P7/@:QTGP]IE]%; ']%CSH7= ZF1 ID4,"T8?.S<H
M.5W;6VD@9P<9(.*,DRAMFY0Y4LJ$C=L4@,^W.2 64$] 2 3T%?SR? C2?"]Z
MO[#]I\-O"?CS3/\ @H%H'QF\+ZG^VMXCUOPKXXT_Q[%X;_LKQ4W[3DOQR\;Z
MQIR:%KG@KQ-JICM?AM8WNMZCI>H:G>^ I/AK;#3[!9;+HO!WP8L_#?P]_9P^
M.VD^#?%=A\=[K_@IIXKT/7/')3Q9/XPA^$WB+]JKXS>"=7\+3F[>>?2?A+J/
MP^N+>:Y\/1P6?@MFN4\7&U&J73:M, ?O5*_7_/'^)/\ AZ5ESOU'K_7_  '
MJS*_7_.3V'T'U_D*S)GZ_B/7ZG\?_KT 4;A^O;_/IZX'Z\5QOB%B;6W_ .PS
MX>_]2#3,_P S74SOU_S]?TQTKD=?;-M;?]AGP[_Z?]-/]?TH R/ K8\'^$Q_
MU+6A?^FNU//ZBN]@?I^&/Z>G!''O7G7@=L>$/"G_ &+>A#_RF6N/UX]J[J%^
MG^?QZ]0>OI0!OQ/T]/Z=Q_45HQ2=.<_U'^(_/]:PXGZ?YY[?G_GO6A%)TYQ_
M0_X'\OUH VXY.G/T/K['_/ZU<23_ /5W'_UO\\<UC1R?_7']1_G^AJXDG3GZ
M'_'_ #]: -=)/?\ $=?Q_P Y^N:LK)Z_F/\ /UZ?E60LF.IP?7L?K_G'TJRL
MGX']/\_7IZT :JR9]_<?Y_PKF==\>>$?#&M^#/#6O^(=.TKQ!\0]8U#P_P""
M-&NIL:AXEU?2?#^K>*]4L]+M45Y)CIWAW0M5U:]F*K;VMI:,9YD>6!)=<2?_
M *Q_G^M? WB>^;7?^"EOP]T'6I"FC^ ?V'_BSXQ\*RO((%LO$7COXS?#7PIX
MJUFUF8 1W^G>'/#.E6"W8):SM-=ND.U+UMX!]N:+\3/AYXD\2Z[X,\/>/?!6
MO^,/"Q*^)_"FB^*=#U3Q+X=82+$1KNA6-_/JFD,)66,C4+2W(D94QN(%=KYG
MM^O_ -:OQ+^$.DWO["^N^!_V=?&'PS^$/B'6M>^%?QX_X9C_ &LOAWH&CVWQ
M)\4Q^ ?"T_Q$\2Z-\<=!U#1Y-2LO%>K:9!:Z]K7C71/$OB3PCX]UZSLGUK3]
M+UJ_MH7U?A+\=_VG[&+]@;QOX@^.NF_&*;]M;X6^*I_$/PS?P)X%\-:'X/\
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MWAH2)_PF7B'Q[>RZC,W@SPV7[#XD?MV?$CQ?%XZ^(OP0\8PZ=\![SXE?LE?
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M]OZ#_P"O_D\5F3/U_P \GIV[#\ZL2OU_SSV'7H/Z>U9DS]>?7G_T(]/P_44
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MXHIIS6_@#4?+\+06!;51J,\/UIX[^$</[('[//Q/_:=\,_%#XZ?$?XQ?"CX
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M_+N/ZC_/\Z -=).WZ'^G^?PJPLGH?P/^?Y5DK)GW'ZC_ !_SS4ZR>^?8]?\
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MR?4#]3_G_/:JCO\ GV'I]?\ //\ ( )'_ ]AZ#U_^O\ TJA+)UY_SW)_I_\
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M2^*-?\7Z!JWABYGUW4KG^RM,TF$7+ZC](>'OV:_@AX8T?PEH6E^"(I;'P/\
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M2>&M#\;6OC'P+XL\,7FKZ)='4M3T7Q5HWAW1-?T;4-?UTZ=>P66HR6*T;_\
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M -O]/L!P?I_IG^??FJT<GOG^H_Q'Y_K5Q)!Z\?J#_G_ZU %A$U+C_B86^/\
MKP.1_P"3G^>U6E34^#_:%L/?^SV/_M[_ )]*@23IS]#_ (_Y_E5E)/?'\C_G
M_)H E5-3XSJ%M]1I[?\ R=_+\JF5-4_Z"%J1_P!@]L_^EO\ .F+)^!_3_/UZ
M>M3"3_\ 6/\ /]: %"ZG_P!!&W'_ '#V(_\ 2W^E2!=3_P"@C:'_ +A[9_\
M2X4@E_VOS_Q_^O4GF>WZT )LU/\ Y_[;_P %[?\ R;1LU/\ Y_[;_P %[?\
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MV[@ #;C'?BK<DG^?4_X?Y]!6?+)UY_\ KG_ ?Y[4 0S/U_/'\A_CQ[UZ_P#
M$YN_B!_V$/#X_'^RI<_K7BLK_P!?S[G\/I_.O9OV?CFX\?G_ *B&@?II<HH
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MPK_T:KB?_P 2CAS_ .=I_:6\G_ZA_7_/X56>3\3Z=A_G_/:OXO?^&C/VA/\
MHN_QE_\ #G^-_P#Y>5^@W_!,[XJ_%CX@?M*GP]XS^*_Q-\2Z,_P\\7WG]GZW
MXZ\2:Q:)=VS:5Y%TEIJNHWMJMQ$))$CG\@RHDLBHRAVSUX'C;#X[&87!QR^O
M3EB:\**J2Q%&48.;:4G&--2:5MDTV?7< _3OX<X]XVX5X*PWAOQ#EN(XISS
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M^R__  ^F^-W_ $2#X2?]_/&O_P TM-_X?2?&S_HD'PD_[^^-O_FFK\:J*/\
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M?_7_ ,^@JG))^7ZD_P"'^>N!0 R63\./R'K]3[5C7;YET\>NM^'_ ,O[<T_
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M_96/B+_ZF&L5Y/7K'QZ_Y+G\9_\ LK'Q%_\ 4PUBO)Z_G7$?[QB/^O\ 7_\
M3]8_YF>)?^2DXC_[*+B#_P!7^>!17VG^S!IOPQE\%?$+5M3TOX)>*/BW9>+?
MA]:>'_"W[07BZ;P=X)F^&%[;>*V^(.J:!=GQ%X6L-1\8QZO;^#=.2&;59=8T
M[0K[4]0\-:9>:D'GL?IV]^$'PBT_QG\8_P!FKX0Z'\!]?^,UK^T!\=/"/A'0
M_C3:?%*]\7ZQX(M=(\,P_#/P_P##OQGH5S:> +3Q3I^H6WCC3XE\:WFG7&JZ
M_'HYN747,<#=E'+:E:E2JQK4DJO,HP7-*HZEING1C%3CSUJG))*FN64?<NJC
MG!/[?)?"W,,[R?*LXH9YD\(9O[>CAL#!5\5F%3,O98RIEV28>A1QN'6-SO,_
MJ.(A#+*,L/BL+*6$4X9C/'X6E/\ (^BO=OV>9]#B^("6NNVGP29+W3Y;:UU7
M]H!O&S?#W0K@75I++?75GX&9]0O=0EM8Y[&UCOK._P!/ACNKFY^SQWT-E=VV
MK^UMX*\-_#S]H[XL^$O!OAF\\(>#]/\ $BW7A/0[N_CU1(_#.M:9I^NZ#J6E
M:A'J.K_:_#>OZ7J5KK_A6:;5-1NCX:U/2A>WEQ=B>5N7ZN_JOUI3BX^W5"4+
M2YXR<)3C*]W%Q:A);0L[).H^94_DI<-U_P#5./%L,9AJF&6>PR'$8%4ZZQ>'
MQ%;!8K'8;$2GSU*$J%:G@Z\/>I8-QJJG3HU<PF\33R_YTK]+?^"4)V_M6*<X
M_P"+9^-N?QTBOS2K]*O^"4IQ^U2"/^B:>-?_ $+1Z[L@_P"1WE7_ &'8?_TJ
M1^@_1V_Y/OX1?]E]P_\ ^GL8?TKO)V_3N?KZ?YZU3DDZ\_4^GL/\_K2/)UY^
MI_P_S]*IR2?_ %A_4_Y_J:_>C_H;$DD_#T]AZG_./ZYER_[N3M\CX]A@\_C_
M )/%322>^?ZG_ ?E^E9MR_[N3_<;/UP<#_/]#0!][?"[_DF?P[_[$7PC_P"H
M_I]=U7"_"[_DF?P[_P"Q%\(_^H_I]=U0 5\+?%5L?%7Q@/\ IEX<Q]?[!M/Y
M_P">M?=-?!WQ:;;\5_%_O#X;X_[@5I_*@#FHY/?']#_@?R_6M".3\OU!_P /
M\]<BL2-_\^H]?_K_ ..*O1R=.?H?7V/O_GK0!M1R?G^A'^/^>F17E_QO^./P
M_P#V=?AEX@^+OQ0OM1T[P1X7?2DUB\TK2[C6;ZW.LZM9:)8&+3K4_:)U?4-0
MM8Y/*#&-':4C8C$>AQR?E^H/^'^>N17YM_\ !7E]W_!/WXX#KF;X=8/_ '4W
MPAUKP>*<RQ.3<-9_F^#5)XO+,GS#'X95H.I1=?"X:=:FJM-2@YTW**YXJ<')
M72DMS]9\!>"<F\2O&[PC\/.(I8V&0<<>(_!_"F=3RW$QP>8QRO/<ZH9?C98'
M%RH8J.&Q<:%63H5Y8:O&G42E*C45XO#7_@MA^P*.OCKQ_P"Q'PP\2Y_]!J4?
M\%M/V!!_S//C_/J/AAXE'_LM?Q445_'G_$Q/'_\ SYX=_P##56_^>1_T@?\
M%&OZ(O\ T,O&7_Q/\O\ _H*/[6A_P6W_ & ^_CCQ^?\ NF/B3_XC_"I!_P %
MNOV Q_S/'Q /U^&'B3_XG-?Q0T4?\3$\?_\ /GAW_P -5;_YY!_Q1K^B+_T,
MO&7_ ,3_ "__ .@H_M@'_!;O]@'OXW^('X?##Q)_\33O^'WG[ /_ $/'Q"_\
M-AXD_P *_B=HH_XF)X__ .?/#O\ X:JW_P \@_XHU_1%_P"AEXR_^)_E_P#]
M!1_;'_P^]_8"_P"AX^(/_AK_ !'_ /$U^:G_  42_:-^%_[4WB'X-?%?X0ZC
MJVJ>#;GX?ZUH,-WK.C76@WCZAHWC?7DOT_L^\/GK$CSHJ2L%$IW%1M 8_P X
M]?I/X._Y-V^ _P#UP^)G_JP-3KZ'AOQ:XJXVQF)R7.:>41P:P4\:G@<#4P];
MVV&Q&&5->TEC*ZY/W\^:/)>7N^\K:_XO_M[/V>O@)]&#]GSG7B9X;8OQ#K\1
MU/&?P;X8E#BCBK"YSEBRW.\WXLGC9+!T.',JG]:3RO#*A6>*<::=6]*HYIP@
MHHHK[ _XA@HHHH **** +-E_Q^6G_7S!_P"C4K^W2S?%E9CJ1:6X ]/W*=?\
MY_"OXB[+_C\M/^OF#_T:E?VT6LG^AVG8?9H/J?W2?Y__ %XK]&\/OBS7_#@_
M_2L0?Z=?LX/]X\7?^P?@K_T_Q&6I).O/U/K[#_/Z52DD]\?T'^)_/]*))/\
M/8?_ %_\^@JE))^/I[GU/^<_T_2C_489(^<C/_UA_B?\]J]__9Q.6\?'_J):
M%_Z:Y/Z5\ZRR=>_//N?3Z#_]7O\ 0W[-IR/'QZ_\3/0__37(* /I^O+?C7_R
M2SQE_P!@V+_TOM*]2KRSXV?\DK\9_P#8,C_]+K2@#XUC?ISCT]C_ ('_ ".3
M2WBW\]JT>F7T&GW99"ES<61U")%#9D4VPNK,MYBY4-YZA#\Q5N15*)_QX'XC
MU^O^>]7XY#]?ZC_'W_R0#)33_&O_ $-NC^X_X1*3\Q_Q4G^?R-74T_QM_P!#
M=H_L?^$2DY]C_P 5)_/\>>NM')TY^A]/8_Y_2KB2?_7'K]/\_GB@#^(/_@K.
MES'^WW\=DO+B.ZNED\ ">XAMS:Q32_\ "LO!VZ1+8S7!A5CTC,\NW^^:_.2O
MTA_X*WG/_!0+X]'_ *;> ?\ U67@ZOS>K_,_C?\ Y+/BW_LI<\_]6>*/^X+Z
M+G_*-/T>_P#LR?A;_P"L1D!]J_ 7]E[P1\;?A;\0O$Z^/_B%X<\9>"/ ?Q.\
M?W-S-\(?M7P*T2V^&OAV;Q);^&O''QEF\:V+Z!XG^($,46B^$;:T\':I;#Q+
MJWAK1)Y[B\\0P1VM/3?V<_A;XO\ V:/BC\:?A_\ %[Q5JWC;X%Z+\*M?^*/@
M[Q'\+HO#7@QX_BIXJL/!<'A_P+X]@\<:U?:]XG\,ZYJ"27UIKG@_PQ;:_HUA
MX@U?P_/<6V@S_:NQ_9C_ &I?AC^SOX(UR9M(^./BCQSJGAGXF>&M3^&5Q\0]
M 3]EWQ_+X_\ ">K^#M,UWXA> )/#CZOJ)\)6&J6>JC1&NM1?6O$/AGP_J-KX
MA\-"V6&"KXV^/W[.VL_LI>#/@%X)\%_&GP+KGAZ#3/%GBPVOBGP#>>"?BI\;
MMLEEJGQ%\>,/"-MXPO\ 3-&T"_U/PU\-?"46KIIO@72I[N>U-WK?B7Q?J^M]
MU&EPV\LH3J3RKZ['(\R^LT)5L=&O6S"=2G'*IX>K3OAJ.+H\U6MBZ=>$Y3HX
M;ZNJ=L9AJM'Y7,,;XTQXXS7"X/#\?+A>OXI<$_V)FE'+>%J^59?PAA\'C:_'
MV'S?+\8Z>=YCP[F"H9?EF08O*J]"CA<QSK^V'C5+AO.\#F69^SW^R&?BM\)?
M$GQQ\5S?&%_ ^E^.)?ASHVB_ CX+WGQL\=:IKVF^&[7Q7XKU[5]+/B?P;HGA
M7P3X,T;5_#<FIZQJNO&]U:_\0V>GZ-ILT=GK.H:7V/@_]B3PEXE\+> ]'N_B
M_J^F_'SXQ? SXF?M%?"?X=Q_#R&[\%W_ ( ^'-O\1]3LM#\9>/?^$RAO_#OC
MOX@:%\*O&&L>%]-TSPCXBT.P \.6.NZ]:W/B!SI'7_!K]L_X'_"73K7P;8>"
M?V@+3X>_"O\ :>A_:A^!%GX>^+>@Z/XHO=7CT/PIHUW\/_C%J]IX2M=)U71M
M1;P)X7NK?Q9X8T*QUGP^A\1VFGZ5<C7O/L2']O'X?WL/A[XL:Y\+?$\7[4/P
M_P#A)\9O@KX$U3PYXDT/2O@LFA?%[4?BU)9^,-7\*OX?F\3P>(OAUH7QJ\6:
M%H&@Z;K9T/6'T3P=J=_=6(L-5T[5NW"X?@RGA,$L1B<%6Q,,-"&.4Y8Z2J3C
M7K_VIB*%:A"E+ZTJ,</3R'#U:,:-6_UJ4DIUJ$/F,^S;Z3&,X@XEGD^2<3Y?
MDE?.\1B.%IX>APK3EA,-5RK*?]1<HS7+<TQ.84GD4\QJYMC/%C.,#F57,LO5
M-9#2I2E0R[-<1^85?9/_  3R65OVY/V5%MY%AG;XW^ UAF>+SDBE.LVXCD>'
MS(C*L;[6:+S8_, *^8F=P^-J^S/^"=O'[=/[*!]/CEX _P#3Y;5\OPS_ ,E)
MP[_V/\C_ /5QE9^\>-__ "93QD_[-'XH_P#KN>.S^]+^SO'/_0Y:+_X1[?\
MS2TAT[QS_P!#EHWX>#Y/Z>):Z;S".N!_GZTTR^X'TY_QK_3T_P"%8Y@Z=XX_
MZ'#1S]?!\G_S34TZ?XX'7QAHW_A(29_3Q+FNG,@/<G/^>G%1F3Z#]?\ /Y4
M<N=/\;]?^$NT;ZGPC)_\TW]:A:P\;_\ 0W:,?KX0E '_ )<O^?6NH:3/J?KT
M_P ^W%0M)[Y]AT_S^= '*-I_C?\ Z&[1C[GPA)@?^7+59M/\;<_\5=HWN?\
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ML>I/<Y->55ZO\>?^2Y?&;_LJ_P 1/_4OUBO**_G7$?[QB/\ L(K_ /I^L?\
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M_P"+I?Y[^M?GE_P5=M_&D7[!?QP;7O$'A?4K#/P^'V;2/"&K:)=^<?B9X/\
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M+"5*^'P5?$TLR6+PF ^:**_5[_@H=^R[\(O@'X/\+ZKX%\"1^#]:N_C9\6/
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MC\4ZW<>+_%WC*^MO[,TK5-:M-&T'P]=:'X8TN/6]4:WT423QO#\N5^C6G_\
M!._Q[J'B_1;2-/B&/ACJG[)(_::E^+Z?"K7Y?!-KJ/\ PR]=_M!GP*=>6Y'A
MUHAKMNOP[.O-KB,+V471TK^T -$/YRUYN=8;.Z=6EB<ZA656NJE"A.M&G!3I
MX-8><E0A2H8:DL/#^TZ4J=2A16'JSQ%:5.I4J?6)'V_ACG7AAC,!C\D\,<3E
ME3 Y6\'FV:87+:N+Q,L-BN(JF<8>C4S3%8[-<[Q\LWQ'^HV-H8O"YIF,LVP6
M'R;+*&+PN"PO]D40K])_!W_)NWP'_P"N'Q,_]6!J=?FQ7Z3^#O\ DW;X#_\
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M$2^-?B+XVN;W7M8\6>*-47P^=1\4WYOP+?1X].T;2?&_B1\1_#?QL^(GQ?\
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M0J5*$HSHU)PHUJ493I3A"5.;7/"4(.,ER1Y?ZPS7A;A?/<7A,?GG#?#^=8[
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M'*_JLJF78?$XFA@:DZ$ZN$I8G$4Z%6G'$8CV_JWB7XY?%SQCX=U'PEXG\?\
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M??\ JLO!U?G97^9_&_\ R6?%O_92YY_ZL\4?]P7T7?\ E&GZ/?\ V9/PM_\
M6(R ****^7/W8**** "OI?\ 8^_Y.)\ ?]</&O\ ZK_Q57S17TO^Q]_R<3X
M_P"N'C7_ -5_XJKV.'O^1_D?_8XRS_U.PI^#?2J_Y1<^DQ_VCMX\_P#KF?%0
M^B:***_K _\ ( "BBB@ HHHH *_:'_@D<VVW^//H9?AL.._R>.:_%ZOV<_X)
M)MMMOCR>G[_X;<_\ \<U]%PG_P E!E_^*O\ ^HM<_IKZ'7_*1WAO_P!A'$'_
M *RN>G[*/)_]8>OUJJ\GN,_H/_K_ .3VICR>Y^O<_3_.?IBJKR?_ %AZ_7_/
MYXK]N/\ >8623KZ'\S_];_/?%&GOG6-#'7_B?Z#GV_XG%EP/\_K5*23KS]3Z
M>P_S^M/TM\ZWH(]?$&@X'_<7LN3_ )_J: .3T=_^)7IH)Z6%F ?0BWCX_P ]
M/I47BG0_^$K\+>)?"W]M^(/#1\2^']9T#_A(O">I?V-XIT'^V-.N=._MOPSJ
M_DW/]E>(-*^T_;]&U+[//]AU&"VNO)E$1C:'29,:=IXSS]BM1['$$?'U[?UR
M:V$D_+^7_P!;_/7(H _/1?\ @G+G_F_+_@I)QZ?M18(_\L;_ #ZU87_@G'GG
M_AO7_@I-]1^U)T_\L;/^>E?H<DG3GZ'_ !_E_.K2R>^/Y'_/OQ[T ?D_XZ_X
M(Z?!CXIWUAJGQ/\ VFOVVOB-J6EV3:;I>H^._C/X5\7WVG:<UQ+=M86-WX@^
M&&HW%G9-=SSW)M;>2. W$TLQC\R1V;BA_P $(/V3._Q6_:A(]O'7PU_^<_7[
M.K)CV/Z'_#_/-3K)^'N.0?\ /;K7G5LGR?$59U\1E&4XBM4?-4K8C*LKKUJD
MK)<U2M7RRM5J2M&*YJE6<K1BKVBDOL\N\1_$;)\#ALLR?Q%\0LHRS!T_8X/+
M<IX_X\RK+<'2YZE3V6#R[*^-\LR_"4O:5:M3V6%P&%I>TJU9^SYZE2=3\7A_
MP0>_9+/_ #5?]J'_ ,+KX:@_K\'Z>/\ @@Y^R3W^*_[40_[GKX:?T^#U?M*)
M/7GW%2"3T;\#_+G^AK+^P<A_Z$61_P#ADR;_ .<YV_\ $6?%C_HZWBG_ .+/
M\2__ *8I^+(_X(-?LDG_ )JO^U$?IX[^&G_SGC3A_P $&?V2/^BK_M2#_N>O
MAI_\Y[^E?M0)/4?E_A_]>GB7_:(^O/\ C1_8.0_]"+(__#)DW_SG#_B+/BQ_
MT=;Q3_\ %G^)?_TQ3\5?^'#'[(__ $5G]J/_ ,+KX:?_ #G:DC_X(-_LF12)
M+%\7/VI8I8G62.2/Q]\-4DCD1@R.CK\'PR.C ,K*0RL 0017[4"7W!^O'^%+
MYONOY_\ UZ?]@Y#_ -"+(_\ PR9-_P#.@3\6?%=II^*OBDTTTT_$_P 2FFFF
MFFGXBM---IIIIIM---I_D#??\$6/@+JE]>:GJ?[1_P"VAJ.I:C=7%]J&H7WQ
M@\&7=]?7UW,]Q=WEY=W'PKDGNKJZGDDGN+B>1YIIG>21V=F8U/\ AR5^SO\
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M'T>PT.R\BQBN'2';8:;;+)M8^9*KRG!<BO+!_P $'?CH?^;AOA</KX3\3_\
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M</\ _-1_/ ?^"1/[5@_YN-^#OU_X0+Q'_6XKWSX(?L1?M^?L\IXE3X<?M+_
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M"X\NRNO>/VS/#^L:I\*?#OC+P_I.J>(M7^"GQB^#_P ;T\/:-9SZAJVM:/\
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M3N?\_A[U TF.G ]3U_S^=0-)U_F?\_Y]* )GD_ >G<_Y_+WJJ\G_ .K/\_\
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M*78G]U?^^1_A0!Y$)/1@?8_YS3_,/<#^7^->M_NUP62/&0,E5&2Q 49QC))
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M_B.H^O\ G-65DZ?S'^?\^E>HKH6B_P#0/@!]?GP?_'_\^M2C0M('2P@_)O\
MXJ@#S!9/Q]QU_P _E4RR>^?8]?\ /YUZ8NB:/WT^#Z@/_P#%?R_*I1HFD'I8
MP'\&_P#BJ /,Q)CN1^H_S^%2"3/H?Y__ %ORKTL:+I0_Y<8/Q#?_ !7\J<-'
MTGO80?@&_P#BJ /-1(/<'^7]:=YG^T?UKTO^R-)_Y\H1]0W]&-*-'TC_ )\H
M#]=X_P#9A0!YKYA_O#]*/,/]X?I7I?\ 8^D?\^-O^;__ !=']CZ1_P ^-O\
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M!MKQPNZ-A@5;# '# @XP017\8^C_ /!4_P#;VNM6TNUG_:!U!X+G4;*":/\
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M_GSL_P#R/_\ '*0^.M0_Y\[(?7S_ /XZ*^H_^&,X_P#HH\W_ (2<7_S0T?\
M#&<?_11YO_"3B_\ FAH ^6CX[U#_ )];(?03'_VJ::?'>H?\^MH?H)Q_[5%?
M4_\ PQG'_P!%'F_\).+_ .:&D_X8RC/_ #4B?_PE(1_+Q!0!\JGQWJ _Y=+(
M?7S_ /XZ*:?'NH#_ )=+(_A/_P#'OY9KZJ_X8PB_Z*1/_P"$I%_\T%'_  QA
M"?\ FI$__A*1#^7B"@#Y1;Q]J ZVED/IY^?_ $:3^-0MX_U <_8[/ZDS\_\
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MEB_GC^>*].'['WQ4[ZQ\/S_W&O$8_P#=0IP_9!^*H_YC'P_/UUKQ&?\ W4*
M/,1X\M/^?"X^HEB_PJ0>/;3_ )\KC\9(_P">/ZUZ9_PR'\5!TU?X?C_N-^(_
M_F/IP_9%^*H_YB_P_/UUOQ'_ /,?0!YH/'EJ?^7&<_26/_Z].'CRT_Y\+D?2
M6+_ZU>E_\,C?%3_H*_#_ /\ !WXC_P#F/I?^&1_BK_T%O '_ (//$?\ \Q]
M'FG_  GMI_SY77_?V/\ QH_X3VT_Y\KK_O['_C7I?_#(_P 5?^@MX _\'GB/
M_P"8^C_AD?XJ_P#06\ ?^#SQ'_\ ,?0!YI_PGEI_SXW7_?V*F_\ "=VG_/A<
M?]_8_P#"O3?^&1_BK_T%O '_ (//$?\ \Q]!_9&^*AZZM\/S]=<\1_\ S'T
M>8'QY:_\^,X_[:QY_P _A3#X\M/^?*Y/TDC'^%>HG]D7XJ=M5^'WXZWXC/\
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M>(_Y_P#"(?RQ0!Y6WC^U'_+A<#W,L7^'^-0GQ_:?] ^X/N9H_P#"O5S^Q_\
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1,8XV$222Q(S[5:2-274 _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $S ;(# 2(  A$! Q$!_\0
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M[.W?[PVW_K?\[.VU_OM^V%%?C/\ LK?MD_%FYU7X41>//&VM_M*:-\3/V/\
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MX8N/%V@1Z?XA^'K2:H]B-%\37GA!8;&:;2Y[G2+RQF>8+QEC_P % _B=\)?
M7B>?Q=X&O/C3;?#3X6_LU^+O%_Q+O_%.@^%==U?QY^U5_92^!_#-KX#\(?#M
M=.T_PCX?OKV__MWQ(EU<ZA8:/9V(M],\1:E=3F$_J_\ P=O+?YA^7=NRVOOM
M^._4_9*BOR0O/^"G^I:1K'P+\-Z]\#ET/Q1\3_%'A7PMXN\,WGC;46U?P</'
MGQ6UCX1>"O%-DT7@1M+O?"^OZWI7]M6PU[4_#/B;^RC?6)\.+JNFRPS>;^&_
M^"G7QIT/X-:#XT\9?"#X7>//$T'PW_:"^,/C8>$?BGJ/A"RTKP3\#/C'I?PT
MU'2[/3=8\#ZW<-XRNUURW:TTNZNK>QECM(-1O=3L/[2DLM./Z_K^MM=M4>?3
M\/O_ "[K7:[7[;T5^0/C+_@J#XP\'7\G@EOV;I/$'Q6TKXF_&+P)K?A?PY\0
MYM1\/7-K\'_#OPV\57K>&/%4O@>S>_\ $/B'2_BCH4&GZ;K6C:!I>GW6GZM=
M:KK=OI:VUW+5^+O_  4E^)_AZP^-=EX0^#OA32;KPK:?M4^'?ASXF\3^.;[5
M)KGQY^S/\/\ P[\1=8?Q?X'TOPO;M8:/?:#KUS;VL-CXLO;F3Q#HQL+M[/2-
M3AUJ$^[[U_P_WI!\U]Z\OGUZI'[$45\ ? _]LCQ)\0?C7X;^"'CKPAX'\-ZI
MK_P>T3XC:'XG\-^-]5\3Z7\0[^70?#FL^*U\!QP>$8--CT7PC+XABTW5X?%'
MB'1/%27(@O;'PYJ&BW4.IG[_ */ZZ_JD']=?U2"BBB@ HHHH **** "BBB@
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M5G++::;I]ZD]I8VTLD%K#%$[(>NHH \WC^#GPBB;PZ\7PK^'$3^$$$?A-X_
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M\45U>6OAVQFUBXM+:28B".XN8;)X89)B(4D=6E(C#5^(<?\ P< _!)XHY!\
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M**9$V^.-CU9$;T^\H/3MUI]?F']=OSU/L0HHHH **** "BBB@ HHHH ****
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M>YB:9CUW[ W[6_QC^/-QJ%C\5=3\$R3W?B.Z&F6_]A:KX6UB32_^$$T?Q/\
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M"26&#DX-?HK_ ,.F?^"@G.?@(<)R?^*\^'_.03A,>)!NQ@ _*=V1\N5X4?\
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M=,U.#1;K4HLZAK6@?#35[RYD T;PWK.CPS:T/L2X^#/P?N_[3^U?"GX;7/\
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MH AMO^/>WZ_ZB+KC/^K7KCC/KCCTXHHMO^/:W_ZX1=\_\LU[]_K10!-1110
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MH1,D\T[2+8?LK?LXZ7_;0T[X+?#RR'B*]\0W^M"W\.6,8O[CQ7H&M^%?$0D
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M/&\VJ0/ T%\WBGP]X9\/Z/K8N8Y%OK#2+&WF#) HK"TG]E/]G30KOP5?Z/\
M!_P5I^H?#J[FOO!6HVVF>7J.@3SZA%JT@M]0\TWEQ;C5((=0AL[Z>ZM+:\BC
MN+:"*1%8']?Y;?UMVU/P7;\M5T[_ "UTUM_M0,&_9K^/;#D-\&_B.03QD-X0
MU;&-RG!(/ ('.!E>H_SW[4 VML3C/DPL6))S\F< D-O R"O 8C)&00:_T)_V
MFH)[K]G/X[VMK;S7=U<_"'XB06MK;1237-S<S>$]5CM[>WAB226:XFF9(X8H
MT=Y)65%4E@*_@:M?A'\6Q;VP_P"%4?%#/EQ +_PKSQ=G[J#8,Z-\D@ ( ;:
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MM_\ KA%V(_Y9KV/(^AY%% $U%%% !1110 4444 %%%% !1110 4444 %%%%
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M7_%/28[OPHMCH>I6U_K,P\/:'I^O:/K.KQ6NF6Z0W&GH]U<NTI]WY/IIU?\
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MXJ/,*E2KTGD18_U$.=P 'EQ#YP<<-E@S @X=4DD8J!&P4EE8+RV!!\Z+).$
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M'HW_ 'P_N/[OM_(]",FX>C?]\/Z9_N_Y/'7BC3NOO7^86?;^OO'44W</1O\
MOA_;_9]_Y^AP;AZ-_P!\MZX]/\CGIS1\U]Z_S"S[?U]XZBF[AZ-_WP_O_L^W
M\O49-P]&_P"^'],_W?\ )XZ\4:=U]Z_S"S[?U]XZBF[AZ-_WP_KCKMQW_+GH
M#1N'HW_?+>_M[?AQGJ*/FOO7^86?;^OO'44W>/1O7[C^F?[OZ=<\=>*-P]&_
M[Y;V]O?\><=#1IW7WK_,+/M_7WCJ*;N'HW_?#^N/[O\ D<].:-P]&_[X?TS_
M '?\GCKQ1IW7WK_,+/M_7WCJ*;N'HW_?#^F?[OO^?'4&C</1O^^6]<>G^1ST
MYHT[K[U_F%GV_K[QU%-W#T;_ +X?W_V?;^7J,FX>C?\ ?#^F?[O^3QUXHT[K
M[U_F%GV_K[QU%-W#T;_OA_\ XFC</1O^^']Q_=]OY'H1D^:^]?YA9]OZ^\=1
M4:R*S;1G.,X/!QG&=I(8?BHJ2C^OZW%^NWWM?FG]P4444 %%%% $%M_Q[6_7
M_41=>#_JUZCC!]>**6V_X]K?_KA%WS_RS7OW^M% $U%%% !7X^?&"^_:5U+X
MW?'B7P/;?M8Z%\,=*E^%/A[4-$TRPU;46\;>'T^(GAF]^,7Q _9_UPQC3_!^
MH:1\/;FY\+>&=!T&_'BOQ7</XIUZ"S@N=.TN>Z_8.@      #  X  Z #L!1
M_7]:!_7]:/\ KR/R#^'/AW]K2/4?AKXM\8:_^T3X>U'P+^SIXA\2?$6:XFG\
M>Z;XV\<^(]:NO"WPD\&+\)5U2R\.:Y\0O!G@+3KCQI\3Y])DL7O?%^H:$+JZ
M$\U]&>N_:0M/VQ;7]JSPQXQ^$$'Q U#X2^&/#?P@35=%TC7-3@\/:UK^K:Q\
M8HO$%A-X+8+X:\1:=J-S;_#C2OB5KNH7UOKGP\\*W]AXH\,K=7$%^B?J:5!Q
MD=#D=1@_A^HZ'O2T:]_Z_J__   UO>_X?UY_\ _&+P=\>O\ @HG9^$_AQK_Q
M)\%/9R3:K\3)/B-9Z=\(]5T1_#NB:?\ #ZQUC0=0\1:IXA%EH6F^'?"7BP:[
M9SW&C+_:/BW3HM(.@ZGXDFM;]+WA?A_\8O\ @H3\2/#>A_$^R\!ZI>:G?_"?
M[=\/_'&H_"Z]\.Q/J7CK_AG"^UI;SX<V_C6?1M9TCP[-KGQ+/@O5]2BBU/Q'
MX>\/7%_;WEK$EY+??NJRJZLCJKHZE71@&5E8$,K*00RL"000002",4D<:0HD
M<2K'%&B1Q11HJ1Q)&-JI&B@!450JJH^554!0!1KW_#?[OZ\@U[_AOKMII_6S
M/QH\1?$#_@HIJ7Q2\7^&4L/B+H7PS\ ?&KX2I8^,=!^$GAJ[UWQKX!L_B!>>
M%_'4^EVPD_LK6?#?B+PVVF^-KV#3VU/5-'TN:59+C39;:[T6UZ[P/\2/^"B?
MC?4=&\/ZOHM]\/(M=^(?A+2O%OC'5_@OINSX:QWWACXQ:EX[\/>%=-G\77-C
MX_\  'AW4_#GPHLM ^+6H-:'5;_Q9J-JMM>#;;VGZU!0,XR223EF+$%NH!8G
M:/11A1T %?/7QJ_:5\#_  )\2_#;PQXPTCQ9=3_$ZX\3V^CZMH]CI0\/:9+X
M5TF/5[NVUO6=;UK1;2#4]3@E$?A_0[%M0US7)(;XZ?ITT5A=R1G]?UW#^OZ[
M_AWL?%W@;X^?MB?$7]D'XR?%S3-#L+7XNZ-XRN/ 'PX\-Z#X+F\6+J<OPPUO
M1O ?Q,\3:5IVG3W+:Q!X]\8:+X[OO!<US#>:=X9TR;1KC4K>]T^UU!'\T\5_
MM(?M]R^)?B5X1\%^$9KO4?A+;_"+Q+JNG:;\.=,\1^,?%-C\;M/T+Q%I_P .
MK>'3M4O?#7AGQK\.;/1?'.C>*/$.I277A"8ZEH&H7-YI]G=6^LP?2.I?\%)/
M@3X>CM(H?!WQ5U"U7POIWCK5I]"\+^')K7PWX.U'PC\-_'VI>)M90^*[1DL]
M#T+XK>'+C6K;3(=1U5[U=3@TW3]2>&%[J];_ /!1'X.2ZWJ?A[3/AY\8;WQ7
M?>(I?#?@G0[7PSX5CO\ XN:S8^/O%WPPU$>"+RY\:6^G-;:-XF\">(X+VZ\8
M7_A58M+L$O+19XI((F/^&]/NOV>_FNEP\_EVMITLW;9[^:Z77SE#X_\ ^"CG
MA3QSH_AFQTW7/%7AW4_VG/BM'XG\4>-?A:;FRTOX7'QEX5D^''AS0;CP,NI[
M?!VI_#_5]>U)/&<AA30_$6E#0M0UM18R6NI]O\*/B!_P42N/B/X N/B-HD=Q
M\/\ 6/$?P[7Q=H)^%-AH5SHVA>-U^-=GXK23Q+;>)KJ>+_A6?_""_##5)KD:
M;YNHW7Q%E@NUCL3I\-MZ%IW_  4=\"^,/^$#N_A7\(?BQX]\.>-/BW\,/A$W
MBAH?"/A72=-UOXG>!E^(-L8(=<\3)JFIWGAWP_/:RZ]8#3[*VBGDE@MM5GEC
MA2Y]$^,/[8ME\--9^(OP_P!'^''BSQ1\7/".AZ1XK\.^$K>&;4]+\7>"M1\0
M:!X>U+QLFI^![7QMJNB:1X/DUY]5\2Z+JWAZV\:W&CZ5>WOAGPUX@B:%R;;^
M>]EMO]W:Z7>_4U3U\]TEMWM:UM-+I=V^OQ9XNO\ ]M?Q/\<O&NNZGX"^(>I:
M+X9\3:)X<\->%=.\+7GAGP/#X<TO]K'X<W6DZUH?BG2_&]M'\1+_ %CX,:;<
M^+=7UO58-'L?#S7&N^&]4M+K2X-2T^O'A^W'^V[X9\9_!CX>_&2V3X.77Q%^
M,#69UGQ/\*4DUVY^'<VK_"O3DT^XT:%6CN9XM0\7>*O#-GJGAC0Y99-:M-)O
M[V_E\-V=_K5W]H? ?_@H[HWQN^)GPQ^'Y\&6?@R#QIX>TUM2UC7-1\6R1W7C
MW6;+XAZCI?@WP3+;> SHMZ;K2/AMKGB&WE\<:WX#UF_T<RC3?#]U?Z7J%JDW
M@G_@H3X.U]-4TCQ]\*?&<GQ.TSXD^)/"/PW\.>%=#T'4!\2XX_BS\1/A;X?U
M#X>:KKWBJRM[:]0> =3?Q7<^);WPG;6,L5RVGR7EI+:+*?/=;Z=G;_/3_ACM
MKTZVV::3^6_?]/%Y?C#_ ,%+M/\ !44FL>"]9.K:Q;^#O$,VO>&O@AIVMZ]X
M0OM?\%_$>]F^'%OX&_X3%+77+&T\<^&? >B^*?&ES>?:/#FF^,;N]:"UMF@O
M-+;JWQ _X* Z_>ZEJ&L?#;4=.\2^"_'6MW?A35=-^'WB.7P)H-MJ/P$^(!6R
ML]!TK7H/$OQ(L]$^(D>B:5?:KJ4/B7P[K=_J.EWOA3SI2UEI?TDO_!2[]GJ?
MP5<^/=/TWXD:GH=O8>(=0$5GX;TS^UIU\+_#GP-\3-5M(=-N?$%O*;Y='\?Z
M1IEO#(\<-SKMKJ5JEQ]DBMK^[^@O@W^TCX7^,WC#XE^ M/\ "?CGP7XL^%$O
MAVW\6:'X]LM TG5(YO$>GO?VSV6G:;XCUF^N=-B,4]FFO?9X_#^JW=M=KH&J
M:M':7,L3?X_+YZ:?\#30;[=5OM\W96MZ;+338^/OB3\6/V^=)^$'[.7BCX9_
M"K4->\>>.?!NI67Q7\*>)_#6B0ZIX#\7:4VA^+;7Q!K\.B:C!:Z?:Z_X4T#Q
MUX(MM)LD(A\7>*_!K2VEA=Q3V\'6^-_B)^VY8? [X$^,?"?@J/4/BA\1]4OM
M!^)'@E_#%I)>_"H?%);Z?X>>*_$%H=12&VTOX&>9I5I\1K87,PUR-+ZXDW21
MC/Z.48'IUZ^]+^OZOO\ UJ+^OZOO_6I^-4OQ2_X*@:EJWQ'TN/PMI'AF.P\>
M^/-/\,W=I\)=0\0?V;X<\,>$_BMJ?A+^SKS4K[2=!\5:-X^U+PQ\-[2+6;/5
M-7O]*U/Q9>6=RUL\MMIECYO\3;/]N[QG:_$2#5=$^+NJ:CJOB77=8\)V6D>'
M)_#=K\/_  IXJ_9W^'^K6FB>#?$?AG6M/&M-:_$\^+_"=W:^)X]6U/1+[36N
MX7T[4-62XD_=VBC^NG^7I_3=S^EHOQTUZ?=YN_XSV?Q,_P""B7B[Q1JD^J>%
M_B%X$\)^#OVI/AQ'I=GI_P -- EUGQ/\'=:@^*FD^*-$U>261].U;PEI.J:9
M\.KN_P#$V@R7U[IFF^))-7EUB^3398X/0_@]\1?V_P#QKXF^'6D^-M%U'P;X
M<UCXB:;_ ,+%\1ZM\'-.T6Z\+Z=:?#'Q1XF\:^ M&T^;Q7J,.H>"[#Q]I?AK
MP9X/^+\KR7/B*#7;R>VL]0FAMYXOU5HH_P"&_K_A^_5W1TM_7WO77U[]7=>2
M?'N:6V^"/Q:GAEEAFA^'?BZ2*:&1XIXI$T.]*2PRQ8D29& >)XB)%D"F,JV"
M/Y-8_'/CGRHV_P"$W\:GY$;:?%NO$9"CO]ORYP%=3MW;#O"%\O7]8O[0?_)"
M_B_[_#CQB,YVXSH5Z,DY&%'5L%3MSAAU'\B$8S%&1Q^[7Y6^0 D"7#''WBS(
M2!^\;]Y\D@96E_@_Z8F,Q>%SS@7ZMBL5AU/)L]=18?%8K#QG;-,"DYQP^)H1
MFTG)1<XR:3:32;1_H-]"G!8+&9'X@?6\%@L6X9WD"A];P>#Q3BGE./;47BL)
MB7!-ZM0<5)[QD]3K/^$X\<@@#QOXQR!D?\51KV2%#<?+?@,240#'!V;E&S>Q
M4^.?''7_ (3?QB1DKG_A*==(8C.0<7Q&W.P98C<K2N?W>]JY;@ XS@C W<@%
MDX0@DXV+M8[@74("@(C+RH5/!'.,YS\PP-JD%E/).\="H&\;&61Q&/XW_M?-
MK/\ X4\QNFDU_:.8;O7_ *&.FUM>O1[+^W?[$R7;^QLGOT_X2,I[[_\ (JT3
MVZ[J^YU7_"<^..<^-O&6,D9_X2?Q!G'.XG-YG<5W$YYW,Y8*3(0#QSXX[^-O
M&/![>*/$'!^7.W_3 <YWE>^5AZ,T8/+'IDY'7)+)@$98_-\HW  O@8VE <1I
ML%LFT C( QP<,IVL#CJ"1@$87A@?)4!6+&.6?[7S>W_(RS'_ ,.68?KF-NJT
M^7D']B9+_P!";)__  SY1V_[%7;RVW[G5?\ "<^./^AV\8YXQ_Q4^OXS@8/_
M !^],XVX_A6,<_N@Q_PG/CCD?\)MXQ(QQGQ1K^,8; .;SH5";@>,-,.BMCE<
M<#TS@8*D$_* !\S9SN"G).0<DOO)NP!> "#G!Y*C(..?O@X8,"?F0@2N^X;3
M(A_;&;_]#',/_#EF/K_T,.MK+[_0_L3);:Y-D_E_PCY1]_\ R*M?P.J_X3GQ
MP.?^$V\9XP?^9GU\' +=<WO7:"3_ +3R#KYP1!XY\<9Y\;^,N<9_XJ?Q!Q]W
M)'^F9R"7Q@DDB+&2>.7.WG)&22<@K_M'/)3!!R2/D.00/+V!;1"!GT//=<\$
MDX)XW+M(P5&3$GRY?RB?VOF__0RS'_PY9C^/_"A_6MM@629+_P!";)__  SY
M3\O^95?R1U1\<^.>#_PFWC($]?\ BI_$!YXX'^FG(W'"D9^58F7CRBR?\)UX
MYZ_\)MXQYZ ^*-? QM( .;W&W C4G.-F\GY!D\O@<X YQP&4]EROWG[85<[\
MC;S(),WB':1P0<^NW!SMX)W' ;*C>3TF9BY4>;1_:^;_ /0RS'_PY9CW6G_(
MP[?)/>P?V)DO_0FR?_PT91_\ZN_<ZK_A.?'';QMXRQG'/BC7^F6QG-[C+ ?-
MNQ@M,'P/-*G_  G'CD?\SOXRZ_\ 0S^(,]0#@?;,EL>:>S;@H.'.!RW YW=N
MY&>=_)Y4@GJ<8PV\'RS&#9I\OKC' R5.W!8# 7DX()("XS&J@#!C0_MC-W_S
M,LPW_P"AEF+_  _M"]T_+MW#^Q,EUODN3]6_^$?*-/7_ (2MNFO^9U7_  G/
MCC_H=O&.<#IXH\08'W<8(O3T))4#G"P[<L8E8_X3GQSV\;>,1UQGQ1K^/N]#
MB\(QD1@=MA;;D 9Y; '3 QU (/3 Q_%NVX 4D$,%3A_,(NT.#CH<^K(<YVGJ
M&/!W $[FXE)R>993^U\W_P"AEF/_ (<LQ_\ G@NSZ_YH_L3)-O[&R?U_L?*?
M_G5Z,ZK_ (3GQOSCQMXR/?GQ/K_.-W7_ $W'0+N[?/-DX$I5?^$X\<]/^$V\
M9]L_\5/X@W=2#D?;,DX\P\C)8Y)R7QRF!@\^G.X#(Y.2-Z%2V=^TLA4O)RI0
MM:+\I[XR>#\G'WN0,K@@+G;A>8P % $<!_:^<?\ 0RS'I_S,LQ]/^AAO?R6O
MW!_8F2_]"7)_3^Q\I\K?\RJ_6W4ZD>.?'!P3XV\99P!D>*-?_P!GH1>],[MI
M _@@(',64_X3GQSU'C;QCG!_YF?7P < J,_;#@;MH[@(!@[!&6Y< >J]L#*G
M^(#&/F'!PHX;[D>0_F!+E#@X Y_%3G&T =6 R6VY+'(DW%SN\RX/[8S?_H99
MCM?_ )&68^3_ .AAV_36VZ_L3)=_[&R?;_H3Y1YZ_P#(J^>YU1\<^.!D?\)M
MXQXSC_BI]?&1\VW.;P<8VALC #3 \!Z#XY\<=/\ A-O&0Y/7Q/K^<?-DG_3,
M[BN]CGG<S X<R <K@9X.?E/4A3P,]-ZG)R6/('[R3#KY?F0+QD#D=0#E<Y^8
M], YRN0 H.4 VH0J6Q_:^;_]#+,=/^IEF/W?\C#TWMIOYO\ L3);_P#(ER?R
M_P"$?*>__8J[WV7XW.I'CGQP2,^-_&6<CD>*/$&1G:"1_I@Y!+D=\K%CYMHH
M/CGQQC_D=O&/8G_BI]?P..<G[8<#*E1@,,1X4-L0-RN!D\\%1R!P%(^;!.0R
M+M4(V"CA!QY9=BI P3@X(!)(&2&PH/W?,&YBJ)@K@A2L@,1!/[8S?KF>96[K
M,LQOT_ZF&[UT=K7\FFO[$R6__(FR?T_L?*/+OE=M/T]&?T;?\$T-<N[O]F#^
MUO$&M7MZUOXZ\<&ZU/7-2N+R6&U@GL) UQ>W]Q<-%:V\3-(6:=;>"+<[%4!*
M_2_AC]J;]GGQAX2TGQWH7Q@\!77A'7_B/_PJ'0-??Q!9VFFZ]\2GU-](M/!^
MB3WS6O\ :VL:M>Q[M"@L5G&NV$UKJFDM=Z=>6US)\B_\$W=)77_V/=:T/R],
MG&M^*/B;I?D:U8/J>CS'4HK:T==7TR.YL9M0TV224K?V,=W8O>6QFMQ/;NXE
M3P'PW_P2Q^)7B'X9_"+3_'GQZO\ P+XA^$GQ>\-_$3X??#'P=9+X^^#_ ,)O
M"N@>./AQKZ> _ US\3W\2>/6EMM(^'DEIX8UZ\\4D>$[?Q1J/A>ST^Z\)V_]
MGW7^N7@_.=7PL\/JE2<ZE2IPIE,YU*DYU*E24J>)O4G4J2G.4I-+6<Y2MRIM
M\ME_C3XS4X4O%GQ%ITH0I4X<7YU"%.G"%*G",<13480A3A3IPC&W*HPIPC%:
M**2/U8T3X_\ P1\2:!X[\5>'_BOX!UKPY\,)]3MOB-K6F>)])O=.\#SZ/;M>
M:G%XIN8+ETT1K.S1[N7[>8!]E4W*EH1OJ&T_:'^!=]IW@'5[;XM> 6TSXJ7>
MM6/PWO9/$VF06_CB[\.6EY?^((/#+W%Q$-7?1++3[Z[U7['YJV%M:S371BC0
MM7PYX1_9(_:$T'_A>>C^-;W]G7XJ_P##5/B+QIJ'QO\ &6K^$O'^B17O@^V\
M#:IX3^%WP[F\&V/C=XKO0?#]G<>'_"ZIH&K>&YXO#6E>)-7O=1OO%?B*.^A\
MR3_@E'K&IO\  W6/%W[0VN^(]3^%/B'Q//?>#=5\/KXC^&J_#WQ5-\4)[[X4
M^"9/%>I:U\3O#GAK['\0-.\)7>HW?Q"U+6M6\(^%],M;FZ@O[+1[O2OTC^NE
MOZ7]:V1^9_UNK?TOE]]D?JQ\//BC\./BUH \5?##QQX6^('AIKZ\TP:]X1UJ
MPU[2?[1L&"WM@;[3I[BW6[M=\;S6[.)5BF@FV^5/"[]Y7QC^Q+^R?+^R9X"\
M;>'M0\5Q>*]>^(/C^3QSJSV \1C0= @M/"7A3P'X=\+^'W\7^(O%GBF[TW1/
M#'@W1[<7^O:]?7US.9546]G!:6\7V=0!!;?\>UOR#^XBY P#^[7D#G ]!D\4
M4MM_Q[6_7_41=>O^K7KCC-% $U%%% !1110 4444 %%%% !7!^+/A=\.O'>L
M^%O$/C/P7X=\4:SX*N[B_P#"E]KFF6^I2:%?721QS7=BETDD,=QB*-HI6C=X
M)8TF@,<RJX[RB@#Y'D_84_93/B7P7XCM_@UX-L4\"3:]?:-X:L=&TZ#PC<:S
MKY\*!]?UC0?LCVVJ:QI,'@W1K/0[FX8Q:?9+/:B"2(P+;Z7AK]BS]FCP[X<\
M:>&Y?A3X8\26_P 1?$VL>+O&^H>*M-LM:UKQ)K6K>,_$'CN.>^U22VAN%31=
M=\2ZF=!6U^SOIMHT422R2K)<2_4U%'_#?+L'^5OEV/(6^ 'P2;2#H"_"OP-#
MHO\ PD_A;QHFEVWAW3K6Q@\6>"-.TG2/"/B&UM[:&*.TU;P]I6A:1IFEWELL
M4MK86$%HC?9PT;;^L_"KX;Z_I/C#0]6\$>&[K3/B#)!/XY@&EVUM)XMN+5;=
M+6Y\07=HD%YJES:QVEK%:W-W<2SVT5O#%#(D<:*._HH#]=SR33?@)\%=&\3^
M%/&>D?"SP+IGBKP-X=A\)^#]=L/#FFVFH>&_#MK;W-G::3I,T$"?9+:SL[Z_
MM+/RP);2TU'4;:VDB@U"\CGQ]8_9E_9]\0:??Z7K/P>\ ZA8:G%-#>P7'AZQ
M/G+/XNO_ !]*ZRK&LT-P_C35=2\3?:H)(KE=8OKJ\642S.3[G10'_#_/N?/[
M?LI_LV-J5WJX^!WPRCU&^\,P>#;NZ@\):3;O-X5MM,LM&@T)E@MXXUTZ/2=-
MTW3E@1%'V/3=/MR3'8VJQ>C>&_AC\/?"'B;Q=XS\,>#M T3Q9X]GL[GQEXBL
M-/AAUCQ%+IXF%D-3O@IGFAM6N;J6&WWK;I<75U<B+[1<SRR=U119::;;>7H*
MRTT6FWEZ!1110,**** "BBB@#D?'ND6'B#P=XAT'586N-+UO39]'U*!)7@>?
M3]3 L;V%)XR)(7FM9Y8DEC(>-W#H0P!'QXG_  3B_9&)$:_#_4U"AE2/_A,_
M%A"KM(*@'5251<L.0")-YY9BS?:GB7']BWN3_P ^^!G&2;J$!<$@-GIL)^;H
M,'!&[7SV><(\+<33P]3B+AW)<\J82%2EA:F:Y;A<=/#4ZLXU*M.A/$4YNE"I
M4A"<XPLI3C&4DVDU])D7&/%G"]/$4N&^)<]R"EBZE.KBJ>3YIC,NAB:E*$J=
M.=>.%JTU5G3IRE"$IIN$9.*:3=_A7_AV]^R1Q_Q;[4S@ $?\)GXL *[E;;@:
ML %)4 JH4'K]Y5*G_#M_]DC.3\/M3/'?QEXKYX(^8_VMDXSE03M4XV@#@_=5
M%>$_"OPS?_- <'_^(_EOGO\ N==_\FCWO^(M>*7_ $<7C;_Q)<V_^:?ZV=SX
M5'_!-_\ 9)# _P#"OM3&TH0?^$T\6?-L((5A_:V-HQVY^=\$9.6G_@G!^R6"
M OP]U0@*0#_PFOBQ=ORE>!_:V-V=K9QC*(3G;M/W913_ .(5^&=T_P#4#@_3
M_JG\N2VMLJ*_KRT#_B+7BC_T<3C7_P 2;-_+_J*OT773I8^%?^'<'[))))^'
M^I_-C*_\)IXLVCA@5 _M8<'>P.<\<# R"?\ #M_]DG;M/@#53R3G_A,_%F<G
MZ:L!QDD<?Q'J, ?=5%+_ (A7X9IM_P"H'!]W_P!4_EO_ ,I_K??47_$6?%'_
M *.+QM_XDV;=-O\ F)_X?K<^%C_P3@_9*XQX U08(/'C/Q9SC!P?^)MR,J&Q
MZY(QFF_\.WOV2?\ H0-4Z$$?\)GXK /IG&K \84@9QE1D'G/W710O"KPS2M_
MJ!P?_P"(_EMUZ/V%UVT:T5@_XBUXH_\ 1Q>-?_$ES;J[_P#03W_X%DVG\*G_
M ()O_LDG/_% :I@]5_X3/Q7C&",?\A;.""0>>_KB@_\ !-_]DH9(^'^J$GM_
MPF?BL9]?^8M_%\P.>SMT^7'W511_Q"KPS:L^ .#[?]D_EO7I?V-^G?YC_P"(
MM>*/_1Q>-O\ Q)LV_3$IKY-/SOJ?"H_X)O\ [)77_A -54D#./&GBO(.0>O]
MK<D$=3G/>@_\$W_V23C'P_U-<=,>,_%GICG.K'T'7/W0>I.?NJBA^%?AHVG_
M *@<(:?]4_EO2^_[C7=[WW=[W=S_ (BUXH_]'%XVZ_\ -2YMU_[F3X4'_!-[
M]DD 8^'^J< C_D<_%?.05R3_ &MU /&,>]+_ ,.W_P!DG&/^%?ZGUR#_ ,)G
MXLRO7('_ !-NA+$D'.23VXK[JHH_XA7X9IW7 '!]_P#LGLM_^4V_X9=E8_XB
MUXH_]'%XU_\ $ES;O?\ Z">_7?SMH?"O_#M[]DG_ *$#5<Y)S_PFGBS().>/
M^)MC@YQQW.<YI#_P3>_9)/\ S(&J#IDCQGXKR<8Y.=6/HH(Z?*..N?NNBC_B
M%?AG_P!$!P?_ .(]EOX?N=+=+;=+*R2_XBUXH_\ 1Q>-O_$ES;_YI\OZZ_"W
M_#M_]DDDD_#_ %3G/'_"9^+,=@,?\3;C   QV SD@&D'_!-_]DGG/@#5#G Y
M\9^+.@)..-6'!W-D=.3@"ONJBC_B%?AG:W^H'!]M'_R3^6].S]C?\=>MP_XB
MUXH_]'%XV_\ $FS;\_K-_G>_F?"H_P"";_[)( '_  K_ %0X)(SXT\6'&6#8
MQ_:V,9SQC^)LYSPG_#M[]DG_ *$#5< ;0/\ A-/%G ].-5'!XR,X& !P6S]U
MT4?\0K\,W;_C .#]-O\ C'\M[WW]C?=OKUTML/\ XBUXI?\ 1Q>-?_$ES;_Y
MI_KY*WPH/^"<'[)2M_R3S4VSU;_A,_%0P<@?=&KJ#@_O=Q4MN4#)4E"#_@F]
M^R1G/_"O]3QDG;_PF?BPCD;<9_M;<1CU.6XWEMJ[?NNBC_B%?AF[?\8!P?LE
M_P D_EMM%;;V-MG;1(/^(M>*/_1Q>-NO_-39MU_[F=-M+;=+'E_PC^#_ ($^
M"'A/_A"/AUI$VC>'%U*^U9;2XU/4-6E-]J3HUY,;G4I[BX E:*-O+$GEH<A%
M4=?4***^TP.!P668/#9?EV$P^!P&#HPP^$P>$I0H8;"T*?-[.C0HTTH4J4%*
M2A3@E&*;221\/CL=C,SQF)S',<5B,=C\;6GB<9C,76GB,3BL15:=2OB*]5RJ
M5:M1I.=2<G*35VPHHHKJ.4**** (+;_CVM_^N$7<G_EFO<\GZGDT46W_ ![6
M^.GD18P,#_5KT'./IDXHH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU^V\+Q7=A<:E:P:Y):Z]>VU[9:?JMGHTE]>:-)>V-Y92ZK!9V][ ;2::2/\
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2B0D_G1110MEZ+\@6R]%^1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex5-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ^ D # 2(  A$! Q$!_\0
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MJ.J^$_!%MX;^'G@W2;OP_P"*?%=WXC>QC\4ZM+?:B$U[3_#_ (:O+:X^DO\
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M** "BBB@ HHHH **** /XV?^"PW_  5^_P""-?QDU+QO^RW^TY^RA\??C_\
M$CX'^-?&?@=-9TOP]HGPGUKX<>,M!U:30O$<?A7XDZCXPL?&5G87>I:.AN[2
M/POJWACQ#%9:;=ZAI.JP16;1_FM\0/\ @AG_ ,$U/C#^S=J7[57[%O\ P5*\
M#^%_"Y\#W?CNV^'7[2NN?#B75O#US#I,VK3^ _&^O^']:\'>(?!GB+3;A/[%
MGM[[X;ZS>M<H'M[?48I[:YN/W1_X+-?\&Z_AW_@H%\0-1_:<_9J\;>&/@_\
MM(:S8V=M\0-"\8VNH+\,_BW/I&GQ:=I.NW^IZ%9:EK'@WQG#IUI9:5?:M:Z)
MKVE^(+2RL'OM-TW4XK_6]1_F.N/^#7;_ (*X0:NVEQ?#3X47=B)S"/$%M\;O
M!":.\>XK]I6"ZO+77_(( ;:^AK<[6 ^S[LJ-$U96DT^J>OX ?B#^SSXY\?\
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MVWBCP#>7E_#;W5SINFW/B'2K31]=O;2VN+B/P]JFKQI;W E:WE_E=_X),_\
M!MK^UI^S1^W;\%_VA_VL7^#=Q\+_ (+WNJ^/]-TKP7XWO/%.KZM\1-*TV>'X
M>J]A<>&-,CM[;0O$MW9^+S>_:LI<^'+:U",;O<I&2Y==UM^@'ZN?M[_M=67_
M  ;_ /\ P2Q_9I^#_P &_#.A>+_C"/#>B?!'X9MK4,I\)P>+-)\-R>(OBI\7
M_$FG6LUC<:M _B.\N]8CT*VN;,ZCXD\7Z>]W*-+M]1C?^7C]BOQ/_P %I/\
M@N3\</B!X6\-?MS^/_A]H7@W2K#Q5\4O%-MX[UWX2>!/#NF:U>ZA8^&]'L?
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M?WMW)]KWSW5Q(S2O_59_P=2R/-\#/^"1TTK%Y9?@Q\2I)'. 7=_"/[.C.Q
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M/AO2;&#P=XH\,?&SQ=X;\>>%M-L-/T;Q-I5AX1,MI;:AX6TN_C- /T@HHHI
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M)FN+ZRF8ZC!+/87T<^FW=[9W/L_A;X4^%/!_Q"^*7Q-T<:I_PDWQ@G\&7'C
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex23-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  P ' # 2(  A$! Q$!_\0
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M#X1?\%L/V^OV1OVDK?X%_P#!0?PEH^OZ/:>(]'T;QO!-X=TOPWXQ\*Z1K/\
MQZ>-?#NJ>&/^*=\3^%^,;L9Z@$9-?T$_\%7/C7\4?@=^P9\3?C[\ ?'\_@KQ
M5X(B\$>(=*UBWT73/$9UNPUCQUX;\.G2C::SD;6'B#.>.0H^8L-O\8=K\7_
M?[<?[>S_ !E_X**?$^+X":%/KOA@ZIX;L/AUXR /AGPX2WA_P<;T*Q\+Z(Q.
MYO&/B(,Q8EB"2:_K>_X++:WX8\0?\$D_VB->\$ZG8ZSX2U/PK\(;OP[J6@2B
M^LKO3O\ A</PX&D'2MK%2"3:E>3R><,IQ\[X@<.91E7%'ATXY'#+,RS>KAH<
M1QHQ53AISJ8BC"=.$TITW;FJ)Q3YE%J7*G9GN<'\1YOBN%?$*#S&7_"-&H^'
MN?3B%14)M3G%\LTFDG>UKW5S\!/V4_VV_P#@NU^VM'X[;]G'XGZ%XV/P\_X1
MB/Q6+S0/V?\ PZ;3_A.QK!\/@#Q.,YQX>U8D<D\D>E>I_$O]MC_@X#_8F3_A
M./V@/ .F^)/ >F2!M9UC4/ 7@SQCX/-MT#:OXA^# #>&,X(![\X/K[#_ ,&M
M.PV_[:J(=\<E]^SSD\9'^B?& =>V-W7(]S7]8.O:%I7B;1[S1-7L]/U;2-5M
M6MM2TZ_MOMME=V-X"AM64_(P(Q]X,IR& &%(X^/N+<LX9X^SCAM\!<'RR+!N
ME3DXTG&JXRI4)2DI\UY2:FY1?+&FFXQELV=/!'#.;\4<&95Q#_K1Q LU7M)<
MKE[MXRFTI)V:5TDWO:[L?CM_P3#_ ."PGPL_;\:?X=Z]H ^%WQ_T32QK&H>"
M)=9.K:+XCL"574M=\$ZNJ$WL2EF9M#?<T7+-E2SI];?MY?M^_!;]@GX5_P#"
MQ/BF;S5-6URY_L'P!X%T.9AXC\:^)6211::4,%=+L@3DZXXVH&#$$A"W\-_Q
M&TM/V%O^"MNKV'P?FDL--^#G[5VC_P#")V=E=?Z/:>%_$FO:/_Q1O/\ U*OB
M$^#^>W)KZ0_X.(_B?X@\<_\ !0?4O MW=W*Z#\)_A9X"T30;?.;*S_X3G1&\
M<^(-?/.?F&ICOT\.=SBO5Q/@SP[F'''"U+!ODX1XBX:EQHZ3TDE2A&I4HIW<
MHVG*,'%MSBK\G1K'#^*W$."X(SB6,O+/<JXC_P!7%4M=6G-TXU--&[:\VD;[
MO=/ZY\&_\%)_^"T__!1[Q)KUG^QQ\/O#'PU^'MA=-I=]K&D:-H1TO2<Y)7Q!
M\2OB!G=K@"Y"^"DX )QU)[KQUX@_X./_ -D[1+[XC^)]:T/XV>$M(M_[1\1Z
M=I&B_##XB3VM@IQSX>\,>%/!'C!L'JO@T'IR../Z2_V)?@OX,^ /[+WP+^&O
M@32[*PT30OASX6N;D6<(A%WJ.LZ4-7\0:\1G=GQ#KC7FH8X_U@'9:^NI(5:-
MHT7(((^;C'!'<^I[9SW/I\!F'B'EF$S66"RGP_X1CD-*<Z+4Z,Y5I*E.5)S=
M1S<U.2I\Z:YE=IOF]X^RR_P]S?'96L;FO%&?O-I156-I+E3E!5(Q2TTO**Z:
M76VW\\'_  3'_P""Z?@O]K_Q3HWP.^.GAFQ^$/QOUH"T\+SZ;J!N?AU\1[[[
M(H.F>'FULC4M&\5  L?"+[Y"2Q!).T_T3K,'R/5<CZ$8Z9R ..?<]>W^<K_P
M6%^'>D?LG_\ !3;X@7GPDDD\*K%??#_XYZ#!H7_$K'A;Q/J__$X\0G2L<9/B
MGP]X@\8G'&?$IP1BO]!OX5>)+GQI\-/A_P"+[L1+=^*?!'A?Q%<Q#A1?ZMI5
MIJN !@ +N./3 [5CXG\*Y3E&%X5XFR"+I99Q/253V$[J5*I:,I02=[1BYN+C
M>23BG%\LK+7POXJSC-<=Q/PUG^N8\.SY8SMI.";C%IVLVTE+1][GQ)_P57'_
M !@M\9DDXQ'X6V>A/_"8>'P?R7\^/Q^"_P#@A#N_X0[]HE0F]'\7>#/-'F<@
MG0HL=L=O;]:^^?\ @JU;37_[$'Q;CM8KBXN=GAA;>U@',^_Q=X>0?B"V<8Z?
MA7YL_P#!,KXC^"?V)O _Q&;]I;Q7X?\ A;JWQ1UGPSK'A/PKKNHK;ZU+I&CZ
M$++^T]4TQK$:[I!^]N'B Y5EVEE/!_F?-:7L>/\ *,4]O9SC)MI1BY1DDG)M
M13=[OWEUM=IG^G? U7^T/H9<?\,8"O+-<_S?Q2I3I\.THSJ5JE.G'(92G"E3
M4JLH0^%RC!Q26LE=7_-;_@OS\$OBU^T+_P %&?A?\/?@UX)UOQ]XOO/V9/"]
M\+/3[#_0=!T__A:'Q?']I^(M6X\/>%]$SD?V_P",A@'&/2OZ"?@!^WI^PO\
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MQA.ZD]*%N?EFWHW[RZ['Y%?\$WOV:_C%_P %*/V_[G]I/Q]H]PGPWTOXO_\
M"\OC%XTEMO\ BG)]9_M3^V/#OPO\/9/^G9.!U \*^%2.AK]$O^#B?]@_QQ?^
M+_#7[:WP]\/WGB3P_%X2T_P%\:;/1[0WNJ^'+?2+J]/AWQY@X_XDI75AH.L
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MTMNV^WEMY#_XCIXP_P#1Q^,=K?\ ([Q>W;X-O+;R/R<_X<S_ +%?_0%\:_\
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9+>)L^X@<+\OUZ2DX]':2C%K32^CMZL__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
